Babylon Holdings Limited (BBLNF) F-4 20 May 22 Registration of securities (foreign) Financial data

Cover

Cover	3 Months Ended
	Mar. 31, 2022
Cover [Abstract]
Document Type	F-4
Entity Registrant Name	Babylon Holdings Ltd
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001866390
Amendment Flag	false

Condensed Consolidated Statemen

Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss - USD ($) $ in Thousands	Jun. 03, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss
Revenue		$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Clinical care delivery expense		(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Claims expense		(247,552)	(23,917)
Platform & application expenses		(16,703)	(6,434)	(42,829)	(38,137)	(23,569)
Research & development expenses		(10,057)	(10,390)	(47,534)	(54,711)	(51,205)
Sales, general & administrative expenses		(58,310)	(31,479)	(196,673)	(94,681)	(84,270)
Recapitalization transaction expense	$ (148,700)			(148,722)
Operating loss		(90,103)	(12,750)	(402,509)	(175,511)	(162,820)
Finance costs		(6,628)	(992)	(14,291)	(4,530)	(1,116)
Finance income		255	14	326	610	1,015
Change in fair value of warrant liabilities		5,575		27,811
Exchange loss		(447)	(573)	868	(2,836)	17,075
Net finance expense		(1,245)	(1,551)	14,714	(6,756)	16,974
Gain on sale of subsidiary			3,917	3,917
Gain on remeasurement of equity interest				10,495
Share of loss of equity-accounted investees			(455)	(2,602)	(1,124)
Loss before taxation		(91,348)	(10,839)	(375,985)	(183,391)	(145,846)
Tax provision		(9)	(8)	1,474	(4,639)	5,559
Loss for the period		(91,357)	(10,847)	(374,511)	(188,030)	(140,287)
Other comprehensive loss Items that may be reclassified subsequently to profit or loss:
Currency translation differences		(3,753)	(1,754)	(1,702)	3,579	(9,693)
Other comprehensive loss for the period, net of income tax		(3,753)	(1,754)	(1,702)	3,579	(9,693)
Total comprehensive loss for the year		(95,110)	(12,601)	(376,213)	(184,451)	(149,980)
Loss attributable to:
Equity holders of the parent		(91,357)	(10,466)	(368,482)	(186,799)	(140,287)
Non-controlling interest			(381)	(6,029)	(1,231)
Loss for the period		(91,357)	(10,847)	(374,511)	(188,030)	(140,287)
Total comprehensive loss attributable to:
Equity holders of the parent		(95,110)	(12,220)	(370,184)	(183,220)	(149,980)
Non-controlling interest			(381)	(6,029)	(1,231)
Total comprehensive loss for the year		$ (95,110)	$ (12,601)	$ (376,213)	$ (184,451)	$ (149,980)
Loss per share
Net loss per share, Basic and Diluted (in usd per share)		$ (0.24)	$ (0.04)	$ (1.36)	$ (0.77)	$ (0.58)
Weighted average shares outstanding, Basic and Diluted (in shares)		384,531,450	245,229,566	271,321,253	242,935,770	241,903,166

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Financial Position - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-current assets
Right-of-use assets	$ 20,014	$ 7,844		$ 2,572
Property, plant and equipment	25,694	24,990		1,334	$ 1,801
Investments in associates				8,876
Goodwill	93,655	93,678		17,832
Other intangible assets	112,830	111,421		78,853
Total non-current assets	252,193	237,933		109,467
Current assets
Right-of-use assets	5,454	3,999		1,942
Trade and other receivables	27,981	24,119		13,525
Prepayments and contract assets	21,971	26,000		8,841
Cash and cash equivalents	274,978	262,581		101,757
Assets held for sale				3,282
Total current assets	330,384	316,699		129,347
Total assets	582,577	554,632		238,814
EQUITY
Ordinary share capital	16	16
Share premium	923,093	922,897		485,221
Share-based payment reserve	89,545	80,371		32,185
Retained earnings	(929,343)	(837,986)		(469,504)
Foreign currency translation reserve	(3,780)	(27)		1,675
Total capital and reserves	79,531	165,271		49,590
Non-controlling interests				(1,231)
Total equity	79,531	165,271	$ 38,940	48,359	$ 173,797	$ (50,484)
Non-current liabilities
Loans and borrowings	262,142	168,601
Contract liabilities	63,763	70,396		57,274
Lease liabilities	20,143	8,442		2,011
Deferred grant income	6,134	7,236		7,488
Deferred tax liability	1,016	1,019
Total non-current liabilities	353,198	255,694		66,773
Current liabilities
Trade and other payables	25,198	22,686		7,745
Accruals and provisions	37,886	36,856		18,636
Claims payable	39,165	24,628		3,890
Contract liabilities	22,663	23,786		18,744
Warrant liability	17,971	20,128
Lease liabilities	5,301	4,190		2,488
Deferred grant income	1,664	1,208
Loans and borrowings		185		70,357
Liabilities directly associated with the assets held for sale				1,822
Total current liabilities	149,848	133,667		123,682
Total liabilities	503,046	389,361		190,455
Total liabilities and equity	$ 582,577	554,632		238,814
Ordinary share capital
EQUITY
Ordinary share capital		$ 16		10
Preference share capital
EQUITY
Ordinary share capital				$ 3

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Changes in Equity - USD ($) $ in Thousands	Share capital	Share premium	Share-based payment reserve	Retained earnings	Foreign exchange revaluation reserve	Equity attributable to owners of the parent company	Non- controlling Interest	Total
Beginning balance at Dec. 31, 2018	$ 10	$ 76,833	$ 7,302	$ (142,418)	$ 7,789	$ (50,484)		$ (50,484)
Loss for the period				(140,287)		(140,287)		(140,287)
Foreign exchange movement					(9,693)	(9,693)		(9,693)
Equity issuance costs		11,048				11,048		11,048
Equity-settled share-based payment transactions			7,966			7,966		7,966
Issuance of shares	3	377,270				377,273		377,273
Effect of share redenomination		70				70		70
Ending balance at Dec. 31, 2019	13	443,125	15,268	(282,705)	(1,904)	173,797		173,797
Loss for the period				(186,799)		(186,799)	$ (1,231)	(188,030)
Foreign exchange movement					3,579	3,579		3,579
Conversion of convertible debt		30,189				30,189		30,189
Equity-settled share-based payment transactions			16,917			16,917		16,917
Issuance of shares		11,907				11,907		11,907
Ending balance at Dec. 31, 2020	13	485,221	32,185	(469,504)	1,675	49,590	(1,231)	48,359
Loss for the period				(10,466)		(10,466)	(381)	(10,847)
Foreign exchange movement					(1,754)	(1,754)		(1,754)
Equity-settled share-based payment transactions			3,182			3,182		3,182
Ending balance at Mar. 31, 2021	13	485,221	35,367	(479,970)	(79)	40,552	(1,612)	38,940
Beginning balance at Dec. 31, 2020	13	485,221	32,185	(469,504)	1,675	49,590	(1,231)	48,359
Loss for the period				(368,482)		(368,482)	(6,029)	(374,511)
Foreign exchange movement					(1,702)	(1,702)		(1,702)
Issuance of shares in the Merger and PIPE financing	2	347,021				347,023		347,023
Fair value of non-controlling interests upon consolidation							64,274	64,274
Acquisition of non-controlling interests		51,033				51,033	$ (57,014)	(5,981)
Equity issuance costs		32,787				32,787		32,787
Conversion of convertible debt	1	69,999				70,000		70,000
Equity issued as consideration for acquisitions		2,349				2,349		2,349
Equity-settled share-based payment transactions			48,186			48,186		48,186
Issuance of shares in connection with option exercises		61				61		61
Ending balance at Dec. 31, 2021	16	922,897	80,371	(837,986)	(27)	165,271		165,271
Loss for the period				(91,357)		(91,357)		(91,357)
Foreign exchange movement					(3,753)	(3,753)		(3,753)
Equity issuance costs		541				541		541
Effect of shares withheld to cover taxes		(1,538)				(1,538)		(1,538)
Other		1,193				1,193		1,193
Equity-settled share-based payment transactions			9,174			9,174		9,174
Ending balance at Mar. 31, 2022	$ 16	$ 923,093	$ 89,545	$ (929,343)	$ (3,780)	$ 79,531		$ 79,531

Consolidated Statement of Cash

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Loss for the period	$ (91,357)	$ (10,847)	$ (374,511)	$ (188,030)	$ (140,287)
Adjustments to reconcile Loss for the period to net cash (used in) provided by operating activities:
Recapitalization transaction expense			148,722
Share-based compensation	8,402	2,802	46,307	9,557	7,966
Depreciation and amortization	9,458	5,848	35,004	14,487	2,496
Change in fair value of warrant liabilities	(5,575)		(27,811)
Gain on remeasurement of equity interest			(10,495)
Finance costs	6,628	992	14,291	4,530	1,116
Gain on sale of subsidiary		(3,917)	(3,917)
Share of loss of equity-accounted investees		455	2,602	1,124
Taxation	9	8	(1,474)	4,639	(5,559)
Impairment expense			941	6,436
Exchange loss	447	573	(868)	2,836	(17,075)
Finance income	(255)	(14)	(326)	(610)	(1,015)
Cash flows from (used in) operations before changes in working capital	(72,243)	(4,100)	(171,535)	(145,031)	(152,358)
Working capital adjustments
(Increase) / Decrease in trade and other receivables	126	(8,704)	(21,829)	738	(9,308)
Increase / (Decrease) in trade and other payables	3,160	34,304	47,496	2,323	18,052
(Increase) / Decrease in assets held for sale				(3,282)
Increase / (Decrease) liabilities directly associated with the assets held for sale				1,822
Net cash (used in) provided by operating activities	(68,957)	21,500	(145,868)	(143,430)	(143,614)
Cash flows from investing activities
Development costs capitalized	(9,298)	(7,198)	(32,120)	(36,509)	(36,036)
Acquisitions, net of cash acquired			(13,798)	(25,671)
Capital expenditures	(2,613)	(311)	(8,103)	(719)	(1,915)
Purchase of shares in associates and joint ventures		(2,000)	(5,000)	(10,000)
Cash assumed upon consolidation through control			3,792
Proceeds from sale of investment in subsidiary		2,213	2,213
Payment of lease deposit			(2,105)
Interest received	255	14	326	673	1,015
Net cash used in investing activities	(11,656)	(7,282)	(54,795)	(72,226)	(36,936)
Cash flows from financing activities
Proceeds from issuance of notes and warrants	100,000		270,563
Repayment of cash loan			(82,000)		(1,231)
Payment of equity and debt issuance costs	(5,002)		(36,043)	(10,245)	(773)
Repayments of borrowings			(7,431)
Principal payments on leases	(460)	(1,520)	(4,156)	(1,541)	(1,228)
Interest paid	(22)	(18)	(5,219)	(252)	(851)
Payments to acquire non-controlling interests			(2,352)
Proceeds from issuance of convertible loan notes				100,000	51,064
Repayment of convertible loan notes					(14,794)
Other financing activities, net	(1,538)	(482)	(470)
Net cash provided by (used in) financing activities	92,978	(2,020)	362,203	100,058	352,521
Net increase in cash and cash equivalents	12,365	12,198	161,540	(115,598)	171,971
Cash and cash equivalents at January 1,	262,581	101,757	101,757	214,888	46,031
Effect of movements in exchange rate on cash held	32	(57)	(716)	2,467	(3,114)
Cash and cash equivalents at March 31,	274,978	113,898	262,581	101,757	$ 214,888
Non-cash financing and investing activities:
Acquisition date fair value of Higi upon consolidation			86,043
Conversion of borrowings			70,000
Acquisitions of non-controlling interests			(54,662)
Fair value of warrants issued in Merger			(31,009)
Fair value of warrants issued in connection with Loans and borrowings	3,418		(16,930)
Equity and debt issuance costs in accruals and provisions			(4,521)
Equity issued as consideration for acquisitions			(2,349)
Share-based compensation expense capitalized in development costs	$ (772)	$ (380)	$ (1,879)	$ (7,616)

Corporate Information

Corporate Information	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Corporate Information
Corporate Information	1. Corporate Information Babylon Holdings Limited (the “Company,” “Babylon,” “we” or “our”) is incorporated, registered and domiciled in Jersey. The address of the registered office is 31 Esplanade, St. Helier, Jersey, JE2 3QA. Babylon is a digital-first, value-based care healthcare company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth. Babylon is re-engineering healthcare, shifting the focus from sick care to proactive healthcare, in order to improve the overall patient experience and reduce healthcare costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare. Babylon works with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals.	1. Corporate Information Babylon Holdings Limited (the “Company,” “Babylon,” “we” or “our”) is incorporated, registered and domiciled in Jersey. The address of the registered office is 31 Esplanade, St. Helier, Jersey, JE1 1FT. Babylon is a digital-first, value-based care healthcare company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth. Babylon is re-engineering healthcare, shifting the focus from sick care to proactive healthcare, in order to improve the overall patient experience and reduce healthcare costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare. Babylon works with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals. On June 3, 2021, Babylon announced it entered into a definitive merger agreement (the "Merger Agreement") with Alkuri Global Acquisition Corp (“Alkuri”), a special purpose acquisition company (the “Merger”) following the unanimous approval of the Board of Directors of the Company and Alkuri. The transaction was consummated on October 21, 2021, and the combined company operates as Babylon and trades on the New York Stock Exchange. The Merger was accounted for as a recapitalization in accordance with IFRS 2, Share-based Payments

Basis of Preparation

Basis of Preparation	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Basis of Preparation
Basis of Preparation	2. Basis of Preparation These financial statements consolidate those of the Company and its subsidiaries (together referred to as the “Group”). These condensed unaudited consolidated interim financial statements for the three months ended March 31, 2022 (“Condensed Consolidated Financial Statements”) have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the IASB, and should be read in conjunction with the Group’s last annual consolidated financial statements as at and for the year ended December 31, 2021 (the “last annual financial statements”). They do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS. However selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s consolidated financial position and consolidated performance since the last annual financial statements. These Condensed Consolidated Financial Statements were authorized for issue on May 20, 2022. Going Concern The Group incurred a loss for the period for the three months ended March 31, 2022 of $91.4 $69.0 Our directors performed a going concern assessment for a period of twelve months from the date of approval of these Condensed Consolidated Financial Statements to assess whether conditions exist that raise substantial doubt regarding the Group’s ability to continue as a going concern. This assessment indicates we have sufficient liquidity to fund our liabilities as they become due through December 31, 2022, but additional funding is required to provide sufficient funds to meet our liabilities that may fall due through May 2023 and beyond if we continue with our planned growth strategy. While there is no assurance that additional funds are available on acceptable terms, the directors believe that they will be successful in raising the additional capital needed to execute our planned growth strategy and to meet working capital and capital expenditure requirements that may fall due through May 2023 and after. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. However, the above indicates that there are material uncertainties (ability to raise further capital) related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, to continue realizing its assets and discharging its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. Basis of Consolidation Subsidiaries Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. To determine whether the Group controls an entity, status of voting or similar rights, contractual arrangements and other specific factors are considered. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date on which that control ceases. The Company consolidates certain professional service corporations (“PCs”) that are owned, directly or indirectly, and operated by appropriately licensed physicians. The Company maintains control of these PCs through contractual arrangements, which can include service agreements, financing agreements, equity transfer restriction agreements, and employment agreements, or a combination thereof, which are primarily established during the formation of the PCs. At inception, the contractual framework established between the Group and the PCs provides the Group with the power to direct the relevant activities in the conduct of the PC’s non-clinical administrative and other non-clinical business activities. The physicians employed by the PC are exclusively in control of, and responsible for, all aspects of the practice of medicine for their patients. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and a substantive process and whether the acquired set has the ability to produce outputs. Intercompany transactions, balances and unrealized gains on transactions between the Group’s companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss, Condensed Consolidated Statement of Financial Position and Condensed Consolidated Statement of Changes in Equity. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Associates Associates are those entities in which the Group has significant influence, but not control, over the financial and operating policies. Associates are accounted for using the equity method and are initially recognized at cost. The Condensed Consolidated Financial Statements include the Group’s share of the total comprehensive income and equity movements of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. When the Group’s share of losses exceeds its interest in an equity accounted investee, the Group’s carrying amount is reduced to nil and recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or has made payments on behalf of an investee. Reclassifications During the first quarter of 2022, following the expansion of the Group’s VBC (Value-Based Care) product and service offerings, management reviewed the presentation of the Consolidated Statement of Profit and Loss and considered whether expanded presentation may provide more relevant information to stakeholders. Upon further review, the Group has expanded the presentation of costs historically presented within Cost of care delivery to discretely present Claims expense, which primarily includes external costs of patient care, and Clinical care delivery expense, which primarily includes internal costs of patient care. With the exception of the expanded presentation of Clinical care delivery expense and Claims expense in the Condensed Consolidated Statement of Profit and Loss, these elective changes had no impact on the Group’s Loss for the period or to the Condensed Consolidated Financial Statements as of and for the period ended March 31, 2022 and 2021.	2. Basis of Preparation These financial statements consolidate those of the Company and its subsidiaries (together referred to as the “Group”). The Group financial statements have been prepared on the historical cost basis and approved by the Directors in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. These Consolidated Financial Statements were authorized for issue on March 30, 2022 . The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these Group financial statements. Judgements made by the directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year, are discussed in Note 3. Going Concern At December 31, 2021, the Group incurred a loss for the year of $374.5 million (2020: loss of $188.0 million, 2019: loss of $140.3 million), which includes a Recapitalization transaction expense of $148.7 million, and operating cash outflows of $145.9 million (2020: $143.4 million, 2019: $143.6 million). As of December 31, 2021 the Group had a net asset position of $165.3 million (2020: $48.4 million). At December 31, 2021, the Group had cash and cash equivalents of $262.6 million (2020: $101.8 million). The Group has financed its operations principally through issuances of debt and equity securities and has a strong record of fundraising, including the closing of the Merger and PIPE Transaction (as defined below) on October 21, 2021 receiving proceeds of $229.3 million (Note 5) and entering into a note subscription agreement for $200.0 million on October 8, 2021 (Note 26). The Group requires significant cash resources to, among other things, fund working capital requirements, increase headcount, make capital expenditures, including those related to product development, and expand our business through acquisitions. The directors have prepared cash flow forecasts for a period of twelve months from the date of approval of these financial statements which indicate that when combined with additional borrowings we expect to receive at the end of March 2022 (Note 26), we have sufficient liquidity to fund our liabilities as they become due for the next twelve months if we continue with our planned growth strategy. While there is no assurance that additional funds are available on acceptable terms, the directors believe that they will be successful in raising the additional capital needed to execute our planned growth strategy and to meet working capital and capital expenditure requirements that may fall due after March 2023. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. However, the above indicates that there are material uncertainties (ability to fund raise further capital) related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, to continue realizing its assets and discharging its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. Funding Requirements As of December 31, 2021, we had a net asset position of $165.3 million (2020: $48.4 million), including cash and cash equivalents of $262.6 million (2020: $101.8 million). Our directors performed a going concern assessment for a period of twelve months from the date of approval of these financial statements to assess whether conditions exist that raise substantial doubt regarding the Company’s ability to continue as a going concern. This assessment, when combined with additional borrowings we expect to receive at the end of March 2022 (Note 26), indicates we have sufficient liquidity to fund our liabilities as they become due for the next twelve months, but that additional funding is required to provide sufficient funds to meet our liabilities that may fall due beyond March 2023 if we continue with our planned growth strategy. We believe that we will be successful in raising the additional capital we need to execute our planned growth strategy and to meet our working capital and capital expenditure requirements that may arise after March 2023. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. Basis of Consolidation Subsidiaries Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. To determine whether the Group controls an entity, status of voting or similar rights, contractual arrangements and other specific factors are considered. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date on which that control ceases. Prior to December 31, 2021, the Group held certain rights in the form of purchase options to acquire additional equity interests in entities that it had an existing shareholding in. These rights are assessed as either substantive or protective in nature to conclude whether the Group exercises control over the entity. This assessment requires judgement relating to both the barriers that may prevent, and the extent to which the Group would benefit from, exercise of those rights and determines whether the Group should consolidate the entity. In addition, the Company consolidates certain professional service corporations (“PCs”) that are owned, directly or indirectly, and operated by appropriately licensed physicians. The Company maintains control of these PCs through contractual arrangements, which can include service agreements, financing agreements, equity transfer restriction agreements, and employment agreements, or a combination thereof, which are primarily established during the formation of the PCs. At inception, the contractual framework established between the Group and the PCs provides the Group with the power to direct the relevant activities in the conduct of the PC’s non-clinical administrative and other non-clinical business activities. The physicians employed by the PC are exclusively in control of, and responsible for, all aspects of the practice of medicine for their patients. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and a substantive process and whether the acquired set has the ability to produce outputs. Intercompany transactions, balances and unrealized gains on transactions between the Group’s companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the Consolidated Statement of Profit and Loss and Other Comprehensive Loss, Consolidated Statement of Financial Position and Consolidated Statement of Changes in Equity. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Associates Associates are those entities in which the Group has significant influence, but not control, over the financial and operating policies. Associates are accounted for using the equity method and are initially recognized at cost. The Consolidated Financial Statements include the Group’s share of the total comprehensive income and equity movements of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. When the Group’s share of losses exceeds its interest in an equity accounted investee, the Group’s carrying amount is reduced to nil and recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or has made payments on behalf of an investee. Reclassifications During the fourth quarter of 2021, the Group identified and corrected the classification of certain costs related to the below departments during the year ended December 31, 2020. The reclassifications resulted in the following impact on the Consolidated Statement of Profit and Loss: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ As previously ​ ​ ​ ​ ​ ​ reported ​ Adjustment ​ As reported ​ ​ $’000 ​ $’000 ​ $’000 Platform & application expenses ​ (48,664) ​ 10,527 ​ (38,137) Research & development expenses (35,524) (19,187) (54,711) Sales, general & administrative expenses (103,341) 8,660 (94,681) Operating loss (175,511) — (175,511) Loss for the financial year (188,030) — (188,030) ​ The reclassifications also had an immaterial impact on the Consolidated Statement of Profit and Loss for the year ended December 31, 2019, which is not shown in the table above. The Group has evaluated the effect of the reclassifications, both quantitatively and qualitatively, and concluded that the correction did not have a material impact on, nor require amendment of, any previously filed financial statements.

Summary of Significant Accounti

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies With the exception of the extension to our accounting policies described below, the accounting policies applied in these Condensed Consolidated Financial Statements are the same as those applied in the Group’s consolidated financial statements as of and for the year ended December 31, 2021. Clinical Care Delivery Expense Clinical care delivery expense includes the internal costs that we incur in the provision of healthcare services to patients, which is substantially composed of employee-related expenses such as salaries and wages for Babylon healthcare professionals. Other costs within Clinical care delivery expense include operating costs incurred for the delivery of healthcare services to patients, such as occupancy, medical supplies, and other support-related costs. Claims Expense Claims expense includes the costs of healthcare services rendered by third parties on behalf of patients which the Company is contractually obligated to pay, which includes estimates for medical expenses incurred but not yet paid (“IBNP”) using actuarial processes that are applied on a systematic and consistent basis. This process includes the development of estimates using historical claims experience and actuarial models when sufficient claims history is available from health plans and payors. Claims expense also includes other external costs incurred in the delivery of healthcare services including insurance.	4. Summary of Significant Accounting Policies The consolidated Group financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in United States Dollar (“USD”) which is the Group’s presentation currency. All values are rounded to the nearest thousands, except where otherwise indicated. The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. Revenue Recognition Revenue is primarily derived from the following sources: (1) capitation revenue from value-based care services, (2) software license fees for the provision of AI services, and (3) patient revenues from the provision of clinical services. Revenue is recognized upon transfer of control of services to customers in an amount that reflects the consideration which the Group expects to receive in exchange for those services. Contract assets are recognized when there is an excess of revenue earned over billings on contracts where the rights are conditional on something other than passage of time. Contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. Income received in advance (“contract liability”) is recognized when there are billings in excess of revenues earned for services rendered. The Group’s contracts with customers could include promises to transfer multiple services to a customer. The Group assesses the services promised in a contract and identifies distinct or bundled performance obligations in the contract. Identification of these performance obligations involves judgement to determine the promises and the ability of the customer to benefit independently from such promises. If multiple performance obligations are identified in the contract the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. Transaction prices are adjusted for the effects of a significant financing component if we expect, at contract inception, that the period between the transfer of the promised goods or services to the customer and when the customer pays for that service will be more than one year. The Group exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time. The Group considers indicators such as how a customer consumes benefits as services are rendered, existence of enforceable rights to payment for performance to date, transfer of significant risks and rewards to the customer and acceptance of delivery of the service by the customer. Value-based Care Revenue Value-based care (“VBC”) revenue consists primarily of per member per month (“PMPM”) allocations for care management services by the Group under arrangements with various customers. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of VBC services to attributed members. PMPM fees are based upon fixed rates per member or a percentage of the per member premium of the health plan and are not dependent upon the volume of specific care services provided. In addition, the arrangements usually include payments dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. Unlike clinical services revenue discussed below, the Group accepts partial or full financial risk (either global or professional) for members attributed to our VBC services in exchange for a fixed monthly allocation, which means we are responsible for the cost of all covered services provided to members. In general, the Group considers all VBC revenue contracts as containing a single performance obligation to stand ready to provide managed VBC services to the attributed members. This performance obligation is satisfied over time as the Group stands ready to fulfill its obligation to the attributed members as a group. Accordingly, the Group recognizes revenue in the month in which attributed members are entitled to receive VBC services during the contract term. Part of the consideration received under VBC revenue contracts is variable as the contracts contain provisions dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. VBC revenue is estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is highly probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Such uncertainties may only be resolved several months after the end of the reporting period because of the availability of sufficient reliable data relating to factors such as quality metrics, member specific attributes and healthcare service costs. Subsequent changes in VBC revenue and the amount of PMPM revenue to be recognized by the Company are reflected in subsequent periods. VBC revenue is recognized gross when it is assessed that the performance obligation relates to the whole of the patient journey with the Group responsible for arranging, providing and controlling the VBC services provided to the attributed members, with expenses payable to other healthcare providers. Software Licensing Revenue Under IFRS 15, Revenue from Contracts with Customers In some cases, we have concluded that upfront payments included in software license contracts with customers have a significant financing component considering the period between the upfront payment and the services provided, when the contract term is more than one year. As a result, the transaction price must be adjusted to account for the time value of money by using an appropriate discount rate. The discount rate utilized is determined based on the rate that would be reflected in a separate financing transaction with the customer. When a significant financing component exists, we recognize a contract liability for the entire upfront cash payment received, excluding the amount relating to the financing component from the transaction price. Additionally, interest expense is recognized over the duration of the contract under the amortized interest method. Clinical Service Revenue Clinical service revenue represents clinical services provided to our business and private patients under an arrangement and is recognized when the services are rendered. Our clinical service fees are based on PMPM subscription fees and fees per appointment (“fee-for-service”). PMPM subscription fees give members access to our clinical services over the contractual period as set forth in the arrangement, recognized monthly based on the number of members covered by the plan in a given month. Fee-for-service is based on contracted rates determined in agreed-upon compensation schedules and is recognized when the services are rendered at a point in time. In arrangements where PMPM subscription fees are charged we assess whether any of the transaction price should be allocated to software licensing revenue and allocate on a contract by contract basis. Cost of Care Delivery Cost of care delivery primarily consists of claims costs from physicians and other health professionals in our provider network and costs incurred in connection with our provider network operations, including rent, insurance and other direct costs incurred in the delivery of patient care. Cost of care delivery is mainly driven by patient activity and required medical services that are relatively variable. Costs incurred relating to the delivery of VBC services is recognized as an expense within cost of care delivery over time as the expense is incurred. Grant Income We recognize income related to grants on a systematic and rational basis when it becomes probable that we have complied with the terms and conditions of the grant and in the period in which the corresponding costs or income related to the grant are recognized. We receive grants in the form of cash contributions towards outreach projects and tax credits for certain qualifying research and development expenditures. These grants are recognized as non-current deferred grant income liability, released either over the period of the grant contract or over the same period that the related capitalized development costs are amortized. The offset to the release of the long term deferred grant income liability is recognized as revenue for outreach grants and a reduction in Platform & application expenses for tax credits. Platform & Application Expenses Platform & application expenses are costs of revenue for our digital healthcare platform. These costs primarily include employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in providing professional services related to support and maintenance of the digital healthcare platform. These costs also include third-party application costs, hosting services, and other direct costs. The amortization of capitalized development costs are also included in Platform & application expenses. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized if the product or process is technically and commercially feasible and if the Group has sufficient resources to complete the development. Capitalized development costs are recorded as intangible assets and amortized from the point at which the development is complete, and the asset is available for use. Costs are capitalized based on a model whereby a percentage is allocated to employee related expenses based on the time spent on the development of assets. Subsequent expenditure on capitalized intangible assets is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All employee expenses included in this balance relate to employees in the product and technology departments, and the percentage attributable varies dependent on the nature of the work performed and the type of asset being developed. Expenses that do not meet the criteria for capitalization are expensed as incurred within Platform & application expenses. The technical feasibility of a new product is determined by a management team consisting of product, technology, and finance leads based on understanding the availability of adequate technical, financial and other resources required to develop the product. The commercial feasibility of a new product is determined by understanding how this product feeds into Babylon’s current offering. Commercial leads ascertain market interest by evaluating against existing and potential customer requirements. Feasibility is challenged with input from finance leads to verify the underlying financial implications of development and assess viability. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. As described in Note 3, development costs of $34.0 million (2020: $43.0 million) were capitalized during the year for those development and technology expenses that were deemed technologically feasible and probable of generating future economic benefits. During the period of development, the asset is tested for impairment at least annually. Research & Development Expenses Research & development expenses primarily included employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in performing activities to develop and improve the Group’s digital healthcare platform. These costs also include third-party application costs, hosting services, and other indirect costs. Research costs and development costs that do not meet the criteria for capitalization are expensed as incurred within Research & development expenses. Sales, General & Administrative Expenses Sales, general & administrative expenses include employee-related expenses, contractors and consultants expense, stock-based compensation, property and facility related expenses, IT and hosting, marketing, training and recruiting expenses. Enterprise IT and hosting costs are primarily software subscriptions, domain and hosting costs. Our Sales, general & administrative expenses also include depreciation of property, fixtures and fittings and amortization of acquired intangible assets. Claim Expenses and Claims Payable Claims expense, presented within Cost of care delivery, and Claims payable includes costs for third party healthcare service providers who provide medical care to our members for which the Group is contractually obligated for financial risks relating to the medical services provided. The estimated reserve for IBNP claims is included in the liability for unpaid claims in the Consolidated Statement of Financial Position. Actual claims expense will differ from the estimated liability due to factors in estimated and actual member utilization of health care services, the amount of charges and other factors. We determine our estimates through a variety of actuarial models based on medical claims history to ensure our estimates represent the best, most reasonable estimate given the data available to us at the time the estimates are made. Taxation Tax on the Consolidated Statement of Profit and Loss for the year comprises current and deferred tax. Tax is recognized in the Consolidated Statement of Profit and Loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the reporting date. Expenditures incurred for R&D activities have been claimed and will be reimbursed through the U.K. research and development expenditure credit scheme (the “RDEC Scheme”). Under the RDEC Scheme tax relief is given at 12.0% (up to April 1, 2020) and 13.0% (after April 1, 2020) of allowable R&D costs, which may result in a payable tax credit at an effective rate of 7.8% of qualifying expenditure for the year ended December 31, 2021. The Group recognizes the gross amount as Deferred grant income on the Consolidated Statement of Financial Position and as a reduction to Platform & application expenses over the period of expected benefit from the expenditure. The related tax charge on the credit is recognized in the year of the tax credit. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares of the Group outstanding during the period. Diluted net loss per share is computed by giving effect to all potential ordinary shares, including outstanding stock options, warrants and convertible notes, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential ordinary shares outstanding would have been anti-dilutive. We have included shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares), including options and warrants, within the computation of basic net loss per share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Comprehensive Loss Comprehensive loss consists of cumulative translation gains or losses. Unrealized gains or losses are net of any reclassification adjustments for realized gains and losses included in the Consolidated Statement of Profit and Loss. Segment Reporting IFRS 8, Operating Segments Segment information is presented based on information used by the CODM in its decision-making processes. The CODM is responsible for the Group’s key strategic and business decisions and driving the direction and growth of the Group. These include but are not limited to international growth, new services, material business agreements and corporate and management structures. The CODM’s key decisions are based on the monthly management accounts in which segment information is presented on the basis of geographic areas. Each segment derives its revenues from software license fees for the provision of AI services, patient revenues from the provision of clinical services and VBC services provided by the segment which may differ from the geographic location of the customer. Earnings before depreciation, amortization, net finance income (costs), and income taxes (“EBITDA”) is used to measure performance of each segment because the Group believes that this information is most relevant in evaluating the results of the respective segments. The accounting policies for segment information, including transactions entered between segments are generally the same as those described in the summary of significant accounting policies. The CODM is not provided with total assets and liabilities by segment, and therefore the disclosures below do not include these measures. Segment information is reported from a geographic presence perspective. The Group’s results are provided to CODM disaggregated by geographic region, including the United Kingdom (“UK”), the United States of America (“US”), Canada (until the disposal of our Canadian subsidiary), Rwanda, and Singapore. The Group assessed the geographical segments within the aggregation guidance provided in IFRS 8 and determined that the UK and U.S. segments each exceed the quantitative thresholds and represent individual reportable segments. The remaining geographical regions individually and in aggregate do not exceed the quantitative thresholds for reportable segments. Therefore, the UK and the U.S. segments are the Group’s reportable segments for the purposes of these Consolidated Financial Statements. Business Combinations The acquisition consideration is measured at fair value which is the aggregate of the fair values of the assets transferred, the liabilities incurred or assumed and the equity interests in exchange for control. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration are recognized in the Consolidated Statement of Profit and Loss. The consideration transferred in a business combination shall be measured at fair value, which shall be calculated as the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree and the equity interests issued by the acquirer. The allocation process requires an analysis of acquired contracts, customer relationships, contractual commitments, and legal contingencies to identify and record the fair value of all assets acquired and liabilities assumed. In valuing acquired assets and assumed liabilities, fair values are based on, but are not limited to, future expected cash flows, current replacement cost for similar capacity for certain fixed assets, market rate assumptions for contractual obligations, and appropriate discount rates and growth rates. Where the consideration transferred, together with the non-controlling interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. Acquisition related costs are expensed as incurred and classified as Sales, general & administrative expenses in the Consolidated Statement of Profit and Loss. Goodwill is capitalized as a separate item in the case of subsidiaries. Goodwill is denominated in the currency of the operation acquired. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in the Consolidated Statement of Profit and Loss. When the Group increases its ownership interests held in one of its consolidated subsidiaries, any difference between the consideration given and the aggregate carrying value of the assets and liabilities of the acquired entity at the date of the transaction is included in equity in retained earnings. Property, Plant and Equipment Property, plant and equipment is stated at historical cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment losses. Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Consolidated Statement of Profit and Loss during the reporting period in which they are incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: ​ ​ ​ ​ – Computer equipment 3 years – Fixtures and fittings 3 – 5 years – Deployed machinery 4 years ​ At the end of each reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. When an asset is disposed of, the gain or loss is calculated by comparing proceeds received with its carrying amount and is recognized in the Consolidated Statement of Profit and Loss. Other Intangible Assets Intangible assets resulting from capitalized development costs in the normal course of business are recorded at historical cost. Intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in Sales, general & administrative expenses. The useful lives of the Group’s intangible assets are: ​ ​ ​ ​ – Development costs 1 – 10 years – Developed technology ​ 5 years – Customer relationships ​ 15 years – Trade names ​ 5 – 11 years – Physician network ​ 3 – 10 years – Licenses ​ 1 – 2 years ​ An intangible asset is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Consolidated Statement of Profit and Loss. Goodwill Goodwill is measured as described in “Business combinations” above. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortized and is reviewed for impairment at least annually as of October 1 or more frequently if triggering events occur or impairment indicators exist. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash generating units (“CGUs”), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Trade Receivables We use a forward-looking expected credit loss (“ECL”) model in determining our allowance for doubtful accounts as it relates to trade receivables, contract assets, and other financial assets. Our allowance is based on historical experience, and includes consideration of the aging of the receivables, the economic environment, industry trend analysis, and the credit history and financial conditions of the customers among other factors. We measure an impairment loss as the excess of the carrying amount over the present value of the estimated future cash flows discounted using the financial asset’s original discount rate, and we recognize this loss in our Consolidated Statement of Profit and Loss. A financial asset is written-off or written-down to its net realizable value as soon as it is known to be impaired. We adjust previous write-downs to reflect changes in estimates or actual experience. Our allowance for doubtful accounts is not material. Non-current Assets Held for Sale and Disposal Groups Non-current assets and disposal groups are classified as held for sale when: ● They are available for immediate sale, ● Management is committed to a plan to sell, ● It is unlikely that significant changes to the plan will be made or that the plan will be withdrawn, ● An active program to locate a buyer has been initiated, ● The asset or disposal group is being marketed at a reasonable price in relation to its fair value, and ● A sale is expected to complete within 12 months from the date of classification. Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount immediately prior to being classified as held for sale in accordance with the Group’s accounting policy; and fair value less costs of disposal. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Following their classification as held for sale, non-current assets (including those in a disposal group) are not depreciated. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized. Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. As of December 31, 2021, the Group had restricted cash of $0.3 million (2020: $0.0 million). Impairment of Non-financial Assets Excluding Deferred Tax Assets Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that carrying values may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal (market value) and value in use determined using estimates of discounted future net cash flows of the asset or group of assets to which it belongs. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). Employee Benefits Defined Contribution Plans Obligations for contributions to defined contribution pension plans are recognized as an expense in the Consolidated Statement of Profit and Loss in the periods during which services are rendered by employees. Short-term Benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. Share-based Payment Transactions The Group and the Company operates an equity compensation scheme. It issues equity settled share-based payments to both employees and non-employees within the Group, whereby services are rendered in exchange for rights to purchase shares of the Company, which are primarily composed of restricted stock awards and options. Non-employees include contractors and advisors. The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards, net of estimated forfeitures. The fair value of the options granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions (if applicable) are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Compensation expense associated with equity compensation awards is recognized on a straight-line basis over the requisite period. The forfeitures rate is estimated and revised at each reporting date based on historical actuals. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes. Valuation of Ordinary Shares As there has been no public market for the Group’s ordinary shares prior to October 21, 2021, the estimated fair value of the ordinary shares has been determined by the Board of Directors as of the date of each grant, with input from management, considering the most recently available third-party valuations of the Group’s ordinary shares, and the assessment of additional objective and subjective factors that they believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Foreign Currency Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

Adoption of New and Revised Int

Adoption of New and Revised International Financial Reporting Standards	3 Months Ended
	Mar. 31, 2022
Adoption of New and Revised International Financial Reporting Standards
Adoption of New and Revised International Financial Reporting Standards	4. Adoption of New and Revised International Financial Reporting Standards The following new and amended standards have been adopted by the Group in these Condensed Consolidated Financial Statements. Their adoption did not have a material effect on the financial statements. ● Amendments to References to the Conceptual Framework in IFRS 3: Business Combinations, Amendments to IAS 16: Property, Plant and Equipment—Proceeds before Intended Use, Annual Improvements to IFRS Standards 2018-2020, and Amendments to IAS 37: Onerous Contracts—Cost of Fulfilling a Contract (effective date January 1, 2022) The following new and amended standards have been issued but have not been applied by the Group in these Condensed Consolidated Financial Statements. Their adoption is not expected to have a material effect on the financial statements unless otherwise indicated. ● Amendments to IAS 1: Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and Classification of Liabilities as Current or Non-current, Amendments to Disclosure of Accounting Policies in IAS I: Presentation of Financial Statements and IFRS Practice Statement 2: Making Materiality Judgements , Amendments to Definition of Accounting Estimates in IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors , Amendments to Deferred Tax related to Assets and Liabilities arising from a Single Transaction in IAS 12: Income Taxes , and IFRS 17: Insurance Contracts (effective date January 1, 2023) ● Amendments to Sale or Contribution of Assets between an Investor and its Associate or Joint Venture in IFRS 10: Consolidated Financial Statements and IAS 28: Investments in Associates and Joint Ventures (effective date deferred indefinitely)

Revenue

Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Revenue	5. Revenue i) Disaggregation of Revenue ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Value-based care 246,575 27,259 Software licensing 7,756 35,964 Clinical services 12,115 8,070 ​ 266,446 71,293 ​ In January 2021, we entered into a License and Support Agreement (“License Agreement”) with TELUS. As part of the License Agreement, the Group received an upfront payment of $66.9 million in exchange for the right to use the Company’s digital healthcare platform (“Software Platform”), specified upgrades to be delivered over a 24-month period, post-contract support (“PCS”), and a right to access enhancements to the Group’s Software Platform over a period of seven years. We identified that the License Agreement included multiple performance obligations and allocated the transaction price to the separate performance obligations on a relative standalone basis. We determined the standalone selling prices based on our overall pricing objectives, taking into consideration market inputs and entity specific factors, including standalone selling prices when available. We also concluded that the upfront payment included a significant financing component. As a result, the transaction price was adjusted to account for the time value of money and interest expense will be recognized over the duration of the contract. ii) Contract Balances The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Trade receivables 7,068 8,278 Contract assets 5,557 4,484 Contract liabilities 86,426 94,182 ​ The contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. There was no impact on contract assets as a result of acquisition of subsidiaries. The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer. The Group’s customers generally pay for invoices in the month following the issuance date. iii) Transaction Price Allocated to the Remaining Performance Obligations The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ Remainder ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ of 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ $’000 $’000 $’000 $’000 $’000 $’000 As of March 31, 2022 ​ 22,663 ​ 18,366 ​ 18,959 ​ 15,539 ​ 10,899 ​ 86,426 ​ The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2022 ​ $’000 Balance on January 1, 94,182 Amounts billed but not recognized 849 Revenue recognized (6,091) Effect of movements in foreign exchange (2,514) Balance on March 31, 86,426 ​ No revenue was recognized from performance obligations satisfied (or partially satisfied) in previous periods.	8. Revenue i) Disaggregation of Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Value-based care ​ 220,852 ​ 26,038 ​ — Software licensing 60,052 24,603 2,002 Clinical services 42,017 28,631 14,032 ​ 322,921 79,272 16,034 ​ In January 2021, we entered into a License and Support Agreement (“License Agreement”) with TELUS. As part of the License Agreement, the Group received an upfront payment of $66.9 million in exchange for the right to use the Company’s digital healthcare platform (“Software Platform”), specified upgrades to be delivered over a 24 -month period, post-contract support (“PCS”), and a right to access enhancements to the Group’s Software Platform over a period of seven years . We identified that the License Agreement included multiple performance obligations and allocated the transaction price to the separate performance obligations on a relative standalone basis. We determined the standalone selling prices based on our overall pricing objectives, taking into consideration market inputs and entity specific factors, including standalone selling prices when available. We also concluded that the upfront payment included a significant financing component. As a result, the transaction price was adjusted to account for the time value of money and interest expense will be recognized over the duration of the contract. ii) Contract Balances The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 20) ​ 8,278 ​ 4,674 Contract assets (Note 20) 4,484 2,378 Contract liabilities (Note 8 iii) 94,182 76,018 ​ The contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. There was no impact on contract assets as a result of acquisition of subsidiaries. The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer. The Group’s customers generally pay for invoices in the month following the issuance date. iii) Transaction Price Allocated to the Remaining Performance Obligations The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 As of December 31, 2021 ​ 23,786 ​ 18,918 ​ 19,349 ​ 17,852 ​ 14,277 ​ 94,182 ​ The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance on January 1 ​ 76,018 ​ 81,584 Amounts billed but not recognized 61,176 18,080 Revenue recognized (43,012) (23,646) Balance on December 31 94,182 76,018 ​ No revenue was recognized from performance obligations satisfied (or partially satisfied) in previous periods.

Segment Information

Segment Information	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [abstract]
Segment Information	6. Segment Information Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Condensed Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue 15,670 250,512 335 266,517 (71) 266,446 Inter-segment revenue — — (64) (64) 64 — Segment revenue 15,670 250,512 271 266,453 (7) 266,446 Clinical care delivery expense (11,872) (12,394) (261) (24,527) 600 (23,927) Claims expense — (247,552) — (247,552) — (247,552) Other operating expenses, excluding amortization and depreciation (31,225) (34,176) (9,505) (74,906) (706) (75,612) Change in fair value of warrant liabilities — — 5,575 5,575 — 5,575 Exchange (loss) / gain (4,078) 2,353 (16,657) (18,382) 17,935 (447) Segment EBITDA (31,505) (41,257) (20,577) (93,339) 17,822 (75,517) Depreciation and amortization ​ (9,458) Change in fair value of warrant liabilities ​ (5,575) Exchange gain ​ 447 Operating loss ​ (90,103) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue 41,242 29,244 434 70,920 373 71,293 Inter-segment revenue — — 4 4 (4) — Segment revenue 41,242 29,244 438 70,924 369 71,293 Clinical care delivery expense (9,269) (4,597) (596) (14,462) 2,639 (11,823) Claims expense — (23,917) — (23,917) — (23,917) Other operating expenses, excluding amortization and depreciation (26,442) (11,316) (2,386) (40,144) (2,311) (42,455) Exchange (loss) / gain (632) (49) 1,788 1,107 (1,680) (573) Gain on sale — — 3,917 3,917 — 3,917 Share of loss of equity-accounted investees — (455) — (455) — (455) Segment EBITDA 4,899 (11,090) 3,161 (3,030) (983) (4,013) Depreciation and amortization ​ (5,848) Exchange loss ​ 573 Gain on sale of subsidiary ​ (3,917) Share of loss of equity-accounted investees ​ 455 Operating loss ​ (12,750) ​ Reconciliation adjustments include allocation and classification differences of costs between management accounts and statutory reporting, reversals of inter-segment revenue and foreign exchange variances. Major Customers Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $‘000 % of revenue $‘000 % of revenue Customer 1 145,043 54.4 % 12,420 17.4 % Customer 2 61,446 23.1 % — — ​ Customer 3 14,381 5.0 % 12,148 17.0 % Customer 4 ​ 2,530 ​ 1.0 % 30,129 ​ 42.3 % ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 UK 9,435 7,786 US 250,597 29,808 Asia-Pacific 3,634 3,410 Canada 2,530 30,129 Rest of World 250 160 Total 266,446 71,293 ​ As of March 31, 2022, 39.4% ($99.3 million) and 59.5% ($150.1 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. As of December 31, 2021, 38.3% ($92.6 million) and 61.1% ($147.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. As of March 31, 2022, 69.4 % ( $4.9 million) and 27.7% ( $2.0 million) of total Group trade receivables were attributable to the UK and US, respectively. As of December 31, 2021, 84.5 % ( $7.0 million) and 11.0% ($ 0.9 million) of total Group trade receivables were attributable to the UK and US, respectively.	9. Segment Information Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue ​ 88,967 ​ 232,296 ​ 1,610 ​ 322,873 ​ 48 ​ 322,921 Inter-segment revenue ​ 2,205 ​ (3,964) ​ 1,756 ​ (3) ​ 3 ​ 0 Segment revenue ​ 91,172 ​ 228,332 ​ 3,366 ​ 322,870 ​ 51 ​ 322,921 Cost of care delivery ​ (41,542) ​ (253,998) ​ (1,590) ​ (297,130) ​ 7,458 ​ (289,672) Other operating expenses, excluding amortization and depreciation ​ (114,975) ​ (105,602) ​ (171,951) ​ (392,528) ​ (8,226) ​ (400,754) Change in fair value of warrant liabilities ​ — ​ — ​ 27,811 ​ 27,811 ​ — ​ 27,811 Exchange (loss) / gain ​ (1,844) ​ 189 ​ 1,390 ​ (265) ​ 1,133 ​ 868 Gain on sale of subsidiary ​ — ​ — ​ 2,687 ​ 2,687 ​ 1,230 ​ 3,917 Gain on remeasurement of equity interest ​ — ​ — ​ 10,495 ​ 10,495 ​ — ​ 10,495 Share of loss of equity-accounted investees ​ — ​ (2,602) ​ — ​ (2,602) ​ — ​ (2,602) Segment EBITDA ​ (67,189) ​ (133,681) ​ (127,792) ​ (328,662) ​ 1,646 ​ (327,016) Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ (35,004) Change in fair value of warrant liabilities ​ ​ ​ ​ ​ ​ ​ (27,811) Exchange gain ​ ​ ​ ​ ​ ​ ​ (868) Gain on sale of subsidiary ​ ​ ​ ​ ​ ​ ​ (3,917) Gain on remeasurement of equity interest ​ ​ ​ ​ ​ ​ ​ (10,495) Share of loss of equity-accounted investees ​ ​ ​ ​ ​ ​ ​ 2,602 Operating loss ​ ​ ​ ​ ​ ​ ​ (402,509) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue ​ 44,000 ​ 32,226 ​ 2,968 ​ 79,194 ​ 78 ​ 79,272 Inter-segment revenue 1,194 (3,094) 1,766 (134) 134 0 Segment revenue 45,194 29,132 4,734 79,060 212 79,272 Cost of care delivery (34,600) (34,381) (7,205) (76,186) 8,932 (67,254) Other operating expenses, excluding amortization and depreciation (127,762) (27,190) (3,990) (158,942) (14,100) (173,042) Exchange (loss) / gain 403 (246) 17,060 17,217 (20,053) (2,836) Share of loss of equity-accounted investees — — (1,124) (1,124) — (1,124) Segment EBITDA (116,765) (32,685) 9,475 (139,975) (25,009) (164,984) Depreciation and amortization ​ (14,487) Exchange loss ​ 2,836 Share of loss of equity-accounted investees ​ 1,124 Operating loss ​ (175,511) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 External revenue ​ 14,633 ​ — ​ 1,410 ​ 16,043 ​ (9) ​ 16,034 Inter-segment revenue ​ 4,081 ​ (2,669) ​ (1,382) ​ 30 ​ (30) ​ — Segment revenue ​ 18,714 ​ (2,669) ​ 28 ​ 16,073 ​ (39) ​ 16,034 Cost of care delivery ​ (25,707) ​ (160) ​ (373) ​ (26,240) ​ 6,430 ​ (19,810) Other operating expenses, excluding amortization and depreciation ​ (119,895) ​ (23,273) ​ (5,340) ​ (148,508) ​ (8,040) ​ (156,548) Exchange (loss) / gain 314 (83) 16,584 16,815 260 17,075 Segment EBITDA (126,574) (26,185) 10,899 (141,860) (1,389) (143,249) Depreciation and amortization ​ (2,496) Exchange gain ​ (17,075) Operating loss ​ (162,820) ​ Reconciliation adjustments include allocation and classification differences of costs between management accounts and statutory reporting, reversals of inter-segment revenue and foreign exchange variances. Major Customers Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue Customer 1 ​ 119,785 ​ 37.1 % 11,918 ​ 15.0 % 2,215 ​ 13.8 % Customer 2 39,764 12.3 % 9,706 12.3 % 2,465 15.4 % Customer 3 38,705 12.0 % 9,505 12.0 % 5,607 34.9 % Customer 4 N/A N/A 14,937 18.9 % N/A N/A ​ ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 UK ​ 35,490 ​ 28,827 ​ 12,189 US 232,708 32,689 — Asia-Pacific 14,965 11,585 2,215 Canada 38,705 3,207 564 Rest of World 1,053 2,964 1,066 Total 322,921 79,272 16,034 ​ In 2021 38.3% ($92.6 million) and 61.1% ($147.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. In 2020 64.8% ($70.9 million) and 34.5% ($37.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. In 2021 84.5% ($7.0 million) and 11.0% ($0.9 million) of total Group trade receivables were attributable to the UK and US, respectively. In 2020 47.6% ($2.2 million) and 50.1% ($2.3 million) of total Group trade receivables were attributable to the UK and US, respectively.

Investments in Subsidiaries and

Investments in Subsidiaries and Associates	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments in Subsidiaries and Associates
Investments in Subsidiaries and Associates	7. Investments in Subsidiaries and Associates As discussed in Note 2, we consolidated certain PCs which are owned, directly or indirectly, and operated by licensed physicians. The following provides summary financial data for the PCs that are included in the Condensed Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Total assets 131,429 104,703 Total liabilities 213,222 168,240 ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Total revenues 127,138 19,756 Clinical care delivery expense (8,912) (2,256) Claims expense (118,985) (15,793) Sales, general & administrative expenses (15,012) (2,875) ​	19. Investments in Subsidiaries and Associates The Group and Company have the following investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Ownership Ownership ​ ​ ​ ​ ​ ​ (As of ​ (As of ​ ​ Country of ​ ​ ​ December 31, ​ December 31, Subsidiary Undertakings ​ Incorporation ​ Principal Activity ​ 2021) ​ 2020) Company: ​ ​ ​ ​ ​ ​ ​ ​ Babylon Partners Limited UK Application development 100.0% ​ 100.0% Babylon Healthcare Services Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Rwanda Limited Rwanda Digital Healthcare services 100.0% ​ 100.0% Babylon Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Health Canada Limited Canada Digital Healthcare services — ​ 100.0% Babylon Liberty Corp. USA Digital Healthcare services 100.0% ​ — Babylon Malaysia SDN BHD Malaysia Digital Healthcare services 100.0% ​ 100.0% Babylon International Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Health Ireland Limited Ireland Digital Healthcare services 100.0% ​ 100.0% Babylon Singapore PTE Limited Singapore Digital Healthcare services 100.0% ​ 100.0% Health Innovators Inc. USA Digital Healthcare services 100.0% ​ 70.1% Babylon Acquisition Corp. USA Digital Healthcare services — ​ 100.0% Babylon Technology LTDA Brazil Digital Healthcare services 100.0% ​ 100.0% Higi SH Holdings Inc. USA Digital Healthcare services 100.0% ​ 19.0% Group: ​ ​ ​ ​ Babylon Healthcare Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Healthcare NJ, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PLLC USA Healthcare services 100.0% ​ 100.0% Babylon Medical Group (formerly Marcus Zachary DO), PC USA Healthcare services 100.0% ​ 100.0% California Telemedicine Associates, PC USA Healthcare services 100.0% ​ 100.0% Telemedicine Associates, P.C. USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare NC, PC USA Healthcare services — ​ 100.0% Babylon Healthcare, PA USA Healthcare services 100.0% ​ — Meritage Medical Network USA Healthcare services 100.0% ​ — Meritage Health Ventures, LLC USA Healthcare services 100.0% ​ — Meritage Health Plan USA Healthcare services 100.0% ​ — Meritage Management, LLC USA Healthcare services 100.0% ​ — Higi SH LLC USA Digital Healthcare services 100.0% ​ 19.0% Higi Health Holdings LLC USA Digital Healthcare services 100.0% ​ — Higi SH Canada ULC Canada Digital Healthcare services 100.0% ​ 19.0% Higi Health LLC USA Digital Healthcare services 51.0% ​ — Health Innovators Limited UK Digital Healthcare services 100.0% ​ 70.1% DTDHI Health India PVT Ltd India Digital Healthcare services 97.8% ​ 68.6% ​ Babylon Acquisition Corp. merged with Higi SH on December 31, 2021, with Higi SH Holdings Inc. being the surviving entity. Professional service corporations As discussed in Note 2, we consolidated certain PCs which are owned, directly or indirectly, and operated by licensed physicians. The following provides summary financial data for the PCs that are included in the Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total assets 104,703 35,535 Total liabilities 168,240 42,699 ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total revenues 154,508 17,436 Cost of care delivery (155,191) (20,175) Sales, general & administrative expenses (55,006) (3,799) ​

Intangible Assets and Goodwill

Intangible Assets and Goodwill	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Intangible Assets and Goodwill	8. Intangible Assets and Goodwill The changes in the carrying amount of goodwill and intangible assets for the three months ended March 31, 2022 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ $’000 $’000 $’000 $’000 $’000 $’000 $’000 $’000 Cost Balance at January 1, 2022 93,678 109,356 21,868 14,700 8,300 5,000 590 159,814 Additions — — 10,071 — — — — 10,071 Transfers — 6,803 (6,803) — — — — — Effect of movements in foreign exchange (23) (2,759) (530) — — — — (3,289) Balance at March 31, 2022 93,655 113,400 24,606 14,700 8,300 5,000 590 166,596 Amortization and impairment Balance at January 1, 2022 — 39,724 — 3,680 3,533 1,063 393 48,393 Amortization for the period — 5,064 — 193 750 329 131 6,467 Effect of movements in foreign exchange — (1,094) — — — — — (1,094) Balance at March 31, 2022 — 43,694 — 3,873 4,283 1,392 524 53,766 Net book value At January 1, 2022 93,678 69,632 21,868 11,020 4,767 3,937 197 111,421 At March 31, 2022 93,655 69,706 24,606 10,827 4,017 3,608 66 112,830 ​ All development costs, including intangibles under development, have been internally generated by the Group. During the three months ended March 31, 2022, $6.8 million of intangibles under development were transferred to development costs as these projects were completed. Intangibles under development are tested for impairment at least annually. The total net book value is considered to be the recoverable amount, as this balance is reviewed annually and impaired as necessary. All development costs are related to the development of our digital healthcare platform and there are no distinguishable individually material intangible assets within the capitalized development costs. There was no impairment of the development costs in the three months ended March 31, 2022 or 2021.	18. Intangible Assets and Goodwill The changes in the carrying amount of goodwill and intangible assets for the years ended December 31, 2021 and 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ 61 ​ 15,558 ​ 28,873 ​ — ​ — ​ — ​ — ​ 44,431 Acquisitions through business combinations ​ 17,771 ​ — ​ — ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 7,900 Additions ​ — ​ 940 ​ 43,027 ​ — ​ — ​ — ​ — ​ 43,967 Transfers ​ — ​ 51,932 ​ (51,932) ​ — ​ — ​ — ​ — ​ — Effect of movements in foreign exchange ​ — ​ 632 ​ 1,170 ​ — ​ — ​ — ​ — ​ 1,802 Balance at December 31, 2020 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Balance at January 1, 2021 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Acquisitions through business combinations ​ 75,846 ​ 8,550 ​ — ​ 11,600 ​ 5,000 ​ 3,500 ​ 590 ​ 29,240 Additions ​ — ​ — ​ 33,999 ​ — ​ — ​ — ​ — ​ 33,999 Transfers ​ — ​ 33,056 ​ (33,056) ​ ​ ​ ​ — ​ — Effect of movements in foreign exchange ​ — ​ (1,312) ​ (213) ​ — ​ — ​ — ​ — ​ (1,525) Balance at December 31, 2021 ​ 93,678 ​ 109,356 ​ 21,868 ​ 14,700 ​ 8,300 ​ 5,000 ​ 590 ​ 159,814 Amortization and impairment ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ — ​ 680 ​ — ​ — ​ — ​ — ​ — ​ 680 Amortization for the year ​ — ​ 10,157 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 11,123 Impairment charge ​ — ​ 6,436 ​ — ​ — ​ — ​ — ​ — ​ 6,436 Effect of movements in foreign exchange ​ — ​ 1,008 ​ — ​ — ​ — ​ — ​ — ​ 1,008 Balance at December 31, 2020 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Balance at January 1, 2021 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Amortization for the year ​ — ​ 21,287 ​ — ​ 2,835 ​ 3,450 ​ 1,025 ​ 393 ​ 28,990 Impairment charge ​ — ​ 941 ​ — ​ — ​ — ​ — ​ — ​ 941 Effect of movements in foreign exchange ​ — ​ (785) ​ — ​ — ​ — ​ — ​ — ​ (785) Balance at December 31, 2021 ​ — ​ 39,724 ​ — ​ 3,680 ​ 3,533 ​ 1,063 ​ 393 ​ 48,393 Net book value ​ ​ ​ ​ ​ ​ ​ ​ At January 1, 2020 ​ 61 ​ 14,878 ​ 28,873 ​ — ​ — ​ — ​ — ​ 43,751 At December 31, 2020 and January 1, 2021 ​ 17,832 ​ 50,781 ​ 21,138 ​ 2,255 ​ 3,217 ​ 1,462 ​ — ​ 78,853 At December 31, 2021 ​ 93,678 ​ 69,632 ​ 21,868 ​ 11,020 ​ 4,767 ​ 3,937 ​ 197 ​ 111,421 ​ Goodwill of $75.8 million (2020: $17.8 million) has been acquired through business combinations (Note 6). All development costs, including intangibles under development, have been internally generated by the Group. During 2021, $33.1 million (2020: $51.9 million) of intangibles under development were transferred to development costs as these projects were completed. Intangibles under development are tested for impairment at least annually. The total net book value is considered to be the recoverable amount, as this balance is reviewed annually and impaired as necessary (Note 4). All development costs are related to software and artificial intelligence development and there are no distinguishable individually material intangible assets within the capitalized development costs. Following an assessment of the future development of our technology, capitalized development costs were impaired by $0.9 million (2020: $6.4 million). The impairment recognized in 2020 was primarily the result of the discontinuation of certain features surrounding a proprietary data structure for encounters on our software platform that were deemed to be no longer technologically feasible. Impairment Analysis for CGUs Containing Goodwill and Intangibles Goodwill and other intangibles are subject to impairment testing on an annual basis or whenever events or circumstances indicate that the carrying amount of goodwill may no longer be recoverable. As of October 1, 2021, the date of the Goodwill impairment testing, all of the Goodwill of the Group was allocated to the California IPA CGU. The fair value of the California Independent Physicians Association CGU (“California IPA CGU”, formerly “Fresno CGU”) was determined using a discounted cash flow model, a form of the income approach. The recoverable amount of the California IPA CGU that included these intangible assets was estimated based on the present value of the future cash flows expected to be derived from the California IPA CGU (value in use), using a discount rate of 14.5% and a terminal value growth rate of 3.0% from 2027. The recoverable amount of the California IPA CGU was estimated to be higher than its carrying amount, and as a result there was no impairment related to the California IPA CGU in 2021. The below are factors considered when performing the 2021 sensitivity analysis: Terminal value growth rate Discount factor No reasonably possible change to the key assumptions would lead to an impairment of goodwill

Claims Payable

Claims Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Claims Payable
Claims Payable	9. Claims Payable The following table is a summary of claims activity for the period presented: ​ ​ ​ ​ ​ $’000 Balance at January 1, 2022 24,628 Claims expense 247,552 Claims paid (233,015) Adjustment, net — Balance at March 31, 2022 39,165 ​ The increase in claims expense during the three months ended March 31, 2022 is primarily attributable to the expansion of our value-based care offerings in the United States.	23. Claims Payable The following table is a summary of claims activity for the periods presented: ​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Claims expense 24,146 Claims paid (21,137) Adjustment, net 881 Balance at December 31, 2020 3,890 Balance at January 1, 2021 3,890 Claims expense 216,791 Claims paid (196,053) Adjustment, net — Balance at December 31, 2021 24,628 ​

Cash and Cash Equivalents

Cash and Cash Equivalents	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents
Cash and Cash Equivalents	10. Cash and Cash Equivalents The components of cash and cash equivalents are reflected in the table below: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Cash in hand and at banks 274,978 262,276 Short term investment funds — — Restricted cash — 305 ​ 274,978 262,581 ​ The Group’s short term investment funds are highly liquid, redeemable within 90 days at a known amount of cash and are subject to an insignificant risk of change in value and therefore meet the definition of a cash equivalent.	24. Cash and Cash Equivalents The components of cash and cash equivalents are reflected in the table below: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Cash in hand and at banks 262,276 97,757 Short term investment funds — 4,000 Restricted cash 305 — ​ 262,581 101,757 ​ The Group’s short term investment funds are highly liquid, redeemable within 90 days at a known amount of cash and are subject to an insignificant risk of change in value and therefore meet the definition of a cash equivalent.

Leases

Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Leases	11. Leases On November 1, 2021, Babylon Inc. entered into a sublease agreement for 37,883 rentable square feet of office space in Austin, Texas. The lease commenced on February 1, 2022 when we obtained access to the property and will automatically terminate on March 31, 2029. Minimum payments for the non-cancellable lease term are $16.6 million. The Company uses the office space as its United States headquarters with capacity for approximately 200 employees. In January 2022, Babylon Healthcare Services Limited entered into two lease agreements for clinic space in London, United Kingdom. The leases commenced on January 6, 2022 and January 14, 2022 when we obtained access to the properties and will automatically terminate on January 6, 2032 and July 13, 2032, respectively. Minimum payments for the lease terms are $6.3 million and $7.0 million, respectively. The Company intends to use the properties as clinics as part of the Company’s operations.	25. Leases The Group leases several assets which consist of buildings and IT equipment. The Group recognizes right-of-use assets and lease liabilities for its building leases only, as the leases for IT equipment meet the exemption requirements as short-term leases and leases of low-value assets. Therefore, the disclosures below for the Group’s right-of-use assets relate only to buildings. ​ ​ ​ ​ Right-of-use asset $’000 Cost Balance at January 1, 2020 6,501 Additions to right-of-use-assets 2,300 Reclassification to assets held for sale (872) Effect of change in foreign currency 228 Balance at December 31, 2020 8,157 Balance at January 1, 2021 8,157 Additions to right-of-use-assets 11,399 Disposals (4,291) Effect of change in foreign currency (166) Balance at December 31, 2021 15,099 Amortization Balance at January 1, 2020 1,272 Amortization charge for the year 2,430 Reclassification to assets held for sale (243) Effect of change in foreign currency 184 Balance at December 31, 2020 3,643 Balance at January 1, 2021 3,643 Amortization charge for the year 3,929 Disposals (4,291) Effect of change in foreign currency (25) Balance at December 31, 2021 3,256 Net book value Balance at January 1, 2020 5,229 Balance at December 31, 2020 and January 1, 2021 4,514 Balance at December 31, 2021 11,843 ​ ​ ​ ​ Lease liability $’000 Balance at January 1, 2020 3,583 Additions to lease liabilities 2,362 Interest expense on lease liabilities (i) 572 Payments on leases (1,541) Reclassification to liabilities associated with the assets held for sale (607) Effect of change in foreign currency 130 Balance at December 31, 2020 4,499 Balance at January 1, 2021 4,499 Additions to lease liabilities 11,826 Interest expense on lease liabilities (i) 617 Payments on leases (4,156) Reclassification to liabilities associated with the assets held for sale — Effect of change in foreign currency (154) Balance at December 31, 2021 12,632 (i) Interest paid on lease liabilities are presented within cash flows from financing activities. In March 2020, the Group renewed its head office lease to December 2022 with intention to hand in notice and vacate in 2021. As such, a lease modification was applied in 2020 as per IFRS 16 to extend the lease to the intended exit date. The Group entered into a new lease agreement for four floors of a building facility as the head office in London. The commencement date of the lease was in June 2021, with the initial term of the lease being 39 months. The lease provides for an annual rent of $4.9 million after a twelve-month rent-free period following the lease commencement date. When measuring the lease liabilities, the Group discounted lease payments using its incremental borrowing rate. The weighted-average rate applied is 12.0%. The following amounts have been recognized in the Consolidated Statement of Profit and Loss for which the Group is a lessee: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Depreciation expense on right-of-use assets 3,929 2,430 1,272 Interest expense on lease liabilities 617 572 265 Expenses relating to short term leases 2,489 4,756 6,127 Profit and loss impact 7,035 7,758 7,664 ​ The following table provides the undiscounted maturities of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Less than one year 4,595 2,348 One to two years 5,612 684 Two to three years 4,290 598 Three to four years 362 572 Four to five years 371 375 More than five years 705 1,282 Total 15,935 5,859 ​

Loans and Borrowings

Loans and Borrowings	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Borrowing costs [abstract]
Loans and Borrowings	12. Loans and Borrowings ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185 ​ AlbaCore Original Notes On October 8, 2021, Babylon entered into a note Subscription Agreement (the “Note Subscription Agreement”). The Note Subscription Agreement provided for the issuance of up to $200.0 million in unsecured notes due 2026 (the “Unsecured Notes”) to affiliates of, or funds managed or controlled by, AlbaCore Capital LLP (the “Note Subscribers”). On November 4, 2021 (“Note Closing Date”), Babylon issued the full $200.0 million (“Principal Amount”) of Unsecured Notes under the Note Subscription Agreement at a discount of 95.5% of the Principal Amount. The Unsecured Notes bear interest accruing on the Principal Amount (which for these purposes shall include any capitalized interest from time to time) at the following rates: (i) 8.00% per annum for the period commencing from (and including) the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date; (ii) 10.00% per annum for the period commencing from (and including) the date falling two years after the Note Closing Date, to (but excluding) the date falling three years after the Note Closing Date; and (iii) 12.00% per annum for the period commencing from (and including) the date falling three years after the Note Closing Date. The applicable interest rate is subject to a step-up margin of 6.5 basis points per annum if Babylon and its subsidiaries do not achieve a target of adding 100,000 Medicaid lives to value-based care contracts by January 1, 2024. Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. The Unsecured Notes will mature five years from the Note Closing Date on November 4, 2026 (the “Final Maturity Date”). Babylon is required to redeem the Unsecured Notes (unless previously purchased and cancelled or redeemed) on the Final Maturity Date at 100% of the principal amount on such date. Babylon may redeem the Unsecured Notes at any time at a redemption amount (the “Redemption Amount”) equal to: (i) from (and including) the Note Closing Date to (but excluding) the date falling one year after the Note Closing Date, the amount that is the greater of (A) 104.00% of the principal amount (including capitalized interest) and (B) 104.00% of the principal amount (including capitalized interest) plus an interest make whole premium; (ii) from (and including) the date falling one year after the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date, 104.00% of the principal amount (including any capitalized interest); and (iii) on or after the date falling two years after the Closing Date and until (but not including or after) the Final Maturity Date, 107.00% of the principal amount (including any capitalized interest). Each holder of Unsecured Notes (each a “Noteholder”) has the option to require Babylon to redeem the Unsecured Notes held by such Noteholder at the Redemption Amount upon specified change of control events. The terms of the Unsecured Notes include covenants, which covenants are subject to certain limitations and exceptions, limiting the ability of Babylon and its subsidiaries to, among other things: incur additional debt; pay or declare dividends or distributions on Babylon’s share capital; repay or distribute any share premium reserve or redeem, repurchase or retire its share capital; incur or allow to remain outstanding guarantees; make certain joint venture investments; enter into finance or capital lease contracts; create liens on Babylon’s or its subsidiaries’ assets; enter into sale and leaseback transactions; pay management and advisory fees outside the ordinary course of business; acquire a company or any shares or securities or a business or undertaking; merge or consolidate with another company; borrow or receive investments from certain shareholders other than through Babylon; and sell, lease, transfer or otherwise dispose of assets. The terms of the Unsecured Notes also include customary events of default. On the Note Closing Date, Babylon issued warrants to subscribe for an aggregate of 1,757,499 Class A ordinary shares (the “AlbaCore Warrants”) to the Note Subscribers on a pro rata basis by reference to the relevant proportion of the Principal Amount of Unsecured Notes subscribed for by each Note Subscriber. The AlbaCore Warrants confer the right to subscribe for up to 1,757,499 Class A ordinary shares exercisable on certain agreed upon exercise events, subject to: (i) Babylon’s right to elect to redeem the AlbaCore Warrants in whole or in part in cash upon an exercise event; (ii) an agreed adjustment formula to reduce the number of Class A Ordinary Shares to be issued upon exercise of the AlbaCore Warrants in certain circumstances linked to Babylon’s trading performance; and (iii) customary adjustments for certain share capital reorganizations (such as share splits and consolidations). The exercise events applicable to the AlbaCore Warrants occur: (i) on the first date following which the closing price of the Class A Ordinary Shares has equaled or exceeded $15.00 per Class A Ordinary Share (subject to customary adjustments) for any 20 trading days within any 30 -trading day period commencing at least 18 months after the Note Closing Date; (ii) where the Noteholders give a redemption notice under the notes deed poll on the occurrence of a change of control in respect of Babylon; (iii) where Babylon elects to redeem the Unsecured Notes prior to the Final Maturity Date in accordance with its rights to do so under the notes deed poll; and (iv) on the Final Maturity Date. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. We capitalized debt issuance costs of $3.4 million in connection with the issuance of the Unsecured Notes. Please refer to Note 15 for additional discussion surrounding the AlbaCore Warrants. AlbaCore Additional Notes and Warrants On December 23, 2021, Babylon entered into an additional note subscription agreement (the “Second Note Subscription Agreement”) providing for the issue of not less than $75 million and not more than $100 million additional Unsecured Notes (the “Additional Notes”) to AlbaCore Partners III Investment Holdings Designated Activity Company, and any new note subscribers that are affiliates of, or funds managed or controlled by, AlbaCore Capital LLP and that adhere to the Second Note Subscription Agreement (the “Second Note Subscribers”). The closing of the issue of the Additional Notes under the Second Note Subscription Agreement, for the principal amount of $100 million, occurred on March 31, 2022 (the “Second Closing Date”). The terms and conditions of the Additional Notes are the same as the terms of the original Unsecured Notes, with the exception that the Additional Notes were issued at 100% of their principal amount. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. On the Second Closing Date, Babylon issued AlbaCore Warrants to subscribe for an aggregate of 878,750 additional Class A ordinary shares (the “Additional AlbaCore Warrants”) to the Second Note Subscribers. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. The exercise events applicable to the Additional AlbaCore Warrants are the same as the AlbaCore Warrants. We capitalized debt issuance costs of $4.0 million in connection with the issuance of the Additional Notes. Upon any exercise event Babylon has a right to elect to satisfy the subscription entitlement in respect of the AlbaCore Warrants by issuing Class A ordinary shares, by making a redemption payment in cash, or by a combination of both (in such proportions as Babylon may in its absolute discretion determine). The cash redemption payment per Note Warrant shall be determined by reference to the closing price for the Class A ordinary shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event, provided that if the closing price is in excess of $15.00 per Class A ordinary share (subject to customary adjustments), the cash redemption payment shall be capped at $15.00 per Note Warrant. Where Babylon elects upon exercise of the AlbaCore Warrants to issue Class A ordinary shares in satisfaction in whole or in part of the subscription entitlement under the AlbaCore Warrants, Babylon is required to issue one Class A ordinary share credited as fully paid and free from all encumbrances (except as set out in Babylon’s memorandum and articles of association from time to time) per AlbaCore Warrant held, subject to a proportionate downwards adjustment to the number of Class A ordinary shares to be issued per AlbaCore Warrant where the closing price of the Class A ordinary shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event is in excess of $15.00 per Class A ordinary share. Changes in Loans and Borrowings from Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other Total Loans ​ ​ AlbaCore ​ Loans and ​ and ​ ​ Notes ​ Borrowings ​ Borrowings ​ $’000 $’000 $’000 Balance at January 1, 2022 ​ 168,601 ​ 185 ​ 168,786 Changes from financing cash flows ​ ​ ​ Proceeds from issuance of notes and warrants ​ 100,000 ​ — ​ 100,000 Payment of debt issuance costs ​ (4,000) ​ — ​ (4,000) Total changes from financing cash flows ​ 96,000 ​ — ​ 96,000 Other changes ​ ​ ​ Fair value of warrants issued ​ (3,418) ​ — ​ (3,418) Unpaid debt issuance costs ​ (257) ​ — ​ (257) Amortization of fair value adjustment, discount, and debt issuance costs ​ 1,202 ​ — ​ 1,202 Other loans and borrowings activity, net ​ — ​ (171) ​ (171) Total other changes ​ (2,473) ​ (171) ​ (2,644) Balance at March 31, 2022 ​ 262,128 ​ 14 ​ 262,142 ​	26. Loans and Borrowings ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Non-current liabilities Loan notes 200,000 — Unamortized fair value adjustment, discount, and debt issuance costs (31,399) — ​ 168,601 — Current liabilities Convertible loan notes — 70,000 Other 185 357 ​ 185 70,357 ​ Albacore Original Notes On October 8, 2021, Babylon entered into a note Subscription Agreement (the “Note Subscription Agreement”). The Note Subscription Agreement provided for the issuance of up to $200.0 million in unsecured notes due 2026 (the “Unsecured Notes”) to affiliates of, or funds managed or controlled by, AlbaCore Capital LLP (the “Note Subscribers”). On November 4, 2021 (“Note Closing Date”), Babylon issued the full $200.0 million (“Principal Amount”) of Unsecured Notes under the Note Subscription Agreement at a discount of 95.5% of the Principal Amount. The Unsecured Notes will bear interest accruing on the Principal Amount (which for these purposes shall include any capitalized interest from time to time) at the following rates: (i) 8.00% per annum for the period commencing from (and including) the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date; (ii) 10.00% per annum for the period commencing from (and including) the date falling two years after the Note Closing Date, to (but excluding) the date falling three years after the Note Closing Date; and (iii) 12.00% per annum for the period commencing from (and including) the date falling three years after the Note Closing Date. The applicable interest rate is subject to a step-up margin of 6.5 basis points per annum if Babylon and its subsidiaries do not achieve a target of adding 100,000 Medicaid lives to value-based care contracts by January 1, 2024. Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. The Unsecured Notes will mature five years from the Note Closing Date on November 4, 2026 (the “Final Maturity Date”). Babylon is required to redeem the Unsecured Notes (unless previously purchased and cancelled or redeemed) on the Final Maturity Date at 100% of the principal amount on such date. Babylon may redeem the Unsecured Notes at any time at a redemption amount (the “Redemption Amount”) equal to: (i) from (and including) the Note Closing Date to (but excluding) the date falling one year after the Note Closing Date, the amount that is the greater of (A) 104.00% of the principal amount (including capitalized interest) and (B) 104.00% of the principal amount (including capitalized interest) plus an interest make whole premium; (ii) from (and including) the date falling one year after the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date, 104.00% of the principal amount (including any capitalized interest); and (iii) on or after the date falling two years after the Closing Date and until (but not including or after) the Final Maturity Date, 107.00% of the principal amount (including any capitalized interest). Each holder of Unsecured Notes (each a “Noteholder”) has the option to require Babylon to redeem the Unsecured Notes held by such Noteholder at the Redemption Amount upon specified change of control events. The terms of the Unsecured Notes include covenants, which covenants are subject to certain limitations and exceptions, limiting the ability of Babylon and its subsidiaries to, among other things: incur additional debt; pay or declare dividends or distributions on Babylon’s share capital; repay or distribute any share premium reserve or redeem, repurchase or retire its share capital; incur or allow to remain outstanding guarantees; make certain joint venture investments; enter into finance or capital lease contracts; create liens on Babylon’s or its subsidiaries’ assets; enter into sale and leaseback transactions; pay management and advisory fees outside the ordinary course of business; acquire a company or any shares or securities or a business or undertaking; merge or consolidate with another company; borrow or receive investments from certain shareholders other than through Babylon; and sell, lease, transfer or otherwise dispose of assets. The terms of the Unsecured Notes also include customary events of default. On the Note Closing Date, Babylon issued warrants to subscribe for an aggregate of 1,757,499 Class A Ordinary Shares (the “AlbaCore Warrants”) to the Note Subscribers on a pro rata basis by reference to the relevant proportion of the Principal Amount of Unsecured Notes subscribed for by each Note Subscriber. The AlbaCore Warrants confer the right to subscribe for up to 1,757,499 Class A Ordinary Shares exercisable on certain agreed upon exercise events, subject to: (i) Babylon’s right to elect to redeem the AlbaCore Warrants in whole or in part in cash upon an exercise event; (ii) an agreed adjustment formula to reduce the number of Class A Ordinary Shares to be issued upon exercise of the AlbaCore Warrants in certain circumstances linked to Babylon’s trading performance; and (iii) customary adjustments for certain share capital reorganizations (such as share splits and consolidations). We capitalized debt issuance costs of $3.4 million in connection with the issuance of the Unsecured Notes. Please refer to Note 29 for additional discussion surrounding the Albacore Warrants. Albacore Additional Notes and Warrants On December 23, 2021, Babylon entered into an additional note subscription agreement (the “Second Note Subscription Agreement”) providing for the issue of not less than $75 million and not more than $100 million additional Unsecured Notes (the “Additional Notes”) to AlbaCore Partners III Investment Holdings Designated Activity Company, and any new note subscribers that are affiliates of, or funds managed or controlled by, AlbaCore Capital LLP and that adhere to the Second Note Subscription Agreement (the “Second Note Subscribers”). The closing of the issue of the Additional Notes under the Second Note Subscription Agreement, for the principal amount of between $75 million to $100 million, is anticipated to occur on March 31, 2022 (the “Second Closing Date”). The terms and conditions of the Additional Notes are the same as the terms of the original Unsecured Notes, with the exception that the Additional Notes will be issued at 100% of their principal amount. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. On the Second Closing Date, Babylon will issue AlbaCore Warrants to subscribe for an aggregate of 878,750 additional Class A Ordinary Shares to the Second Note Subscribers. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. Upon any exercise event Babylon has a right to elect to satisfy the subscription entitlement in respect of the AlbaCore Warrants by issuing Class A Ordinary Shares, by making a redemption payment in cash, or by a combination of both (in such proportions as Babylon may in its absolute discretion determine). The cash redemption payment per Note Warrant shall be determined by reference to the closing price for the Class A Ordinary Shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event, provided that if the closing price is in excess of $15.00 per Class A Ordinary Share (subject to customary adjustments), the cash redemption payment shall be capped at $15.00 per Note Warrant. Where Babylon elects upon exercise of the AlbaCore Warrants to issue Class A Ordinary Shares in satisfaction in whole or in part of the subscription entitlement under the AlbaCore Warrants, Babylon is required to issue one Class A Ordinary Share credited as fully paid and free from all encumbrances (except as set out in Babylon’s memorandum and articles of association from time to time) per AlbaCore Warrant held, subject to a proportionate downwards adjustment to the number of Class A Ordinary Shares to be issued per AlbaCore Warrant where the closing price of the Class A Ordinary Shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event is in excess of $15.00 per Class A Ordinary Share. VNV Loan and Unsecured Bonds On July 15, 2021, Babylon Holdings entered into a loan agreement with VNV Group for $15.0 million (“VNV Loan”). The interest rate on the loan was 14%. On August 18, 2021, the Group issued $50.0 million in unsecured bonds at a discount of 4.0% (“Unsecured Bonds”), including the non-cash conversion of $8.0 million in borrowings under the VNV Loan agreement into Unsecured Bonds. The interest rate on the loan is 10%, with interest payable quarterly. The proceeds from the Unsecured Bonds can be used for general corporate purposes. The Company utilized proceeds of $7.2 million from the Unsecured Bonds to settle the remainder of the VNV Loan principal and interest. Cash proceeds from the bond issuance, net of discounts, repayments of borrowings, and transaction expenses totaled $32.1 million. The Unsecured Bonds had a one-year term and were redeemable by Babylon Holdings at any time. The Unsecured Bonds were repaid in full following the closing of the Merger. Convertible Loan Note Agreements On November 12, 2020, the Group executed a Convertible Loan Note agreement (“CLN” or “Loan Notes”) with a borrowing capacity of up to $200.0 million, under which $30.0 million Tranche 1 Notes and $70.0 million Tranche 2 Notes were issued to Global Health Equity (Cyprus) Ltd (“GHE” or the “Noteholder” or the “Lender”) in November and December 2020. GHE is part of the VNV Global group. VNV Global has a pre-existing equity interest in Babylon. The notes had a nominal value of $1. Tranche 1 Notes Tranche 1 Notes of $30.0 million were issued to GHE on November 12, 2020. Interest accrues at a fixed non-compounding rate of 11% per annum from the date of issuance to redemption or conversion. These notes were subsequently converted into Series C Preferred Shares after the issuance of the Tranche 2 Notes and shareholder approval of the conversion feature. Tranche 2 Notes Tranche 2 Notes of $70.0 million were issued on December 16, 2020 and are not interest bearing. The Tranche 2 Notes are exchangeable into a variable number of Series C Preferred Shares upon the earlier of the occurrence of certain events or June 30, 2021. These notes were subsequently converted into Series C Preferred Shares after shareholder approval of the conversion feature. As the Tranche 2 Notes fail the definition of equity, the Group considered whether the conversion feature in the Tranche 2 Notes is a non-closely related embedded derivative which would require separation from the debt host contract and to be accounted for separately as a standalone derivative at fair value through profit or loss (“FVTPL”). It has been determined that the Tranche 2 Notes represent a hybrid instrument containing a debt host debt contract and a non-closely related embedded derivative for the conversion feature. The debt host contract is measured at amortized cost using the effective interest rate (“EIR”) method. The fair value of the embedded derivative and transaction costs associated with issuance of the instrument are not material. On June 30, 2021, the $70.0 million Tranche 2 notes were converted into 41,012,358 “C” preference shares. Changes in Loans and Borrowings from Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ Total Loans ​ ​ Albacore ​ VNV Loan ​ Unsecured ​ Convertible ​ Loans and ​ and ​ Notes Notes Bonds Loan Notes Borrowings Borrowings ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at January 1, 2020 — — — — — — Changes from financing cash flows Proceeds from issuance of notes and warrants — — — 100,000 357 100,357 Total changes from financing cash flows — — — 100,000 357 100,357 Other changes Convertible loan notes converted — — — (30,000) — (30,000) Total other changes — — — (30,000) — (30,000) Balance at December 31, 2020 — — — 70,000 357 70,357 Balance at January 1, 2021 — — — 70,000 357 70,357 Changes from financing cash flows Proceeds from issuance of notes and warrants 191,000 15,000 64,563 — — 270,563 Payment of debt issuance costs (3,429) — (1,375) — — (4,804) Repayment of cash loan — (7,000) (75,000) — — (82,000) Total changes from financing cash flows 187,571 8,000 (11,812) — — 183,759 Other changes Fair value of warrants issued (16,930) — — — — (16,930) Unpaid debt issuance costs (2,801) — (171) — — (2,972) Amortization of fair value adjustment, discount, and debt issuance costs 761 — 3,983 — — 4,744 Convertible loan notes converted — — — (70,000) — (70,000) Non-cash conversion of loan notes to bonds — (8,000) 8,000 — — — Other loans and borrowings activity, net — — — — (172) (172) Total other changes (18,970) (8,000) 11,812 (70,000) (172) (85,330) Balance at December 31, 2021 168,601 — — — 185 168,786 ​ During the year ended December 31, 2021, interest paid on Loans and borrowings was $1.4 million (2020: $0.2 million). As of December 31, 2021, the unpaid portion of interest on Loans and borrowings, recognized within Accruals and provisions, was $2.5 million (2020: $0.0 million).

Employee Benefits

Employee Benefits	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Employee Benefits
Employee Benefits	13. Employee Benefits Equity Incentive Plans On October 21, 2021, we effected a reclassification (referred to below as the “Reclassification”) whereby all outstanding shares of Babylon, including the various options previously granted under the below plans, were reclassified to Class A ordinary shares or Class B ordinary shares, subject to a conversion ratio of approximately 0.3 (the “Conversion Ratio”). The description of activity in the narratives and tables below have been adjusted to reflect the Reclassification. On July 27, 2015, the Board of Directors adopted the Babylon Holdings Limited Long Term Incentive Plan (the “LTIP”). Options granted under the LTIP were originally granted over Company’s Class B Shares. Following the Reclassification, the options subsist over Class A ordinary shares. Upon approval of the Babylon Holdings Limited 2021 Equity Incentive Plan, including the Non-Employee Sub-Plan (collectively, the "2021 Plan"), the LTIP Plan was no longer available for future awards. On February 21, 2021, the Board of Directors adopted the Company Share Option Plan (“CSOP”), which was intended to qualify as a company share option plan that meet certain requirements under the Income Tax Act of 2003. The options granted under the CSOP are, subject to certain qualifying conditions being met, potentially U.K. tax-favored options. Upon approval of the 2021 Plan, the CSOP Plan was no longer available for future awards. On October 21, 2021, the shareholders approved the 2021 Plan. The 2021 Plan authorizes (a) the issuance of 13,700,125 Class A ordinary shares plus, (b) unless a lesser amount is approved by the Board prior to January 1st of a given year, an automatic increase on January 1st of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of Class A ordinary shares outstanding on December 31st of the preceding calendar year, and (c) all or any part of an option or options to acquire unissued shares granted under the prior plans (the LTIP or CSOP described above) shall become available for award granted under the 2021 Plan subject to a maximum of 7,223,177 shares. Upon approval of the 2021 Plan, the LTIP and CSOP were no longer available for future awards. The 2021 Plan provides for the grant of options, share appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted share units (“RSUs”), and other share-based awards. As of March 31, 2022, there are 43,761,708 shares available for issuance pursuant to future awards under the 2021 Plan. Share-based Payments The Group issues equity settled share-based payments to employees of the Group and advisors, whereby services are rendered in exchange for rights over shares in the Group. Employees of all Group companies participate within this scheme through the LTIP, CSOP and 2021 Plan described above. Share-based payments are recognized as expense for RSUs, RSAs and options, net of estimated forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ 2022 2021 ​ ​ $’000 ​ $’000 Total share-based compensation expense 8,402 2,802 ​ Restricted Stock Units The following table displays RSU activity for the periods presented: ​ ​ ​ ​ ​ RSUs Balance at January 1, 2022 6,997,284 Granted 14,758,592 Vested and issued (895,627) Forfeited / canceled during the period (1,099,073) Balance at March 31, 2022 19,761,176 Vested and unissued at March 31, 2022 39,022 Unvested at March 31, 2022 19,722,154 ​ On March 14, 2022, the Remuneration Committee of the Board of Directors granted employees RSUs under the 2021 Plan, under which the holders have the rights to receive an aggregate 14,758,592 shares of the Company’s Class A ordinary shares. Pursuant to the terms of the RSU awards, unvested shares are forfeited upon separation from the Company. Options The following table displays option activity and weighted average exercise price for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ $ ​ $ ​ Outstanding at the beginning of the period 1.47 22,896,265 0.02 21,107,487 Granted during the period — — 3.67 8,155,289 Forfeited / canceled during the period 1.26 (650,232) 0.18 (6,204,471) Exercised during the period 0.35 (27,942) 1.42 (162,040) Outstanding at the end of the period 1.48 22,218,091 1.47 22,896,265 ​	27. Employee Benefits Pension Plans The Group operates a defined contribution plan, under which the Group pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. During fiscal year 2021, the Group paid fixed contributions totaling $6.3 million (2020: $5.2 million, 2019: $3.1 million). Equity Incentive Plans Immediately prior to the closing of the Merger referred to in Note 5, we effected a reclassification (referred to below as the “Reclassification”) whereby all outstanding shares of Babylon, including the various options previously granted under the below plans, were reclassified to Class A Ordinary Shares or Class B Ordinary Shares, subject to a conversion ratio of approximately 0.3 (the “Conversion Ratio”). The description of activity in the narratives and tables below have been adjusted to reflect the Reclassification. On July 27, 2015, the Board of Directors adopted the Babylon Holdings Limited Long Term Incentive Plan (the “LTIP”). Options granted under the LTIP were originally granted over Company’s Class B Shares. Following the Reclassification, the options subsist over Class A Ordinary Shares. On February 21, 2021, the Board of Directors adopted the Company Share Option Plan (“CSOP”) and was intended to qualify as a company share option plan that meet certain requirements under the Income Tax Act of 2003. The options granted under the CSOP are, subject to certain qualifying conditions being met, potentially U.K. tax-favored options. In March 2021, the Company made an offer to all existing UK participants in the LTIP to convert their LTIP share options into the CSOP or into restricted stock awards (“RSAs”). All employees who elected to have their LTIP option converted to a new CSOP or RSA had their existing LTIP options forfeited and were granted an increased number of share options in line with the increased exercise price under the CSOP and RSA plans resulting in an equivalent economic value as compared to the grantee’s original award. There were no changes made to other terms, including vesting conditions or the period the original share options were granted. For the participants who accepted the offer to transfer their LTIP awards into RSAs, a total of 4,265,770 LTIP options were cancelled and replaced with 5,046,059 RSAs during the year ending December 31, 2021. For the participants who accepted the offer to transfer their awards into CSOP options, a total of 6,660,027 LTIP options were cancelled and replaced with 7,726,002 CSOP options during year ending December 31, 2021. On October 21, 2021, the shareholders approved the Babylon Holdings Limited 2021 Equity Incentive Plan, including the Non-Employee Sub-Plan (collectively, the “2021 Plan”). The 2021 Plan authorizes (a) the issuance of 13,700,125 Class A Ordinary Shares plus, (b) unless a lesser amount is approved by the Board prior to January 1st of a given year, an automatic increase on January 1st of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of Class A Ordinary Shares outstanding on December 31st of the preceding calendar year, and (c) all or any part of an option or options to acquire unissued shares granted under the prior plans (the LTIP or CSOP described above) shall become available for award granted under the 2021 Plan subject to a maximum of 7,223,177 shares. Upon approval of the 2021 Plan, the LTIP and CSOP were no longer available for future awards. The 2021 Plan provides for the grant of options, share appreciation rights (“SARs”), RSAs, restricted share units (“RSUs”), and other share-based awards. Share-based Payments The Group issues equity settled share-based payments to employees of the Group and advisors, whereby services are rendered in exchange for rights over shares in the Group. Employees of all Group companies participate within this scheme through a variety of plans described above. Under these plans, options are granted to employees at the start of their employment and typically expire between 10 to 15 years. Generally, upon completion of the first year of employment, 25.0% of options will vest, and the remainder will vest monthly over the next three years. In certain circumstances, additional options are granted to employees to recognize performance. Such options vest in the same manner as those granted on joining. Share-based compensation expense is recognized using the graded vesting method. Share-based payments are recognized as expense for RSUs, RSAs and options, net of forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Total share-based compensation expense 46,307 9,557 7,966 ​ Restricted Stock Awards The Company recorded share-based compensation expense related to RSAs of $3.6 million during the year ended December 31, 2021. As of December 31, 2021, the unrecognized compensation cost related to unvested RSAs is $1.3 million, which is expected to be recognized over the next one Restricted Stock Units The following table displays RSU activity and weighted average grant date fair values for the year ended December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant Date Fair Value ​ ​ RSUs ​ Per RSU (1) Balance at January 1, 2021 — ​ $ — Granted 6,997,284 ​ $ 6.23 Vested and issued — ​ $ — Forfeited — ​ $ — Balance at December 31, 2021 6,997,284 ​ $ 6.23 Vested and unissued at December 31, 2021 1,760,363 ​ $ 6.23 Unvested at December 31, 2021 5,236,921 ​ $ 6.23 (1) The calculation of weighted average grant date fair value excludes RSUs issued to Higi employees further discussed below. In connection with the acquisition of Higi described in Note 6, Babylon exchanged vested and unvested options held by employees of Higi for 1,980,000 RSUs of Babylon to be issued from the 2021 Plan, which are included in amounts granted in the table above. Of the RSUs issued to Higi under the Second Amended and Restated Agreement and Plan of Merger, 1,167,669 RSUs awarded to the former Higi employees were vested upon grant date in exchange for the surrender of vested Higi awards upon exercise of the option to acquire the remaining non-controlling interests. The vesting conditions associated with the unvested RSUs issued to the former Higi employees reflect the vesting of the original Higi equity award. The transaction was accounted for under IFRS 2 for replacement awards and the Company will recognized the compensatory portion of the award over the service period of the unvested RSUs issued to Higi employees. As of December 31, 2021, the unrecognized compensation cost associated with the 812,331 remaining unvested RSUs is $5.4 million, which is expected to be recognized over a weighted average period of 1.3 years. The Company recorded share-based compensation expense related to RSUs of $6.5 million during the year ended December 31, 2021. There were no RSUs granted prior to 2021. As of December 31, 2021, the Company had $24.4 million in unrecognized compensation cost related to unvested RSUs unrelated to the acquisition of Higi described above, which is expected to be recognized over a weighted average period of 3.4 years. Options Options have been granted under the LTIP and CSOP described above. The fair value of each employee and non-employee stock option award was estimated on the date of grant for each option using the Black-Scholes option pricing model yielding a weighted average fair value of $7.79 for options granted during the year ended December 31, 2021. The key assumptions used for options granted during the year ended December 31, 2021, were as follows: ​ ​ ​ ​ Fair value of underlying stock $2.97  – $9.20 Volatility ​ 63.4%  – 70.0% Risk-free interest rate ​ 0.12%  – 1.68% Dividend yield ​ 0%  – 0% Expected term (in years) ​ 10.00  – 14.50 ​ The number and weighted average exercise price of share options for the Group are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ price ​ options ​ ​ $ ​ ​ ​ $ ​ ​ ​ $ ​ ​ Outstanding at the beginning of the year 0.02 ​ 21,107,487 — ​ 20,120,425 — 19,666,539 Granted during the year ​ 3.67 ​ 8,155,289 ​ 0.11 ​ 4,109,243 ​ — ​ 2,786,856 Forfeited / canceled during the year ​ 0.18 ​ (6,204,471) ​ 0.04 ​ (3,122,181) ​ — ​ (2,332,970) Exercised during the year ​ 1.42 ​ (162,040) ​ — ​ — ​ — ​ — Outstanding at the end of the year ​ 1.47 ​ 22,896,265 ​ 0.02 ​ 21,107,487 ​ — ​ 20,120,425 Exercisable at the end of the year ​ 1.54 ​ 19,105,908 ​ 0.01 ​ 16,461,945 ​ — ​ 11,817,828 ​ As of December 31, 2021, the outstanding options had remaining contractual terms ranging from 6.9 –  15.0 years. Restricted Growth Shares In February 2021, the Board approved a grant of 10,150,368 of Class G Shares to three employees (“Growth Shares”), with a subscription price of $0.03 per share. The Growth Shares had vesting terms of one year from the grantee’s date of hire. The Growth Shares allowed the grantee to benefit from the difference between the value of the number of Growth Shares awarded and the benchmark valuation. The Growth Shares included a conversion feature to convert into the Company’s Class A Ordinary Shares upon an exit event, which included a business merger, an initial public offering, or certain other events (collectively referred to as an “Exit Event”). The Growth Shares were redeemable at the sole discretion of the Company at $0.00001227 or at some other amount at the discretion of the Board of Directors prior to an Exit Event upon cessation of employment. Using a Monte Carlo simulation, the Group calculated the grant date fair value of $9.7 million for the Growth Shares, all of which was recognized during the year ended December 31, 2021. The key assumptions used were a pre-money equity valuation of $3.5 billion and a volatility rate of 54%. All outstanding Growth Shares were converted into 712,413 Class A Ordinary Shares, subject to achievement of the original vesting conditions, following the Merger in October 2021. There were no Growth Shares outstanding as of December 31, 2021.

Capital and Reserves

Capital and Reserves	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Capital and Reserves	14. Capital and Reserves Share Capital ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A Ordinary Class B Ordinary ​ In thousands of shares Shares Shares Deferred Shares Authorized 6,500,000 3,100,000 100,000 On issue at January 1, 2022 333,925 79,638 — Issued during the period 924 — — On issue at March 31, 2022—fully paid 334,848 79,638 — ​ Share Rights Each Class A ordinary share will have the right to exercise one vote at any general meeting of the shareholders of the Company, to participate pro rata in all dividends declared by the Company, and the rights in the event of the Company’s dissolution. Each Class B ordinary share will have the same economic terms as the Babylon Class A ordinary shares, but the Class B ordinary shares will have 15 votes per share. The Deferred Shares are non-voting shares and did not convey upon the holder the right to be paid a dividend or notice to attend, vote or speak at a shareholder meeting. No Deferred Shares have been issued. Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are recognized in other comprehensive loss and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ 2022 ​ $’000 January 1, (27) Foreign operations – foreign currency translation differences (3,753) March 31, (3,780) ​ Retained Earnings The retained earnings account represents retained profits or losses less amounts distributed to shareholders. Share-based Payment Reserve The share-based payment reserve represents amounts accruing for equity-based share options granted.	28. Capital and Reserves Capital and Reserves Following the Merger As outlined in Note 5, the Consolidated Financial Statements are prepared as a continuation of the financial statements of Babylon Holdings Limited, which have been adjusted to reflect the conversion of historical Ordinary A Shares, Ordinary B Shares, and Series C shares into Class A and Class B Ordinary Shares following the listing on the New York Stock Exchange, as well as the application of the Conversion Ratio. The share capital of Babylon Holdings Limited immediately following the closing of the transaction is as follows: ​ ​ ​ ​ ​ ​ ​ In thousands of shares Number of Shares Share Capital Description Class A Ordinary Shares 295,589 12 Issuance to Babylon Shareholders Class A Ordinary Shares 22,400 1 Issuance to PIPE Investors Class A Ordinary Shares 12,268 — Issuance to SPAC Investors and Shareholders ​ 330,257 13 ​ ​ Class B Ordinary Shares 79,638 3 Issuance to Babylon Shareholders ​ 409,895 16 ​ ​ ​ Each Class A The following tables display the number of shares of Babylon Holdings Limited prior and following the Merger: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A ​ Class B ​ ​ ​ ​ ​ ​ ​ Ordinary ​ ​ Ordinary ​ Ordinary ​ Ordinary A ​ Ordinary B ​ Preference C ​ Redeemable G1 ​ Shares Shares Shares Shares Shares Shares In thousands of shares ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 Authorized ​ 6,500,000 ​ 3,100,000 ​ 10,000,000 ​ 11,000,000 ​ 10,000,000 ​ 50,000 On issue at January 1, 2021 ​ — ​ — ​ 135,136 ​ 664,605 ​ 252,065 ​ — Issued during the year prior to Merger — — — 17,206 41,012 10,150 Conversion into Class A and B Shares 330,257 79,638 (135,136) (681,811) (293,077) (10,150) Issued following the Merger 3,668 — — — — — On issue at December 31, 2021  –  fully paid 333,925 79,638 — — — — ​ Share Rights Each Class A Ordinary Share will have the right to exercise one vote at any general meeting of the shareholders of the Company, to participate pro rata in all dividends declared by the Company, and the rights in the event of the Company’s dissolution. Each Class B Ordinary Share will have the same economic terms as the Babylon Class A Ordinary Shares except for the Class B Ordinary Shares will have 15 votes per share. There were 100,000 Deferred Shares with a par value of $0.00004, which are non-voting shares and did not convey upon the holder the right to be paid a dividend or notice to attend, vote or speak at a shareholder meeting. No Deferred Shares have been issued. Capital & Reserves Prior to the Merger During the year ended December 31, 2021, $70.0 million Loan Notes were converted into 41,012,358 “C” preference shares. These shares had a fixed for fixed conversion feature and are therefore accounted for as equity investments. During the year ended December 31, 2020, the Group issued 24,796,225 $0.00001277 “C” preference shares for a consideration of $42.1 million. $30.0 million Loan Notes were converted into 17,708,792 shares related to the principle and $0.2 million Loan Notes were converted to 111,239 shares related to interest. The Loan Notes that were converted into our “C” preference shares had a fixed conversion feature and are therefore accounted for as equity investments. The remaining 6,976,194 shares were settled in cash for a consideration of $11.9 million. Tranche 1 Notes On November 12, 2020 Tranche 1 Notes of $30.0 million were issued to GHE and paid to Babylon in two parts of $15.0 million on November 16, 2020 and December 2, 2020. The Tranche 1 Notes accrue interest of 11% per year and shareholder approval is required for the Tranche 1 Notes to be convertible into a fixed number of Series C Preferred Shares at a price of US $1.706802577 per share within six months of the first issuance date. The conversion of the Tranche 1 Notes was approved by shareholders on December 16, 2020. Subsequent to this conversion approval, the principal of the Tranche 1 Notes was reclassified from being recognized as a financial liability to be classified as equity. No material gain or loss was recognized on conversion. The share capital in relation to the Series C Preferred Shares issued on conversion was recorded at the nominal value of the shares issued. Tranche 2 Notes Tranche 2 Notes of $70.0 million were issued on December 16, 2020 and are not interest bearing. The Tranche 2 Notes are exchangeable into a variable number of Series C Preferred Shares upon the earlier of the occurrence of certain events or June 30, 2021. Tranche 2 Notes converted to equity on June 30, 2021. The principal of the Tranche 2 Notes was reclassified from being recognized as a financial liability to be classified as equity. No material gain or loss was recognized on conversion. The share capital in relation to the Series C Preferred Shares issued on conversion was recorded at the nominal value of the shares issued. All shares issued rank pari-passu aside from the following: ● the A Ordinary Shares in issue at any time shall (as a separate class) carry fifty per cent ( 50.0% ) of the total voting rights of the Shares; and ● the B Ordinary Shares and the Series C Preferred Shares in issue at any time shall (as if the B Ordinary Shares and the Series C Preferred Shares constituted one and the same class) carry fifty per cent ( 50.0% ) of the total voting rights of the Shares; ● the Holders of a majority of the A Ordinary Shares shall have the right from time to time to appoint such number of persons to be Directors of each Group Company equal to the number of Directors which the Holders of B Ordinary Shares and Series C Preferred Shares are entitled to appoint (in aggregate) plus one additional Director; and in each case to remove from office any persons appointed and to appoint another person in his or her place ● The Series C Largest Shareholder shall have the right from time to time to appoint one person to be a Director and to remove from office any person so appointed and to appoint another person in his or her place. ● For so long as a holder of B Ordinary Shares or Series C Preferred Shares is also a Qualifying Stakeholder, each such Qualifying Stakeholder shall have the right from time to time to appoint one person to be a Director for each whole Qualifying Stake held by them and to remove from office any person so appointed and to appoint another person in his or her place. ● G1 Ordinary Redeemable Shares do not have the right to vote, nor to receive dividends, and have capital rights to convert into Ordinary B Shares in connection with an exit event. G1 Ordinary Redeemable shares are redeemable at the sole discretion of the Company. On any return of capital on liquidation, the assets of the Group available for distribution shall be distributed: a) first, in paying to each of the Series C Preferred Shareholders, in priority to any other classes of Shares, an amount per Series C Preferred Share held equal to the Preference Amount b) second, in paying to the 2016/2017 Subscribers pro rata to their respective holdings of Hoxton Shares and Kinnevik Shares an amount equal to the Hurdle Amount; and c) the balance of the surplus assets (if any) shall be distributed among the holders of the A Ordinary Shares and the B Ordinary Shares pro rata as if they constituted one and the same class. Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are recognized in other comprehensive loss and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 January 1, 1,675 (1,904) 7,789 Foreign operations – foreign currency translation differences (1,702) 3,579 (9,693) December 31, (27) 1,675 (1,904) ​ Retained Earnings The retained earnings account represents retained profits or losses less amounts distributed to shareholders. Share-based Payment Reserve The share-based payment reserve represents amounts accruing for equity-based share options granted.

Warrant Liability

Warrant Liability	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Abstract]
Warrant Liability	15. Warrant Liability The Company’s warrants are classified and accounted for as liabilities at fair value, with changes if fair value recorded in the Condensed Consolidated Statement of Profit and Loss. The following table displays the number of warrants outstanding as of March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Tradeable Non-tradeable Total ​ No. of warrants No. of warrants No. of warrants In issue at January 1, 2022 8,625 7,691 16,316 Issuance of Additional AlbaCore Warrants on March 31, 2022 — 879 879 In issue at March 31, 2022 8,625 8,570 17,195 ​ Alkuri Warrants Pursuant to the merger agreement with Alkuri Global Acquisition Corp (“Alkuri”), the Company assumed warrants previously issued by Alkuri, consisting of 5,933,333 private placement warrants and 8,625,000 public warrants, which were converted into warrants to purchase 14,558,333 Class A ordinary shares (“Alkuri Warrants”). The warrants to purchase 14,558,333 Class A ordinary shares give the holder the right to purchase such shares at a fixed amount for a period of five years subject to the terms and conditions of the warrant agreement. As of March 31, 2022 there were 14,558,313 Alkuri Warrants outstanding. The warrants entitle the holder to purchase one Class A ordinary share of Babylon Holdings Limited at an exercise price of $11.50 per share. Until warrant holders acquire the Company’s ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on October 21, 2026, or earlier upon redemption or liquidation in accordance with their terms. AlbaCore Warrants As of March 31, 2022 there were 1,757,499 AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share upon occurrence of an exercise event. Until warrant holders acquire the Company’s Class A ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. Additional AlbaCore Warrants As of March 31, 2022 there were 878,750 Additional AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share upon occurrence of an exercise event. Until warrant holders acquire the Company’s Class A ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the Additional AlbaCore Warrants on the date of issuance was determined utilizing a price per warrant of $3.89, which has been derived using a Monte Carlo simulation. Changes in Warrant Liability The fair value of the Alkuri Warrants is determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at March 31, 2022 was $0.53. The fair value of the AlbaCore Warrants and Additional AlbaCore Warrants is determined utilizing a price per warrant of $3.89, which has been derived using a Monte Carlo simulation. See reconciliation of fair values below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ (Level 1) (Level 2) (Level 3) Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at December 31, 2021 5,865 4,035 10,228 20,128 Fair value of Additional AlbaCore Warrants upon issuance — — 3,418 3,418 Change in fair value of warrant liabilities (1,294) (890) (3,391) (5,575) Balance at March 31, 2022 4,571 3,145 10,255 17,971 ​	29. Warrant Liability The Company’s warrants are classified and accounted for as liabilities at fair value, with changes if fair value recorded in the Consolidated Statement of Profit and Loss. The following table displays the number of warrants in issue as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable ​ Non-tradeable ​ Total (In thousands) No. of warrants No. of warrants No. of warrants In issue at January 1, 2021 — — — Issuance of Alkuri Warrants on October 21, 2021 8,625 5,933 14,558 Issuance of AlbaCore Warrants on November 4, 2021 — 1,758 1,758 In issue at December 31, 2021 8,625 7,691 16,316 ​ Alkuri Warrants As of December 31, 2021 there were 14,558,333 Alkuri Warrants outstanding related to the Merger. The warrants entitle the holder to purchase one Class A Ordinary Share of Babylon Holdings Limited at an exercise price of $11.50 per share. Until warrant holders acquire the Company’s ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on October 21, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the Alkuri Warrants on the date of issuance was determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at October 22, 2021 was $2.13. AlbaCore Warrants As of December 31, 2021 there were 1,757,499 AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share. Until warrant holders acquire the Company’s Class A Ordinary Shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the AlbaCore Warrants on the date of issuance was determined utilizing a price per warrant of $9.63, which has been derived using a Monte Carlo simulation. Changes in Warrant Liability The fair value of the Alkuri Warrants is determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at December 31, 2021 was $0.68. The fair value of the AlbaCore Warrants is determined utilizing a price per warrant of $5.82, which has been derived using a Monte Carlo simulation. See reconciliation of fair values below: ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total ​ ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ Balance at December 31, 2019 ​ — ​ — ​ — ​ — ​ Balance at December 31, 2020 ​ — ​ — ​ — ​ — ​ Fair value of Alkuri Warrants upon issuance ​ 18,371 ​ 12,638 ​ — ​ 31,009 ​ Fair value of AlbaCore Warrants upon issuance ​ — ​ — ​ 16,930 ​ 16,930 ​ Change in fair value of warrant liabilities ​ (12,506) ​ (8,603) ​ (6,702) ​ (27,811) ​ Balance at December 31, 2021 ​ 5,865 ​ 4,035 ​ 10,228 ​ 20,128 ​ ​ ​

Related Parties

Related Parties	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Parties
Related Parties	16. Related Parties Transactions with Key Management Personnel During the three months ended March 31, 2022, the remuneration of directors and other key management personnel - including company pension contributions made to money purchase schemes on their behalf - amounted to $0.9 million (2021: $0.9 million). The remuneration of the highest paid key manager was $0.2 million (2021: $0.3 million). These remuneration costs are recorded as an operating expense in Sales, general & administrative expenses. For the three months ended March 31, 2022, share-based compensation expense related to key management personnel was $1.0 million (2021: $0.6 million). Directors’ cash remuneration is borne by the Company’s subsidiary, Babylon Partners Limited.	30. Related Parties Transactions with Key Management Personnel During 2021, the remuneration of directors and other key management personnel  — including company pension contributions made to money purchase schemes on their behalf  — amounted to $6.5 million (2020: $1.0 million, 2019: $0.9 million). The remuneration of the highest paid key manager was $2.2 million (2020: $0.3 million, 2019: $0.3 million). These remuneration costs are recorded as an operating expense in Sales, general & administrative expenses. For the year ended December 31, 2021, share-based compensation expense related to key management personnel was $32.1 million (2020: $0.0 million, 2019: $0.1 million). Directors’ remuneration is borne by the Company’s subsidiary, Babylon Partners Limited. ALP Note On June 3, 2020, in connection with our initial investment in Higi, ALP Partners Limited (“ALP”), as lender, entered into a promissory note with Higi, as borrower, in which Higi promised to pay ALP an aggregate principal sum of $5.0 million (the “ALP Note”). On December 7, 2021, we exercised our option to acquire the remaining equity interest in Higi pursuant to the Higi Acquisition Agreement. The closing of this acquisition occurred on December 31, 2021. The exercise price of the option to acquire the remaining Higi equity stake included the payment of $5.4 million at the closing to satisfy the principal and interest payable by a subsidiary of Higi pursuant to the ALP Note. Refer to Note 6. PIPE Transaction On June 3, 2021, we completed the PIPE Transaction, in which we issued and sold, in private placements that closed immediately prior to the Merger, an aggregate of 22,400,000 of our Class A Ordinary Shares to certain Babylon shareholders for $10.00 per share. The PIPE Transaction included the issuance of 500,000 Class A Ordinary Shares to VNV (Cyprus) Limited, 500,000 Class A Ordinary Shares to Black Ice Capital Limited, an affiliate of VNV (Cyprus) Limited, 500,000 Class A Ordinary Shares to Invik S.A. and 200,000 Class A Ordinary Shares to ALP.

Financial Instruments

Financial Instruments	3 Months Ended
	Mar. 31, 2022
Financial Instruments
Financial Instruments and Risk Management	17. Financial Instruments The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: ● Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities; ● Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and ● Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. There were no transfers between fair value levels during the period. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 4,571 — — 4,571 Non-tradeable Alkuri Warrants — 3,145 — 3,145 AlbaCore Warrants — — 6,837 6,837 Additional AlbaCore Warrants — — 3,418 3,418 ​ 4,571 3,145 10,255 17,971 ​ The tradeable Alkuri Warrants were valued using the instrument’s publicly listed trading price as of the date of the Condensed Consolidated Statement of Financial Position, which is considered to be a Level 1 measurement due to the use of an observable market quote in an active market. As the non-tradeable Alkuri Warrants have identical terms as the tradeable Alkuri Warrants, the non-tradeable Alkuri Warrants were valued using the tradeable Alkuri Warrants’ publicly listed trading price, which is considered to be a Level 2 fair value measurement due to the use of an observable market quote from a similar instrument in an active market. The AlbaCore Warrants and Additional AlbaCore Warrants were valued using a Monte Carlo simulation, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the AlbaCore Warrants and Additional AlbaCore Warrants is the expected volatility of our ordinary shares. The expected volatility of the Company’s ordinary shares was determined using peer group companies. Due to the nominal exercise price of the AlbaCore Warrants and Additional AlbaCore Warrants, changes in volatility would not result in a material change in the fair value of the warrants. The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants and Additional AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of As of ​ March 31, 2022 December 31, 2021 Underlying stock price (USD) ​ $ 3.89 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 74.1 % 71.6 % Remaining term (years) ​ 4.6 ​ 4.85 ​ Risk-free rate ​ 2.40 % 1.23 % ​

Subsequent Events

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events
Subsequent Events	18. Subsequent Events Unsecured Notes Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. As of May 4, 2022, the interest payable on the Unsecured Notes was $8.8 million. In accordance with the Note Subscription Agreement, Babylon elected to satisfy 50.00% of the interest payable by the issuance of further Unsecured Notes, which were immediately consolidated and formed into a single series with the outstanding Unsecured Notes. The remaining $4.4 million of the interest payable was settled in cash.	34. Subsequent Events Austin Office Lease On November 1, 2021, Babylon Inc. entered into a sublease agreement for 37,883 rentable square feet of office space in Austin, Texas. The lease commenced on February 1, 2022 and shall automatically terminate on March 31, 2029. Minimum payments for the non-cancellable lease term are $16.6 million. The Company intends to use the office space as its United States headquarters and will house approximately 200 employees. Grant of RSUs On March 14, 2022, the Remuneration Committee of the Board of Directors granted employees RSUs under the 2021 Equity Incentive Plan, under which the holders have the rights to receive an aggregate 17,233,274 shares of the Company’s Class A Ordinary Shares. Pursuant to the terms of the RSU awards, unvested shares are forfeited upon separation from the Company.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Revenue Recognition		Revenue Recognition Revenue is primarily derived from the following sources: (1) capitation revenue from value-based care services, (2) software license fees for the provision of AI services, and (3) patient revenues from the provision of clinical services. Revenue is recognized upon transfer of control of services to customers in an amount that reflects the consideration which the Group expects to receive in exchange for those services. Contract assets are recognized when there is an excess of revenue earned over billings on contracts where the rights are conditional on something other than passage of time. Contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. Income received in advance (“contract liability”) is recognized when there are billings in excess of revenues earned for services rendered. The Group’s contracts with customers could include promises to transfer multiple services to a customer. The Group assesses the services promised in a contract and identifies distinct or bundled performance obligations in the contract. Identification of these performance obligations involves judgement to determine the promises and the ability of the customer to benefit independently from such promises. If multiple performance obligations are identified in the contract the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. Transaction prices are adjusted for the effects of a significant financing component if we expect, at contract inception, that the period between the transfer of the promised goods or services to the customer and when the customer pays for that service will be more than one year. The Group exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time. The Group considers indicators such as how a customer consumes benefits as services are rendered, existence of enforceable rights to payment for performance to date, transfer of significant risks and rewards to the customer and acceptance of delivery of the service by the customer.
Value-based Care Revenue		Value-based Care Revenue Value-based care (“VBC”) revenue consists primarily of per member per month (“PMPM”) allocations for care management services by the Group under arrangements with various customers. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of VBC services to attributed members. PMPM fees are based upon fixed rates per member or a percentage of the per member premium of the health plan and are not dependent upon the volume of specific care services provided. In addition, the arrangements usually include payments dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. Unlike clinical services revenue discussed below, the Group accepts partial or full financial risk (either global or professional) for members attributed to our VBC services in exchange for a fixed monthly allocation, which means we are responsible for the cost of all covered services provided to members. In general, the Group considers all VBC revenue contracts as containing a single performance obligation to stand ready to provide managed VBC services to the attributed members. This performance obligation is satisfied over time as the Group stands ready to fulfill its obligation to the attributed members as a group. Accordingly, the Group recognizes revenue in the month in which attributed members are entitled to receive VBC services during the contract term. Part of the consideration received under VBC revenue contracts is variable as the contracts contain provisions dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. VBC revenue is estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is highly probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Such uncertainties may only be resolved several months after the end of the reporting period because of the availability of sufficient reliable data relating to factors such as quality metrics, member specific attributes and healthcare service costs. Subsequent changes in VBC revenue and the amount of PMPM revenue to be recognized by the Company are reflected in subsequent periods. VBC revenue is recognized gross when it is assessed that the performance obligation relates to the whole of the patient journey with the Group responsible for arranging, providing and controlling the VBC services provided to the attributed members, with expenses payable to other healthcare providers.
Software Licensing Revenue		Software Licensing Revenue Under IFRS 15, Revenue from Contracts with Customers In some cases, we have concluded that upfront payments included in software license contracts with customers have a significant financing component considering the period between the upfront payment and the services provided, when the contract term is more than one year. As a result, the transaction price must be adjusted to account for the time value of money by using an appropriate discount rate. The discount rate utilized is determined based on the rate that would be reflected in a separate financing transaction with the customer. When a significant financing component exists, we recognize a contract liability for the entire upfront cash payment received, excluding the amount relating to the financing component from the transaction price. Additionally, interest expense is recognized over the duration of the contract under the amortized interest method.
Clinical Care Delivery Expense	Clinical Care Delivery Expense Clinical care delivery expense includes the internal costs that we incur in the provision of healthcare services to patients, which is substantially composed of employee-related expenses such as salaries and wages for Babylon healthcare professionals. Other costs within Clinical care delivery expense include operating costs incurred for the delivery of healthcare services to patients, such as occupancy, medical supplies, and other support-related costs.	Clinical Service Revenue Clinical service revenue represents clinical services provided to our business and private patients under an arrangement and is recognized when the services are rendered. Our clinical service fees are based on PMPM subscription fees and fees per appointment (“fee-for-service”). PMPM subscription fees give members access to our clinical services over the contractual period as set forth in the arrangement, recognized monthly based on the number of members covered by the plan in a given month. Fee-for-service is based on contracted rates determined in agreed-upon compensation schedules and is recognized when the services are rendered at a point in time. In arrangements where PMPM subscription fees are charged we assess whether any of the transaction price should be allocated to software licensing revenue and allocate on a contract by contract basis.
Cost of Care Delivery		Cost of Care Delivery Cost of care delivery primarily consists of claims costs from physicians and other health professionals in our provider network and costs incurred in connection with our provider network operations, including rent, insurance and other direct costs incurred in the delivery of patient care. Cost of care delivery is mainly driven by patient activity and required medical services that are relatively variable. Costs incurred relating to the delivery of VBC services is recognized as an expense within cost of care delivery over time as the expense is incurred.
Grant Income		Grant Income We recognize income related to grants on a systematic and rational basis when it becomes probable that we have complied with the terms and conditions of the grant and in the period in which the corresponding costs or income related to the grant are recognized. We receive grants in the form of cash contributions towards outreach projects and tax credits for certain qualifying research and development expenditures. These grants are recognized as non-current deferred grant income liability, released either over the period of the grant contract or over the same period that the related capitalized development costs are amortized. The offset to the release of the long term deferred grant income liability is recognized as revenue for outreach grants and a reduction in Platform & application expenses for tax credits.
Platform & Application Expenses		Platform & Application Expenses Platform & application expenses are costs of revenue for our digital healthcare platform. These costs primarily include employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in providing professional services related to support and maintenance of the digital healthcare platform. These costs also include third-party application costs, hosting services, and other direct costs. The amortization of capitalized development costs are also included in Platform & application expenses. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized if the product or process is technically and commercially feasible and if the Group has sufficient resources to complete the development. Capitalized development costs are recorded as intangible assets and amortized from the point at which the development is complete, and the asset is available for use. Costs are capitalized based on a model whereby a percentage is allocated to employee related expenses based on the time spent on the development of assets. Subsequent expenditure on capitalized intangible assets is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All employee expenses included in this balance relate to employees in the product and technology departments, and the percentage attributable varies dependent on the nature of the work performed and the type of asset being developed. Expenses that do not meet the criteria for capitalization are expensed as incurred within Platform & application expenses. The technical feasibility of a new product is determined by a management team consisting of product, technology, and finance leads based on understanding the availability of adequate technical, financial and other resources required to develop the product. The commercial feasibility of a new product is determined by understanding how this product feeds into Babylon’s current offering. Commercial leads ascertain market interest by evaluating against existing and potential customer requirements. Feasibility is challenged with input from finance leads to verify the underlying financial implications of development and assess viability. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. As described in Note 3, development costs of $34.0 million (2020: $43.0 million) were capitalized during the year for those development and technology expenses that were deemed technologically feasible and probable of generating future economic benefits. During the period of development, the asset is tested for impairment at least annually.
Research & Development Expenses		Research & Development Expenses Research & development expenses primarily included employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in performing activities to develop and improve the Group’s digital healthcare platform. These costs also include third-party application costs, hosting services, and other indirect costs. Research costs and development costs that do not meet the criteria for capitalization are expensed as incurred within Research & development expenses.
Sales, General & Administrative Expenses		Sales, General & Administrative Expenses Sales, general & administrative expenses include employee-related expenses, contractors and consultants expense, stock-based compensation, property and facility related expenses, IT and hosting, marketing, training and recruiting expenses. Enterprise IT and hosting costs are primarily software subscriptions, domain and hosting costs. Our Sales, general & administrative expenses also include depreciation of property, fixtures and fittings and amortization of acquired intangible assets.
Claims Expense	Claims Expense Claims expense includes the costs of healthcare services rendered by third parties on behalf of patients which the Company is contractually obligated to pay, which includes estimates for medical expenses incurred but not yet paid (“IBNP”) using actuarial processes that are applied on a systematic and consistent basis. This process includes the development of estimates using historical claims experience and actuarial models when sufficient claims history is available from health plans and payors. Claims expense also includes other external costs incurred in the delivery of healthcare services including insurance.	Claim Expenses and Claims Payable Claims expense, presented within Cost of care delivery, and Claims payable includes costs for third party healthcare service providers who provide medical care to our members for which the Group is contractually obligated for financial risks relating to the medical services provided. The estimated reserve for IBNP claims is included in the liability for unpaid claims in the Consolidated Statement of Financial Position. Actual claims expense will differ from the estimated liability due to factors in estimated and actual member utilization of health care services, the amount of charges and other factors. We determine our estimates through a variety of actuarial models based on medical claims history to ensure our estimates represent the best, most reasonable estimate given the data available to us at the time the estimates are made.
Taxation		Taxation Tax on the Consolidated Statement of Profit and Loss for the year comprises current and deferred tax. Tax is recognized in the Consolidated Statement of Profit and Loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the reporting date. Expenditures incurred for R&D activities have been claimed and will be reimbursed through the U.K. research and development expenditure credit scheme (the “RDEC Scheme”). Under the RDEC Scheme tax relief is given at 12.0% (up to April 1, 2020) and 13.0% (after April 1, 2020) of allowable R&D costs, which may result in a payable tax credit at an effective rate of 7.8% of qualifying expenditure for the year ended December 31, 2021. The Group recognizes the gross amount as Deferred grant income on the Consolidated Statement of Financial Position and as a reduction to Platform & application expenses over the period of expected benefit from the expenditure. The related tax charge on the credit is recognized in the year of the tax credit. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized.
Net Loss Per Share		Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares of the Group outstanding during the period. Diluted net loss per share is computed by giving effect to all potential ordinary shares, including outstanding stock options, warrants and convertible notes, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential ordinary shares outstanding would have been anti-dilutive. We have included shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares), including options and warrants, within the computation of basic net loss per share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).
Comprehensive Loss		Comprehensive Loss Comprehensive loss consists of cumulative translation gains or losses. Unrealized gains or losses are net of any reclassification adjustments for realized gains and losses included in the Consolidated Statement of Profit and Loss.
Segment Reporting		Segment Reporting IFRS 8, Operating Segments Segment information is presented based on information used by the CODM in its decision-making processes. The CODM is responsible for the Group’s key strategic and business decisions and driving the direction and growth of the Group. These include but are not limited to international growth, new services, material business agreements and corporate and management structures. The CODM’s key decisions are based on the monthly management accounts in which segment information is presented on the basis of geographic areas. Each segment derives its revenues from software license fees for the provision of AI services, patient revenues from the provision of clinical services and VBC services provided by the segment which may differ from the geographic location of the customer. Earnings before depreciation, amortization, net finance income (costs), and income taxes (“EBITDA”) is used to measure performance of each segment because the Group believes that this information is most relevant in evaluating the results of the respective segments. The accounting policies for segment information, including transactions entered between segments are generally the same as those described in the summary of significant accounting policies. The CODM is not provided with total assets and liabilities by segment, and therefore the disclosures below do not include these measures. Segment information is reported from a geographic presence perspective. The Group’s results are provided to CODM disaggregated by geographic region, including the United Kingdom (“UK”), the United States of America (“US”), Canada (until the disposal of our Canadian subsidiary), Rwanda, and Singapore. The Group assessed the geographical segments within the aggregation guidance provided in IFRS 8 and determined that the UK and U.S. segments each exceed the quantitative thresholds and represent individual reportable segments. The remaining geographical regions individually and in aggregate do not exceed the quantitative thresholds for reportable segments. Therefore, the UK and the U.S. segments are the Group’s reportable segments for the purposes of these Consolidated Financial Statements.
Business Combinations		Business Combinations The acquisition consideration is measured at fair value which is the aggregate of the fair values of the assets transferred, the liabilities incurred or assumed and the equity interests in exchange for control. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration are recognized in the Consolidated Statement of Profit and Loss. The consideration transferred in a business combination shall be measured at fair value, which shall be calculated as the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree and the equity interests issued by the acquirer. The allocation process requires an analysis of acquired contracts, customer relationships, contractual commitments, and legal contingencies to identify and record the fair value of all assets acquired and liabilities assumed. In valuing acquired assets and assumed liabilities, fair values are based on, but are not limited to, future expected cash flows, current replacement cost for similar capacity for certain fixed assets, market rate assumptions for contractual obligations, and appropriate discount rates and growth rates. Where the consideration transferred, together with the non-controlling interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. Acquisition related costs are expensed as incurred and classified as Sales, general & administrative expenses in the Consolidated Statement of Profit and Loss. Goodwill is capitalized as a separate item in the case of subsidiaries. Goodwill is denominated in the currency of the operation acquired. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in the Consolidated Statement of Profit and Loss. When the Group increases its ownership interests held in one of its consolidated subsidiaries, any difference between the consideration given and the aggregate carrying value of the assets and liabilities of the acquired entity at the date of the transaction is included in equity in retained earnings.
Property, Plant and Equipment		Property, Plant and Equipment Property, plant and equipment is stated at historical cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment losses. Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Consolidated Statement of Profit and Loss during the reporting period in which they are incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: ​ ​ ​ ​ – Computer equipment 3 years – Fixtures and fittings 3 – 5 years – Deployed machinery 4 years ​ At the end of each reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. When an asset is disposed of, the gain or loss is calculated by comparing proceeds received with its carrying amount and is recognized in the Consolidated Statement of Profit and Loss.
Other Intangible Assets		Other Intangible Assets Intangible assets resulting from capitalized development costs in the normal course of business are recorded at historical cost. Intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in Sales, general & administrative expenses. The useful lives of the Group’s intangible assets are: ​ ​ ​ ​ – Development costs 1 – 10 years – Developed technology ​ 5 years – Customer relationships ​ 15 years – Trade names ​ 5 – 11 years – Physician network ​ 3 – 10 years – Licenses ​ 1 – 2 years ​ An intangible asset is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Consolidated Statement of Profit and Loss.
Goodwill		Goodwill Goodwill is measured as described in “Business combinations” above. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortized and is reviewed for impairment at least annually as of October 1 or more frequently if triggering events occur or impairment indicators exist. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash generating units (“CGUs”), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units represents the lowest level within the entity at which the goodwill is monitored for internal management purposes.
Trade Receivables		Trade Receivables We use a forward-looking expected credit loss (“ECL”) model in determining our allowance for doubtful accounts as it relates to trade receivables, contract assets, and other financial assets. Our allowance is based on historical experience, and includes consideration of the aging of the receivables, the economic environment, industry trend analysis, and the credit history and financial conditions of the customers among other factors. We measure an impairment loss as the excess of the carrying amount over the present value of the estimated future cash flows discounted using the financial asset’s original discount rate, and we recognize this loss in our Consolidated Statement of Profit and Loss. A financial asset is written-off or written-down to its net realizable value as soon as it is known to be impaired. We adjust previous write-downs to reflect changes in estimates or actual experience. Our allowance for doubtful accounts is not material.
Non-current Assets Held for Sale and Disposal Groups		Non-current Assets Held for Sale and Disposal Groups Non-current assets and disposal groups are classified as held for sale when: ● They are available for immediate sale, ● Management is committed to a plan to sell, ● It is unlikely that significant changes to the plan will be made or that the plan will be withdrawn, ● An active program to locate a buyer has been initiated, ● The asset or disposal group is being marketed at a reasonable price in relation to its fair value, and ● A sale is expected to complete within 12 months from the date of classification. Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount immediately prior to being classified as held for sale in accordance with the Group’s accounting policy; and fair value less costs of disposal. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Following their classification as held for sale, non-current assets (including those in a disposal group) are not depreciated. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized.
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. As of December 31, 2021, the Group had restricted cash of $0.3 million (2020: $0.0 million).
Impairment of Non-financial Assets Excluding Deferred Tax Assets		Impairment of Non-financial Assets Excluding Deferred Tax Assets Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that carrying values may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal (market value) and value in use determined using estimates of discounted future net cash flows of the asset or group of assets to which it belongs. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units).
Employee Benefits		Employee Benefits Defined Contribution Plans Obligations for contributions to defined contribution pension plans are recognized as an expense in the Consolidated Statement of Profit and Loss in the periods during which services are rendered by employees. Short-term Benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Share-based Payment Transactions		Share-based Payment Transactions The Group and the Company operates an equity compensation scheme. It issues equity settled share-based payments to both employees and non-employees within the Group, whereby services are rendered in exchange for rights to purchase shares of the Company, which are primarily composed of restricted stock awards and options. Non-employees include contractors and advisors. The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards, net of estimated forfeitures. The fair value of the options granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions (if applicable) are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Compensation expense associated with equity compensation awards is recognized on a straight-line basis over the requisite period. The forfeitures rate is estimated and revised at each reporting date based on historical actuals. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes.
Valuation of Ordinary Shares		Valuation of Ordinary Shares As there has been no public market for the Group’s ordinary shares prior to October 21, 2021, the estimated fair value of the ordinary shares has been determined by the Board of Directors as of the date of each grant, with input from management, considering the most recently available third-party valuations of the Group’s ordinary shares, and the assessment of additional objective and subjective factors that they believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
Foreign Currency		Foreign Currency Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are retranslated to the functional currency at foreign exchange rates ruling at the dates the fair value was determined. Foreign exchange differences arising on translation are recognized in the Consolidated Statement of Profit and Loss. The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on consolidation, are translated to the Group’s presentational currency, United States Dollars, at foreign exchange rates ruling at the reporting date. The revenues and expenses of foreign operations are translated at an average rate for the year where this rate approximates to the foreign exchange rates ruling at the dates of the transactions. Foreign exchange differences arising on translation are recognized as other comprehensive loss.
Provisions		Provisions A provision is recognized in the Consolidated Statement of Financial Position when the Group has a present legal or constructive obligation as a result of a past event, that can be reliably measured, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects risks specific to the liability.
Equity Issuance Costs		Equity Issuance Costs The Group recognizes incremental external costs directly attributable to an equity issuance transaction as a deduction from equity. Any transaction costs are therefore deducted from share premium where possible to do so.
Debt Issuance Costs		Debt Issuance Costs The Group recognizes incremental external costs directly attributable to a debt issuance transaction as a reduction of the carrying value of the related debt liability. The costs are amortized over the life of the debt using the effective interest rate method. The amortized costs are reported as Finance costs on the Consolidated Statement of Profit and Loss.
Leases		Leases Our lease contracts primarily include real estate leases for buildings and are accounted for under IFRS 16, Leases We assess whether a contract is or contains a lease, at inception of a contract. We recognize a right-of-use asset and a corresponding lease liability with respect to all lease agreements in which we are the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, we recognize the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
Financial Instruments		Financial Instruments Derivatives Derivatives are initially measured at fair value and are subsequently remeasured to fair value at each reporting date. Warrants are derivatives that give the holder the right, but not the obligation to subscribe to the Company’s Ordinary Shares at a fixed or determinable price for a specified period. Changes in fair value are recognized in Change in fair value of warrant liabilities in the Consolidated Statement of Profit and Loss. For warrants that are tradeable, fair value is determined using market price on the NYSE under the ticker BBLN.W. For non-tradeable warrants, fair value is determined based on the terms of the warrants. For non-tradeable warrants with identical terms to the tradeable warrants, fair value is determined using market price of the tradeable warrants. For non-tradeable warrants with terms that are not identical to the tradeable warrants, fair value is determined using a Monte Carlo simulation that takes into account the exercise price, the term of the warrant, the underlying share price (BBLN) at the measurement date, the risk-free rate, and a volatility rate derived from peer group companies. Loans and Borrowings Interest-bearing loans and borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. Convertible Loan Notes Under IAS 32, the liability and equity components of convertible loan notes must be presented separately on the Consolidated Statement of Financial Position. If the conversion option exchanges a fixed number of shares for a fixed amount of cash (“fixed for fixed”) then it is classified as an equity instrument. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. The Group considers loans where the holder on the principal amount, for which there is no obligation to settle in cash, is also recognized in the share premium reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the share premium reserve to share capital and share premium. The Group considers convertible loans where the holder does have the option to repay in cash or where there is not a fixed for fixed conversion feature to be convertible debt instruments with an embedded equity conversion feature and recognizes the principal of the loan note as a debt liability in the liabilities section of the Consolidated Statement of Financial Position and the equity conversion feature as an equity derivative instrument that is measured at fair value through profit or loss. The accrued interest on the principal amount is recorded as interest expense in the Consolidated Statement of Profit and Loss and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium. Fair Value Measurements The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization at the end of each reporting period. The carrying amounts reported in the Consolidated Statement of Financial Position for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Group does not have any other material assets or liabilities that are recognized at fair value on a recurring basis.
New Standards and Interpretations Not Yet Adopted		New Standards and Interpretations Not Yet Adopted The following new and amended standards have been issued but have not been applied by the Group in these Consolidated Financial Statements. Their adoption is not expected to have a material effect on the financial statements unless otherwise indicated. ● Amendments to References to the Conceptual Framework in IFRS 3: Business Combinations, Amendments to IAS 16: Property, Plant and Equipment — Proceeds before Intended Use, and Annual Improvements to IFRS Standards 2018-2020 (effective date January 1, 2022) ● Amendments to IAS 1: Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and Classification of Liabilities as Current or Non-current, Amendments to Disclosure of Accounting Policies in IAS I: Presentation of Financial Statements and IFRS Practice Statement 2: Making Materiality Judgements , Amendments to Definition of Accounting Estimates in IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors , and Amendments to Deferred Tax related to Assets and Liabilities arising from a Single Transaction in IAS 12: Income Taxes (effective date January 1, 2023) ● Amendments to Sale or Contribution of Assets between an Investor and its Associate or Joint Venture in IFRS 10: Consolidated Financial Statements and IAS 28: Investments in Associates and Joint Ventures (effective date deferred indefinitely) The adoption of the following new and amended standards may have a material effect on the financial statements. The Company is still assessing the impact. ● Amendments to IAS 37: Onerous Contracts — Cost of Fulfilling a Contract (effective date January 1, 2022) ● IFRS 17: Insurance Contracts (effective date January 1, 2023)

Revenue (Tables)

Revenue (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Disclosure of disaggregation of revenue from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Value-based care 246,575 27,259 Software licensing 7,756 35,964 Clinical services 12,115 8,070 ​ 266,446 71,293	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Value-based care ​ 220,852 ​ 26,038 ​ — Software licensing 60,052 24,603 2,002 Clinical services 42,017 28,631 14,032 ​ 322,921 79,272 16,034
Disclosure of receivables, contract assets, and contract liabilities	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Trade receivables 7,068 8,278 Contract assets 5,557 4,484 Contract liabilities 86,426 94,182	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 20) ​ 8,278 ​ 4,674 Contract assets (Note 20) 4,484 2,378 Contract liabilities (Note 8 iii) 94,182 76,018
Disclosure of performance obligations	The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ Remainder ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ of 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ $’000 $’000 $’000 $’000 $’000 $’000 As of March 31, 2022 ​ 22,663 ​ 18,366 ​ 18,959 ​ 15,539 ​ 10,899 ​ 86,426	The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 As of December 31, 2021 ​ 23,786 ​ 18,918 ​ 19,349 ​ 17,852 ​ 14,277 ​ 94,182
Disclosure of contract liabilities	The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2022 ​ $’000 Balance on January 1, 94,182 Amounts billed but not recognized 849 Revenue recognized (6,091) Effect of movements in foreign exchange (2,514) Balance on March 31, 86,426	The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance on January 1 ​ 76,018 ​ 81,584 Amounts billed but not recognized 61,176 18,080 Revenue recognized (43,012) (23,646) Balance on December 31 94,182 76,018

Segment Information (Tables)

Segment Information (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [abstract]
Schedule of Consolidated Statements of Profit and Loss	Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Condensed Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue 15,670 250,512 335 266,517 (71) 266,446 Inter-segment revenue — — (64) (64) 64 — Segment revenue 15,670 250,512 271 266,453 (7) 266,446 Clinical care delivery expense (11,872) (12,394) (261) (24,527) 600 (23,927) Claims expense — (247,552) — (247,552) — (247,552) Other operating expenses, excluding amortization and depreciation (31,225) (34,176) (9,505) (74,906) (706) (75,612) Change in fair value of warrant liabilities — — 5,575 5,575 — 5,575 Exchange (loss) / gain (4,078) 2,353 (16,657) (18,382) 17,935 (447) Segment EBITDA (31,505) (41,257) (20,577) (93,339) 17,822 (75,517) Depreciation and amortization ​ (9,458) Change in fair value of warrant liabilities ​ (5,575) Exchange gain ​ 447 Operating loss ​ (90,103) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue 41,242 29,244 434 70,920 373 71,293 Inter-segment revenue — — 4 4 (4) — Segment revenue 41,242 29,244 438 70,924 369 71,293 Clinical care delivery expense (9,269) (4,597) (596) (14,462) 2,639 (11,823) Claims expense — (23,917) — (23,917) — (23,917) Other operating expenses, excluding amortization and depreciation (26,442) (11,316) (2,386) (40,144) (2,311) (42,455) Exchange (loss) / gain (632) (49) 1,788 1,107 (1,680) (573) Gain on sale — — 3,917 3,917 — 3,917 Share of loss of equity-accounted investees — (455) — (455) — (455) Segment EBITDA 4,899 (11,090) 3,161 (3,030) (983) (4,013) Depreciation and amortization ​ (5,848) Exchange loss ​ 573 Gain on sale of subsidiary ​ (3,917) Share of loss of equity-accounted investees ​ 455 Operating loss ​ (12,750)	Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue ​ 88,967 ​ 232,296 ​ 1,610 ​ 322,873 ​ 48 ​ 322,921 Inter-segment revenue ​ 2,205 ​ (3,964) ​ 1,756 ​ (3) ​ 3 ​ 0 Segment revenue ​ 91,172 ​ 228,332 ​ 3,366 ​ 322,870 ​ 51 ​ 322,921 Cost of care delivery ​ (41,542) ​ (253,998) ​ (1,590) ​ (297,130) ​ 7,458 ​ (289,672) Other operating expenses, excluding amortization and depreciation ​ (114,975) ​ (105,602) ​ (171,951) ​ (392,528) ​ (8,226) ​ (400,754) Change in fair value of warrant liabilities ​ — ​ — ​ 27,811 ​ 27,811 ​ — ​ 27,811 Exchange (loss) / gain ​ (1,844) ​ 189 ​ 1,390 ​ (265) ​ 1,133 ​ 868 Gain on sale of subsidiary ​ — ​ — ​ 2,687 ​ 2,687 ​ 1,230 ​ 3,917 Gain on remeasurement of equity interest ​ — ​ — ​ 10,495 ​ 10,495 ​ — ​ 10,495 Share of loss of equity-accounted investees ​ — ​ (2,602) ​ — ​ (2,602) ​ — ​ (2,602) Segment EBITDA ​ (67,189) ​ (133,681) ​ (127,792) ​ (328,662) ​ 1,646 ​ (327,016) Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ (35,004) Change in fair value of warrant liabilities ​ ​ ​ ​ ​ ​ ​ (27,811) Exchange gain ​ ​ ​ ​ ​ ​ ​ (868) Gain on sale of subsidiary ​ ​ ​ ​ ​ ​ ​ (3,917) Gain on remeasurement of equity interest ​ ​ ​ ​ ​ ​ ​ (10,495) Share of loss of equity-accounted investees ​ ​ ​ ​ ​ ​ ​ 2,602 Operating loss ​ ​ ​ ​ ​ ​ ​ (402,509) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue ​ 44,000 ​ 32,226 ​ 2,968 ​ 79,194 ​ 78 ​ 79,272 Inter-segment revenue 1,194 (3,094) 1,766 (134) 134 0 Segment revenue 45,194 29,132 4,734 79,060 212 79,272 Cost of care delivery (34,600) (34,381) (7,205) (76,186) 8,932 (67,254) Other operating expenses, excluding amortization and depreciation (127,762) (27,190) (3,990) (158,942) (14,100) (173,042) Exchange (loss) / gain 403 (246) 17,060 17,217 (20,053) (2,836) Share of loss of equity-accounted investees — — (1,124) (1,124) — (1,124) Segment EBITDA (116,765) (32,685) 9,475 (139,975) (25,009) (164,984) Depreciation and amortization ​ (14,487) Exchange loss ​ 2,836 Share of loss of equity-accounted investees ​ 1,124 Operating loss ​ (175,511) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 External revenue ​ 14,633 ​ — ​ 1,410 ​ 16,043 ​ (9) ​ 16,034 Inter-segment revenue ​ 4,081 ​ (2,669) ​ (1,382) ​ 30 ​ (30) ​ — Segment revenue ​ 18,714 ​ (2,669) ​ 28 ​ 16,073 ​ (39) ​ 16,034 Cost of care delivery ​ (25,707) ​ (160) ​ (373) ​ (26,240) ​ 6,430 ​ (19,810) Other operating expenses, excluding amortization and depreciation ​ (119,895) ​ (23,273) ​ (5,340) ​ (148,508) ​ (8,040) ​ (156,548) Exchange (loss) / gain 314 (83) 16,584 16,815 260 17,075 Segment EBITDA (126,574) (26,185) 10,899 (141,860) (1,389) (143,249) Depreciation and amortization ​ (2,496) Exchange gain ​ (17,075) Operating loss ​ (162,820) ​
Disaggregation of Revenue	Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $‘000 % of revenue $‘000 % of revenue Customer 1 145,043 54.4 % 12,420 17.4 % Customer 2 61,446 23.1 % — — ​ Customer 3 14,381 5.0 % 12,148 17.0 % Customer 4 ​ 2,530 ​ 1.0 % 30,129 ​ 42.3 % ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 UK 9,435 7,786 US 250,597 29,808 Asia-Pacific 3,634 3,410 Canada 2,530 30,129 Rest of World 250 160 Total 266,446 71,293	Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue Customer 1 ​ 119,785 ​ 37.1 % 11,918 ​ 15.0 % 2,215 ​ 13.8 % Customer 2 39,764 12.3 % 9,706 12.3 % 2,465 15.4 % Customer 3 38,705 12.0 % 9,505 12.0 % 5,607 34.9 % Customer 4 N/A N/A 14,937 18.9 % N/A N/A ​ ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 UK ​ 35,490 ​ 28,827 ​ 12,189 US 232,708 32,689 — Asia-Pacific 14,965 11,585 2,215 Canada 38,705 3,207 564 Rest of World 1,053 2,964 1,066 Total 322,921 79,272 16,034 ​

Investments in Subsidiaries a_2

Investments in Subsidiaries and Associates (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments in Subsidiaries and Associates
Disclosure of significant judgements and assumptions made in relation to interests in other entities		​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Ownership Ownership ​ ​ ​ ​ ​ ​ (As of ​ (As of ​ ​ Country of ​ ​ ​ December 31, ​ December 31, Subsidiary Undertakings ​ Incorporation ​ Principal Activity ​ 2021) ​ 2020) Company: ​ ​ ​ ​ ​ ​ ​ ​ Babylon Partners Limited UK Application development 100.0% ​ 100.0% Babylon Healthcare Services Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Rwanda Limited Rwanda Digital Healthcare services 100.0% ​ 100.0% Babylon Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Health Canada Limited Canada Digital Healthcare services — ​ 100.0% Babylon Liberty Corp. USA Digital Healthcare services 100.0% ​ — Babylon Malaysia SDN BHD Malaysia Digital Healthcare services 100.0% ​ 100.0% Babylon International Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Health Ireland Limited Ireland Digital Healthcare services 100.0% ​ 100.0% Babylon Singapore PTE Limited Singapore Digital Healthcare services 100.0% ​ 100.0% Health Innovators Inc. USA Digital Healthcare services 100.0% ​ 70.1% Babylon Acquisition Corp. USA Digital Healthcare services — ​ 100.0% Babylon Technology LTDA Brazil Digital Healthcare services 100.0% ​ 100.0% Higi SH Holdings Inc. USA Digital Healthcare services 100.0% ​ 19.0% Group: ​ ​ ​ ​ Babylon Healthcare Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Healthcare NJ, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PLLC USA Healthcare services 100.0% ​ 100.0% Babylon Medical Group (formerly Marcus Zachary DO), PC USA Healthcare services 100.0% ​ 100.0% California Telemedicine Associates, PC USA Healthcare services 100.0% ​ 100.0% Telemedicine Associates, P.C. USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare NC, PC USA Healthcare services — ​ 100.0% Babylon Healthcare, PA USA Healthcare services 100.0% ​ — Meritage Medical Network USA Healthcare services 100.0% ​ — Meritage Health Ventures, LLC USA Healthcare services 100.0% ​ — Meritage Health Plan USA Healthcare services 100.0% ​ — Meritage Management, LLC USA Healthcare services 100.0% ​ — Higi SH LLC USA Digital Healthcare services 100.0% ​ 19.0% Higi Health Holdings LLC USA Digital Healthcare services 100.0% ​ — Higi SH Canada ULC Canada Digital Healthcare services 100.0% ​ 19.0% Higi Health LLC USA Digital Healthcare services 51.0% ​ — Health Innovators Limited UK Digital Healthcare services 100.0% ​ 70.1% DTDHI Health India PVT Ltd India Digital Healthcare services 97.8% ​ 68.6%
Summarized financial information for unconsolidated professional service corporations	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Total assets 131,429 104,703 Total liabilities 213,222 168,240 ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Total revenues 127,138 19,756 Clinical care delivery expense (8,912) (2,256) Claims expense (118,985) (15,793) Sales, general & administrative expenses (15,012) (2,875)	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total assets 104,703 35,535 Total liabilities 168,240 42,699 ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total revenues 154,508 17,436 Cost of care delivery (155,191) (20,175) Sales, general & administrative expenses (55,006) (3,799)

Intangible Assets and Goodwill

Intangible Assets and Goodwill (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [text block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ $’000 $’000 $’000 $’000 $’000 $’000 $’000 $’000 Cost Balance at January 1, 2022 93,678 109,356 21,868 14,700 8,300 5,000 590 159,814 Additions — — 10,071 — — — — 10,071 Transfers — 6,803 (6,803) — — — — — Effect of movements in foreign exchange (23) (2,759) (530) — — — — (3,289) Balance at March 31, 2022 93,655 113,400 24,606 14,700 8,300 5,000 590 166,596 Amortization and impairment Balance at January 1, 2022 — 39,724 — 3,680 3,533 1,063 393 48,393 Amortization for the period — 5,064 — 193 750 329 131 6,467 Effect of movements in foreign exchange — (1,094) — — — — — (1,094) Balance at March 31, 2022 — 43,694 — 3,873 4,283 1,392 524 53,766 Net book value At January 1, 2022 93,678 69,632 21,868 11,020 4,767 3,937 197 111,421 At March 31, 2022 93,655 69,706 24,606 10,827 4,017 3,608 66 112,830 ​	The changes in the carrying amount of goodwill and intangible assets for the years ended December 31, 2021 and 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ 61 ​ 15,558 ​ 28,873 ​ — ​ — ​ — ​ — ​ 44,431 Acquisitions through business combinations ​ 17,771 ​ — ​ — ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 7,900 Additions ​ — ​ 940 ​ 43,027 ​ — ​ — ​ — ​ — ​ 43,967 Transfers ​ — ​ 51,932 ​ (51,932) ​ — ​ — ​ — ​ — ​ — Effect of movements in foreign exchange ​ — ​ 632 ​ 1,170 ​ — ​ — ​ — ​ — ​ 1,802 Balance at December 31, 2020 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Balance at January 1, 2021 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Acquisitions through business combinations ​ 75,846 ​ 8,550 ​ — ​ 11,600 ​ 5,000 ​ 3,500 ​ 590 ​ 29,240 Additions ​ — ​ — ​ 33,999 ​ — ​ — ​ — ​ — ​ 33,999 Transfers ​ — ​ 33,056 ​ (33,056) ​ ​ ​ ​ — ​ — Effect of movements in foreign exchange ​ — ​ (1,312) ​ (213) ​ — ​ — ​ — ​ — ​ (1,525) Balance at December 31, 2021 ​ 93,678 ​ 109,356 ​ 21,868 ​ 14,700 ​ 8,300 ​ 5,000 ​ 590 ​ 159,814 Amortization and impairment ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ — ​ 680 ​ — ​ — ​ — ​ — ​ — ​ 680 Amortization for the year ​ — ​ 10,157 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 11,123 Impairment charge ​ — ​ 6,436 ​ — ​ — ​ — ​ — ​ — ​ 6,436 Effect of movements in foreign exchange ​ — ​ 1,008 ​ — ​ — ​ — ​ — ​ — ​ 1,008 Balance at December 31, 2020 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Balance at January 1, 2021 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Amortization for the year ​ — ​ 21,287 ​ — ​ 2,835 ​ 3,450 ​ 1,025 ​ 393 ​ 28,990 Impairment charge ​ — ​ 941 ​ — ​ — ​ — ​ — ​ — ​ 941 Effect of movements in foreign exchange ​ — ​ (785) ​ — ​ — ​ — ​ — ​ — ​ (785) Balance at December 31, 2021 ​ — ​ 39,724 ​ — ​ 3,680 ​ 3,533 ​ 1,063 ​ 393 ​ 48,393 Net book value ​ ​ ​ ​ ​ ​ ​ ​ At January 1, 2020 ​ 61 ​ 14,878 ​ 28,873 ​ — ​ — ​ — ​ — ​ 43,751 At December 31, 2020 and January 1, 2021 ​ 17,832 ​ 50,781 ​ 21,138 ​ 2,255 ​ 3,217 ​ 1,462 ​ — ​ 78,853 At December 31, 2021 ​ 93,678 ​ 69,632 ​ 21,868 ​ 11,020 ​ 4,767 ​ 3,937 ​ 197 ​ 111,421

Claims Payable (Tables)

Claims Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Claims Payable
Summary of Claims Activity	​ ​ ​ ​ ​ $’000 Balance at January 1, 2022 24,628 Claims expense 247,552 Claims paid (233,015) Adjustment, net — Balance at March 31, 2022 39,165	​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Claims expense 24,146 Claims paid (21,137) Adjustment, net 881 Balance at December 31, 2020 3,890 Balance at January 1, 2021 3,890 Claims expense 216,791 Claims paid (196,053) Adjustment, net — Balance at December 31, 2021 24,628

Cash and Cash Equivalents (Tabl

Cash and Cash Equivalents (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents
Summary of Cash and Cash Equivalents	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Cash in hand and at banks 274,978 262,276 Short term investment funds — — Restricted cash — 305 ​ 274,978 262,581	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Cash in hand and at banks 262,276 97,757 Short term investment funds — 4,000 Restricted cash 305 — ​ 262,581 101,757

Loans and Borrowings (Tables)

Loans and Borrowings (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Borrowing costs [abstract]
Schedule of Non-Current and Current Liabilities	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185
Disclosure of Changes in Loans and Borrowings from Financing Activities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other Total Loans ​ ​ AlbaCore ​ Loans and ​ and ​ ​ Notes ​ Borrowings ​ Borrowings ​ $’000 $’000 $’000 Balance at January 1, 2022 ​ 168,601 ​ 185 ​ 168,786 Changes from financing cash flows ​ ​ ​ Proceeds from issuance of notes and warrants ​ 100,000 ​ — ​ 100,000 Payment of debt issuance costs ​ (4,000) ​ — ​ (4,000) Total changes from financing cash flows ​ 96,000 ​ — ​ 96,000 Other changes ​ ​ ​ Fair value of warrants issued ​ (3,418) ​ — ​ (3,418) Unpaid debt issuance costs ​ (257) ​ — ​ (257) Amortization of fair value adjustment, discount, and debt issuance costs ​ 1,202 ​ — ​ 1,202 Other loans and borrowings activity, net ​ — ​ (171) ​ (171) Total other changes ​ (2,473) ​ (171) ​ (2,644) Balance at March 31, 2022 ​ 262,128 ​ 14 ​ 262,142	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ Total Loans ​ ​ Albacore ​ VNV Loan ​ Unsecured ​ Convertible ​ Loans and ​ and ​ Notes Notes Bonds Loan Notes Borrowings Borrowings ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at January 1, 2020 — — — — — — Changes from financing cash flows Proceeds from issuance of notes and warrants — — — 100,000 357 100,357 Total changes from financing cash flows — — — 100,000 357 100,357 Other changes Convertible loan notes converted — — — (30,000) — (30,000) Total other changes — — — (30,000) — (30,000) Balance at December 31, 2020 — — — 70,000 357 70,357 Balance at January 1, 2021 — — — 70,000 357 70,357 Changes from financing cash flows Proceeds from issuance of notes and warrants 191,000 15,000 64,563 — — 270,563 Payment of debt issuance costs (3,429) — (1,375) — — (4,804) Repayment of cash loan — (7,000) (75,000) — — (82,000) Total changes from financing cash flows 187,571 8,000 (11,812) — — 183,759 Other changes Fair value of warrants issued (16,930) — — — — (16,930) Unpaid debt issuance costs (2,801) — (171) — — (2,972) Amortization of fair value adjustment, discount, and debt issuance costs 761 — 3,983 — — 4,744 Convertible loan notes converted — — — (70,000) — (70,000) Non-cash conversion of loan notes to bonds — (8,000) 8,000 — — — Other loans and borrowings activity, net — — — — (172) (172) Total other changes (18,970) (8,000) 11,812 (70,000) (172) (85,330) Balance at December 31, 2021 168,601 — — — 185 168,786 ​

Employee Benefits (Tables)

Employee Benefits (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Employee Benefits
Disclosure of Share-based Payments Recognized As Expense for RSUs, RSAs and Options, Net of Forfeitures	Share-based payments are recognized as expense for RSUs, RSAs and options, net of estimated forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ 2022 2021 ​ ​ $’000 ​ $’000 Total share-based compensation expense 8,402 2,802	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Total share-based compensation expense 46,307 9,557 7,966
Disclosure of Restricted Stock Unit Activity and Weighted Average Grant Date Fair Values	The following table displays RSU activity for the periods presented: ​ ​ ​ ​ ​ RSUs Balance at January 1, 2022 6,997,284 Granted 14,758,592 Vested and issued (895,627) Forfeited / canceled during the period (1,099,073) Balance at March 31, 2022 19,761,176 Vested and unissued at March 31, 2022 39,022 Unvested at March 31, 2022 19,722,154	​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant Date Fair Value ​ ​ RSUs ​ Per RSU (1) Balance at January 1, 2021 — ​ $ — Granted 6,997,284 ​ $ 6.23 Vested and issued — ​ $ — Forfeited — ​ $ — Balance at December 31, 2021 6,997,284 ​ $ 6.23 Vested and unissued at December 31, 2021 1,760,363 ​ $ 6.23 Unvested at December 31, 2021 5,236,921 ​ $ 6.23
Disclosure of Stock Options Granted		​ ​ ​ ​ Fair value of underlying stock $2.97  – $9.20 Volatility ​ 63.4%  – 70.0% Risk-free interest rate ​ 0.12%  – 1.68% Dividend yield ​ 0%  – 0% Expected term (in years) ​ 10.00  – 14.50
Disclosure of Number and Weighted Average Exercise Prices of Share Options	The following table displays option activity and weighted average exercise price for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ $ ​ $ ​ Outstanding at the beginning of the period 1.47 22,896,265 0.02 21,107,487 Granted during the period — — 3.67 8,155,289 Forfeited / canceled during the period 1.26 (650,232) 0.18 (6,204,471) Exercised during the period 0.35 (27,942) 1.42 (162,040) Outstanding at the end of the period 1.48 22,218,091 1.47 22,896,265	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ price ​ options ​ ​ $ ​ ​ ​ $ ​ ​ ​ $ ​ ​ Outstanding at the beginning of the year 0.02 ​ 21,107,487 — ​ 20,120,425 — 19,666,539 Granted during the year ​ 3.67 ​ 8,155,289 ​ 0.11 ​ 4,109,243 ​ — ​ 2,786,856 Forfeited / canceled during the year ​ 0.18 ​ (6,204,471) ​ 0.04 ​ (3,122,181) ​ — ​ (2,332,970) Exercised during the year ​ 1.42 ​ (162,040) ​ — ​ — ​ — ​ — Outstanding at the end of the year ​ 1.47 ​ 22,896,265 ​ 0.02 ​ 21,107,487 ​ — ​ 20,120,425 Exercisable at the end of the year ​ 1.54 ​ 19,105,908 ​ 0.01 ​ 16,461,945 ​ — ​ 11,817,828

Capital and Reserves (Tables)

Capital and Reserves (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Disclosure of Share Capital	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A Ordinary Class B Ordinary ​ In thousands of shares Shares Shares Deferred Shares Authorized 6,500,000 3,100,000 100,000 On issue at January 1, 2022 333,925 79,638 — Issued during the period 924 — — On issue at March 31, 2022—fully paid 334,848 79,638 —	The share capital of Babylon Holdings Limited immediately following the closing of the transaction is as follows: ​ ​ ​ ​ ​ ​ ​ In thousands of shares Number of Shares Share Capital Description Class A Ordinary Shares 295,589 12 Issuance to Babylon Shareholders Class A Ordinary Shares 22,400 1 Issuance to PIPE Investors Class A Ordinary Shares 12,268 — Issuance to SPAC Investors and Shareholders ​ 330,257 13 ​ ​ Class B Ordinary Shares 79,638 3 Issuance to Babylon Shareholders ​ 409,895 16 ​ ​ The following tables display the number of shares of Babylon Holdings Limited prior and following the Merger: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A ​ Class B ​ ​ ​ ​ ​ ​ ​ Ordinary ​ ​ Ordinary ​ Ordinary ​ Ordinary A ​ Ordinary B ​ Preference C ​ Redeemable G1 ​ Shares Shares Shares Shares Shares Shares In thousands of shares ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 Authorized ​ 6,500,000 ​ 3,100,000 ​ 10,000,000 ​ 11,000,000 ​ 10,000,000 ​ 50,000 On issue at January 1, 2021 ​ — ​ — ​ 135,136 ​ 664,605 ​ 252,065 ​ — Issued during the year prior to Merger — — — 17,206 41,012 10,150 Conversion into Class A and B Shares 330,257 79,638 (135,136) (681,811) (293,077) (10,150) Issued following the Merger 3,668 — — — — — On issue at December 31, 2021  –  fully paid 333,925 79,638 — — — —
Disclosure of Other Comprehensive Income Accumulated in Reserves, Net of Tax	​ ​ ​ ​ ​ ​ 2022 ​ $’000 January 1, (27) Foreign operations – foreign currency translation differences (3,753) March 31, (3,780)	Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 January 1, 1,675 (1,904) 7,789 Foreign operations – foreign currency translation differences (1,702) 3,579 (9,693) December 31, (27) 1,675 (1,904)

Warrant Liability (Tables)

Warrant Liability (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Abstract]
Number of Warrants in Issue	​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Tradeable Non-tradeable Total ​ No. of warrants No. of warrants No. of warrants In issue at January 1, 2022 8,625 7,691 16,316 Issuance of Additional AlbaCore Warrants on March 31, 2022 — 879 879 In issue at March 31, 2022 8,625 8,570 17,195	​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable ​ Non-tradeable ​ Total (In thousands) No. of warrants No. of warrants No. of warrants In issue at January 1, 2021 — — — Issuance of Alkuri Warrants on October 21, 2021 8,625 5,933 14,558 Issuance of AlbaCore Warrants on November 4, 2021 — 1,758 1,758 In issue at December 31, 2021 8,625 7,691 16,316 ​
Schedule of Reconciliation of Fair Values	See reconciliation of fair values below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ (Level 1) (Level 2) (Level 3) Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at December 31, 2021 5,865 4,035 10,228 20,128 Fair value of Additional AlbaCore Warrants upon issuance — — 3,418 3,418 Change in fair value of warrant liabilities (1,294) (890) (3,391) (5,575) Balance at March 31, 2022 4,571 3,145 10,255 17,971	See reconciliation of fair values below: ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total ​ ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ Balance at December 31, 2019 ​ — ​ — ​ — ​ — ​ Balance at December 31, 2020 ​ — ​ — ​ — ​ — ​ Fair value of Alkuri Warrants upon issuance ​ 18,371 ​ 12,638 ​ — ​ 31,009 ​ Fair value of AlbaCore Warrants upon issuance ​ — ​ — ​ 16,930 ​ 16,930 ​ Change in fair value of warrant liabilities ​ (12,506) ​ (8,603) ​ (6,702) ​ (27,811) ​ Balance at December 31, 2021 ​ 5,865 ​ 4,035 ​ 10,228 ​ 20,128 ​

Financial Instruments (Tables)

Financial Instruments (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Financial Instruments
Schedule of Assets and Liabilities that are Measured at Fair Value	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 4,571 — — 4,571 Non-tradeable Alkuri Warrants — 3,145 — 3,145 AlbaCore Warrants — — 6,837 6,837 Additional AlbaCore Warrants — — 3,418 3,418 ​ 4,571 3,145 10,255 17,971	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 5,865 — — 5,865 Non-tradeable Alkuri Warrants — 4,035 — 4,035 AlbaCore Warrants — — 10,228 10,228 ​ 5,865 4,035 10,228 20,128
Schedule of the Monte Carlo Simulation Model for the AlbaCore Warrants	The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants and Additional AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of As of ​ March 31, 2022 December 31, 2021 Underlying stock price (USD) ​ $ 3.89 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 74.1 % 71.6 % Remaining term (years) ​ 4.6 ​ 4.85 ​ Risk-free rate ​ 2.40 % 1.23 %	The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ November 4, 2021 December 31, 2021 Underlying stock price (USD) ​ $ 9.66 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 66.7 % 71.6 % Remaining term (years) ​ 5.00 ​ 4.85 ​ Risk-free rate ​ 1.09 % 1.23 %
Schedule of Significant Exchange Rates		The Group has applied the following significant exchange rates: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average Rate ​ Year-end spot rate United States Dollar 2021 2020 2019 2021 2020 2019 GBP 0.7277 0.7760 0.7835 0.7409 0.7321 0.7618 CAD 1.2536 1.3433 1.3251 1.2725 1.2750 1.3033 RWF 1,003.4066 959.1820 914.2488 1,037.6458 988.0837 947.0750 SGD 1.3427 1.3789 1.3111 1.3496 1.3224 1.3456 INR 73.7902 74.0038 N/A 74.3047 73.2901 N/A
Schedule of Sensitivity Analysis		This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. The fluctuation seen primarily relates to the impacts of Brexit and COVID-19 over the last two years but is expected to stabilize moving forward. ​ ​ ​ ​ ​ ​ ​ ​ Profit or loss ​ Strengthening Weakening ​ ​ $’000 ​ $’000 December 31, 2021 GBP (5.0% movement) (373,578) (371,938) December 31, 2020 GBP (5.0% movement) (184,067) (184,416) December 31, 2019 GBP (5.0% movement) (156,489) (150,290) ​ ​ ​ ​ ​ ​ ​ ​ Equity, net of tax ​ ​ Strengthening ​ Weakening ​ ​ $’000 ​ $’000 December 31, 2021 GBP (5.0% movement) (168,522) (168,930) December 31, 2020 GBP (5.0% movement) (48,743) (48,394) December 31, 2019 GBP (5.0% movement) (175,371) (173,872)

Basis of Preparation - Narrativ

Basis of Preparation - Narrative (Details) - USD ($) $ in Thousands	Oct. 21, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basis of Preparation
Loss for the period		$ (91,357)	$ (10,847)	$ (374,511)	$ (188,030)	$ (140,287)
Net cash (used in) provided by operating activities		(68,957)	21,500	(145,868)	(143,430)	(143,614)
Equity		79,531	$ 38,940	165,271	48,359	173,797	$ (50,484)
Cash and cash equivalents		274,978		262,581	101,757
Proceeds from issuance of share capital	$ 229,300	$ 329,300		$ 229,311	$ 12,096	$ 320,334

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of changes in accounting estimates [line items]
Contract period (in year)	1 year
Development costs	$ 34,000	$ 43,000
Restricted cash	$ 305	$ 0
Lease term	12 months
Bottom of range
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	12.00%
Top of range
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	13.00%
Weighted average.
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	7.80%
Software Licensing
Disclosure of changes in accounting estimates [line items]
Contract period (in year)	1 year

Revenue - Disaggregation of Rev

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Value-Based Care
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	246,575	27,259	220,852	26,038
Software Licensing
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	7,756	35,964	60,052	24,603	2,002
Clinical Services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	$ 12,115	$ 8,070	$ 42,017	$ 28,631	$ 14,032

Revenue - Narrative (Details)

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Upfront payment on license and support agreement	$ 66.9	$ 66.9
Post contract support period	24 months	24 months
Right to access enhancements period	7 years	7 years

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from contracts with customers [Abstract]
Trade receivables	$ 7,068	$ 8,278	$ 4,674
Contract assets	5,557	4,484	2,378	$ 1,541
Contract liabilities	$ 86,426	$ 94,182	$ 76,018	$ 81,584

Revenue - Revenue to Be Recogni

Revenue - Revenue to Be Recognized (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	$ 86,426	$ 94,182
Remainder of 2022
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	22,663	23,786
2023
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	18,366	18,918
2024
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	18,959	19,349
2025
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	15,539	17,852
2026 and beyond
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	$ 10,899	$ 14,277

Revenue - Contract Liabilities

Revenue - Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from contracts with customers [Abstract]
Contract liabilities at beginning of period	$ 94,182	$ 76,018	$ 81,584
Amounts billed but not recognized	849	61,176	18,080
Revenue recognized	(6,091)	(43,012)	(23,646)
Effect of movements in foreign exchange	(2,514)
Contract liabilities at end of period	$ 86,426	$ 94,182	$ 76,018

Segment Information - Consolida

Segment Information - Consolidated Statements of Profit and Loss (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of operating segments [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Clinical care delivery expense	(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Claims expense	(247,552)	(23,917)
Other operating income (expense)			(400,754)	(173,042)	(156,548)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(75,612)	(42,455)
Change in fair value of warrant liabilities	5,575		27,811
Exchange loss	(447)	(573)	868	(2,836)	17,075
Gain on sale of subsidiary		3,917	3,917
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees		(455)	(2,602)	(1,124)
Segment EBITDA	(75,517)	(4,013)	(327,016)	(164,984)	(143,249)
Depreciation and amortization	(9,458)	(5,848)	(35,004)	(14,487)	(2,496)
Operating loss	(90,103)	(12,750)	(402,509)	(175,511)	(162,820)
Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	266,517	70,920	322,873	79,194	16,043
Operating segments
Disclosure of operating segments [line items]
Revenue	266,453	70,924	322,870	79,060	16,073
Clinical care delivery expense	(24,527)	(14,462)	(297,130)	(76,186)	(26,240)
Claims expense	(247,552)	(23,917)
Other operating income (expense)			(392,528)	(158,942)	(148,508)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(74,906)	(40,144)
Change in fair value of warrant liabilities	5,575		27,811
Exchange loss	(18,382)	1,107	(265)	17,217	16,815
Gain on sale of subsidiary		3,917	2,687
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees		(455)	(2,602)	(1,124)
Segment EBITDA	(93,339)	(3,030)	(328,662)	(139,975)	(141,860)
Reconciliation adjustments
Disclosure of operating segments [line items]
Revenue	(7)	369	51	212	(39)
Clinical care delivery expense	600	2,639	7,458	8,932	6,430
Other operating income (expense)			(8,226)	(14,100)	(8,040)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(706)	(2,311)
Exchange loss	17,935	(1,680)	1,133	(20,053)	260
Gain on sale of subsidiary			1,230
Segment EBITDA	17,822	(983)	1,646	(25,009)	(1,389)
Unallocated amounts
Disclosure of operating segments [line items]
Revenue	(71)	373	48	78	(9)
Inter-segment revenue
Disclosure of operating segments [line items]
Revenue	(64)	4	3	134	(30)
UK | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	15,670	41,242	88,967	44,000	14,633
UK | Operating segments
Disclosure of operating segments [line items]
Revenue	15,670	41,242	91,172	45,194	18,714
Clinical care delivery expense	(11,872)	(9,269)	(41,542)	(34,600)	(25,707)
Other operating income (expense)			(114,975)	(127,762)	(119,895)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(31,225)	(26,442)
Exchange loss	(4,078)	(632)	(1,844)	403	314
Segment EBITDA	(31,505)	4,899	(67,189)	(116,765)	(126,574)
UK | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue			2,205	1,194	4,081
US | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	250,512	29,244	232,296	32,226
US | Operating segments
Disclosure of operating segments [line items]
Revenue	250,512	29,244	228,332	29,132	(2,669)
Clinical care delivery expense	(12,394)	(4,597)	(253,998)	(34,381)	(160)
Claims expense	(247,552)	(23,917)
Other operating income (expense)			(105,602)	(27,190)	(23,273)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(34,176)	(11,316)
Exchange loss	2,353	(49)	189	(246)	(83)
Share of loss of equity-accounted investees		(455)	(2,602)
Segment EBITDA	(41,257)	(11,090)	(133,681)	(32,685)	(26,185)
US | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue			(3,964)	(3,094)	(2,669)
All other segments | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	335	434	1,610	2,968	1,410
All other segments | Operating segments
Disclosure of operating segments [line items]
Revenue	271	438	3,366	4,734	28
Clinical care delivery expense	(261)	(596)	(1,590)	(7,205)	(373)
Other operating income (expense)			(171,951)	(3,990)	(5,340)
Other Operating Income (Expense) Excluding Amortization And Depreciation	(9,505)	(2,386)
Change in fair value of warrant liabilities	5,575		27,811
Exchange loss	(16,657)	1,788	1,390	17,060	16,584
Gain on sale of subsidiary		3,917	2,687
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees				(1,124)
Segment EBITDA	(20,577)	3,161	(127,792)	9,475	10,899
All other segments | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue	$ (64)	$ 4	$ 1,756	$ 1,766	$ (1,382)

Segment Information - Major Cus

Segment Information - Major Customers (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of operating segments [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
UK
Disclosure of operating segments [line items]
Percentage of revenue	39.40%		38.30%	64.80%
Revenue	$ 9,435	7,786	$ 35,490	$ 28,827	12,189
US
Disclosure of operating segments [line items]
Percentage of revenue	59.50%		61.10%	34.50%
Revenue	$ 250,597	29,808	$ 232,708	$ 32,689
Asia-Pacific
Disclosure of operating segments [line items]
Revenue	3,634	3,410	14,965	11,585	2,215
Canada
Disclosure of operating segments [line items]
Revenue	2,530	30,129	38,705	3,207	564
Rest of World
Disclosure of operating segments [line items]
Revenue	$ 250	$ 160	$ 1,053	$ 2,964	$ 1,066
Customer 1
Disclosure of operating segments [line items]
Percentage of revenue	54.40%	17.40%	37.10%	15.00%	13.80%
Revenue	$ 145,043	$ 12,420	$ 119,785	$ 11,918	$ 2,215
Customer 2
Disclosure of operating segments [line items]
Percentage of revenue	23.10%		12.30%	12.30%	15.40%
Revenue	$ 61,446		$ 39,764	$ 9,706	$ 2,465
Customer 3
Disclosure of operating segments [line items]
Percentage of revenue	5.00%	17.00%	12.00%	12.00%	34.90%
Revenue	$ 14,381	$ 12,148	$ 38,705	$ 9,505	$ 5,607
Customer 4
Disclosure of operating segments [line items]
Percentage of revenue	1.00%	42.30%		18.90%
Revenue	$ 2,530	$ 30,129		$ 14,937

Segment Information - Narrative

Segment Information - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of operating segments [line items]
Non-current assets	$ 252,193	$ 237,933	$ 109,467
UK
Disclosure of operating segments [line items]
Percentage of revenue	39.40%	38.30%	64.80%
Non-current assets	$ 99,300	$ 92,600	$ 70,900
Trade receivables	$ 4,900	$ 7,000	$ 2,200
Percentage of receivables	69.40%	84.50%	47.60%
US
Disclosure of operating segments [line items]
Percentage of revenue	59.50%	61.10%	34.50%
Non-current assets	$ 150,100	$ 147,800	$ 37,800
Trade receivables	$ 2,000	$ 900	$ 2,300
Percentage of receivables	27.70%	11.00%	50.10%

Investments in Subsidiaries a_3

Investments in Subsidiaries and Associates - Professional Service Corporations (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of information about unconsolidated structured entities controlled by investment entity [line items]
Total assets	$ 582,577		$ 554,632	$ 238,814
Total liabilities	503,046		389,361	190,455
Revenue	266,446	$ 71,293	322,921	79,272	$ 16,034
Clinical care delivery expense	(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Claims expense	247,552	23,917
Sales, general & administrative expenses	(58,310)	(31,479)	(196,673)	(94,681)	$ (84,270)
Professional Service Corporations
Disclosure of information about unconsolidated structured entities controlled by investment entity [line items]
Total assets	131,429		104,703	35,535
Total liabilities	213,222		168,240	42,699
Revenue	127,138	19,756	154,508	17,436
Clinical care delivery expense	(8,912)	(2,256)	(155,191)	(20,175)
Claims expense	(118,985)	(15,793)
Sales, general & administrative expenses	$ (15,012)	$ (2,875)	$ (55,006)	$ (3,799)

Intangible Assets and Goodwil_2

Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	$ 111,421	$ 78,853	$ 43,751
Intangible assets and goodwill at end of period	112,830	111,421	78,853
Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	93,678	17,832	61
Intangible assets and goodwill at end of period	93,655	93,678	17,832
Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	69,632	50,781	14,878
Intangible assets and goodwill at end of period	69,706	69,632	50,781
Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	21,868	21,138	28,873
Intangible assets and goodwill at end of period	24,606	21,868	21,138
Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	11,020	2,255	0
Intangible assets and goodwill at end of period	10,827	11,020	2,255
Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	4,767	3,217	0
Intangible assets and goodwill at end of period	4,017	4,767	3,217
Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	3,937	1,462	0
Intangible assets and goodwill at end of period	3,608	3,937	1,462
Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	197	0	0
Intangible assets and goodwill at end of period	66	197	0
Cost
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	159,814	98,100	44,431
Acquisitions through business combinations		29,240	7,900
Additions	10,071	33,999	43,967
Transfers		0	0
Effect of movements in foreign exchange	(3,289)	(1,525)	1,802
Intangible assets and goodwill at end of period	166,596	159,814	98,100
Cost | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	93,678	17,832	61
Acquisitions through business combinations		75,846	17,771
Additions		0	0
Transfers		0	0
Effect of movements in foreign exchange	(23)	0	0
Intangible assets and goodwill at end of period	93,655	93,678	17,832
Cost | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	109,356	69,062	15,558
Acquisitions through business combinations		8,550	0
Additions		0	940
Transfers	6,803	33,056	51,932
Effect of movements in foreign exchange	(2,759)	(1,312)	632
Intangible assets and goodwill at end of period	113,400	109,356	69,062
Cost | Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	21,868	21,138	28,873
Acquisitions through business combinations		0	0
Additions	10,071	33,999	43,027
Transfers	(6,803)	(33,056)	(51,932)
Effect of movements in foreign exchange	(530)	(213)	1,170
Intangible assets and goodwill at end of period	24,606	21,868	21,138
Cost | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	14,700	3,100	0
Acquisitions through business combinations		11,600	3,100
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	14,700	14,700	3,100
Cost | Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	8,300	3,300	0
Acquisitions through business combinations		5,000	3,300
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	8,300	8,300	3,300
Cost | Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	5,000	1,500	0
Acquisitions through business combinations		3,500	1,500
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	5,000	5,000	1,500
Cost | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	590	0	0
Acquisitions through business combinations		590	0
Additions		0	0
Transfers		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	590	590	0
Amortization and impairment
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(48,393)	(19,247)	(680)
Amortization for the period	6,467	28,990	11,123
Impairment charge		(941)	(6,436)
Effect of movements in foreign exchange	(1,094)	(785)	1,008
Intangible assets and goodwill at end of period	(53,766)	(48,393)	(19,247)
Amortization and impairment | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	0	0	0
Amortization for the period		0	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period		0	0
Amortization and impairment | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(39,724)	(18,281)	(680)
Transfers	6,800
Amortization for the period	5,064	21,287	10,157
Impairment charge		(941)	(6,436)
Effect of movements in foreign exchange	(1,094)	(785)	1,008
Intangible assets and goodwill at end of period	(43,694)	(39,724)	(18,281)
Amortization and impairment | Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	0	0	0
Amortization for the period		0	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period		0	0
Amortization and impairment | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(3,680)	(845)	0
Amortization for the period	193	2,835	845
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(3,873)	(3,680)	(845)
Amortization and impairment | Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(3,533)	(83)	0
Amortization for the period	750	3,450	83
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(4,283)	(3,533)	(83)
Amortization and impairment | Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(1,063)	(38)	0
Amortization for the period	329	1,025	38
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(1,392)	(1,063)	(38)
Amortization and impairment | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(393)	0	0
Amortization for the period	131	393	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	$ (524)	$ (393)	$ 0

Claims Payable (Details)

Claims Payable (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020
Claims Payable
Claims payable beginning balance	$ 24,628	$ 3,890	$ 3,890
Claims expense	247,552	$ 23,917
Claims paid	(233,015)		(196,053)	$ (21,137)
Adjustment, net				881
Claims payable ending balance	$ 39,165		$ 24,628	$ 3,890

Cash and Cash Equivalents (Deta

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents
Cash in hand and at banks	$ 274,978	$ 262,276	$ 97,757
Short term investment funds			4,000
Restricted cash		305	0
Cash and cash equivalents	$ 274,978	$ 262,581	$ 101,757

Leases - Narrative (Details)

Leases - Narrative (Details) $ in Millions	Nov. 01, 2021ft²	Mar. 31, 2020USD ($)	Feb. 01, 2022USD ($)employee	Jan. 14, 2022USD ($)	Jan. 06, 2022USD ($)	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Sublease rentable square feet | ft²	37,883
Minimum payments for the non-cancellable lease			$ 16.6	$ 7	$ 6.3
Number of employees housed in lease property | employee			200
Initial term of the lease		39 months
Annual lease rent		$ 4.9
Rent free period		12 months
Weighted-average rate						12.00%

Loans and Borrowings - Non-Curr

Loans and Borrowings - Non-Current and Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	$ 262,142	$ 168,601	$ 0
Current liabilities		185	70,357
Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		185	70,357
Unamortized fair value adjustment, discount, and debt issuance costs
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	(37,858)	(31,399)	0
Loan Notes | Cost
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	$ 300,000	200,000	0
Convertible Loan Notes | Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		0	70,000
Other Borrowings | Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		$ 185	$ 357

Loans and Borrowings - Narrativ

Loans and Borrowings - Narrative (Details) $ / shares in Units, $ in Thousands

Nov. 04, 2026

Jan. 01, 2024item

Nov. 04, 2022

Dec. 23, 2021USD ($)$ / sharesshares

Nov. 04, 2021USD ($)

Oct. 08, 2021USD ($)shares

Aug. 18, 2021USD ($)

Aug. 10, 2021

Jul. 15, 2021USD ($)

Apr. 11, 2021

Nov. 12, 2020USD ($)

Jun. 30, 2021USD ($)shares

Mar. 31, 2022USD ($)shares

Nov. 04, 2024

Nov. 04, 2022

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)shares

Nov. 05, 2026

Nov. 04, 2023

Jan. 01, 2024

Nov. 04, 2026

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 100,000

Debt instrument interest rate

50.00%

50.00%

50.00%

Debt instrument, interest rate stated percentage

104.00%

Proceeds from issuance of notes and warrants

$ 100,000

$ 270,563

Repayments of borrowings, and transaction expenses

$ 32,100

Ordinary share capital

$ 16

16

Debt instrument, payment frequency, term

6 months

6 months

Interest expense on borrowings

1,400

$ 200

Interest payable

2,500

$ 0

Trading Days Adjustment Subject To Customary

20 days

Trading Days With In Period Commencing Adjustment Subject To Customary

30 days

Trading Days At least Period Commencing Adjustment Subject To Customary

18 months

Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

104.00%

Unsecured Notes due 2026

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 200,000

Unsecured Notes

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 100,000

$ 200,000

$ 50,000

$ 4,000

$ 3,400

Debt discount percentage

95.50%

4.00%

Debt instrument, basis rate

6.50%

6.50%

Debt instrument, term

5 years

1 year

Debt instrument, redemption price, percentage

100.00%

Proceeds from issuance of notes and warrants

$ 7,200

Debt instrument, step-up margin, target number of Medicaid Lives to value-based care contracts

100,000

100,000

Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

107.00%

107.00%

Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

100.00%

Debt instrument principal amount

$ 100,000

VNV Loan

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 15,000

Debt discount percentage

10.00%

Debt instrument interest rate

14.00%

Debt instruments non-cash conversion

$ 8,000

Convertible Loan Note Agreement

Disclosure of defined benefit plans [line items]

Borrowing capacity

$ 200,000

Ordinary share capital

1

Convertible Loan Note Agreement | Tranche 1 Notes

Disclosure of defined benefit plans [line items]

Borrowing capacity

30,000

Convertible Loan Note Agreement | Tranche 2 Notes

Disclosure of defined benefit plans [line items]

Borrowing capacity

70,000

GHE | Tranche 1 Notes

Disclosure of defined benefit plans [line items]

Issue of convertible instruments

$ 30,000

Debt of issuance to redemption or conversion percentage

11.00%

Class A ordinary shares

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

1,757,499

334,848

333,925

0

Warrant exercised shares (in shares) | shares

1,757,499

Warrant exercise price per share (in usd per share) | $ / shares

$ 15

$ 15

Redemption price per share (in usd per share) | $ / shares

$ 15

Class A ordinary shares | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

878,750

878,750

Class B ordinary shares

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

79,638

79,638

0

C Preference Shares

Disclosure of defined benefit plans [line items]

Debt converted in preference shares (in shares) | shares

41,012,358

C Preference Shares | Tranche 2 Notes

Disclosure of defined benefit plans [line items]

Issue of convertible instruments

$ 70,000

Bottom of range | Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

104.00%

104.00%

Bottom of range | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

8.00%

Bottom of range | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

8.00%

Bottom of range | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument principal amount

$ 75,000

Weighted average. | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

10.00%

Weighted average. | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

10.00%

Weighted average. | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instruments issued

75,000

Top of range | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

12.00%

Top of range | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

12.00%

Top of range | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument principal amount

$ 100,000

Loans and Borrowings - Loans an

Loans and Borrowings - Loans and Borrowings from Financing Activities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	$ 168,786
Changes from financing cash flows
Proceeds from issuance of notes and warrants	100,000
Payment of debt issuance costs	(4,000)
Total changes from financing cash flows	96,000
Other changes
Fair value of warrants issued	(3,418)
Unpaid debt issuance costs	(257)
Amortization of fair value adjustment, discount, and debt issuance costs	1,202
Other loans and borrowings activity, net	(171)
Total other changes	(2,644)
Changes in loans and borrowings, Ending balance	262,142	$ 168,786
Albacore Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	168,601	0	$ 0
Changes from financing cash flows
Proceeds from issuance of notes and warrants	100,000	191,000	0
Payment of debt issuance costs	(4,000)	(3,429)
Repayment of cash loan		0
Total changes from financing cash flows	96,000	187,571	0
Other changes
Fair value of warrants issued	(3,418)	(16,930)
Unpaid debt issuance costs	(257)	(2,801)
Amortization of fair value adjustment, discount, and debt issuance costs	1,202	761
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		0
Total other changes	(2,473)	(18,970)	0
Changes in loans and borrowings, Ending balance	262,128	168,601	0
VNV Loan Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	0	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		15,000	0
Payment of debt issuance costs		0
Repayment of cash loan		(7,000)
Total changes from financing cash flows		8,000	0
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		(8,000)
Other loans and borrowings activity, net		0
Total other changes		(8,000)	0
Changes in loans and borrowings, Ending balance		0	0
Unsecured Bonds
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	0	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		64,563	0
Payment of debt issuance costs		(1,375)
Repayment of cash loan		(75,000)
Total changes from financing cash flows		(11,812)	0
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		(171)
Amortization of fair value adjustment, discount, and debt issuance costs		3,983
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		8,000
Other loans and borrowings activity, net		0
Total other changes		11,812	0
Changes in loans and borrowings, Ending balance		0	0
Convertible Loan Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	70,000	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		0	100,000
Payment of debt issuance costs		0
Repayment of cash loan		0
Total changes from financing cash flows		0	100,000
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		(70,000)	(30,000)
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		0
Total other changes		(70,000)	(30,000)
Changes in loans and borrowings, Ending balance		0	70,000
Other Loans and Borrowings
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	185	357	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		0	357
Payment of debt issuance costs		0
Repayment of cash loan		0
Total changes from financing cash flows		0	357
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net	(171)	(172)
Total other changes	(171)	(172)	0
Changes in loans and borrowings, Ending balance	14	185	357
Unsecured Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	$ 168,786	70,357	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		270,563	100,357
Payment of debt issuance costs		(4,804)
Repayment of cash loan		(82,000)
Total changes from financing cash flows		183,759	100,357
Other changes
Fair value of warrants issued		(16,930)
Unpaid debt issuance costs		(2,972)
Amortization of fair value adjustment, discount, and debt issuance costs		4,744
Convertible loan notes converted		(70,000)	(30,000)
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		(172)
Total other changes		(85,330)	(30,000)
Changes in loans and borrowings, Ending balance		$ 168,786	$ 70,357

Employee Benefits - Narrative (

Employee Benefits - Narrative (Details)	Oct. 21, 2021shares	Oct. 31, 2021shares	Mar. 31, 2021shares	Feb. 28, 2021employee$ / shares	Mar. 31, 2022shares	Dec. 31, 2021USD ($)item$ / sharesshares	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)	Mar. 14, 2022shares	Dec. 07, 2021item	Jun. 03, 2021shares
Disclosure of defined benefit plans [line items]
Fixed contribution | $						$ 6,300,000	$ 5,200,000	$ 3,100,000
Stock conversion ratio	0.3					0.3
Stock options granted (in shares)	7,223,177
Stock options vested percentage						25.00%
Option vesting period						3 years
Unrecognized compensation cost | $						$ 24,400,000
Weighted average contractual life						3 years 4 months 24 days
Weighted average share price, share options granted | $ / shares						$ 7.79
Subscription price (in usd per share) | $ / shares				$ 0.03
Redeemable stock price per share (in usd per share) | $ / shares				$ 0.00001227
Granted value | $						$ 9,700,000
Pre-money equity valuation | $						$ 3,500,000,000
Volatility (in percent)						54.00%
Shares available for issuance					43,761,708
Higi SH Holdings Inc.
Disclosure of defined benefit plans [line items]
Number of instruments or interests issued or issuable (in shares) | item										3,412,107
Continuing Employees | Higi SH Holdings Inc.
Disclosure of defined benefit plans [line items]
Number of instruments or interests issued or issuable (in shares) | item						1,980,000
Bottom of range
Disclosure of defined benefit plans [line items]
Expiration of options, term						10 years
Weighted average remaining contractual life of outstanding share options						6 years 10 months 24 days
Volatility (in percent)						63.40%
Top of range
Disclosure of defined benefit plans [line items]
Expiration of options, term						15 years
Weighted average remaining contractual life of outstanding share options						15 years
Volatility (in percent)						70.00%
Class A ordinary shares
Disclosure of defined benefit plans [line items]
Number of shares issued (in shares)											10,973,903
Conversion of stock, shares (in shares)		712,413
Number of shares authorised for issuance	13,700,125
Number of shares authorised for issuance, automatic annual increase percentage	5.00%
Number shares authorized									14,758,592
Class G
Disclosure of defined benefit plans [line items]
Number of employees granted options | employee				3
Vesting term						1 year
Restricted Stock Award
Disclosure of defined benefit plans [line items]
Options cancelled (in shares)			5,046,059
Unrecognized compensation cost | $						$ 1,300,000
Restricted Stock Award | Bottom of range
Disclosure of defined benefit plans [line items]
Weighted average contractual life						1 year
Restricted Stock Award | Top of range
Disclosure of defined benefit plans [line items]
Weighted average contractual life						2 years
Restricted Stock Unit
Disclosure of defined benefit plans [line items]
Unrecognized compensation cost | $						$ 812,331
Vested (in shares)						1,167,669
Unvested value | $						$ 5,400,000
Weighted average contractual life						1 year 3 months 18 days
Long Term Incentive Plan
Disclosure of defined benefit plans [line items]
Options cancelled (in shares)			4,265,770
Number of stock options shares (in shares)						6,660,027
Company Share Option Plan
Disclosure of defined benefit plans [line items]
Options cancelled (in shares)						7,726,002

Employee Benefits - Share-based

Employee Benefits - Share-based Payments (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Benefits
Total share-based compensation expense	$ 8,402	$ 2,802	$ 46,307	$ 9,557	$ 7,966

Employee Benefits - Restricted

Employee Benefits - Restricted Stock Unit Activity and Weighted Average Grant Date Fair Value (Details) - Restricted Stock Award - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
RSUs
Beginning balance (in shares)	6,997,284	0
Granted (in shares)	14,758,592	6,997,284
Vested and issued (in shares)	(895,627)	0
Forfeited (in shares)	(1,099,073)	0
Ending balance (in shares)	19,761,176	6,997,284
Vested and unissued (in shares)	39,022	1,760,363
Unvested (in shares)	19,722,154	5,236,921
Weighted Average Grant Date Fair Value Per RSU
Beginning balance (in usd per share)	$ 6.23	$ 0
Granted (in usd per share)		6.23
Vested and issued (in usd per share)		0
Forfeited (in usd per share)		0
Ending balance (in usd per share)		6.23
Vested and unissued (in usd per share)		6.23
Unvested (in usd per share)		$ 6.23

Employee Benefits - Weighted Av

Employee Benefits - Weighted Average Exercise Price (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022$ / shares	Mar. 31, 2022Options	Dec. 31, 2021$ / shares	Dec. 31, 2021Options$ / shares	Dec. 31, 2021$ / shares	Dec. 31, 2020$ / shares	Dec. 31, 2020Options$ / shares	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Weighted average exercise price
Outstanding at the beginning of the year (in usd per share)	$ 1.47		$ 0.02			$ 0			$ 0
Granted during the year (in usd per share)			3.67			0.11			0
Forfeited / canceled during the year (in usd per share)	1.26		0.18			0.04			0
Exercised during the year (in usd per share)	0.35		1.42			0			0
Outstanding at the end of the year (in usd per share)	$ 1.48		1.47			0.02			0
Exercisable at the end of the year (in usd per share)			$ 1.54	$ 1.54	$ 1.54	$ 0.01	$ 0.01	$ 0.01	$ 0
Number of options
Outstanding at the beginning of the year (in shares)		22,896,265		21,107,487	21,107,487			20,120,425	19,666,539
Granted during the year (in shares)				8,155,289	8,155,289			4,109,243	2,786,856
Forfeited / canceled during the year (in shares)		(650,232)		(6,204,471)	(6,204,471)			(3,122,181)	(2,332,970)
Exercised during the year (in shares)		(27,942)		(162,040)	(162,040)			0	0
Outstanding at the end of the year (in shares)		22,218,091		22,896,265	22,896,265		21,107,487	21,107,487	20,120,425
Exercisable at the end of the year (in shares)			19,105,908	19,105,908	19,105,908	16,461,945	16,461,945	16,461,945	11,817,828

Capital and Reserves - Share Ca

Capital and Reserves - Share Capital (Details) - shares	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Class A ordinary shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	6,500,000	6,500,000
Issued (in shares)	0
Issued during the period		924
Issued (in shares)	333,925
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	330,257,000
Issued following the Merger (in shares)	3,668,000
Class B ordinary shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	3,100,000	3,100,000
Issued (in shares)	0
Issued (in shares)	79,638
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	79,638,000
Issued following the Merger (in shares)	0
Deferred Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)		100,000
Ordinary A Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	10,000,000
Issued (in shares)	135,136,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	(135,136,000)
Issued following the Merger (in shares)	0
Ordinary B Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	11,000,000
Issued (in shares)	664,605,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	17,206,000
Conversion into Class A and B Shares (in shares)	(681,811,000)
Issued following the Merger (in shares)	0
Preference C Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	10,000,000
Issued (in shares)	252,065,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	41,012,000
Conversion into Class A and B Shares (in shares)	(293,077,000)
Issued following the Merger (in shares)	0
Ordinary Redeemable G1 Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	50,000
Issued (in shares)	0
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	10,150,000
Conversion into Class A and B Shares (in shares)	(10,150,000)
Issued following the Merger (in shares)	0

Capital and Reserves - Narrativ

Capital and Reserves - Narrative (Details) $ / shares in Units, $ in Millions	Nov. 12, 2020USD ($)$ / shares	Dec. 31, 2021USD ($)Vote$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2022Voteshares	Dec. 16, 2020USD ($)	Dec. 02, 2020USD ($)	Nov. 16, 2020USD ($)
Disclosure of classes of share capital [line items]
Number of deferred shares (in shares) | shares		100,000
Deferred shares, par value per share (in usd per share) | $ / shares		$ 0.00004
Deferred shares issued (in shares) | shares		0		0
Loan Notes
Disclosure of classes of share capital [line items]
Debt conversion, related to principal | $			$ 30
Tranche 1 Notes
Disclosure of classes of share capital [line items]
Debt instrument, issued amount | $	$ 30					$ 15	$ 15
Accrued interest, percentage	11.00%
Tranche 2 Notes
Disclosure of classes of share capital [line items]
Debt instrument, issued amount | $					$ 70
Class A ordinary shares
Disclosure of classes of share capital [line items]
Number of votes per share | Vote		1		1
Deferred shares, par value per share (in usd per share) | $ / shares		$ 0.000422573245084686
Voting rights, percentage		50.00%
Class B ordinary shares
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares		$ 0.0000422573245084686
Number of votes per share | Vote		15		15
Voting rights, percentage		50.00%
Preference C Shares
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares			$ 0.00001277
Number of shares issued (in shares) | shares			24,796,225
Aggregate purchase price | $			$ 42.1
Debt conversion, shares issued (in shares) | shares			111,239
Number of shares settled in cash (in shares) | shares			6,976,194
Cash paid, net of cash acquired | $			$ 11.9
Preference C Shares | Loan Notes
Disclosure of classes of share capital [line items]
Debt conversion, amount | $		$ 70
Debt conversion, shares issued (in shares) | shares		41,012,358
Debt conversion, related to principal | $			$ 0.2
Debt conversion, shares issued (in shares) | shares			17,708,792
Preference C Shares | Tranche 1 Notes
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares	$ 1.706802577

Capital and Reserves - Other Co

Capital and Reserves - Other Comprehensive Income Accumulated in Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Comprehensive Income (Loss) Accumulated in Reserves [Roll Forward]
Beginning balance	$ (27)	$ 1,675	$ 1,675	$ (1,904)	$ 7,789
Foreign exchange movement	(3,753)	$ (1,754)	(1,702)	3,579	(9,693)
Ending balance	$ (3,780)		$ (27)	$ 1,675	$ (1,904)

Warrant Liability - Table Displ

Warrant Liability - Table Displays the Number of Warrants in Issue (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Line Items]
Number of warrants issued at, beginning	16,316	0
Number of warrants issued at, ending	17,195	16,316
Tradeable Warrants
Warrant Liability [Line Items]
Number of warrants issued at, beginning	8,625	0
Number of warrants issued at, ending	8,625	8,625
Non-Tradeable Warrants
Warrant Liability [Line Items]
Number of warrants issued at, beginning	7,691	0
Number of warrants issued at, ending	8,570	7,691
Alkuri Warrants
Warrant Liability [Line Items]
Issued during period		14,558,000
Alkuri Warrants | Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		8,625,000
Alkuri Warrants | Non-Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		5,933,000
AlbaCore Warrants
Warrant Liability [Line Items]
Issued during period	879	1,758,000
AlbaCore Warrants | Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		0
AlbaCore Warrants | Non-Tradeable Warrants
Warrant Liability [Line Items]
Issued during period	879	1,758,000

Warrant Liability - Reconciliat

Warrant Liability - Reconciliation of Fair Values (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of financial liabilities [line items]
Fair value at beginning	$ 20,128	$ 0
Change in fair value of warrant liabilities	(5,575)	(27,811)
Fair value at ending	17,971	20,128
Tradeable Warrants | Level 1
Disclosure of financial liabilities [line items]
Fair value at beginning	5,865	0
Change in fair value of warrant liabilities	(1,294)	(12,506)
Fair value at ending	4,571	5,865
Non-Tradeable Warrants | Level 2
Disclosure of financial liabilities [line items]
Fair value at beginning	4,035	0
Change in fair value of warrant liabilities	(890)	(8,603)
Fair value at ending	3,145	4,035
Non-Tradeable Warrants | Level 3
Disclosure of financial liabilities [line items]
Fair value at beginning	10,228	0
Change in fair value of warrant liabilities	(3,391)	(6,702)
Fair value at ending	10,255	10,228
Alkuri Warrants
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		31,009
Alkuri Warrants | Tradeable Warrants | Level 1
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		18,371
Alkuri Warrants | Non-Tradeable Warrants | Level 2
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		12,638
AlbaCore Warrants
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance	3,418	16,930
AlbaCore Warrants | Non-Tradeable Warrants | Level 3
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance	$ 3,418	$ 16,930

Warrant Liability - Narrative (

Warrant Liability - Narrative (Details) - $ / shares	Jun. 03, 2021	Mar. 31, 2022	Dec. 31, 2021	Oct. 22, 2021
Disclosure of financial liabilities [line items]
Number of securities called by warrants (in shares)			14,558,333
Conversion of warrant and rights, term	5 years	5 years
Tradeable warrant, market price per warrant (in dollars per share)		$ 0.53	$ 0.68
Price per warrant (in dollars per share)		$ 3.89	$ 5.82
Class A ordinary shares
Disclosure of financial liabilities [line items]
Converted warrants to purchase ordinary shares (in shares)	14,558,333	14,558,333
Private Placement Warrants
Disclosure of financial liabilities [line items]
Number of securities called by warrants (in shares)	5,933,333	5,933,333
Public Warrants
Disclosure of financial liabilities [line items]
Number of securities called by warrants (in shares)	8,625,000	8,625,000
Alkuri Warrants
Disclosure of financial liabilities [line items]
Number of warrants outstanding (in shares)		14,558,313	14,558,333
Warrants exercise price, per share (in dollars per share)		$ 11.50	$ 11.50
Tradeable warrant, market price per warrant (in dollars per share)				$ 2.13
Warrant, Shares Issued Per Warrant On Exercise		1	1
AlbaCore Warrants
Disclosure of financial liabilities [line items]
Number of warrants outstanding (in shares)		1,757,499	1,757,499
Warrants subscription price, per share (in dollars per share)		$ 0.00004	$ 0.00004
Price per warrant (in dollars per share)			$ 9.63
Warrant, Shares Issued Per Warrant On Exercise		1	1
Additional AlbaCore Warrants
Disclosure of financial liabilities [line items]
Number of warrants outstanding (in shares)		878,750
Warrants subscription price, per share (in dollars per share)		$ 0.00004
Price per warrant (in dollars per share)		$ 3.89
Warrant, Shares Issued Per Warrant On Exercise		1

Related Parties (Details)

Related Parties (Details) - USD ($) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Related Parties
Pension contributions to related party transactions	$ 0.9	$ 0.9	$ 6.5	$ 1	$ 0.9
Remuneration of the highest paid key manager	0.2	0.3	2.2	0.3	0.3
Key management personnel compensation	$ 1	$ 0.6	$ 32.1	$ 0	$ 0.1

Financial Instruments - Assets

Financial Instruments - Assets and Liabilities that are Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of fair value measurement of assets [line items]
Total liabilities	$ 503,046	$ 389,361	$ 190,455
Recurring fair value measurement
Disclosure of fair value measurement of assets [line items]
Total liabilities	17,971	20,128
Recurring fair value measurement | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities	4,571	5,865
Recurring fair value measurement | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities	10,255	10,228
Recurring fair value measurement | Tradeable Alkuri Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	6,837	5,865
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities		5,865
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities	6,837	0
Recurring fair value measurement | Non-tradeable Alkuri Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | AlbaCore Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	4,571	10,228
Recurring fair value measurement | AlbaCore Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities	4,571	0
Recurring fair value measurement | AlbaCore Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | AlbaCore Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities		$ 10,228
Recurring fair value measurement | Additional AlbaCore Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,418
Recurring fair value measurement | Additional AlbaCore Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities	$ 3,418

Financial Instruments - The Mon

Financial Instruments - The Monte Carlo Simulation Model for the AlbaCore Warrants (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Nov. 04, 2021
Financial Instruments
Underlying stock price (USD)	$ 3.89	$ 5.83	$ 9.66
Exercise price (USD)	$ 0.00004	$ 0.00004	$ 0.00004
Volatility (in percent)	74.10%	71.60%	66.70%
Remaining term (years)	4 years 6 months	4 years 10 months 6 days
Risk-free rate (in percent)	2.40%	1.23%	1.09%

Subsequent Events (Details)

Subsequent Events (Details) - USD ($) $ in Millions	May 04, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of non-adjusting events after reporting period [line items]
Interest payable		$ 2.5	$ 0
Entering into significant commitments or contingent liabilities
Disclosure of non-adjusting events after reporting period [line items]
Voting rights, percentage	50.00%
Interest payable settled in cash	$ 4.4
Entering into significant commitments or contingent liabilities | Unsecured Notes
Disclosure of non-adjusting events after reporting period [line items]
Interest payable	$ 8.8

Consolidated Statement of Profi

Consolidated Statement of Profit and Loss and Other Comprehensive Loss - USD ($) $ in Thousands	Jun. 03, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss
Revenue		$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Cost of care delivery		(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Platform & application expenses		(16,703)	(6,434)	(42,829)	(38,137)	(23,569)
Research & development expenses		(10,057)	(10,390)	(47,534)	(54,711)	(51,205)
Sales, general & administrative expenses		(58,310)	(31,479)	(196,673)	(94,681)	(84,270)
Recapitalization transaction expense	$ (148,700)			(148,722)
Operating loss		(90,103)	(12,750)	(402,509)	(175,511)	(162,820)
Finance costs		(6,628)	(992)	(14,291)	(4,530)	(1,116)
Finance income		255	14	326	610	1,015
Change in fair value of warrant liabilities		5,575		27,811
Exchange gain / (loss)		(447)	(573)	868	(2,836)	17,075
Net finance expense		(1,245)	(1,551)	14,714	(6,756)	16,974
Gain on sale of subsidiary			3,917	3,917
Gain on remeasurement of equity interest				10,495
Share of loss of equity-accounted investees			(455)	(2,602)	(1,124)
Loss before taxation		(91,348)	(10,839)	(375,985)	(183,391)	(145,846)
Tax benefit / (provision)		(9)	(8)	1,474	(4,639)	5,559
Loss for the financial year		(91,357)	(10,847)	(374,511)	(188,030)	(140,287)
Other comprehensive loss Items that may be reclassified subsequently to profit or loss:
Currency translation differences		(3,753)	(1,754)	(1,702)	3,579	(9,693)
Other comprehensive loss for the period, net of income tax		(3,753)	(1,754)	(1,702)	3,579	(9,693)
Total comprehensive loss for the year		(95,110)	(12,601)	(376,213)	(184,451)	(149,980)
Loss attributable to:
Equity holders of the parent		(91,357)	(10,466)	(368,482)	(186,799)	(140,287)
Non-controlling interest			(381)	(6,029)	(1,231)
Loss for the financial year		(91,357)	(10,847)	(374,511)	(188,030)	(140,287)
Total comprehensive loss attributable to:
Equity holders of the parent		(95,110)	(12,220)	(370,184)	(183,220)	(149,980)
Non-controlling interest			(381)	(6,029)	(1,231)
Total comprehensive loss for the year		$ (95,110)	$ (12,601)	$ (376,213)	$ (184,451)	$ (149,980)
Loss per share
Net loss per share, Basic and Diluted		$ (0.24)	$ (0.04)	$ (1.36)	$ (0.77)	$ (0.58)
Weighted average shares outstanding, Basic and Diluted		384,531,450	245,229,566	271,321,253	242,935,770	241,903,166

Consolidated Statement of Finan

Consolidated Statement of Financial Position - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-current assets
Right-of-use assets	$ 20,014	$ 7,844		$ 2,572
Property, plant and equipment	25,694	24,990		1,334	$ 1,801
Investments in associates				8,876
Goodwill	93,655	93,678		17,832
Other intangible assets	112,830	111,421		78,853
Total non-current assets	252,193	237,933		109,467
Current assets
Right-of-use assets	5,454	3,999		1,942
Trade and other receivables	27,981	24,119		13,525
Prepayments and contract assets	21,971	26,000		8,841
Cash and cash equivalents	274,978	262,581		101,757
Assets held for sale				3,282
Total current assets	330,384	316,699		129,347
Total assets	582,577	554,632		238,814
EQUITY
Share capital	16	16
Share premium	923,093	922,897		485,221
Share-based payment reserve	89,545	80,371		32,185
Retained earnings	(929,343)	(837,986)		(469,504)
Foreign currency translation reserve	(3,780)	(27)		1,675
Total capital and reserves	79,531	165,271		49,590
Non-controlling interests				(1,231)
Total equity	79,531	165,271	$ 38,940	48,359	$ 173,797	$ (50,484)
Non-current liabilities
Loans and borrowings	262,142	168,601
Contract liabilities	63,763	70,396		57,274
Lease liabilities	20,143	8,442		2,011
Deferred grant income	6,134	7,236		7,488
Deferred tax liability	1,016	1,019
Total non-current liabilities	353,198	255,694		66,773
Current liabilities
Trade and other payables	25,198	22,686		7,745
Accruals and provisions	37,886	36,856		18,636
Claims payable	39,165	24,628		3,890
Contract liabilities	22,663	23,786		18,744
Warrant liability	17,971	20,128
Lease liabilities	5,301	4,190		2,488
Deferred grant income	1,664	1,208
Loans and borrowings		185		70,357
Liabilities directly associated with the assets held for sale				1,822
Total current liabilities	149,848	133,667		123,682
Total liabilities	503,046	389,361		190,455
Total liabilities and equity	$ 582,577	554,632		238,814
Ordinary share capital
EQUITY
Share capital		$ 16		10
Preference share capital
EQUITY
Share capital				$ 3

Consolidated Statement of Chang

Consolidated Statement of Changes in Equity - USD ($) $ in Thousands	Share capital	Share premium	Share-based payment reserve	Retained earnings	Foreign exchange revaluation reserve	Equity attributable to owners of the parent company	Non- controlling Interest	Total
Beginning balance at Dec. 31, 2018	$ 10	$ 76,833	$ 7,302	$ (142,418)	$ 7,789	$ (50,484)		$ (50,484)
Loss for the financial year				(140,287)		(140,287)		(140,287)
Currency translation differences					(9,693)	(9,693)		(9,693)
Equity issuance costs		(11,048)				(11,048)		(11,048)
Equity-settled share-based payment transactions			7,966			7,966		7,966
Issuance of shares	3	377,270				377,273		377,273
Effect of share redenomination		70				70		70
Ending balance at Dec. 31, 2019	13	443,125	15,268	(282,705)	(1,904)	173,797		173,797
Loss for the financial year				(186,799)		(186,799)	$ (1,231)	(188,030)
Currency translation differences					3,579	3,579		3,579
Conversion of convertible debt		30,189				30,189		30,189
Equity-settled share-based payment transactions			16,917			16,917		16,917
Issuance of shares		11,907				11,907		11,907
Ending balance at Dec. 31, 2020	13	485,221	32,185	(469,504)	1,675	49,590	(1,231)	48,359
Loss for the financial year				(10,466)		(10,466)	(381)	(10,847)
Currency translation differences					(1,754)	(1,754)		(1,754)
Equity-settled share-based payment transactions			3,182			3,182		3,182
Ending balance at Mar. 31, 2021	13	485,221	35,367	(479,970)	(79)	40,552	(1,612)	38,940
Beginning balance at Dec. 31, 2020	13	485,221	32,185	(469,504)	1,675	49,590	(1,231)	48,359
Loss for the financial year				(368,482)		(368,482)	(6,029)	(374,511)
Currency translation differences					(1,702)	(1,702)		(1,702)
Issuance of shares in the Merger and PIPE financing	2	347,021				347,023		347,023
Fair value of non-controlling interests upon consolidation							64,274	64,274
Acquisition of non-controlling interests		51,033				51,033	$ (57,014)	(5,981)
Equity issuance costs		(32,787)				(32,787)		(32,787)
Conversion of convertible debt	1	69,999				70,000		70,000
Equity issued as consideration for acquisitions		2,349				2,349		2,349
Equity-settled share-based payment transactions			48,186			48,186		48,186
Issuance of shares in connection with option exercises		61				61		61
Ending balance at Dec. 31, 2021	16	922,897	80,371	(837,986)	(27)	165,271		165,271
Loss for the financial year				(91,357)		(91,357)		(91,357)
Currency translation differences					(3,753)	(3,753)		(3,753)
Equity issuance costs		(541)				(541)		(541)
Equity-settled share-based payment transactions			9,174			9,174		9,174
Ending balance at Mar. 31, 2022	$ 16	$ 923,093	$ 89,545	$ (929,343)	$ (3,780)	$ 79,531		$ 79,531

Consolidated Statement of Cas_2

Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Cash flows from operating activities
Loss for the financial year	$ (91,357)	$ (10,847)	$ (374,511)	$ (188,030)	$ (140,287)
Adjustments to reconcile Loss for the year to net cash used in operating activities:
Recapitalization transaction expense			148,722
Share-based compensation	8,402	2,802	46,307	9,557	7,966
Depreciation and amortization	9,458	5,848	35,004	14,487	2,496
Change in fair value of warrant liabilities	(5,575)		(27,811)
Gain on remeasurement of equity interest			(10,495)
Finance costs	6,628	992	14,291	4,530	1,116
Gain on sale of subsidiary		(3,917)	(3,917)
Share of loss of equity-accounted investees		455	2,602	1,124
Taxation	9	8	(1,474)	4,639	(5,559)
Impairment expense			941	6,436
Exchange (gain) / loss	447	573	(868)	2,836	(17,075)
Finance income	(255)	(14)	(326)	(610)	(1,015)
Cash flows from (used in) operations before changes in working capital	(72,243)	(4,100)	(171,535)	(145,031)	(152,358)
Working capital adjustments
(Increase) / Decrease in trade and other receivables	126	(8,704)	(21,829)	738	(9,308)
Increase / (Decrease) in trade and other payables	3,160	34,304	47,496	2,323	18,052
(Increase) / Decrease in assets held for sale				(3,282)
Increase / (Decrease) liabilities directly associated with the assets held for sale				1,822
Net cash (used in) provided by operating activities	(68,957)	21,500	(145,868)	(143,430)	(143,614)
Cash flows from investing activities
Development costs capitalized	(9,298)	(7,198)	(32,120)	(36,509)	(36,036)
Acquisitions, net of cash acquired			(13,798)	(25,671)
Capital expenditure	(2,613)	(311)	(8,103)	(719)	(1,915)
Purchase of shares in associates and joint ventures		(2,000)	(5,000)	(10,000)
Cash assumed upon consolidation through control			3,792
Proceeds from sale of investment in subsidiary		2,213	2,213
Payment of lease deposit			(2,105)
Interest received	255	14	326	673	1,015
Net cash used in investing activities	(11,656)	(7,282)	(54,795)	(72,226)	(36,936)
Cash flows from financing activities
Proceeds from issuance of notes and warrants	100,000		270,563
Proceeds from issuance of share capital	329,300		229,311	12,096	320,334
Repayment of cash loan			(82,000)		(1,231)
Payment of equity and debt issuance costs	(5,002)		(36,043)	(10,245)	(773)
Repayments of borrowings			(7,431)
Interest paid	(22)	(18)	(5,219)	(252)	(851)
Principal payments on leases	(460)	(1,520)	(4,156)	(1,541)	(1,228)
Payments to acquire non-controlling interests			(2,352)
Proceeds from issuance of convertible loan notes				100,000	51,064
Repayment of convertible loan notes					(14,794)
Other financing activities, net	(1,538)	(482)	(470)
Net cash provided by (used in) financing activities	92,978	(2,020)	362,203	100,058	352,521
Net increase in cash and cash equivalents	12,365	12,198	161,540	(115,598)	171,971
Cash and cash equivalents at January 1,	262,581	101,757	101,757	214,888	46,031
Effect of movements in exchange rate on cash held	32	(57)	(716)	2,467	(3,114)
Cash and cash equivalents at March 31,	274,978	113,898	262,581	101,757	$ 214,888
Non-cash financing and investing activities:
Acquisition date fair value of Higi upon consolidation			86,043
Conversion of borrowings			70,000
Acquisitions of non-controlling interests			(54,662)
Fair value of warrants issued in Merger			(31,009)
Fair value of warrants issued in connection with Loans and borrowings	3,418		(16,930)
Equity and debt issuance costs in accruals and provisions			(4,521)
Equity issued as consideration for acquisitions			(2,349)
Share-based compensation expense capitalized in development costs	$ (772)	$ (380)	$ (1,879)	$ (7,616)

Corporate information_2

Corporate information	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Corporate Information
Corporate information	1. Corporate Information Babylon Holdings Limited (the “Company,” “Babylon,” “we” or “our”) is incorporated, registered and domiciled in Jersey. The address of the registered office is 31 Esplanade, St. Helier, Jersey, JE2 3QA. Babylon is a digital-first, value-based care healthcare company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth. Babylon is re-engineering healthcare, shifting the focus from sick care to proactive healthcare, in order to improve the overall patient experience and reduce healthcare costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare. Babylon works with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals.	1. Corporate Information Babylon Holdings Limited (the “Company,” “Babylon,” “we” or “our”) is incorporated, registered and domiciled in Jersey. The address of the registered office is 31 Esplanade, St. Helier, Jersey, JE1 1FT. Babylon is a digital-first, value-based care healthcare company whose mission is to make high-quality healthcare accessible and affordable for everyone on Earth. Babylon is re-engineering healthcare, shifting the focus from sick care to proactive healthcare, in order to improve the overall patient experience and reduce healthcare costs. This is achieved by leveraging a highly scalable, digital-first platform combined with high quality, virtual clinical operations to provide integrated, personalized healthcare. Babylon works with governments, health providers and insurers across the globe, and support healthcare facilities from small local practices to large hospitals. On June 3, 2021, Babylon announced it entered into a definitive merger agreement (the "Merger Agreement") with Alkuri Global Acquisition Corp (“Alkuri”), a special purpose acquisition company (the “Merger”) following the unanimous approval of the Board of Directors of the Company and Alkuri. The transaction was consummated on October 21, 2021, and the combined company operates as Babylon and trades on the New York Stock Exchange. The Merger was accounted for as a recapitalization in accordance with IFRS 2, Share-based Payments

Basis of Preparation_2

Basis of Preparation	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Basis of Preparation
Basis of Preparation	2. Basis of Preparation These financial statements consolidate those of the Company and its subsidiaries (together referred to as the “Group”). These condensed unaudited consolidated interim financial statements for the three months ended March 31, 2022 (“Condensed Consolidated Financial Statements”) have been prepared in accordance with IAS 34 Interim Financial Reporting as issued by the IASB, and should be read in conjunction with the Group’s last annual consolidated financial statements as at and for the year ended December 31, 2021 (the “last annual financial statements”). They do not include all of the information required for a complete set of financial statements prepared in accordance with IFRS. However selected explanatory notes are included to explain events and transactions that are significant to an understanding of the changes in the Group’s consolidated financial position and consolidated performance since the last annual financial statements. These Condensed Consolidated Financial Statements were authorized for issue on May 20, 2022. Going Concern The Group incurred a loss for the period for the three months ended March 31, 2022 of $91.4 $69.0 Our directors performed a going concern assessment for a period of twelve months from the date of approval of these Condensed Consolidated Financial Statements to assess whether conditions exist that raise substantial doubt regarding the Group’s ability to continue as a going concern. This assessment indicates we have sufficient liquidity to fund our liabilities as they become due through December 31, 2022, but additional funding is required to provide sufficient funds to meet our liabilities that may fall due through May 2023 and beyond if we continue with our planned growth strategy. While there is no assurance that additional funds are available on acceptable terms, the directors believe that they will be successful in raising the additional capital needed to execute our planned growth strategy and to meet working capital and capital expenditure requirements that may fall due through May 2023 and after. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. However, the above indicates that there are material uncertainties (ability to raise further capital) related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, to continue realizing its assets and discharging its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. Basis of Consolidation Subsidiaries Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. To determine whether the Group controls an entity, status of voting or similar rights, contractual arrangements and other specific factors are considered. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date on which that control ceases. The Company consolidates certain professional service corporations (“PCs”) that are owned, directly or indirectly, and operated by appropriately licensed physicians. The Company maintains control of these PCs through contractual arrangements, which can include service agreements, financing agreements, equity transfer restriction agreements, and employment agreements, or a combination thereof, which are primarily established during the formation of the PCs. At inception, the contractual framework established between the Group and the PCs provides the Group with the power to direct the relevant activities in the conduct of the PC’s non-clinical administrative and other non-clinical business activities. The physicians employed by the PC are exclusively in control of, and responsible for, all aspects of the practice of medicine for their patients. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and a substantive process and whether the acquired set has the ability to produce outputs. Intercompany transactions, balances and unrealized gains on transactions between the Group’s companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the Condensed Consolidated Statement of Profit and Loss and Other Comprehensive Loss, Condensed Consolidated Statement of Financial Position and Condensed Consolidated Statement of Changes in Equity. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Associates Associates are those entities in which the Group has significant influence, but not control, over the financial and operating policies. Associates are accounted for using the equity method and are initially recognized at cost. The Condensed Consolidated Financial Statements include the Group’s share of the total comprehensive income and equity movements of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. When the Group’s share of losses exceeds its interest in an equity accounted investee, the Group’s carrying amount is reduced to nil and recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or has made payments on behalf of an investee. Reclassifications During the first quarter of 2022, following the expansion of the Group’s VBC (Value-Based Care) product and service offerings, management reviewed the presentation of the Consolidated Statement of Profit and Loss and considered whether expanded presentation may provide more relevant information to stakeholders. Upon further review, the Group has expanded the presentation of costs historically presented within Cost of care delivery to discretely present Claims expense, which primarily includes external costs of patient care, and Clinical care delivery expense, which primarily includes internal costs of patient care. With the exception of the expanded presentation of Clinical care delivery expense and Claims expense in the Condensed Consolidated Statement of Profit and Loss, these elective changes had no impact on the Group’s Loss for the period or to the Condensed Consolidated Financial Statements as of and for the period ended March 31, 2022 and 2021.	2. Basis of Preparation These financial statements consolidate those of the Company and its subsidiaries (together referred to as the “Group”). The Group financial statements have been prepared on the historical cost basis and approved by the Directors in accordance with International Financial Reporting Standards as issued by the International Accounting Standards Board. These Consolidated Financial Statements were authorized for issue on March 30, 2022 . The accounting policies set out below have, unless otherwise stated, been applied consistently to all periods presented in these Group financial statements. Judgements made by the directors, in the application of these accounting policies that have significant effect on the financial statements and estimates with a significant risk of material adjustment in the next year, are discussed in Note 3. Going Concern At December 31, 2021, the Group incurred a loss for the year of $374.5 million (2020: loss of $188.0 million, 2019: loss of $140.3 million), which includes a Recapitalization transaction expense of $148.7 million, and operating cash outflows of $145.9 million (2020: $143.4 million, 2019: $143.6 million). As of December 31, 2021 the Group had a net asset position of $165.3 million (2020: $48.4 million). At December 31, 2021, the Group had cash and cash equivalents of $262.6 million (2020: $101.8 million). The Group has financed its operations principally through issuances of debt and equity securities and has a strong record of fundraising, including the closing of the Merger and PIPE Transaction (as defined below) on October 21, 2021 receiving proceeds of $229.3 million (Note 5) and entering into a note subscription agreement for $200.0 million on October 8, 2021 (Note 26). The Group requires significant cash resources to, among other things, fund working capital requirements, increase headcount, make capital expenditures, including those related to product development, and expand our business through acquisitions. The directors have prepared cash flow forecasts for a period of twelve months from the date of approval of these financial statements which indicate that when combined with additional borrowings we expect to receive at the end of March 2022 (Note 26), we have sufficient liquidity to fund our liabilities as they become due for the next twelve months if we continue with our planned growth strategy. While there is no assurance that additional funds are available on acceptable terms, the directors believe that they will be successful in raising the additional capital needed to execute our planned growth strategy and to meet working capital and capital expenditure requirements that may fall due after March 2023. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. However, the above indicates that there are material uncertainties (ability to fund raise further capital) related to events or conditions that may cast significant doubt on the Group’s ability to continue as a going concern and therefore, to continue realizing its assets and discharging its liabilities in the normal course of business. The financial statements do not include any adjustments that would result from the basis of preparation being inappropriate. Funding Requirements As of December 31, 2021, we had a net asset position of $165.3 million (2020: $48.4 million), including cash and cash equivalents of $262.6 million (2020: $101.8 million). Our directors performed a going concern assessment for a period of twelve months from the date of approval of these financial statements to assess whether conditions exist that raise substantial doubt regarding the Company’s ability to continue as a going concern. This assessment, when combined with additional borrowings we expect to receive at the end of March 2022 (Note 26), indicates we have sufficient liquidity to fund our liabilities as they become due for the next twelve months, but that additional funding is required to provide sufficient funds to meet our liabilities that may fall due beyond March 2023 if we continue with our planned growth strategy. We believe that we will be successful in raising the additional capital we need to execute our planned growth strategy and to meet our working capital and capital expenditure requirements that may arise after March 2023. Based on this, we believe it remains appropriate to prepare our financial statements on a going concern basis. Basis of Consolidation Subsidiaries Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity. To determine whether the Group controls an entity, status of voting or similar rights, contractual arrangements and other specific factors are considered. Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are deconsolidated from the date on which that control ceases. Prior to December 31, 2021, the Group held certain rights in the form of purchase options to acquire additional equity interests in entities that it had an existing shareholding in. These rights are assessed as either substantive or protective in nature to conclude whether the Group exercises control over the entity. This assessment requires judgement relating to both the barriers that may prevent, and the extent to which the Group would benefit from, exercise of those rights and determines whether the Group should consolidate the entity. In addition, the Company consolidates certain professional service corporations (“PCs”) that are owned, directly or indirectly, and operated by appropriately licensed physicians. The Company maintains control of these PCs through contractual arrangements, which can include service agreements, financing agreements, equity transfer restriction agreements, and employment agreements, or a combination thereof, which are primarily established during the formation of the PCs. At inception, the contractual framework established between the Group and the PCs provides the Group with the power to direct the relevant activities in the conduct of the PC’s non-clinical administrative and other non-clinical business activities. The physicians employed by the PC are exclusively in control of, and responsible for, all aspects of the practice of medicine for their patients. In determining whether a particular set of activities and assets is a business, the Group assesses whether the set of assets and activities acquired includes, at a minimum, an input and a substantive process and whether the acquired set has the ability to produce outputs. Intercompany transactions, balances and unrealized gains on transactions between the Group’s companies are eliminated. Unrealized losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Non-controlling interests in the results and equity of subsidiaries are shown separately in the Consolidated Statement of Profit and Loss and Other Comprehensive Loss, Consolidated Statement of Financial Position and Consolidated Statement of Changes in Equity. Changes in the Group’s interest in a subsidiary that do not result in a loss of control are accounted for as equity transactions. Associates Associates are those entities in which the Group has significant influence, but not control, over the financial and operating policies. Associates are accounted for using the equity method and are initially recognized at cost. The Consolidated Financial Statements include the Group’s share of the total comprehensive income and equity movements of equity accounted investees, from the date that significant influence commences until the date that significant influence ceases. When the Group’s share of losses exceeds its interest in an equity accounted investee, the Group’s carrying amount is reduced to nil and recognition of further losses is discontinued except to the extent that the Group has incurred legal or constructive obligations or has made payments on behalf of an investee. Reclassifications During the fourth quarter of 2021, the Group identified and corrected the classification of certain costs related to the below departments during the year ended December 31, 2020. The reclassifications resulted in the following impact on the Consolidated Statement of Profit and Loss: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ As previously ​ ​ ​ ​ ​ ​ reported ​ Adjustment ​ As reported ​ ​ $’000 ​ $’000 ​ $’000 Platform & application expenses ​ (48,664) ​ 10,527 ​ (38,137) Research & development expenses (35,524) (19,187) (54,711) Sales, general & administrative expenses (103,341) 8,660 (94,681) Operating loss (175,511) — (175,511) Loss for the financial year (188,030) — (188,030) ​ The reclassifications also had an immaterial impact on the Consolidated Statement of Profit and Loss for the year ended December 31, 2019, which is not shown in the table above. The Group has evaluated the effect of the reclassifications, both quantitatively and qualitatively, and concluded that the correction did not have a material impact on, nor require amendment of, any previously filed financial statements.

Significant Accounting Judgemen

Significant Accounting Judgements, Estimates and Assumptions	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Significant Accounting Judgements, Estimates and Assumptions	3. Significant Accounting Judgements, Estimates and Assumptions The preparation of the Group’s Consolidated Financial Statements requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. The judgments, estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant, including expectations of future events that are believed to be reasonable under the circumstances. However, the resulting accounting estimates may differ from actual results. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to estimates are recognized prospectively. No changes were made to the estimates and assumptions used in the last year. The areas involving significant estimates or judgements are: Business Combinations (Note 6) We record tangible and intangible assets acquired and liabilities assumed in business combinations under the acquisition method of accounting. Acquisition consideration typically includes cash payments and equity issued as consideration. In acquisitions where no consideration is transferred, goodwill is measured based on the fair value of the acquiree. Amounts paid for each acquisition are allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition inclusive of identifiable intangible assets. The estimated fair value of identifiable assets and liabilities, including intangibles, are based on valuations that use information and assumptions available to management. We allocate any excess purchase price over the fair value of the tangible and identifiable intangible assets acquired and liabilities assumed to goodwill. Significant management judgments and assumptions are required in determining the fair value of assets acquired and liabilities assumed, particularly acquired intangible assets, including estimated useful lives. The valuation of purchased intangible assets is based upon estimates of the future performance and discounted cash flows of the acquired business. Each asset acquired or liability assumed is measured at estimated fair value from the perspective of a market participant. Revenue Recognition (Note 8) Certain of the Group’s contracts with customers include promises to transfer multiple services to a customer. The Group assesses the services promised in a contract and identifies distinct or bundled performance obligations in the contract. Identification of these performance obligations involves judgement to determine the promises and the ability of the customer to benefit independently from such promises. If multiple performance obligations are identified in the contract the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. Significant judgment is required to determine the stand-alone selling price for each distinct performance obligation and the determination may not always be discernible from past transactions or other observable evidence. We utilize several inputs when determining stand-alone selling price, including the price of services sold on a standalone basis, our overall pricing strategies, the cost of providing the service, market data and the geographic locations in which the service is provided. The Group has determined that a portion of the transaction price under value-based care agreements is variable as it is dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. The variable portion of our value-based care revenue is estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is highly probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Value-based care revenue is recognized gross when it is assessed that the performance obligation relates to the whole of the patient journey with the Group responsible for arranging, providing and controlling the value-based care services provided to the attributed members. This is a significant judgement when assessing the performance obligation. For the year ended December 31, 2021, revenue related to value-based care arrangements totaling $220.9 million (2020: $26.0 million, 2019: $0.0 million) was recognized gross. Capitalization of Development Costs (Note 18) The Group capitalizes expenditures for the development of technology to the extent that it is expected to meet the criteria in accordance with IAS 38, Intangible Assets Impairment of Intangible Assets (Note 18) The carrying values of our long-lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may no longer be recoverable. If any indication exists, then the asset’s recoverable amount is estimated. Determining the recoverable amount is subjective and requires management to estimate future growth, profitability, discount and terminal growth rates, and project future cash flows, among other factors. Future events and changing market conditions may impact our assumptions as to prices, costs or other factors that may result in changes to our estimates of future cash flows. If we conclude that a definite or indefinite long-lived intangible asset is impaired, we recognize a loss in an amount equal to the excess of the carrying value of the asset over its fair value at the date of impairment. The fair value at the date of the impairment becomes the new cost basis and will result in a lower depreciation expense than for periods before the asset’s impairment. Consolidation (Note 19) Prior to December 31, 2021, the Group held certain rights in the form of purchase options to acquire additional equity interests in entities that it had an existing shareholding in. These rights are assessed as either substantive or protective in nature to conclude whether the Group exercises control over the entity. This assessment requires judgement relating to both the barriers that may prevent, and the extent to which the Group would benefit from, exercise of those rights and determines whether the Group should consolidate the entity. Claims Payable (Note 23) Claims payable includes estimates of our obligations for medical care services that have been rendered on behalf of our members, but for which claims have either not yet been received or processed, and loss adjustment expense reserve for the expected costs of settling these claims. We utilize independent actuaries to develop estimates for medical expenses incurred but not yet paid (“IBNP”) using actuarial processes that are applied on a systematic and consistent basis. These estimates use actuarial methods that are commonly used by health insurance actuaries and meet Actuarial Standards of Practice. These actuarial methods consider factors, such as historical data for payment patterns, seasonal variances, membership volume, as well as other medical cost trends. The independent actuaries provide us with reports that includes the results of their analysis of our medical claims liability. We do not solely rely on their report to adjust our claims liability. We utilize their calculation of our claims liability, together with management’s judgment, to determine the assumptions to be used in the calculation of our liability for claims. Claims payable includes claims reported but not yet paid, estimates for claims incurred but not reported, and estimates for the costs necessary to process unpaid claims at the end of each period. Each period, we re-examine previously established claims payable estimates based on actual claim submissions and other changes in facts and circumstances. As the Claims payable estimates recorded in prior periods develop, we adjust the amount of the estimates and include the changes in estimates in medical expenses in the period in which the change is identified. Actuarial Standards of Practice generally require that the medical claims liability estimates be adequate to cover obligations under moderately adverse conditions. Moderately adverse conditions are situations in which the actual claims are expected to be higher than the otherwise estimated value of such claims at the time of estimate. In many situations, the claims amount ultimately settled will be different than the estimate that satisfies the Actuarial Standards of Practice. We include in our IBNP an estimate for medical claims liability under moderately adverse conditions, which represents the risk of adverse deviation of the estimates in its actuarial method of reserving. We believe that Claims payable is adequate to cover future claims payments required. However, such estimates are based on knowledge of current events and anticipated future events. Therefore, the actual liability could differ materially from the amounts provided. Classification of Warrants Assumed in the Merger (Note 29) Warrants assumed in the Merger give the holder the right, but not the obligation to subscribe to the Company’s Ordinary Shares at a fixed or determinable price for a specified period of five years. These instruments were considered to be part of the net assets acquired in the Merger and, therefore, have applied the provisions of debt and equity classification under IAS 32, Financial Instruments: Presentation

Summary of Significant Accoun_4

Summary of Significant Accounting Policies	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	3. Summary of Significant Accounting Policies With the exception of the extension to our accounting policies described below, the accounting policies applied in these Condensed Consolidated Financial Statements are the same as those applied in the Group’s consolidated financial statements as of and for the year ended December 31, 2021. Clinical Care Delivery Expense Clinical care delivery expense includes the internal costs that we incur in the provision of healthcare services to patients, which is substantially composed of employee-related expenses such as salaries and wages for Babylon healthcare professionals. Other costs within Clinical care delivery expense include operating costs incurred for the delivery of healthcare services to patients, such as occupancy, medical supplies, and other support-related costs. Claims Expense Claims expense includes the costs of healthcare services rendered by third parties on behalf of patients which the Company is contractually obligated to pay, which includes estimates for medical expenses incurred but not yet paid (“IBNP”) using actuarial processes that are applied on a systematic and consistent basis. This process includes the development of estimates using historical claims experience and actuarial models when sufficient claims history is available from health plans and payors. Claims expense also includes other external costs incurred in the delivery of healthcare services including insurance.	4. Summary of Significant Accounting Policies The consolidated Group financial statements have been prepared under the historical cost basis, as modified by the recognition of certain financial instruments measured at fair value and are presented in United States Dollar (“USD”) which is the Group’s presentation currency. All values are rounded to the nearest thousands, except where otherwise indicated. The principal accounting policies adopted in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated. Revenue Recognition Revenue is primarily derived from the following sources: (1) capitation revenue from value-based care services, (2) software license fees for the provision of AI services, and (3) patient revenues from the provision of clinical services. Revenue is recognized upon transfer of control of services to customers in an amount that reflects the consideration which the Group expects to receive in exchange for those services. Contract assets are recognized when there is an excess of revenue earned over billings on contracts where the rights are conditional on something other than passage of time. Contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. Income received in advance (“contract liability”) is recognized when there are billings in excess of revenues earned for services rendered. The Group’s contracts with customers could include promises to transfer multiple services to a customer. The Group assesses the services promised in a contract and identifies distinct or bundled performance obligations in the contract. Identification of these performance obligations involves judgement to determine the promises and the ability of the customer to benefit independently from such promises. If multiple performance obligations are identified in the contract the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. Transaction prices are adjusted for the effects of a significant financing component if we expect, at contract inception, that the period between the transfer of the promised goods or services to the customer and when the customer pays for that service will be more than one year. The Group exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time. The Group considers indicators such as how a customer consumes benefits as services are rendered, existence of enforceable rights to payment for performance to date, transfer of significant risks and rewards to the customer and acceptance of delivery of the service by the customer. Value-based Care Revenue Value-based care (“VBC”) revenue consists primarily of per member per month (“PMPM”) allocations for care management services by the Group under arrangements with various customers. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of VBC services to attributed members. PMPM fees are based upon fixed rates per member or a percentage of the per member premium of the health plan and are not dependent upon the volume of specific care services provided. In addition, the arrangements usually include payments dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. Unlike clinical services revenue discussed below, the Group accepts partial or full financial risk (either global or professional) for members attributed to our VBC services in exchange for a fixed monthly allocation, which means we are responsible for the cost of all covered services provided to members. In general, the Group considers all VBC revenue contracts as containing a single performance obligation to stand ready to provide managed VBC services to the attributed members. This performance obligation is satisfied over time as the Group stands ready to fulfill its obligation to the attributed members as a group. Accordingly, the Group recognizes revenue in the month in which attributed members are entitled to receive VBC services during the contract term. Part of the consideration received under VBC revenue contracts is variable as the contracts contain provisions dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. VBC revenue is estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is highly probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Such uncertainties may only be resolved several months after the end of the reporting period because of the availability of sufficient reliable data relating to factors such as quality metrics, member specific attributes and healthcare service costs. Subsequent changes in VBC revenue and the amount of PMPM revenue to be recognized by the Company are reflected in subsequent periods. VBC revenue is recognized gross when it is assessed that the performance obligation relates to the whole of the patient journey with the Group responsible for arranging, providing and controlling the VBC services provided to the attributed members, with expenses payable to other healthcare providers. Software Licensing Revenue Under IFRS 15, Revenue from Contracts with Customers In some cases, we have concluded that upfront payments included in software license contracts with customers have a significant financing component considering the period between the upfront payment and the services provided, when the contract term is more than one year. As a result, the transaction price must be adjusted to account for the time value of money by using an appropriate discount rate. The discount rate utilized is determined based on the rate that would be reflected in a separate financing transaction with the customer. When a significant financing component exists, we recognize a contract liability for the entire upfront cash payment received, excluding the amount relating to the financing component from the transaction price. Additionally, interest expense is recognized over the duration of the contract under the amortized interest method. Clinical Service Revenue Clinical service revenue represents clinical services provided to our business and private patients under an arrangement and is recognized when the services are rendered. Our clinical service fees are based on PMPM subscription fees and fees per appointment (“fee-for-service”). PMPM subscription fees give members access to our clinical services over the contractual period as set forth in the arrangement, recognized monthly based on the number of members covered by the plan in a given month. Fee-for-service is based on contracted rates determined in agreed-upon compensation schedules and is recognized when the services are rendered at a point in time. In arrangements where PMPM subscription fees are charged we assess whether any of the transaction price should be allocated to software licensing revenue and allocate on a contract by contract basis. Cost of Care Delivery Cost of care delivery primarily consists of claims costs from physicians and other health professionals in our provider network and costs incurred in connection with our provider network operations, including rent, insurance and other direct costs incurred in the delivery of patient care. Cost of care delivery is mainly driven by patient activity and required medical services that are relatively variable. Costs incurred relating to the delivery of VBC services is recognized as an expense within cost of care delivery over time as the expense is incurred. Grant Income We recognize income related to grants on a systematic and rational basis when it becomes probable that we have complied with the terms and conditions of the grant and in the period in which the corresponding costs or income related to the grant are recognized. We receive grants in the form of cash contributions towards outreach projects and tax credits for certain qualifying research and development expenditures. These grants are recognized as non-current deferred grant income liability, released either over the period of the grant contract or over the same period that the related capitalized development costs are amortized. The offset to the release of the long term deferred grant income liability is recognized as revenue for outreach grants and a reduction in Platform & application expenses for tax credits. Platform & Application Expenses Platform & application expenses are costs of revenue for our digital healthcare platform. These costs primarily include employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in providing professional services related to support and maintenance of the digital healthcare platform. These costs also include third-party application costs, hosting services, and other direct costs. The amortization of capitalized development costs are also included in Platform & application expenses. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized if the product or process is technically and commercially feasible and if the Group has sufficient resources to complete the development. Capitalized development costs are recorded as intangible assets and amortized from the point at which the development is complete, and the asset is available for use. Costs are capitalized based on a model whereby a percentage is allocated to employee related expenses based on the time spent on the development of assets. Subsequent expenditure on capitalized intangible assets is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All employee expenses included in this balance relate to employees in the product and technology departments, and the percentage attributable varies dependent on the nature of the work performed and the type of asset being developed. Expenses that do not meet the criteria for capitalization are expensed as incurred within Platform & application expenses. The technical feasibility of a new product is determined by a management team consisting of product, technology, and finance leads based on understanding the availability of adequate technical, financial and other resources required to develop the product. The commercial feasibility of a new product is determined by understanding how this product feeds into Babylon’s current offering. Commercial leads ascertain market interest by evaluating against existing and potential customer requirements. Feasibility is challenged with input from finance leads to verify the underlying financial implications of development and assess viability. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. As described in Note 3, development costs of $34.0 million (2020: $43.0 million) were capitalized during the year for those development and technology expenses that were deemed technologically feasible and probable of generating future economic benefits. During the period of development, the asset is tested for impairment at least annually. Research & Development Expenses Research & development expenses primarily included employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in performing activities to develop and improve the Group’s digital healthcare platform. These costs also include third-party application costs, hosting services, and other indirect costs. Research costs and development costs that do not meet the criteria for capitalization are expensed as incurred within Research & development expenses. Sales, General & Administrative Expenses Sales, general & administrative expenses include employee-related expenses, contractors and consultants expense, stock-based compensation, property and facility related expenses, IT and hosting, marketing, training and recruiting expenses. Enterprise IT and hosting costs are primarily software subscriptions, domain and hosting costs. Our Sales, general & administrative expenses also include depreciation of property, fixtures and fittings and amortization of acquired intangible assets. Claim Expenses and Claims Payable Claims expense, presented within Cost of care delivery, and Claims payable includes costs for third party healthcare service providers who provide medical care to our members for which the Group is contractually obligated for financial risks relating to the medical services provided. The estimated reserve for IBNP claims is included in the liability for unpaid claims in the Consolidated Statement of Financial Position. Actual claims expense will differ from the estimated liability due to factors in estimated and actual member utilization of health care services, the amount of charges and other factors. We determine our estimates through a variety of actuarial models based on medical claims history to ensure our estimates represent the best, most reasonable estimate given the data available to us at the time the estimates are made. Taxation Tax on the Consolidated Statement of Profit and Loss for the year comprises current and deferred tax. Tax is recognized in the Consolidated Statement of Profit and Loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the reporting date. Expenditures incurred for R&D activities have been claimed and will be reimbursed through the U.K. research and development expenditure credit scheme (the “RDEC Scheme”). Under the RDEC Scheme tax relief is given at 12.0% (up to April 1, 2020) and 13.0% (after April 1, 2020) of allowable R&D costs, which may result in a payable tax credit at an effective rate of 7.8% of qualifying expenditure for the year ended December 31, 2021. The Group recognizes the gross amount as Deferred grant income on the Consolidated Statement of Financial Position and as a reduction to Platform & application expenses over the period of expected benefit from the expenditure. The related tax charge on the credit is recognized in the year of the tax credit. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized. Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares of the Group outstanding during the period. Diluted net loss per share is computed by giving effect to all potential ordinary shares, including outstanding stock options, warrants and convertible notes, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential ordinary shares outstanding would have been anti-dilutive. We have included shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares), including options and warrants, within the computation of basic net loss per share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent). Comprehensive Loss Comprehensive loss consists of cumulative translation gains or losses. Unrealized gains or losses are net of any reclassification adjustments for realized gains and losses included in the Consolidated Statement of Profit and Loss. Segment Reporting IFRS 8, Operating Segments Segment information is presented based on information used by the CODM in its decision-making processes. The CODM is responsible for the Group’s key strategic and business decisions and driving the direction and growth of the Group. These include but are not limited to international growth, new services, material business agreements and corporate and management structures. The CODM’s key decisions are based on the monthly management accounts in which segment information is presented on the basis of geographic areas. Each segment derives its revenues from software license fees for the provision of AI services, patient revenues from the provision of clinical services and VBC services provided by the segment which may differ from the geographic location of the customer. Earnings before depreciation, amortization, net finance income (costs), and income taxes (“EBITDA”) is used to measure performance of each segment because the Group believes that this information is most relevant in evaluating the results of the respective segments. The accounting policies for segment information, including transactions entered between segments are generally the same as those described in the summary of significant accounting policies. The CODM is not provided with total assets and liabilities by segment, and therefore the disclosures below do not include these measures. Segment information is reported from a geographic presence perspective. The Group’s results are provided to CODM disaggregated by geographic region, including the United Kingdom (“UK”), the United States of America (“US”), Canada (until the disposal of our Canadian subsidiary), Rwanda, and Singapore. The Group assessed the geographical segments within the aggregation guidance provided in IFRS 8 and determined that the UK and U.S. segments each exceed the quantitative thresholds and represent individual reportable segments. The remaining geographical regions individually and in aggregate do not exceed the quantitative thresholds for reportable segments. Therefore, the UK and the U.S. segments are the Group’s reportable segments for the purposes of these Consolidated Financial Statements. Business Combinations The acquisition consideration is measured at fair value which is the aggregate of the fair values of the assets transferred, the liabilities incurred or assumed and the equity interests in exchange for control. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration are recognized in the Consolidated Statement of Profit and Loss. The consideration transferred in a business combination shall be measured at fair value, which shall be calculated as the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree and the equity interests issued by the acquirer. The allocation process requires an analysis of acquired contracts, customer relationships, contractual commitments, and legal contingencies to identify and record the fair value of all assets acquired and liabilities assumed. In valuing acquired assets and assumed liabilities, fair values are based on, but are not limited to, future expected cash flows, current replacement cost for similar capacity for certain fixed assets, market rate assumptions for contractual obligations, and appropriate discount rates and growth rates. Where the consideration transferred, together with the non-controlling interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. Acquisition related costs are expensed as incurred and classified as Sales, general & administrative expenses in the Consolidated Statement of Profit and Loss. Goodwill is capitalized as a separate item in the case of subsidiaries. Goodwill is denominated in the currency of the operation acquired. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in the Consolidated Statement of Profit and Loss. When the Group increases its ownership interests held in one of its consolidated subsidiaries, any difference between the consideration given and the aggregate carrying value of the assets and liabilities of the acquired entity at the date of the transaction is included in equity in retained earnings. Property, Plant and Equipment Property, plant and equipment is stated at historical cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment losses. Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Consolidated Statement of Profit and Loss during the reporting period in which they are incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: ​ ​ ​ ​ – Computer equipment 3 years – Fixtures and fittings 3 – 5 years – Deployed machinery 4 years ​ At the end of each reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. When an asset is disposed of, the gain or loss is calculated by comparing proceeds received with its carrying amount and is recognized in the Consolidated Statement of Profit and Loss. Other Intangible Assets Intangible assets resulting from capitalized development costs in the normal course of business are recorded at historical cost. Intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in Sales, general & administrative expenses. The useful lives of the Group’s intangible assets are: ​ ​ ​ ​ – Development costs 1 – 10 years – Developed technology ​ 5 years – Customer relationships ​ 15 years – Trade names ​ 5 – 11 years – Physician network ​ 3 – 10 years – Licenses ​ 1 – 2 years ​ An intangible asset is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Consolidated Statement of Profit and Loss. Goodwill Goodwill is measured as described in “Business combinations” above. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortized and is reviewed for impairment at least annually as of October 1 or more frequently if triggering events occur or impairment indicators exist. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash generating units (“CGUs”), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units represents the lowest level within the entity at which the goodwill is monitored for internal management purposes. Trade Receivables We use a forward-looking expected credit loss (“ECL”) model in determining our allowance for doubtful accounts as it relates to trade receivables, contract assets, and other financial assets. Our allowance is based on historical experience, and includes consideration of the aging of the receivables, the economic environment, industry trend analysis, and the credit history and financial conditions of the customers among other factors. We measure an impairment loss as the excess of the carrying amount over the present value of the estimated future cash flows discounted using the financial asset’s original discount rate, and we recognize this loss in our Consolidated Statement of Profit and Loss. A financial asset is written-off or written-down to its net realizable value as soon as it is known to be impaired. We adjust previous write-downs to reflect changes in estimates or actual experience. Our allowance for doubtful accounts is not material. Non-current Assets Held for Sale and Disposal Groups Non-current assets and disposal groups are classified as held for sale when: ● They are available for immediate sale, ● Management is committed to a plan to sell, ● It is unlikely that significant changes to the plan will be made or that the plan will be withdrawn, ● An active program to locate a buyer has been initiated, ● The asset or disposal group is being marketed at a reasonable price in relation to its fair value, and ● A sale is expected to complete within 12 months from the date of classification. Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount immediately prior to being classified as held for sale in accordance with the Group’s accounting policy; and fair value less costs of disposal. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Following their classification as held for sale, non-current assets (including those in a disposal group) are not depreciated. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized. Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. As of December 31, 2021, the Group had restricted cash of $0.3 million (2020: $0.0 million). Impairment of Non-financial Assets Excluding Deferred Tax Assets Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that carrying values may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal (market value) and value in use determined using estimates of discounted future net cash flows of the asset or group of assets to which it belongs. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units). Employee Benefits Defined Contribution Plans Obligations for contributions to defined contribution pension plans are recognized as an expense in the Consolidated Statement of Profit and Loss in the periods during which services are rendered by employees. Short-term Benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably. Share-based Payment Transactions The Group and the Company operates an equity compensation scheme. It issues equity settled share-based payments to both employees and non-employees within the Group, whereby services are rendered in exchange for rights to purchase shares of the Company, which are primarily composed of restricted stock awards and options. Non-employees include contractors and advisors. The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards, net of estimated forfeitures. The fair value of the options granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions (if applicable) are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Compensation expense associated with equity compensation awards is recognized on a straight-line basis over the requisite period. The forfeitures rate is estimated and revised at each reporting date based on historical actuals. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes. Valuation of Ordinary Shares As there has been no public market for the Group’s ordinary shares prior to October 21, 2021, the estimated fair value of the ordinary shares has been determined by the Board of Directors as of the date of each grant, with input from management, considering the most recently available third-party valuations of the Group’s ordinary shares, and the assessment of additional objective and subjective factors that they believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant. Foreign Currency Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction.

Alkuri Merger and PIPE Transact

Alkuri Merger and PIPE Transaction	12 Months Ended
	Dec. 31, 2021
Disclosure Of Detailed Information About Reverse Recapitalization [Abstract]
Alkuri Merger and PIPE Transaction	5. Alkuri Merger and PIPE Transaction On June 3, 2021, we entered into the Merger Agreement with Alkuri, Alkuri’s sponsor and the Founder and Chief Executive Officer of Babylon. The Merger Agreement provided for the Merger, and Alkuri and Babylon entered into subscriptions agreements (the “Subscription Agreements”) with certain accredited investors (the “PIPE Investors”) providing for issuance and the sale, in private placements, of an aggregate of 22,400,000 Class A Ordinary Shares to the PIPE Investors at a price of $10.00 per share (the “PIPE Transaction”). The Merger and the PIPE Transaction closed on October 21, 2021 and were effectuated as follows: ● The shareholders of Alkuri, including Alkuri’s sponsor, exchanged their equity interests for Class A Ordinary Shares of Babylon Holdings Limited. As Alkuri does not meet the definition of a business, the Merger was accounted for as a recapitalization in accordance with IFRS 2 with Babylon Holdings Limited being the accounting successor. At the closing of the Merger, Alkuri merged with and into Liberty USA Merger Sub, Inc., a new wholly owned subsidiary, with Alkuri continuing as the surviving company and a wholly owned subsidiary of Babylon Holdings Limited. Each Alkuri unit consisting of Alkuri common stock and warrants was automatically separated into its component securities without any action on the part of the holders of such units. Each share of Alkuri common stock was automatically converted into the right to receive one Class A Ordinary Share of Babylon Holdings Limited. Each warrant to purchase shares of Alkuri’s common stock that was outstanding immediately prior to the Merger was assumed by the Company and automatically converted into a warrant to purchase Class A Ordinary Shares in the Company. ● Pursuant to the Merger Agreement, the Company issued 10,973,903 Class A Ordinary Shares to the shareholders of Alkuri (excluding the Sponsor Earnout Shares discussed below) and assumed warrants previously issued by Alkuri, consisting of 5,933,333 private placement warrants and 8,625,000 public warrants, which were converted into warrants to purchase 14,558,333 Class A Ordinary Shares (“Alkuri Warrants”). The warrants to purchase 14,558,333 Class A Ordinary Shares give the holder the right to purchase such shares at a fixed amount for a period of five years subject to the terms and conditions of the warrant agreement. The issuance of shares to shareholders and investors in Alkuri as part of the Merger resulted in a $ 122.8 million increase in Share premium. The impact to Share capital was not material. ● As part of the Merger, Babylon issued 38,800,000 Class B Ordinary Shares to its Founder and Chief Executive Officer (“Stockholder Earnout”) and 1,293,750 Class A Ordinary Shares to Alkuri’s sponsor (“Sponsor Earnout Shares”), subject to transfer restrictions if and until milestones based on the trading price of the Class A Ordinary Shares on the New York Stock Exchange following the closing of the Merger are achieved (collectively “Earnout Shares”). The restrictions on the Earnout Shares are to be released in four equal portions subject to achieving milestones on the trading price of our Class A ordinary Shares on the New York Stock Exchange of $ 12.50 , $ 15.00 , $ 17.50 and $ 20.00 within and for specified time periods. In the event that such milestones are not met within and for the required time periods, all of the Earnout Shares for which the applicable milestone has not been met will be automatically converted into redeemable shares of Babylon, which Babylon can redeem for $ 1.00 . As continuing employment is not a condition for achievement of the Earnout Shares, it was concluded that the Earnout Shares were not compensatory in nature and should be accounted for as an equity transaction between parties to the Merger. Therefore, the Earnout Shares were reflected in the measurement of the Recapitalization transaction expense. See Note 15 for additional discussion. ● In exchange for the Class A Ordinary Shares and warrants issued to Alkuri, and the issuance of the Stockholder Earnout Shares and the Sponsor Earnout Shares, the Company received the net assets held by Alkuri of $ 5.3 million, which was primarily composed of cash held in Alkuri’s trust account of $ 36.4 million and current liabilities of $ 31.1 million. In accordance with IFRS 2, the difference between the fair value of the identifiable net assets contributed by Alkuri and the fair value of the equity instruments issued to the former Alkuri shareholders (including its sponsor) is treated as an expense, resulting in a Recapitalization transaction expense of $ 148.7 million included within Operating loss. ● Concurrent with the Merger, the Company received proceeds of $ 224.0 million through the private placement of Class A Ordinary Shares to the PIPE Investors, which included existing investors, Alkuri’s sponsor, and other new investors in the PIPE Transaction. The PIPE Transaction has been treated as a capital contribution, which resulted in a $ 224.2 million increase in Share premium. The impact to Share capital was not material. Upon the closing of the Merger and PIPE Transaction, Babylon Holdings Limited became a publicly traded corporation, listing its Class A Ordinary Shares and its public warrants on the New York Stock Exchange under the ticker symbols BBLN and BBLN.W, respectively. Babylon incurred incremental transaction costs directly attributable to the issuance of shares the shareholders of Alkuri pursuant to the Merger Agreement and to the PIPE Investors in the PIPE Transaction, which were reflected as a reduction in Share premium.

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about business combination [abstract]
Acquisitions	6. Acquisitions As part of our business strategy, we have acquired, and may acquire in the future, certain businesses and technologies primarily to expand our service offerings. Acquisitions in the Current Period Higi Prior to October 29, 2021, higi SH Holdings Inc. (“Higi”), a provider of digital healthcare services via a network of smart health stations in the United States, was accounted for as an associate because the Group was able to demonstrate significant influence through representation on the board and the power to participate in the financial and operating policy decisions. On November 1, 2021, the Group determined that through its option to acquire the outstanding shares of Higi, it possessed substantive rights which provided the Group with the power to exert control, not just significant influence, over Higi and thus, November 1, 2021 was determined to be the acquisition date with a 25% ownership interest. On December 7, 2021, the Company exercised its option to acquire the remaining equity interest in Higi pursuant to the Second Amended and Restated Agreement and Plan of Merger dated October 29, 2021. The closing of this acquisition occurred on December 31, 2021. The exercise price of the option to acquire the remaining Higi equity stake included the payment of $8.4 million of cash and the issuance of 3,412,107 Class A Ordinary Shares at the closing; the payment of $7.4 million at the closing to satisfy the principal and interest payable by a subsidiary of Higi pursuant to a promissory notes including one in favor of ALP Partners Limited (further disclosed in Note 30), an entity owned by our founder and Chief Executive Officer; the future payment of up to $0.3 million in cash and issuance of up to 490,782 additional Class A Ordinary Shares after the expiration of a 15-month indemnification holdback period, and the issuance of 1,980,000 restricted stock units for Higi continuing employees and consultants in respect of Class A Ordinary Shares. The Higi shareholders receiving our shares are subject to a lockup and were granted certain registration rights. The transfer of cash and shares upon exercise of the option to acquire the remaining non-controlling interest after November 1, 2021 was accounted for as an equity transaction between consolidated subsidiaries under IFRS 10, Consolidated Financial Statements We accounted for the consolidation of Higi using the acquisition method of accounting for business combinations achieved without the transfer of consideration, as control of Higi was obtained through contract. The fair value of the 74.7% non-controlling interest was estimated to be $64.3 million. The most significant input to the fair value of the non-controlling interest in Higi was the transaction price, given the proximity of the legal closing of the transaction to the time control was obtained. Prior to consolidating Higi, the Company accounted for its 25.5% interest as an investment in an associate. The acquisition-date fair value of the previous equity interest was $21.8 million, which resulted in a non-cash gain of $10.5 million upon remeasurement of the equity interest in Higi prior to the business combination. The gain is included in Gain on remeasurement of equity interest in the Consolidated Statement of Profit and Loss. The intangible assets acquired include developed technology, license agreements and licensed trade names. We estimated the fair values of the property, plant and equipment and license arrangements using a cost approach that reflects the costs necessary to replace the service capacity of the acquired assets. We estimated the fair value of developed technology utilizing the relief from royalty method. This form of the income approach utilizes management's estimates of future operating results and cash flows using a royalty rate that reflects market participant assumptions. The royalty rate used in the valuation of developed technology was 3%. We estimated the fair value of the trade name utilizing the relief from royalty method. This form of the income approach utilizes management’s estimates of future operating results and cash flows using a royalty rate that reflects market participant assumptions. The royalty rate used in the valuation of the trade name was 1%. The income approaches described above utilize management’s estimates of future operating results and cash flows using a weighted average cost of capital that reflects market participant assumptions. The group has recorded the excess of the aggregate acquisition date fair values of non-controlling interest and the interest the Group previously held in Higi over the fair value of net assets acquired as goodwill. The goodwill reflects our expectations of favorable future growth opportunities, anticipated synergies through the use of our digital healthcare platform, and the assembled workforce. We expect that the majority of the goodwill acquired in the acquisition will not be deductible for corporate income tax purposes. Transaction related costs are included in Sales, general & administrative expenses in our Consolidated Financial Statements. Total transaction related costs incurred during the year ended December 31, 2021 were $0.4 million. We have performed a preliminary valuation analysis of the fair market value of the assets and liabilities of Higi upon consolidation. The final purchase price allocations will be determined when we have completed and fully reviewed the detailed valuations and could differ materially from the preliminary allocation. The final allocation may include changes of acquired intangible assets as well as goodwill and other changes to assets and liabilities, including deferred taxes. The estimated useful lives of acquired intangible assets are also preliminary. The acquisition-date fair value of Higi has been allocated on a preliminary basis as follows: ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Carrying value of existing equity interest ​ 11,274 Gain on remeasurement of existing equity interest 10,495 Fair value of non-controlling interest 64,274 Acquisition date fair value of Higi 86,043 Accounts receivable 2,314 Property, plant and equipment 17,618 License arrangements 2,650 Trade names 3,100 Developed technology 5,900 Deferred tax liability (730) Other assets and liabilities, net (5,983) Net assets acquired 24,869 Goodwill 61,174 ​ For the two months ended December 31, 2021, Higi contributed revenue of $2.1 million and losses before tax of $4.0 million to the Group’s consolidated results. If the acquisition had occurred on January 1, 2021, management estimates that consolidated revenue for the year ended December 31, 2021 would have been $331 million (higher by $7.9 million) and consolidated losses before tax would have been $390.0 million (higher by $14.1 million). In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2021. Meritage Medical Network On April 1, 2021, the Group acquired all the outstanding equity interests of Meritage Medical Network (“Meritage”), a California professional corporation, for total consideration of $16.1 million, of which $27.9 million related to cash paid, net of $14.1 million in cash acquired, and $2.3 million related to the fair value of warrants issued to the former shareholders of Meritage. This acquisition is intended to expand the growth of our value-based care services to patients within the Meritage network. We accounted for this acquisition under the acquisition method of accounting and have reported the results of operations as of the acquisition date. The intangible assets acquired include customer relationships, trade names, physician networks and a license. We estimated the fair value of customer relationship intangibles using an income approach, utilizing the excess earnings method for customer relationships. This form of the income approach utilizes management’s estimates of future operating results and cash flows using a weighted average cost of capital that reflects market participant assumptions. We estimated the fair value of trade names and the license using a cost approach that reflects the costs necessary to replace the service capacity of the acquired assets. We estimated the fair value of the trade name using an income approach, utilizing the relief from royalty method. This form of the income approach utilizes management’s estimates of future operating results and cash flows using a royalty rate that reflects market participant assumptions. Other significant judgements used in the valuation of tangible liabilities assumed in the acquisition included a valuation of the healthcare related liabilities acquired, which were primarily based on historical claims experience to estimate the liability on the acquisition date. The Group has recorded the excess of the fair value of the consideration transferred in the acquisitions over the fair value of net assets acquired as goodwill. The goodwill reflects our expectations of favorable future growth opportunities, anticipated synergies through the use of our digital healthcare platform and the assembled workforce. We expect that the majority of the goodwill acquired in the acquisition will not be deductible for corporate income tax purposes. Acquisition related costs are included in Sales, general & administrative expenses in our Consolidated Financial Statements. Total acquisition related costs incurred for this acquisition during the year ended December 31, 2021 were $0.2 million. The estimated fair value of assets acquired as of the acquisition date were as follows: ​ ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Cash paid, net of cash acquired ​ 13,798 Issuance of warrants 2,349 Aggregate purchase price 16,147 Accounts receivable 751 Customer relationships 11,600 Physician’s network 3,500 Trademark 1,900 License 590 Claims payable (13,436) Deferred tax liability (2,610) Other assets and liabilities, net (817) Net assets acquired 1,478 Goodwill 14,669 ​ For the nine months ended December 31, 2021, Meritage contributed revenue of $53.0 million and losses before tax of $15.5 million to the Group’s consolidated results. If the acquisition had occurred on January 1, 2021, management estimates that consolidated revenue would have been $339.4 million (higher by $16.5 million) and consolidated losses before tax would have been $376.1 million (higher by $0.1 million) for the year ended December 31, 2021. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2021. Health Innovators, Inc. In fiscal year 2019, the Group acquired preference shares in Health Innovators Inc. for initial consideration of $4.0 million satisfied in cash. As a result, the Group has rights associated with the ownership of $56.7 million shares (approximately 80% ownership), subject to further investments, repurchase by Health Innovators Inc. if further investments were not made, and restrictions and limitations in Health Innovators Inc’s charter and the stock purchase agreement through which the Group made its investment. Additionally, the Group has power over the investee, exposure and rights to variable returns and the ability to influence returns, giving the group control over the investee. Babylon Holdings Limited has the option to increase their investment in stages, exercisable for a period of 4-years. The investment option is considered a derivative and has no impact to the Consolidated Financial Statements given it is eliminated upon consolidation. Management has elected to recognize non-controlling interest (“NCI”) on the proportionate basis. In the event of a liquidation, Babylon has a preferential right to recover amounts invested prior to any distribution to other shareholders or Babylon will receive its percentage of net assets of Health Innovators, whichever is greater. On the acquisition date, the net assets of Health Innovators were valued at $3.9 million which was less than the priority payment of $4.0 million. Net assets at December 31, 2020 and December 31, 2021 were lower than Babylon’s total investment at that date. As a result, in the Consolidated Statement of Financial Position as of December 31, 2020 and December 31, 2021, Babylon consolidated 100% of Health Innovators Inc.’s net assets and no NCI has been recognized. In fiscal year 2020, Babylon invested further in Health Innovators Inc. for consideration of $6.6 million satisfied in cash resulting in approximately 80% ownership. In December 2021, Babylon acquired all of the remaining outstanding equity interests of Health Innovators Inc. in exchange for 247,112 Babylon Class A Ordinary Shares. The transaction was accounted for as an equity transaction between consolidated subsidiaries and did not have a material impact on the Consolidated Financial Statements. Fiscal Year 2020 Acquisitions On October 1, 2020, the Group entered into an Asset Purchase Agreement to acquire the contracts of the Fresno Health Care business of FirstChoice Medical Group (together, “Fresno”) for $25.7 million of cash consideration. The acquisition of the contracts and transfer of related operational processes is required to be accounted for under IFRS 3 . The fair value of assets acquired as of the acquisition date were as follows: ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Acquiree’s net assets at the acquisition date: ​ Intangible assets 7,900 Right-of-use asset 153 Lease liability (153) Net identifiable assets and liabilities 7,900 Goodwill 17,771 Consideration paid 25,671 ​ The assets acquired include customer relationships, trademarks and trade names, and physician networks. To determine the fair value of the acquired assets the Company used the present value of future cash flows for customer relationships, the expected revenue attributable over ten years with a 0.5% royalty rate and 10% discount rate for trademarks and trade names, and the expected replacement costs over two years for physician networks. The purchase price of $25.7 million exceeded the fair value of the net assets acquired from Fresno by $17.8 million and was recorded as goodwill, which has been allocated to the Fresno CGU. Goodwill represents benefits from Fresno’s assembled workforce and expected synergies and has been calculated by subtracting the fair value of net assets acquired from the consideration paid. Total revenues attributable to the assets acquired from Fresno since the acquisition were $16.1 million for the year ended December 31, 2020. Net loss attributable to the assets acquired from Fresno since the acquisition was $2.8 million for the year ended December 31, 2020. If the acquisition had occurred on January 1, 2020, management estimates that consolidated revenue would have been $128.3 million (higher by $49.0 million) and consolidated losses would have been $179.4 million (lower by $4.0 million) for the year ended December 31, 2020. In determining these amounts, management has assumed that the fair value adjustments that arose on the date of acquisition would have been the same if the acquisition had occurred on January 1, 2020.

Disposals of Subsidiaries

Disposals of Subsidiaries	12 Months Ended
	Dec. 31, 2021
Disposals Of Subsidiaries [Abstract]
Disposals of Subsidiaries	7. Disposals of Subsidiaries On January 14, 2021, the Group entered into a Share Purchase Agreement (“SPA”) with TELUS Corporation (“TELUS”), a Canadian publicly traded holding company which is the parent of various telecommunication subsidiaries, for the sale of the Babylon Health Canada Limited business. The entire issued share capital of Babylon Health Canada Limited was transferred to TELUS for a base price of $1.8 million in Canadian dollars (“CAD”), which has been adjusted for working capital and net indebtedness. An additional $3.5 million CAD payment was made by TELUS that was attributable to a partial repayment of an Intercompany Loan due from Babylon Canada to Babylon Partners Limited. The remaining amount of the Intercompany loan was forgiven immediately prior to the execution of the SPA. Effect of disposal: ​ ​ ​ ​ For the Year ​ ​ Ended December ​ ​ 31, 2021 ​ ​ $‘000 Cash and cash equivalents (57) Prepayments and contract assets (1,322) Property, plant and equipment (922) Right-of-use assets (797) Trade and other receivables (619) Accruals and provisions 658 Lease liabilities 837 Borrowings 3,075 Trade and other payables 588 Net assets and liabilities derecognized 1,441 Consideration received 2,344 Working capital adjustment 132 Gain on disposal 3,917 ​ There were no disposals of subsidiaries in the years ended December 31, 2020 and 2019.

Revenue_2

Revenue	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Revenue	5. Revenue i) Disaggregation of Revenue ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Value-based care 246,575 27,259 Software licensing 7,756 35,964 Clinical services 12,115 8,070 ​ 266,446 71,293 ​ In January 2021, we entered into a License and Support Agreement (“License Agreement”) with TELUS. As part of the License Agreement, the Group received an upfront payment of $66.9 million in exchange for the right to use the Company’s digital healthcare platform (“Software Platform”), specified upgrades to be delivered over a 24-month period, post-contract support (“PCS”), and a right to access enhancements to the Group’s Software Platform over a period of seven years. We identified that the License Agreement included multiple performance obligations and allocated the transaction price to the separate performance obligations on a relative standalone basis. We determined the standalone selling prices based on our overall pricing objectives, taking into consideration market inputs and entity specific factors, including standalone selling prices when available. We also concluded that the upfront payment included a significant financing component. As a result, the transaction price was adjusted to account for the time value of money and interest expense will be recognized over the duration of the contract. ii) Contract Balances The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Trade receivables 7,068 8,278 Contract assets 5,557 4,484 Contract liabilities 86,426 94,182 ​ The contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. There was no impact on contract assets as a result of acquisition of subsidiaries. The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer. The Group’s customers generally pay for invoices in the month following the issuance date. iii) Transaction Price Allocated to the Remaining Performance Obligations The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ Remainder ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ of 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ $’000 $’000 $’000 $’000 $’000 $’000 As of March 31, 2022 ​ 22,663 ​ 18,366 ​ 18,959 ​ 15,539 ​ 10,899 ​ 86,426 ​ The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2022 ​ $’000 Balance on January 1, 94,182 Amounts billed but not recognized 849 Revenue recognized (6,091) Effect of movements in foreign exchange (2,514) Balance on March 31, 86,426 ​ No revenue was recognized from performance obligations satisfied (or partially satisfied) in previous periods.	8. Revenue i) Disaggregation of Revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Value-based care ​ 220,852 ​ 26,038 ​ — Software licensing 60,052 24,603 2,002 Clinical services 42,017 28,631 14,032 ​ 322,921 79,272 16,034 ​ In January 2021, we entered into a License and Support Agreement (“License Agreement”) with TELUS. As part of the License Agreement, the Group received an upfront payment of $66.9 million in exchange for the right to use the Company’s digital healthcare platform (“Software Platform”), specified upgrades to be delivered over a 24 -month period, post-contract support (“PCS”), and a right to access enhancements to the Group’s Software Platform over a period of seven years . We identified that the License Agreement included multiple performance obligations and allocated the transaction price to the separate performance obligations on a relative standalone basis. We determined the standalone selling prices based on our overall pricing objectives, taking into consideration market inputs and entity specific factors, including standalone selling prices when available. We also concluded that the upfront payment included a significant financing component. As a result, the transaction price was adjusted to account for the time value of money and interest expense will be recognized over the duration of the contract. ii) Contract Balances The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 20) ​ 8,278 ​ 4,674 Contract assets (Note 20) 4,484 2,378 Contract liabilities (Note 8 iii) 94,182 76,018 ​ The contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. There was no impact on contract assets as a result of acquisition of subsidiaries. The contract assets are transferred to receivables when the rights become unconditional. This usually occurs when the Group issues an invoice to the customer. The Group’s customers generally pay for invoices in the month following the issuance date. iii) Transaction Price Allocated to the Remaining Performance Obligations The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 As of December 31, 2021 ​ 23,786 ​ 18,918 ​ 19,349 ​ 17,852 ​ 14,277 ​ 94,182 ​ The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance on January 1 ​ 76,018 ​ 81,584 Amounts billed but not recognized 61,176 18,080 Revenue recognized (43,012) (23,646) Balance on December 31 94,182 76,018 ​ No revenue was recognized from performance obligations satisfied (or partially satisfied) in previous periods.

Segment Information_2

Segment Information	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [abstract]
Segment Information	6. Segment Information Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Condensed Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue 15,670 250,512 335 266,517 (71) 266,446 Inter-segment revenue — — (64) (64) 64 — Segment revenue 15,670 250,512 271 266,453 (7) 266,446 Clinical care delivery expense (11,872) (12,394) (261) (24,527) 600 (23,927) Claims expense — (247,552) — (247,552) — (247,552) Other operating expenses, excluding amortization and depreciation (31,225) (34,176) (9,505) (74,906) (706) (75,612) Change in fair value of warrant liabilities — — 5,575 5,575 — 5,575 Exchange (loss) / gain (4,078) 2,353 (16,657) (18,382) 17,935 (447) Segment EBITDA (31,505) (41,257) (20,577) (93,339) 17,822 (75,517) Depreciation and amortization ​ (9,458) Change in fair value of warrant liabilities ​ (5,575) Exchange gain ​ 447 Operating loss ​ (90,103) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue 41,242 29,244 434 70,920 373 71,293 Inter-segment revenue — — 4 4 (4) — Segment revenue 41,242 29,244 438 70,924 369 71,293 Clinical care delivery expense (9,269) (4,597) (596) (14,462) 2,639 (11,823) Claims expense — (23,917) — (23,917) — (23,917) Other operating expenses, excluding amortization and depreciation (26,442) (11,316) (2,386) (40,144) (2,311) (42,455) Exchange (loss) / gain (632) (49) 1,788 1,107 (1,680) (573) Gain on sale — — 3,917 3,917 — 3,917 Share of loss of equity-accounted investees — (455) — (455) — (455) Segment EBITDA 4,899 (11,090) 3,161 (3,030) (983) (4,013) Depreciation and amortization ​ (5,848) Exchange loss ​ 573 Gain on sale of subsidiary ​ (3,917) Share of loss of equity-accounted investees ​ 455 Operating loss ​ (12,750) ​ Reconciliation adjustments include allocation and classification differences of costs between management accounts and statutory reporting, reversals of inter-segment revenue and foreign exchange variances. Major Customers Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $‘000 % of revenue $‘000 % of revenue Customer 1 145,043 54.4 % 12,420 17.4 % Customer 2 61,446 23.1 % — — ​ Customer 3 14,381 5.0 % 12,148 17.0 % Customer 4 ​ 2,530 ​ 1.0 % 30,129 ​ 42.3 % ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 UK 9,435 7,786 US 250,597 29,808 Asia-Pacific 3,634 3,410 Canada 2,530 30,129 Rest of World 250 160 Total 266,446 71,293 ​ As of March 31, 2022, 39.4% ($99.3 million) and 59.5% ($150.1 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. As of December 31, 2021, 38.3% ($92.6 million) and 61.1% ($147.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. As of March 31, 2022, 69.4 % ( $4.9 million) and 27.7% ( $2.0 million) of total Group trade receivables were attributable to the UK and US, respectively. As of December 31, 2021, 84.5 % ( $7.0 million) and 11.0% ($ 0.9 million) of total Group trade receivables were attributable to the UK and US, respectively.	9. Segment Information Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue ​ 88,967 ​ 232,296 ​ 1,610 ​ 322,873 ​ 48 ​ 322,921 Inter-segment revenue ​ 2,205 ​ (3,964) ​ 1,756 ​ (3) ​ 3 ​ 0 Segment revenue ​ 91,172 ​ 228,332 ​ 3,366 ​ 322,870 ​ 51 ​ 322,921 Cost of care delivery ​ (41,542) ​ (253,998) ​ (1,590) ​ (297,130) ​ 7,458 ​ (289,672) Other operating expenses, excluding amortization and depreciation ​ (114,975) ​ (105,602) ​ (171,951) ​ (392,528) ​ (8,226) ​ (400,754) Change in fair value of warrant liabilities ​ — ​ — ​ 27,811 ​ 27,811 ​ — ​ 27,811 Exchange (loss) / gain ​ (1,844) ​ 189 ​ 1,390 ​ (265) ​ 1,133 ​ 868 Gain on sale of subsidiary ​ — ​ — ​ 2,687 ​ 2,687 ​ 1,230 ​ 3,917 Gain on remeasurement of equity interest ​ — ​ — ​ 10,495 ​ 10,495 ​ — ​ 10,495 Share of loss of equity-accounted investees ​ — ​ (2,602) ​ — ​ (2,602) ​ — ​ (2,602) Segment EBITDA ​ (67,189) ​ (133,681) ​ (127,792) ​ (328,662) ​ 1,646 ​ (327,016) Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ (35,004) Change in fair value of warrant liabilities ​ ​ ​ ​ ​ ​ ​ (27,811) Exchange gain ​ ​ ​ ​ ​ ​ ​ (868) Gain on sale of subsidiary ​ ​ ​ ​ ​ ​ ​ (3,917) Gain on remeasurement of equity interest ​ ​ ​ ​ ​ ​ ​ (10,495) Share of loss of equity-accounted investees ​ ​ ​ ​ ​ ​ ​ 2,602 Operating loss ​ ​ ​ ​ ​ ​ ​ (402,509) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue ​ 44,000 ​ 32,226 ​ 2,968 ​ 79,194 ​ 78 ​ 79,272 Inter-segment revenue 1,194 (3,094) 1,766 (134) 134 0 Segment revenue 45,194 29,132 4,734 79,060 212 79,272 Cost of care delivery (34,600) (34,381) (7,205) (76,186) 8,932 (67,254) Other operating expenses, excluding amortization and depreciation (127,762) (27,190) (3,990) (158,942) (14,100) (173,042) Exchange (loss) / gain 403 (246) 17,060 17,217 (20,053) (2,836) Share of loss of equity-accounted investees — — (1,124) (1,124) — (1,124) Segment EBITDA (116,765) (32,685) 9,475 (139,975) (25,009) (164,984) Depreciation and amortization ​ (14,487) Exchange loss ​ 2,836 Share of loss of equity-accounted investees ​ 1,124 Operating loss ​ (175,511) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 External revenue ​ 14,633 ​ — ​ 1,410 ​ 16,043 ​ (9) ​ 16,034 Inter-segment revenue ​ 4,081 ​ (2,669) ​ (1,382) ​ 30 ​ (30) ​ — Segment revenue ​ 18,714 ​ (2,669) ​ 28 ​ 16,073 ​ (39) ​ 16,034 Cost of care delivery ​ (25,707) ​ (160) ​ (373) ​ (26,240) ​ 6,430 ​ (19,810) Other operating expenses, excluding amortization and depreciation ​ (119,895) ​ (23,273) ​ (5,340) ​ (148,508) ​ (8,040) ​ (156,548) Exchange (loss) / gain 314 (83) 16,584 16,815 260 17,075 Segment EBITDA (126,574) (26,185) 10,899 (141,860) (1,389) (143,249) Depreciation and amortization ​ (2,496) Exchange gain ​ (17,075) Operating loss ​ (162,820) ​ Reconciliation adjustments include allocation and classification differences of costs between management accounts and statutory reporting, reversals of inter-segment revenue and foreign exchange variances. Major Customers Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue Customer 1 ​ 119,785 ​ 37.1 % 11,918 ​ 15.0 % 2,215 ​ 13.8 % Customer 2 39,764 12.3 % 9,706 12.3 % 2,465 15.4 % Customer 3 38,705 12.0 % 9,505 12.0 % 5,607 34.9 % Customer 4 N/A N/A 14,937 18.9 % N/A N/A ​ ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 UK ​ 35,490 ​ 28,827 ​ 12,189 US 232,708 32,689 — Asia-Pacific 14,965 11,585 2,215 Canada 38,705 3,207 564 Rest of World 1,053 2,964 1,066 Total 322,921 79,272 16,034 ​ In 2021 38.3% ($92.6 million) and 61.1% ($147.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. In 2020 64.8% ($70.9 million) and 34.5% ($37.8 million) of non-current assets of the Group are derived from and located within the UK and US, respectively. In 2021 84.5% ($7.0 million) and 11.0% ($0.9 million) of total Group trade receivables were attributable to the UK and US, respectively. In 2020 47.6% ($2.2 million) and 50.1% ($2.3 million) of total Group trade receivables were attributable to the UK and US, respectively.

Employee Benefits Expense

Employee Benefits Expense	12 Months Ended
	Dec. 31, 2021
Claims Payable
Employee Benefits Expense	10. Employee Benefits Expense ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Wages and salaries ​ 148,728 ​ 108,018 ​ 57,388 Social security and pension contributions ​ 17,118 ​ 13,404 ​ 8,254 Share-based compensation 46,307 9,557 7,966 Total 212,153 130,979 73,608 ​ Of the total employee benefits expense, $62.3 million (2020:$34.5 million, 2019: $3.7 million) has been recognized in Cost of care delivery, $6.9 million (2020: $8.8 million, 2019: $7.2 million) in Platform & application expenses, $42.9 million (2020: $53.3 million, 2019: $36.6 million) in Research & development expenses, and $100.1 million (2020: $34.4 million, 2019: $26.0 million) in Sales, general & administrative expenses. During 2021, the Group capitalized employee costs of $34.0 million (2020: $43.0 million, 2019: $36.0 million) as development costs. Average Staff Numbers ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 Engineers ​ 427 ​ 515 ​ 670 Sales & marketing 89 88 108 Finance, HR & legal 242 146 178 Clinical operations 856 586 476 Clinicians 959 773 124 ​ 2,573 2,108 1,556 ​

Platform & Application Expense

Platform & Application Expense	12 Months Ended
	Dec. 31, 2021
Platform & Application Expenses [Abstract]
Platform & Application Expenses	11. Platform & Application Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020* ​ 2019* ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits 6,873 8,800 7,225 Depreciation and amortization 16,842 11,088 1,182 IT and hosting costs 14,760 8,660 6,621 Contractors and consultants expense 1,941 3,010 7,381 Impairment 941 6,436 — Other 1,472 143 1,160 Total 42,829 38,137 23,569 * Restated to reflect reclassification of certain expense items described in Note 2.

Research Development Expenses

Research Development Expenses	12 Months Ended
	Dec. 31, 2021
Claims Payable
Research & Development Expenses	12. Research & Development Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ 2021 ​ 2020* ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits ​ 42,877 53,332 ​ 36,630 Contractors and consultants expense 3,917 645 14,752 Other 740 734 (177) Total 47,534 54,711 51,205 * Restated to reflect reclassification of certain expense items described in Note 2 .

Sales, General & Administrative

Sales, General & Administrative Expenses	12 Months Ended
	Dec. 31, 2021
Claims Payable
Sales, General & Administrative Expenses	13. Sales, General & Administrative Expenses ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020* ​ 2019* ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits expense 100,095 34,362 26,020 Professional fees 19,200 8,645 4,469 IT and hosting costs 16,430 11,559 9,988 Depreciation and amortization 16,222 3,399 1,315 Marketing 9,982 6,575 7,691 Insurance 9,598 4,172 2,444 Contractors and consultants expense 7,425 2,501 7,008 Staffing, training and recruitment 6,321 3,494 6,393 Property related expenses 5,677 8,651 10,214 Local taxes 2,311 2,359 2,321 Office and clinical supplies 1,119 2,120 2,362 Other 2,293 6,844 4,045 Total 196,673 94,681 84,270 * Restated to reflect reclassification of certain expense items described in Note 2. ​

Finance Income and Costs

Finance Income and Costs	12 Months Ended
	Dec. 31, 2021
Finance Income and Costs [Abstract]
Finance Income and Costs	14. Finance Income and Costs ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Finance costs(i) (14,291) (4,530) (1,116) Finance income(ii) 326 610 1,015 Change in fair value of warrant liabilities 27,811 — — Exchange gain / (loss) 868 (2,836) 17,075 Net finance income (expense) 14,714 (6,756) 16,974 (i) The following items are included under finance costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Interest payable 10,234 252 851 Interest on leases 617 572 265 Interest on contract liabilities 3,440 3,706 — Total finance costs 14,291 4,530 1,116 (ii) In 2021, 2020 and 2019 finance income related to interest received .

Recapitalization Transaction Ex

Recapitalization Transaction Expense	12 Months Ended
	Dec. 31, 2021
Disclosure Of Recapitalization Transaction Expense [Abstract]
Recapitalization Transaction Expense	15. Recapitalization Transaction Expense As discussed in Note 5, the Merger resulted in a non-cash Recapitalization transaction expense. The Company issued Class A Ordinary Shares and warrants with a combined fair value of $153.8 million to Alkuri’s shareholders (including its sponsor), based on the opening prices of Babylon Holdings Limited Class A Ordinary Shares and warrants as reported by the New York Stock Exchange on October 22, 2021 of $10.01 and $2.13, respectively. In exchange for the Class A Ordinary Shares and warrants issued to Alkuri, and the issuance of the Stockholder Earnout Shares and the Sponsor Earnout Shares, the Company received identifiable net assets with a fair value of $5.3 million. The fair value of the Class A Ordinary Shares and warrants in excess of the fair value of identifiable net assets contributed by Alkuri resulted in a Recapitalization transaction expense of $148.5 million in accordance with IFRS 2. This one- time expense as a result of the Merger of $148.5 million, is recognized as Recapitalization transaction expenses in the Consolidated Statement of Profit and Loss. As continuing employment is not a condition for achievement of the Stockholder Earnout Shares, it was concluded that the Stockholder Earnout Shares issued in the transaction were not compensatory in nature, but instead were part of an equity transaction between parties to the Merger. The Stockholder Earnout Shares are accounted for as part of the Merger and reflected in the stock price of $10.01 used in the measurement of the Recapitalization transaction expense under IFRS 2. The Sponsor Earnout Shares have been included within Alkuri Ordinary in the table below, and the Stockholder Earnout Shares have been included through their direct impact to the opening share price used to determine the fair value of shares exchanged. In addition, the Company incurred a non-cash Recapitalization transaction expense relating to the PIPE Transaction. The fair value of the equity instruments issued to the PIPE investors was $224.2 million. In exchange, the Company received cash of $224.0 million. The excess of the fair value of equity instruments issued over the cash acquired of $0.2 million has also been recorded as a non-cash IFRS 2 expense. The following table displays the calculation of the Recapitalization transaction expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Amount shares/warrants ​ ​ $’000 ​ ​ (a) Alkuri Ordinary Shares 12,267,653 (b) Opening price of Babylon Ordinary Shares on NYSE as of October 22, 2021 10.01 (c) Fair value of Company shares issued to Alkuri shareholders (a*b) 122,799 (d) Outstanding Alkuri Warrants on October 22, 2021 14,558,333 (e) Opening price of Babylon Warrants on NYSE as of October 22, 2021 Public warrants 2.13 8,625,000 Private placement warrants 2.13 5,933,333 (f) Fair value of outstanding Alkuri Warrants (d*e) 31,009 Total fair value of Alkuri Ordinary Shares and Alkuri Warrants (c+f) 153,808 Alkuri’s identifiable net assets 5,310 IFRS 2 Expense on the closing date 148,498 PIPE Transaction (a) PIPE Ordinary Shares 22,400,000 (b) Opening price of Babylon Ordinary Shares on NYSE as of October 22, 2021 10.01 (c) Fair value of Company shares issued to PIPE investors (a*b) 224,224 PIPE’s identifiable net assets 224,000 IFRS 2 Expense on the closing date 224 Total IFRS 2 Expense 148,722 ​ ​ ​ ​ ​ Total cash proceeds received 229,311 Expense of share issue (32,787) Cash proceeds 196,524 ​

Taxation

Taxation	12 Months Ended
	Dec. 31, 2021
Major components of tax expense (income) [abstract]
Taxation	16. Taxation Recognized in the Consolidated Statement of Profit and Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Current tax Current tax on loss for the period 801 569 (3,457) Adjustments to tax in respect of previous periods 31 4,070 (2,102) Total current tax 832 4,639 (5,559) ​ ​ ​ ​ ​ ​ ​ Deferred tax Origination and reversal of timing differences (2,306) — — Total deferred tax (2,306) — — ​ ​ ​ ​ ​ ​ ​ Tax (benefit) provision (1,474) 4,639 (5,559) ​ Analysis of tax recognized in the Consolidated Statement of Profit and Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Loss before tax (375,985) (183,391) (145,846) Tax on loss on ordinary activities at standard CT rate (19.00%) (71,437) (34,844) (27,711) State and local income taxes, net of federal benefit (320) — — Benefit of foreign operations (218) — — Deferred tax not recognized 38,563 31,271 25,552 Expenses not deductible for tax purposes 33,512 4,142 187 Non-taxable income (11,003) — — Change in fair value of warrants 8,903 — — Tax arising on share in associates 495 — — Adjustments to tax in respect of previous periods 31 4,070 (2,102) All other, net — — (1,485) Tax (benefit) provision (1,474) 4,639 (5,559) ​ A reduction in the UK corporation tax rate from 19.0% to 17.0% (effective April 1, 2020) was substantively enacted on September 6, 2016. The March 2020 Budget announced that a rate of 19.0% would continue to apply with effect from April 1, 2020, and this change was substantively enacted on March 17, 2020. An increase in the UK corporation rate from 19.0% to 25.0% (effective April 1, 2023) was substantively enacted on May 24, 2021. This will increase the Company's future tax charge accordingly. The deferred tax liability at December 31, 2021 has been calculated based on these rates, reflecting the expected timing of reversal of the related temporary differences (2020: 19.0%). Unrecognized deferred tax assets Due to uncertainty over future profitability, a deferred tax asset of $179.3 million (2020: $80.8 million) relating to losses and other deductions, as well as intangible asset and short-term timing differences, has not been recognized. The unrecognized deferred tax assets in each jurisdiction have been measured using the rates that would be expected to apply in the periods when the underlying timing differences, on which deferred tax is computed, are expected to unwind.

Property, Plant and Equipment

Property, Plant and Equipment	12 Months Ended
	Dec. 31, 2021
Property, plant and equipment [abstract]
Property, Plant and Equipment	17. Property, Plant and Equipment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Computer ​ Fixtures and ​ Deployed ​ ​ ​ Equipment Fittings Machinery Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost Balance at January 1, 2020 2,463 390 — 2,853 Additions 308 411 — 719 Reclassification to assets held for sale — (621) — (621) Effect of movements in foreign exchange 89 — — 89 Balance at December 31, 2020 2,860 180 — 3,040 Balance at January 1, 2021 2,860 180 — 3,040 Additions 2,830 5,273 — 8,103 Acquisitions through business combinations 105 41 17,618 17,764 Effect of movements in foreign exchange (107) (103) — (210) Balance at December 31, 2021 5,688 5,391 17,618 28,697 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Computer ​ Fixtures and ​ Deployed ​ ​ ​ Equipment Fittings Machinery Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Depreciation Balance at January 1, 2020 991 61 — 1,052 Depreciation 931 3 — 934 Effect of movements in foreign exchange (346) 66 — (280) Balance at December 31, 2020 1,576 130 — 1,706 Balance at January 1, 2021 1,576 130 — 1,706 Depreciation 1,255 81 750 2,086 Effect of movements in foreign exchange (76) (9) — (85) Balance at December 31, 2021 2,755 202 750 3,707 Net book value At January 1, 2020 1,472 329 — 1,801 At December 31, 2020 and January 1, 2021 1,284 50 — 1,334 At December 31, 2021 2,933 5,189 16,868 24,990 ​

Intangible Assets and Goodwil_3

Intangible Assets and Goodwill	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Intangible Assets and Goodwill	8. Intangible Assets and Goodwill The changes in the carrying amount of goodwill and intangible assets for the three months ended March 31, 2022 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ $’000 $’000 $’000 $’000 $’000 $’000 $’000 $’000 Cost Balance at January 1, 2022 93,678 109,356 21,868 14,700 8,300 5,000 590 159,814 Additions — — 10,071 — — — — 10,071 Transfers — 6,803 (6,803) — — — — — Effect of movements in foreign exchange (23) (2,759) (530) — — — — (3,289) Balance at March 31, 2022 93,655 113,400 24,606 14,700 8,300 5,000 590 166,596 Amortization and impairment Balance at January 1, 2022 — 39,724 — 3,680 3,533 1,063 393 48,393 Amortization for the period — 5,064 — 193 750 329 131 6,467 Effect of movements in foreign exchange — (1,094) — — — — — (1,094) Balance at March 31, 2022 — 43,694 — 3,873 4,283 1,392 524 53,766 Net book value At January 1, 2022 93,678 69,632 21,868 11,020 4,767 3,937 197 111,421 At March 31, 2022 93,655 69,706 24,606 10,827 4,017 3,608 66 112,830 ​ All development costs, including intangibles under development, have been internally generated by the Group. During the three months ended March 31, 2022, $6.8 million of intangibles under development were transferred to development costs as these projects were completed. Intangibles under development are tested for impairment at least annually. The total net book value is considered to be the recoverable amount, as this balance is reviewed annually and impaired as necessary. All development costs are related to the development of our digital healthcare platform and there are no distinguishable individually material intangible assets within the capitalized development costs. There was no impairment of the development costs in the three months ended March 31, 2022 or 2021.	18. Intangible Assets and Goodwill The changes in the carrying amount of goodwill and intangible assets for the years ended December 31, 2021 and 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ 61 ​ 15,558 ​ 28,873 ​ — ​ — ​ — ​ — ​ 44,431 Acquisitions through business combinations ​ 17,771 ​ — ​ — ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 7,900 Additions ​ — ​ 940 ​ 43,027 ​ — ​ — ​ — ​ — ​ 43,967 Transfers ​ — ​ 51,932 ​ (51,932) ​ — ​ — ​ — ​ — ​ — Effect of movements in foreign exchange ​ — ​ 632 ​ 1,170 ​ — ​ — ​ — ​ — ​ 1,802 Balance at December 31, 2020 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Balance at January 1, 2021 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Acquisitions through business combinations ​ 75,846 ​ 8,550 ​ — ​ 11,600 ​ 5,000 ​ 3,500 ​ 590 ​ 29,240 Additions ​ — ​ — ​ 33,999 ​ — ​ — ​ — ​ — ​ 33,999 Transfers ​ — ​ 33,056 ​ (33,056) ​ ​ ​ ​ — ​ — Effect of movements in foreign exchange ​ — ​ (1,312) ​ (213) ​ — ​ — ​ — ​ — ​ (1,525) Balance at December 31, 2021 ​ 93,678 ​ 109,356 ​ 21,868 ​ 14,700 ​ 8,300 ​ 5,000 ​ 590 ​ 159,814 Amortization and impairment ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ — ​ 680 ​ — ​ — ​ — ​ — ​ — ​ 680 Amortization for the year ​ — ​ 10,157 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 11,123 Impairment charge ​ — ​ 6,436 ​ — ​ — ​ — ​ — ​ — ​ 6,436 Effect of movements in foreign exchange ​ — ​ 1,008 ​ — ​ — ​ — ​ — ​ — ​ 1,008 Balance at December 31, 2020 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Balance at January 1, 2021 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Amortization for the year ​ — ​ 21,287 ​ — ​ 2,835 ​ 3,450 ​ 1,025 ​ 393 ​ 28,990 Impairment charge ​ — ​ 941 ​ — ​ — ​ — ​ — ​ — ​ 941 Effect of movements in foreign exchange ​ — ​ (785) ​ — ​ — ​ — ​ — ​ — ​ (785) Balance at December 31, 2021 ​ — ​ 39,724 ​ — ​ 3,680 ​ 3,533 ​ 1,063 ​ 393 ​ 48,393 Net book value ​ ​ ​ ​ ​ ​ ​ ​ At January 1, 2020 ​ 61 ​ 14,878 ​ 28,873 ​ — ​ — ​ — ​ — ​ 43,751 At December 31, 2020 and January 1, 2021 ​ 17,832 ​ 50,781 ​ 21,138 ​ 2,255 ​ 3,217 ​ 1,462 ​ — ​ 78,853 At December 31, 2021 ​ 93,678 ​ 69,632 ​ 21,868 ​ 11,020 ​ 4,767 ​ 3,937 ​ 197 ​ 111,421 ​ Goodwill of $75.8 million (2020: $17.8 million) has been acquired through business combinations (Note 6). All development costs, including intangibles under development, have been internally generated by the Group. During 2021, $33.1 million (2020: $51.9 million) of intangibles under development were transferred to development costs as these projects were completed. Intangibles under development are tested for impairment at least annually. The total net book value is considered to be the recoverable amount, as this balance is reviewed annually and impaired as necessary (Note 4). All development costs are related to software and artificial intelligence development and there are no distinguishable individually material intangible assets within the capitalized development costs. Following an assessment of the future development of our technology, capitalized development costs were impaired by $0.9 million (2020: $6.4 million). The impairment recognized in 2020 was primarily the result of the discontinuation of certain features surrounding a proprietary data structure for encounters on our software platform that were deemed to be no longer technologically feasible. Impairment Analysis for CGUs Containing Goodwill and Intangibles Goodwill and other intangibles are subject to impairment testing on an annual basis or whenever events or circumstances indicate that the carrying amount of goodwill may no longer be recoverable. As of October 1, 2021, the date of the Goodwill impairment testing, all of the Goodwill of the Group was allocated to the California IPA CGU. The fair value of the California Independent Physicians Association CGU (“California IPA CGU”, formerly “Fresno CGU”) was determined using a discounted cash flow model, a form of the income approach. The recoverable amount of the California IPA CGU that included these intangible assets was estimated based on the present value of the future cash flows expected to be derived from the California IPA CGU (value in use), using a discount rate of 14.5% and a terminal value growth rate of 3.0% from 2027. The recoverable amount of the California IPA CGU was estimated to be higher than its carrying amount, and as a result there was no impairment related to the California IPA CGU in 2021. The below are factors considered when performing the 2021 sensitivity analysis: Terminal value growth rate Discount factor No reasonably possible change to the key assumptions would lead to an impairment of goodwill

Investments in Subsidiaries a_4

Investments in Subsidiaries and Associates	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments in Subsidiaries and Associates
Investments in Subsidiaries and Associates	7. Investments in Subsidiaries and Associates As discussed in Note 2, we consolidated certain PCs which are owned, directly or indirectly, and operated by licensed physicians. The following provides summary financial data for the PCs that are included in the Condensed Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Total assets 131,429 104,703 Total liabilities 213,222 168,240 ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Total revenues 127,138 19,756 Clinical care delivery expense (8,912) (2,256) Claims expense (118,985) (15,793) Sales, general & administrative expenses (15,012) (2,875) ​	19. Investments in Subsidiaries and Associates The Group and Company have the following investments: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Ownership Ownership ​ ​ ​ ​ ​ ​ (As of ​ (As of ​ ​ Country of ​ ​ ​ December 31, ​ December 31, Subsidiary Undertakings ​ Incorporation ​ Principal Activity ​ 2021) ​ 2020) Company: ​ ​ ​ ​ ​ ​ ​ ​ Babylon Partners Limited UK Application development 100.0% ​ 100.0% Babylon Healthcare Services Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Rwanda Limited Rwanda Digital Healthcare services 100.0% ​ 100.0% Babylon Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Health Canada Limited Canada Digital Healthcare services — ​ 100.0% Babylon Liberty Corp. USA Digital Healthcare services 100.0% ​ — Babylon Malaysia SDN BHD Malaysia Digital Healthcare services 100.0% ​ 100.0% Babylon International Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Health Ireland Limited Ireland Digital Healthcare services 100.0% ​ 100.0% Babylon Singapore PTE Limited Singapore Digital Healthcare services 100.0% ​ 100.0% Health Innovators Inc. USA Digital Healthcare services 100.0% ​ 70.1% Babylon Acquisition Corp. USA Digital Healthcare services — ​ 100.0% Babylon Technology LTDA Brazil Digital Healthcare services 100.0% ​ 100.0% Higi SH Holdings Inc. USA Digital Healthcare services 100.0% ​ 19.0% Group: ​ ​ ​ ​ Babylon Healthcare Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Healthcare NJ, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PLLC USA Healthcare services 100.0% ​ 100.0% Babylon Medical Group (formerly Marcus Zachary DO), PC USA Healthcare services 100.0% ​ 100.0% California Telemedicine Associates, PC USA Healthcare services 100.0% ​ 100.0% Telemedicine Associates, P.C. USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare NC, PC USA Healthcare services — ​ 100.0% Babylon Healthcare, PA USA Healthcare services 100.0% ​ — Meritage Medical Network USA Healthcare services 100.0% ​ — Meritage Health Ventures, LLC USA Healthcare services 100.0% ​ — Meritage Health Plan USA Healthcare services 100.0% ​ — Meritage Management, LLC USA Healthcare services 100.0% ​ — Higi SH LLC USA Digital Healthcare services 100.0% ​ 19.0% Higi Health Holdings LLC USA Digital Healthcare services 100.0% ​ — Higi SH Canada ULC Canada Digital Healthcare services 100.0% ​ 19.0% Higi Health LLC USA Digital Healthcare services 51.0% ​ — Health Innovators Limited UK Digital Healthcare services 100.0% ​ 70.1% DTDHI Health India PVT Ltd India Digital Healthcare services 97.8% ​ 68.6% ​ Babylon Acquisition Corp. merged with Higi SH on December 31, 2021, with Higi SH Holdings Inc. being the surviving entity. Professional service corporations As discussed in Note 2, we consolidated certain PCs which are owned, directly or indirectly, and operated by licensed physicians. The following provides summary financial data for the PCs that are included in the Consolidated Financial Statements: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total assets 104,703 35,535 Total liabilities 168,240 42,699 ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total revenues 154,508 17,436 Cost of care delivery (155,191) (20,175) Sales, general & administrative expenses (55,006) (3,799) ​

Trade and Other Receivables, Pr

Trade and Other Receivables, Prepayments and Contract Assets	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade and Other Receivables, Prepayments and Contract Assets	20. Trade and Other Receivables, Prepayments and Contract Assets ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 8) 8,278 4,674 Other receivables 13,796 8,914 Prepayments 21,516 6,463 Contract assets 4,484 2,378 VAT receivable (payable) 2,045 (63) ​ 50,119 22,366 ​ The Group has assessed its expected credit loss estimate, in line with the requirements of IFRS 9 by taking into consideration historical credit loss experience and financial factors specific to the debtors and general economic conditions. As part of this assessment, the Group has performed a recoverability assessment of its outstanding trade and other receivables at the reporting date and concluded that the expected credit loss as of December 31, 2021 is immaterial (2020: $0.0 million). The table below shows significant changes in contract assets: ​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance at January 1 2,378 1,541 Revenues recognized but not billed 3,444 1,511 Amounts reclassified to trade receivable (1,338) (674) Balance at December 31 4,484 2,378 ​

Trade and Other Payables, Accru

Trade and Other Payables, Accruals and Provisions	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Trade and Other Payables, Accruals and Provisions	21. Trade and Other Payables, Accruals and Provisions The components of Trade and other payables and Accruals and provisions are reflected in the table below: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade payables 17,178 3,739 Accruals 36,366 15,409 Provisions 490 3,227 Taxation and Social Security 4,039 4,006 Employee loans 1,193 — Other 276 — ​ 59,542 26,381 ​

Deferred Grant Income

Deferred Grant Income	12 Months Ended
	Dec. 31, 2021
Deferred Grant Income [Abstract]
Deferred Grant Income	22. Deferred Grant Income The following table is a summary of activity related to deferred grants for the periods presented: ​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Grants related to prior years 3,173 Grants received in 2020 4,315 Grant income recognized — Adjustment, net — Balance at December 31, 2020 7,488 ​ ​ ​ Balance at January 1, 2021 7,488 Grants related to prior years — Grants received in 2021 2,769 Grant income recognized (1,959) Adjustment, net 146 Balance at December 31, 2021 8,444 ​

Claims Payable_2

Claims Payable	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Claims Payable
Claims Payable	9. Claims Payable The following table is a summary of claims activity for the period presented: ​ ​ ​ ​ ​ $’000 Balance at January 1, 2022 24,628 Claims expense 247,552 Claims paid (233,015) Adjustment, net — Balance at March 31, 2022 39,165 ​ The increase in claims expense during the three months ended March 31, 2022 is primarily attributable to the expansion of our value-based care offerings in the United States.	23. Claims Payable The following table is a summary of claims activity for the periods presented: ​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Claims expense 24,146 Claims paid (21,137) Adjustment, net 881 Balance at December 31, 2020 3,890 Balance at January 1, 2021 3,890 Claims expense 216,791 Claims paid (196,053) Adjustment, net — Balance at December 31, 2021 24,628 ​

Cash and Cash Equivalents_2

Cash and Cash Equivalents	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents
Cash and Cash Equivalents	10. Cash and Cash Equivalents The components of cash and cash equivalents are reflected in the table below: ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Cash in hand and at banks 274,978 262,276 Short term investment funds — — Restricted cash — 305 ​ 274,978 262,581 ​ The Group’s short term investment funds are highly liquid, redeemable within 90 days at a known amount of cash and are subject to an insignificant risk of change in value and therefore meet the definition of a cash equivalent.	24. Cash and Cash Equivalents The components of cash and cash equivalents are reflected in the table below: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Cash in hand and at banks 262,276 97,757 Short term investment funds — 4,000 Restricted cash 305 — ​ 262,581 101,757 ​ The Group’s short term investment funds are highly liquid, redeemable within 90 days at a known amount of cash and are subject to an insignificant risk of change in value and therefore meet the definition of a cash equivalent.

Leases_2

Leases	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Leases	11. Leases On November 1, 2021, Babylon Inc. entered into a sublease agreement for 37,883 rentable square feet of office space in Austin, Texas. The lease commenced on February 1, 2022 when we obtained access to the property and will automatically terminate on March 31, 2029. Minimum payments for the non-cancellable lease term are $16.6 million. The Company uses the office space as its United States headquarters with capacity for approximately 200 employees. In January 2022, Babylon Healthcare Services Limited entered into two lease agreements for clinic space in London, United Kingdom. The leases commenced on January 6, 2022 and January 14, 2022 when we obtained access to the properties and will automatically terminate on January 6, 2032 and July 13, 2032, respectively. Minimum payments for the lease terms are $6.3 million and $7.0 million, respectively. The Company intends to use the properties as clinics as part of the Company’s operations.	25. Leases The Group leases several assets which consist of buildings and IT equipment. The Group recognizes right-of-use assets and lease liabilities for its building leases only, as the leases for IT equipment meet the exemption requirements as short-term leases and leases of low-value assets. Therefore, the disclosures below for the Group’s right-of-use assets relate only to buildings. ​ ​ ​ ​ Right-of-use asset $’000 Cost Balance at January 1, 2020 6,501 Additions to right-of-use-assets 2,300 Reclassification to assets held for sale (872) Effect of change in foreign currency 228 Balance at December 31, 2020 8,157 Balance at January 1, 2021 8,157 Additions to right-of-use-assets 11,399 Disposals (4,291) Effect of change in foreign currency (166) Balance at December 31, 2021 15,099 Amortization Balance at January 1, 2020 1,272 Amortization charge for the year 2,430 Reclassification to assets held for sale (243) Effect of change in foreign currency 184 Balance at December 31, 2020 3,643 Balance at January 1, 2021 3,643 Amortization charge for the year 3,929 Disposals (4,291) Effect of change in foreign currency (25) Balance at December 31, 2021 3,256 Net book value Balance at January 1, 2020 5,229 Balance at December 31, 2020 and January 1, 2021 4,514 Balance at December 31, 2021 11,843 ​ ​ ​ ​ Lease liability $’000 Balance at January 1, 2020 3,583 Additions to lease liabilities 2,362 Interest expense on lease liabilities (i) 572 Payments on leases (1,541) Reclassification to liabilities associated with the assets held for sale (607) Effect of change in foreign currency 130 Balance at December 31, 2020 4,499 Balance at January 1, 2021 4,499 Additions to lease liabilities 11,826 Interest expense on lease liabilities (i) 617 Payments on leases (4,156) Reclassification to liabilities associated with the assets held for sale — Effect of change in foreign currency (154) Balance at December 31, 2021 12,632 (i) Interest paid on lease liabilities are presented within cash flows from financing activities. In March 2020, the Group renewed its head office lease to December 2022 with intention to hand in notice and vacate in 2021. As such, a lease modification was applied in 2020 as per IFRS 16 to extend the lease to the intended exit date. The Group entered into a new lease agreement for four floors of a building facility as the head office in London. The commencement date of the lease was in June 2021, with the initial term of the lease being 39 months. The lease provides for an annual rent of $4.9 million after a twelve-month rent-free period following the lease commencement date. When measuring the lease liabilities, the Group discounted lease payments using its incremental borrowing rate. The weighted-average rate applied is 12.0%. The following amounts have been recognized in the Consolidated Statement of Profit and Loss for which the Group is a lessee: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Depreciation expense on right-of-use assets 3,929 2,430 1,272 Interest expense on lease liabilities 617 572 265 Expenses relating to short term leases 2,489 4,756 6,127 Profit and loss impact 7,035 7,758 7,664 ​ The following table provides the undiscounted maturities of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Less than one year 4,595 2,348 One to two years 5,612 684 Two to three years 4,290 598 Three to four years 362 572 Four to five years 371 375 More than five years 705 1,282 Total 15,935 5,859 ​

Loans and Borrowings_2

Loans and Borrowings	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Borrowing costs [abstract]
Loans and Borrowings	12. Loans and Borrowings ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185 ​ AlbaCore Original Notes On October 8, 2021, Babylon entered into a note Subscription Agreement (the “Note Subscription Agreement”). The Note Subscription Agreement provided for the issuance of up to $200.0 million in unsecured notes due 2026 (the “Unsecured Notes”) to affiliates of, or funds managed or controlled by, AlbaCore Capital LLP (the “Note Subscribers”). On November 4, 2021 (“Note Closing Date”), Babylon issued the full $200.0 million (“Principal Amount”) of Unsecured Notes under the Note Subscription Agreement at a discount of 95.5% of the Principal Amount. The Unsecured Notes bear interest accruing on the Principal Amount (which for these purposes shall include any capitalized interest from time to time) at the following rates: (i) 8.00% per annum for the period commencing from (and including) the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date; (ii) 10.00% per annum for the period commencing from (and including) the date falling two years after the Note Closing Date, to (but excluding) the date falling three years after the Note Closing Date; and (iii) 12.00% per annum for the period commencing from (and including) the date falling three years after the Note Closing Date. The applicable interest rate is subject to a step-up margin of 6.5 basis points per annum if Babylon and its subsidiaries do not achieve a target of adding 100,000 Medicaid lives to value-based care contracts by January 1, 2024. Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. The Unsecured Notes will mature five years from the Note Closing Date on November 4, 2026 (the “Final Maturity Date”). Babylon is required to redeem the Unsecured Notes (unless previously purchased and cancelled or redeemed) on the Final Maturity Date at 100% of the principal amount on such date. Babylon may redeem the Unsecured Notes at any time at a redemption amount (the “Redemption Amount”) equal to: (i) from (and including) the Note Closing Date to (but excluding) the date falling one year after the Note Closing Date, the amount that is the greater of (A) 104.00% of the principal amount (including capitalized interest) and (B) 104.00% of the principal amount (including capitalized interest) plus an interest make whole premium; (ii) from (and including) the date falling one year after the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date, 104.00% of the principal amount (including any capitalized interest); and (iii) on or after the date falling two years after the Closing Date and until (but not including or after) the Final Maturity Date, 107.00% of the principal amount (including any capitalized interest). Each holder of Unsecured Notes (each a “Noteholder”) has the option to require Babylon to redeem the Unsecured Notes held by such Noteholder at the Redemption Amount upon specified change of control events. The terms of the Unsecured Notes include covenants, which covenants are subject to certain limitations and exceptions, limiting the ability of Babylon and its subsidiaries to, among other things: incur additional debt; pay or declare dividends or distributions on Babylon’s share capital; repay or distribute any share premium reserve or redeem, repurchase or retire its share capital; incur or allow to remain outstanding guarantees; make certain joint venture investments; enter into finance or capital lease contracts; create liens on Babylon’s or its subsidiaries’ assets; enter into sale and leaseback transactions; pay management and advisory fees outside the ordinary course of business; acquire a company or any shares or securities or a business or undertaking; merge or consolidate with another company; borrow or receive investments from certain shareholders other than through Babylon; and sell, lease, transfer or otherwise dispose of assets. The terms of the Unsecured Notes also include customary events of default. On the Note Closing Date, Babylon issued warrants to subscribe for an aggregate of 1,757,499 Class A ordinary shares (the “AlbaCore Warrants”) to the Note Subscribers on a pro rata basis by reference to the relevant proportion of the Principal Amount of Unsecured Notes subscribed for by each Note Subscriber. The AlbaCore Warrants confer the right to subscribe for up to 1,757,499 Class A ordinary shares exercisable on certain agreed upon exercise events, subject to: (i) Babylon’s right to elect to redeem the AlbaCore Warrants in whole or in part in cash upon an exercise event; (ii) an agreed adjustment formula to reduce the number of Class A Ordinary Shares to be issued upon exercise of the AlbaCore Warrants in certain circumstances linked to Babylon’s trading performance; and (iii) customary adjustments for certain share capital reorganizations (such as share splits and consolidations). The exercise events applicable to the AlbaCore Warrants occur: (i) on the first date following which the closing price of the Class A Ordinary Shares has equaled or exceeded $15.00 per Class A Ordinary Share (subject to customary adjustments) for any 20 trading days within any 30 -trading day period commencing at least 18 months after the Note Closing Date; (ii) where the Noteholders give a redemption notice under the notes deed poll on the occurrence of a change of control in respect of Babylon; (iii) where Babylon elects to redeem the Unsecured Notes prior to the Final Maturity Date in accordance with its rights to do so under the notes deed poll; and (iv) on the Final Maturity Date. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. We capitalized debt issuance costs of $3.4 million in connection with the issuance of the Unsecured Notes. Please refer to Note 15 for additional discussion surrounding the AlbaCore Warrants. AlbaCore Additional Notes and Warrants On December 23, 2021, Babylon entered into an additional note subscription agreement (the “Second Note Subscription Agreement”) providing for the issue of not less than $75 million and not more than $100 million additional Unsecured Notes (the “Additional Notes”) to AlbaCore Partners III Investment Holdings Designated Activity Company, and any new note subscribers that are affiliates of, or funds managed or controlled by, AlbaCore Capital LLP and that adhere to the Second Note Subscription Agreement (the “Second Note Subscribers”). The closing of the issue of the Additional Notes under the Second Note Subscription Agreement, for the principal amount of $100 million, occurred on March 31, 2022 (the “Second Closing Date”). The terms and conditions of the Additional Notes are the same as the terms of the original Unsecured Notes, with the exception that the Additional Notes were issued at 100% of their principal amount. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. On the Second Closing Date, Babylon issued AlbaCore Warrants to subscribe for an aggregate of 878,750 additional Class A ordinary shares (the “Additional AlbaCore Warrants”) to the Second Note Subscribers. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. The exercise events applicable to the Additional AlbaCore Warrants are the same as the AlbaCore Warrants. We capitalized debt issuance costs of $4.0 million in connection with the issuance of the Additional Notes. Upon any exercise event Babylon has a right to elect to satisfy the subscription entitlement in respect of the AlbaCore Warrants by issuing Class A ordinary shares, by making a redemption payment in cash, or by a combination of both (in such proportions as Babylon may in its absolute discretion determine). The cash redemption payment per Note Warrant shall be determined by reference to the closing price for the Class A ordinary shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event, provided that if the closing price is in excess of $15.00 per Class A ordinary share (subject to customary adjustments), the cash redemption payment shall be capped at $15.00 per Note Warrant. Where Babylon elects upon exercise of the AlbaCore Warrants to issue Class A ordinary shares in satisfaction in whole or in part of the subscription entitlement under the AlbaCore Warrants, Babylon is required to issue one Class A ordinary share credited as fully paid and free from all encumbrances (except as set out in Babylon’s memorandum and articles of association from time to time) per AlbaCore Warrant held, subject to a proportionate downwards adjustment to the number of Class A ordinary shares to be issued per AlbaCore Warrant where the closing price of the Class A ordinary shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event is in excess of $15.00 per Class A ordinary share. Changes in Loans and Borrowings from Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other Total Loans ​ ​ AlbaCore ​ Loans and ​ and ​ ​ Notes ​ Borrowings ​ Borrowings ​ $’000 $’000 $’000 Balance at January 1, 2022 ​ 168,601 ​ 185 ​ 168,786 Changes from financing cash flows ​ ​ ​ Proceeds from issuance of notes and warrants ​ 100,000 ​ — ​ 100,000 Payment of debt issuance costs ​ (4,000) ​ — ​ (4,000) Total changes from financing cash flows ​ 96,000 ​ — ​ 96,000 Other changes ​ ​ ​ Fair value of warrants issued ​ (3,418) ​ — ​ (3,418) Unpaid debt issuance costs ​ (257) ​ — ​ (257) Amortization of fair value adjustment, discount, and debt issuance costs ​ 1,202 ​ — ​ 1,202 Other loans and borrowings activity, net ​ — ​ (171) ​ (171) Total other changes ​ (2,473) ​ (171) ​ (2,644) Balance at March 31, 2022 ​ 262,128 ​ 14 ​ 262,142 ​	26. Loans and Borrowings ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Non-current liabilities Loan notes 200,000 — Unamortized fair value adjustment, discount, and debt issuance costs (31,399) — ​ 168,601 — Current liabilities Convertible loan notes — 70,000 Other 185 357 ​ 185 70,357 ​ Albacore Original Notes On October 8, 2021, Babylon entered into a note Subscription Agreement (the “Note Subscription Agreement”). The Note Subscription Agreement provided for the issuance of up to $200.0 million in unsecured notes due 2026 (the “Unsecured Notes”) to affiliates of, or funds managed or controlled by, AlbaCore Capital LLP (the “Note Subscribers”). On November 4, 2021 (“Note Closing Date”), Babylon issued the full $200.0 million (“Principal Amount”) of Unsecured Notes under the Note Subscription Agreement at a discount of 95.5% of the Principal Amount. The Unsecured Notes will bear interest accruing on the Principal Amount (which for these purposes shall include any capitalized interest from time to time) at the following rates: (i) 8.00% per annum for the period commencing from (and including) the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date; (ii) 10.00% per annum for the period commencing from (and including) the date falling two years after the Note Closing Date, to (but excluding) the date falling three years after the Note Closing Date; and (iii) 12.00% per annum for the period commencing from (and including) the date falling three years after the Note Closing Date. The applicable interest rate is subject to a step-up margin of 6.5 basis points per annum if Babylon and its subsidiaries do not achieve a target of adding 100,000 Medicaid lives to value-based care contracts by January 1, 2024. Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. The Unsecured Notes will mature five years from the Note Closing Date on November 4, 2026 (the “Final Maturity Date”). Babylon is required to redeem the Unsecured Notes (unless previously purchased and cancelled or redeemed) on the Final Maturity Date at 100% of the principal amount on such date. Babylon may redeem the Unsecured Notes at any time at a redemption amount (the “Redemption Amount”) equal to: (i) from (and including) the Note Closing Date to (but excluding) the date falling one year after the Note Closing Date, the amount that is the greater of (A) 104.00% of the principal amount (including capitalized interest) and (B) 104.00% of the principal amount (including capitalized interest) plus an interest make whole premium; (ii) from (and including) the date falling one year after the Note Closing Date to (but excluding) the date falling two years after the Note Closing Date, 104.00% of the principal amount (including any capitalized interest); and (iii) on or after the date falling two years after the Closing Date and until (but not including or after) the Final Maturity Date, 107.00% of the principal amount (including any capitalized interest). Each holder of Unsecured Notes (each a “Noteholder”) has the option to require Babylon to redeem the Unsecured Notes held by such Noteholder at the Redemption Amount upon specified change of control events. The terms of the Unsecured Notes include covenants, which covenants are subject to certain limitations and exceptions, limiting the ability of Babylon and its subsidiaries to, among other things: incur additional debt; pay or declare dividends or distributions on Babylon’s share capital; repay or distribute any share premium reserve or redeem, repurchase or retire its share capital; incur or allow to remain outstanding guarantees; make certain joint venture investments; enter into finance or capital lease contracts; create liens on Babylon’s or its subsidiaries’ assets; enter into sale and leaseback transactions; pay management and advisory fees outside the ordinary course of business; acquire a company or any shares or securities or a business or undertaking; merge or consolidate with another company; borrow or receive investments from certain shareholders other than through Babylon; and sell, lease, transfer or otherwise dispose of assets. The terms of the Unsecured Notes also include customary events of default. On the Note Closing Date, Babylon issued warrants to subscribe for an aggregate of 1,757,499 Class A Ordinary Shares (the “AlbaCore Warrants”) to the Note Subscribers on a pro rata basis by reference to the relevant proportion of the Principal Amount of Unsecured Notes subscribed for by each Note Subscriber. The AlbaCore Warrants confer the right to subscribe for up to 1,757,499 Class A Ordinary Shares exercisable on certain agreed upon exercise events, subject to: (i) Babylon’s right to elect to redeem the AlbaCore Warrants in whole or in part in cash upon an exercise event; (ii) an agreed adjustment formula to reduce the number of Class A Ordinary Shares to be issued upon exercise of the AlbaCore Warrants in certain circumstances linked to Babylon’s trading performance; and (iii) customary adjustments for certain share capital reorganizations (such as share splits and consolidations). We capitalized debt issuance costs of $3.4 million in connection with the issuance of the Unsecured Notes. Please refer to Note 29 for additional discussion surrounding the Albacore Warrants. Albacore Additional Notes and Warrants On December 23, 2021, Babylon entered into an additional note subscription agreement (the “Second Note Subscription Agreement”) providing for the issue of not less than $75 million and not more than $100 million additional Unsecured Notes (the “Additional Notes”) to AlbaCore Partners III Investment Holdings Designated Activity Company, and any new note subscribers that are affiliates of, or funds managed or controlled by, AlbaCore Capital LLP and that adhere to the Second Note Subscription Agreement (the “Second Note Subscribers”). The closing of the issue of the Additional Notes under the Second Note Subscription Agreement, for the principal amount of between $75 million to $100 million, is anticipated to occur on March 31, 2022 (the “Second Closing Date”). The terms and conditions of the Additional Notes are the same as the terms of the original Unsecured Notes, with the exception that the Additional Notes will be issued at 100% of their principal amount. At Babylon’s election, up to 50.00% of the interest payable in respect of any interest period may be satisfied by the issuance by Babylon of further Unsecured Notes to be immediately consolidated and form a single series with the outstanding Unsecured Notes. On the Second Closing Date, Babylon will issue AlbaCore Warrants to subscribe for an aggregate of 878,750 additional Class A Ordinary Shares to the Second Note Subscribers. Upon an exercise event, the AlbaCore Warrants are exercisable in full and not in part only. Upon any exercise event Babylon has a right to elect to satisfy the subscription entitlement in respect of the AlbaCore Warrants by issuing Class A Ordinary Shares, by making a redemption payment in cash, or by a combination of both (in such proportions as Babylon may in its absolute discretion determine). The cash redemption payment per Note Warrant shall be determined by reference to the closing price for the Class A Ordinary Shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event, provided that if the closing price is in excess of $15.00 per Class A Ordinary Share (subject to customary adjustments), the cash redemption payment shall be capped at $15.00 per Note Warrant. Where Babylon elects upon exercise of the AlbaCore Warrants to issue Class A Ordinary Shares in satisfaction in whole or in part of the subscription entitlement under the AlbaCore Warrants, Babylon is required to issue one Class A Ordinary Share credited as fully paid and free from all encumbrances (except as set out in Babylon’s memorandum and articles of association from time to time) per AlbaCore Warrant held, subject to a proportionate downwards adjustment to the number of Class A Ordinary Shares to be issued per AlbaCore Warrant where the closing price of the Class A Ordinary Shares on such date as is specified in the Amended and Restated Warrant Instrument in respect of each exercise event is in excess of $15.00 per Class A Ordinary Share. VNV Loan and Unsecured Bonds On July 15, 2021, Babylon Holdings entered into a loan agreement with VNV Group for $15.0 million (“VNV Loan”). The interest rate on the loan was 14%. On August 18, 2021, the Group issued $50.0 million in unsecured bonds at a discount of 4.0% (“Unsecured Bonds”), including the non-cash conversion of $8.0 million in borrowings under the VNV Loan agreement into Unsecured Bonds. The interest rate on the loan is 10%, with interest payable quarterly. The proceeds from the Unsecured Bonds can be used for general corporate purposes. The Company utilized proceeds of $7.2 million from the Unsecured Bonds to settle the remainder of the VNV Loan principal and interest. Cash proceeds from the bond issuance, net of discounts, repayments of borrowings, and transaction expenses totaled $32.1 million. The Unsecured Bonds had a one-year term and were redeemable by Babylon Holdings at any time. The Unsecured Bonds were repaid in full following the closing of the Merger. Convertible Loan Note Agreements On November 12, 2020, the Group executed a Convertible Loan Note agreement (“CLN” or “Loan Notes”) with a borrowing capacity of up to $200.0 million, under which $30.0 million Tranche 1 Notes and $70.0 million Tranche 2 Notes were issued to Global Health Equity (Cyprus) Ltd (“GHE” or the “Noteholder” or the “Lender”) in November and December 2020. GHE is part of the VNV Global group. VNV Global has a pre-existing equity interest in Babylon. The notes had a nominal value of $1. Tranche 1 Notes Tranche 1 Notes of $30.0 million were issued to GHE on November 12, 2020. Interest accrues at a fixed non-compounding rate of 11% per annum from the date of issuance to redemption or conversion. These notes were subsequently converted into Series C Preferred Shares after the issuance of the Tranche 2 Notes and shareholder approval of the conversion feature. Tranche 2 Notes Tranche 2 Notes of $70.0 million were issued on December 16, 2020 and are not interest bearing. The Tranche 2 Notes are exchangeable into a variable number of Series C Preferred Shares upon the earlier of the occurrence of certain events or June 30, 2021. These notes were subsequently converted into Series C Preferred Shares after shareholder approval of the conversion feature. As the Tranche 2 Notes fail the definition of equity, the Group considered whether the conversion feature in the Tranche 2 Notes is a non-closely related embedded derivative which would require separation from the debt host contract and to be accounted for separately as a standalone derivative at fair value through profit or loss (“FVTPL”). It has been determined that the Tranche 2 Notes represent a hybrid instrument containing a debt host debt contract and a non-closely related embedded derivative for the conversion feature. The debt host contract is measured at amortized cost using the effective interest rate (“EIR”) method. The fair value of the embedded derivative and transaction costs associated with issuance of the instrument are not material. On June 30, 2021, the $70.0 million Tranche 2 notes were converted into 41,012,358 “C” preference shares. Changes in Loans and Borrowings from Financing Activities ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ Total Loans ​ ​ Albacore ​ VNV Loan ​ Unsecured ​ Convertible ​ Loans and ​ and ​ Notes Notes Bonds Loan Notes Borrowings Borrowings ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at January 1, 2020 — — — — — — Changes from financing cash flows Proceeds from issuance of notes and warrants — — — 100,000 357 100,357 Total changes from financing cash flows — — — 100,000 357 100,357 Other changes Convertible loan notes converted — — — (30,000) — (30,000) Total other changes — — — (30,000) — (30,000) Balance at December 31, 2020 — — — 70,000 357 70,357 Balance at January 1, 2021 — — — 70,000 357 70,357 Changes from financing cash flows Proceeds from issuance of notes and warrants 191,000 15,000 64,563 — — 270,563 Payment of debt issuance costs (3,429) — (1,375) — — (4,804) Repayment of cash loan — (7,000) (75,000) — — (82,000) Total changes from financing cash flows 187,571 8,000 (11,812) — — 183,759 Other changes Fair value of warrants issued (16,930) — — — — (16,930) Unpaid debt issuance costs (2,801) — (171) — — (2,972) Amortization of fair value adjustment, discount, and debt issuance costs 761 — 3,983 — — 4,744 Convertible loan notes converted — — — (70,000) — (70,000) Non-cash conversion of loan notes to bonds — (8,000) 8,000 — — — Other loans and borrowings activity, net — — — — (172) (172) Total other changes (18,970) (8,000) 11,812 (70,000) (172) (85,330) Balance at December 31, 2021 168,601 — — — 185 168,786 ​ During the year ended December 31, 2021, interest paid on Loans and borrowings was $1.4 million (2020: $0.2 million). As of December 31, 2021, the unpaid portion of interest on Loans and borrowings, recognized within Accruals and provisions, was $2.5 million (2020: $0.0 million).

Employee Benefits_2

Employee Benefits	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Employee Benefits
Employee Benefits	13. Employee Benefits Equity Incentive Plans On October 21, 2021, we effected a reclassification (referred to below as the “Reclassification”) whereby all outstanding shares of Babylon, including the various options previously granted under the below plans, were reclassified to Class A ordinary shares or Class B ordinary shares, subject to a conversion ratio of approximately 0.3 (the “Conversion Ratio”). The description of activity in the narratives and tables below have been adjusted to reflect the Reclassification. On July 27, 2015, the Board of Directors adopted the Babylon Holdings Limited Long Term Incentive Plan (the “LTIP”). Options granted under the LTIP were originally granted over Company’s Class B Shares. Following the Reclassification, the options subsist over Class A ordinary shares. Upon approval of the Babylon Holdings Limited 2021 Equity Incentive Plan, including the Non-Employee Sub-Plan (collectively, the "2021 Plan"), the LTIP Plan was no longer available for future awards. On February 21, 2021, the Board of Directors adopted the Company Share Option Plan (“CSOP”), which was intended to qualify as a company share option plan that meet certain requirements under the Income Tax Act of 2003. The options granted under the CSOP are, subject to certain qualifying conditions being met, potentially U.K. tax-favored options. Upon approval of the 2021 Plan, the CSOP Plan was no longer available for future awards. On October 21, 2021, the shareholders approved the 2021 Plan. The 2021 Plan authorizes (a) the issuance of 13,700,125 Class A ordinary shares plus, (b) unless a lesser amount is approved by the Board prior to January 1st of a given year, an automatic increase on January 1st of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of Class A ordinary shares outstanding on December 31st of the preceding calendar year, and (c) all or any part of an option or options to acquire unissued shares granted under the prior plans (the LTIP or CSOP described above) shall become available for award granted under the 2021 Plan subject to a maximum of 7,223,177 shares. Upon approval of the 2021 Plan, the LTIP and CSOP were no longer available for future awards. The 2021 Plan provides for the grant of options, share appreciation rights (“SARs”), restricted stock awards (“RSAs”), restricted share units (“RSUs”), and other share-based awards. As of March 31, 2022, there are 43,761,708 shares available for issuance pursuant to future awards under the 2021 Plan. Share-based Payments The Group issues equity settled share-based payments to employees of the Group and advisors, whereby services are rendered in exchange for rights over shares in the Group. Employees of all Group companies participate within this scheme through the LTIP, CSOP and 2021 Plan described above. Share-based payments are recognized as expense for RSUs, RSAs and options, net of estimated forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ 2022 2021 ​ ​ $’000 ​ $’000 Total share-based compensation expense 8,402 2,802 ​ Restricted Stock Units The following table displays RSU activity for the periods presented: ​ ​ ​ ​ ​ RSUs Balance at January 1, 2022 6,997,284 Granted 14,758,592 Vested and issued (895,627) Forfeited / canceled during the period (1,099,073) Balance at March 31, 2022 19,761,176 Vested and unissued at March 31, 2022 39,022 Unvested at March 31, 2022 19,722,154 ​ On March 14, 2022, the Remuneration Committee of the Board of Directors granted employees RSUs under the 2021 Plan, under which the holders have the rights to receive an aggregate 14,758,592 shares of the Company’s Class A ordinary shares. Pursuant to the terms of the RSU awards, unvested shares are forfeited upon separation from the Company. Options The following table displays option activity and weighted average exercise price for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ $ ​ $ ​ Outstanding at the beginning of the period 1.47 22,896,265 0.02 21,107,487 Granted during the period — — 3.67 8,155,289 Forfeited / canceled during the period 1.26 (650,232) 0.18 (6,204,471) Exercised during the period 0.35 (27,942) 1.42 (162,040) Outstanding at the end of the period 1.48 22,218,091 1.47 22,896,265 ​	27. Employee Benefits Pension Plans The Group operates a defined contribution plan, under which the Group pays fixed contributions into a separate entity and will have no legal or constructive obligation to pay further amounts. During fiscal year 2021, the Group paid fixed contributions totaling $6.3 million (2020: $5.2 million, 2019: $3.1 million). Equity Incentive Plans Immediately prior to the closing of the Merger referred to in Note 5, we effected a reclassification (referred to below as the “Reclassification”) whereby all outstanding shares of Babylon, including the various options previously granted under the below plans, were reclassified to Class A Ordinary Shares or Class B Ordinary Shares, subject to a conversion ratio of approximately 0.3 (the “Conversion Ratio”). The description of activity in the narratives and tables below have been adjusted to reflect the Reclassification. On July 27, 2015, the Board of Directors adopted the Babylon Holdings Limited Long Term Incentive Plan (the “LTIP”). Options granted under the LTIP were originally granted over Company’s Class B Shares. Following the Reclassification, the options subsist over Class A Ordinary Shares. On February 21, 2021, the Board of Directors adopted the Company Share Option Plan (“CSOP”) and was intended to qualify as a company share option plan that meet certain requirements under the Income Tax Act of 2003. The options granted under the CSOP are, subject to certain qualifying conditions being met, potentially U.K. tax-favored options. In March 2021, the Company made an offer to all existing UK participants in the LTIP to convert their LTIP share options into the CSOP or into restricted stock awards (“RSAs”). All employees who elected to have their LTIP option converted to a new CSOP or RSA had their existing LTIP options forfeited and were granted an increased number of share options in line with the increased exercise price under the CSOP and RSA plans resulting in an equivalent economic value as compared to the grantee’s original award. There were no changes made to other terms, including vesting conditions or the period the original share options were granted. For the participants who accepted the offer to transfer their LTIP awards into RSAs, a total of 4,265,770 LTIP options were cancelled and replaced with 5,046,059 RSAs during the year ending December 31, 2021. For the participants who accepted the offer to transfer their awards into CSOP options, a total of 6,660,027 LTIP options were cancelled and replaced with 7,726,002 CSOP options during year ending December 31, 2021. On October 21, 2021, the shareholders approved the Babylon Holdings Limited 2021 Equity Incentive Plan, including the Non-Employee Sub-Plan (collectively, the “2021 Plan”). The 2021 Plan authorizes (a) the issuance of 13,700,125 Class A Ordinary Shares plus, (b) unless a lesser amount is approved by the Board prior to January 1st of a given year, an automatic increase on January 1st of each year, commencing on January 1, 2022 and ending on (and including) January 1, 2031, in an amount equal to 5% of the total number of Class A Ordinary Shares outstanding on December 31st of the preceding calendar year, and (c) all or any part of an option or options to acquire unissued shares granted under the prior plans (the LTIP or CSOP described above) shall become available for award granted under the 2021 Plan subject to a maximum of 7,223,177 shares. Upon approval of the 2021 Plan, the LTIP and CSOP were no longer available for future awards. The 2021 Plan provides for the grant of options, share appreciation rights (“SARs”), RSAs, restricted share units (“RSUs”), and other share-based awards. Share-based Payments The Group issues equity settled share-based payments to employees of the Group and advisors, whereby services are rendered in exchange for rights over shares in the Group. Employees of all Group companies participate within this scheme through a variety of plans described above. Under these plans, options are granted to employees at the start of their employment and typically expire between 10 to 15 years. Generally, upon completion of the first year of employment, 25.0% of options will vest, and the remainder will vest monthly over the next three years. In certain circumstances, additional options are granted to employees to recognize performance. Such options vest in the same manner as those granted on joining. Share-based compensation expense is recognized using the graded vesting method. Share-based payments are recognized as expense for RSUs, RSAs and options, net of forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Total share-based compensation expense 46,307 9,557 7,966 ​ Restricted Stock Awards The Company recorded share-based compensation expense related to RSAs of $3.6 million during the year ended December 31, 2021. As of December 31, 2021, the unrecognized compensation cost related to unvested RSAs is $1.3 million, which is expected to be recognized over the next one Restricted Stock Units The following table displays RSU activity and weighted average grant date fair values for the year ended December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant Date Fair Value ​ ​ RSUs ​ Per RSU (1) Balance at January 1, 2021 — ​ $ — Granted 6,997,284 ​ $ 6.23 Vested and issued — ​ $ — Forfeited — ​ $ — Balance at December 31, 2021 6,997,284 ​ $ 6.23 Vested and unissued at December 31, 2021 1,760,363 ​ $ 6.23 Unvested at December 31, 2021 5,236,921 ​ $ 6.23 (1) The calculation of weighted average grant date fair value excludes RSUs issued to Higi employees further discussed below. In connection with the acquisition of Higi described in Note 6, Babylon exchanged vested and unvested options held by employees of Higi for 1,980,000 RSUs of Babylon to be issued from the 2021 Plan, which are included in amounts granted in the table above. Of the RSUs issued to Higi under the Second Amended and Restated Agreement and Plan of Merger, 1,167,669 RSUs awarded to the former Higi employees were vested upon grant date in exchange for the surrender of vested Higi awards upon exercise of the option to acquire the remaining non-controlling interests. The vesting conditions associated with the unvested RSUs issued to the former Higi employees reflect the vesting of the original Higi equity award. The transaction was accounted for under IFRS 2 for replacement awards and the Company will recognized the compensatory portion of the award over the service period of the unvested RSUs issued to Higi employees. As of December 31, 2021, the unrecognized compensation cost associated with the 812,331 remaining unvested RSUs is $5.4 million, which is expected to be recognized over a weighted average period of 1.3 years. The Company recorded share-based compensation expense related to RSUs of $6.5 million during the year ended December 31, 2021. There were no RSUs granted prior to 2021. As of December 31, 2021, the Company had $24.4 million in unrecognized compensation cost related to unvested RSUs unrelated to the acquisition of Higi described above, which is expected to be recognized over a weighted average period of 3.4 years. Options Options have been granted under the LTIP and CSOP described above. The fair value of each employee and non-employee stock option award was estimated on the date of grant for each option using the Black-Scholes option pricing model yielding a weighted average fair value of $7.79 for options granted during the year ended December 31, 2021. The key assumptions used for options granted during the year ended December 31, 2021, were as follows: ​ ​ ​ ​ Fair value of underlying stock $2.97  – $9.20 Volatility ​ 63.4%  – 70.0% Risk-free interest rate ​ 0.12%  – 1.68% Dividend yield ​ 0%  – 0% Expected term (in years) ​ 10.00  – 14.50 ​ The number and weighted average exercise price of share options for the Group are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ price ​ options ​ ​ $ ​ ​ ​ $ ​ ​ ​ $ ​ ​ Outstanding at the beginning of the year 0.02 ​ 21,107,487 — ​ 20,120,425 — 19,666,539 Granted during the year ​ 3.67 ​ 8,155,289 ​ 0.11 ​ 4,109,243 ​ — ​ 2,786,856 Forfeited / canceled during the year ​ 0.18 ​ (6,204,471) ​ 0.04 ​ (3,122,181) ​ — ​ (2,332,970) Exercised during the year ​ 1.42 ​ (162,040) ​ — ​ — ​ — ​ — Outstanding at the end of the year ​ 1.47 ​ 22,896,265 ​ 0.02 ​ 21,107,487 ​ — ​ 20,120,425 Exercisable at the end of the year ​ 1.54 ​ 19,105,908 ​ 0.01 ​ 16,461,945 ​ — ​ 11,817,828 ​ As of December 31, 2021, the outstanding options had remaining contractual terms ranging from 6.9 –  15.0 years. Restricted Growth Shares In February 2021, the Board approved a grant of 10,150,368 of Class G Shares to three employees (“Growth Shares”), with a subscription price of $0.03 per share. The Growth Shares had vesting terms of one year from the grantee’s date of hire. The Growth Shares allowed the grantee to benefit from the difference between the value of the number of Growth Shares awarded and the benchmark valuation. The Growth Shares included a conversion feature to convert into the Company’s Class A Ordinary Shares upon an exit event, which included a business merger, an initial public offering, or certain other events (collectively referred to as an “Exit Event”). The Growth Shares were redeemable at the sole discretion of the Company at $0.00001227 or at some other amount at the discretion of the Board of Directors prior to an Exit Event upon cessation of employment. Using a Monte Carlo simulation, the Group calculated the grant date fair value of $9.7 million for the Growth Shares, all of which was recognized during the year ended December 31, 2021. The key assumptions used were a pre-money equity valuation of $3.5 billion and a volatility rate of 54%. All outstanding Growth Shares were converted into 712,413 Class A Ordinary Shares, subject to achievement of the original vesting conditions, following the Merger in October 2021. There were no Growth Shares outstanding as of December 31, 2021.

Capital and Reserves_2

Capital and Reserves	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Capital and Reserves	14. Capital and Reserves Share Capital ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A Ordinary Class B Ordinary ​ In thousands of shares Shares Shares Deferred Shares Authorized 6,500,000 3,100,000 100,000 On issue at January 1, 2022 333,925 79,638 — Issued during the period 924 — — On issue at March 31, 2022—fully paid 334,848 79,638 — ​ Share Rights Each Class A ordinary share will have the right to exercise one vote at any general meeting of the shareholders of the Company, to participate pro rata in all dividends declared by the Company, and the rights in the event of the Company’s dissolution. Each Class B ordinary share will have the same economic terms as the Babylon Class A ordinary shares, but the Class B ordinary shares will have 15 votes per share. The Deferred Shares are non-voting shares and did not convey upon the holder the right to be paid a dividend or notice to attend, vote or speak at a shareholder meeting. No Deferred Shares have been issued. Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are recognized in other comprehensive loss and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ 2022 ​ $’000 January 1, (27) Foreign operations – foreign currency translation differences (3,753) March 31, (3,780) ​ Retained Earnings The retained earnings account represents retained profits or losses less amounts distributed to shareholders. Share-based Payment Reserve The share-based payment reserve represents amounts accruing for equity-based share options granted.	28. Capital and Reserves Capital and Reserves Following the Merger As outlined in Note 5, the Consolidated Financial Statements are prepared as a continuation of the financial statements of Babylon Holdings Limited, which have been adjusted to reflect the conversion of historical Ordinary A Shares, Ordinary B Shares, and Series C shares into Class A and Class B Ordinary Shares following the listing on the New York Stock Exchange, as well as the application of the Conversion Ratio. The share capital of Babylon Holdings Limited immediately following the closing of the transaction is as follows: ​ ​ ​ ​ ​ ​ ​ In thousands of shares Number of Shares Share Capital Description Class A Ordinary Shares 295,589 12 Issuance to Babylon Shareholders Class A Ordinary Shares 22,400 1 Issuance to PIPE Investors Class A Ordinary Shares 12,268 — Issuance to SPAC Investors and Shareholders ​ 330,257 13 ​ ​ Class B Ordinary Shares 79,638 3 Issuance to Babylon Shareholders ​ 409,895 16 ​ ​ ​ Each Class A The following tables display the number of shares of Babylon Holdings Limited prior and following the Merger: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A ​ Class B ​ ​ ​ ​ ​ ​ ​ Ordinary ​ ​ Ordinary ​ Ordinary ​ Ordinary A ​ Ordinary B ​ Preference C ​ Redeemable G1 ​ Shares Shares Shares Shares Shares Shares In thousands of shares ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 Authorized ​ 6,500,000 ​ 3,100,000 ​ 10,000,000 ​ 11,000,000 ​ 10,000,000 ​ 50,000 On issue at January 1, 2021 ​ — ​ — ​ 135,136 ​ 664,605 ​ 252,065 ​ — Issued during the year prior to Merger — — — 17,206 41,012 10,150 Conversion into Class A and B Shares 330,257 79,638 (135,136) (681,811) (293,077) (10,150) Issued following the Merger 3,668 — — — — — On issue at December 31, 2021  –  fully paid 333,925 79,638 — — — — ​ Share Rights Each Class A Ordinary Share will have the right to exercise one vote at any general meeting of the shareholders of the Company, to participate pro rata in all dividends declared by the Company, and the rights in the event of the Company’s dissolution. Each Class B Ordinary Share will have the same economic terms as the Babylon Class A Ordinary Shares except for the Class B Ordinary Shares will have 15 votes per share. There were 100,000 Deferred Shares with a par value of $0.00004, which are non-voting shares and did not convey upon the holder the right to be paid a dividend or notice to attend, vote or speak at a shareholder meeting. No Deferred Shares have been issued. Capital & Reserves Prior to the Merger During the year ended December 31, 2021, $70.0 million Loan Notes were converted into 41,012,358 “C” preference shares. These shares had a fixed for fixed conversion feature and are therefore accounted for as equity investments. During the year ended December 31, 2020, the Group issued 24,796,225 $0.00001277 “C” preference shares for a consideration of $42.1 million. $30.0 million Loan Notes were converted into 17,708,792 shares related to the principle and $0.2 million Loan Notes were converted to 111,239 shares related to interest. The Loan Notes that were converted into our “C” preference shares had a fixed conversion feature and are therefore accounted for as equity investments. The remaining 6,976,194 shares were settled in cash for a consideration of $11.9 million. Tranche 1 Notes On November 12, 2020 Tranche 1 Notes of $30.0 million were issued to GHE and paid to Babylon in two parts of $15.0 million on November 16, 2020 and December 2, 2020. The Tranche 1 Notes accrue interest of 11% per year and shareholder approval is required for the Tranche 1 Notes to be convertible into a fixed number of Series C Preferred Shares at a price of US $1.706802577 per share within six months of the first issuance date. The conversion of the Tranche 1 Notes was approved by shareholders on December 16, 2020. Subsequent to this conversion approval, the principal of the Tranche 1 Notes was reclassified from being recognized as a financial liability to be classified as equity. No material gain or loss was recognized on conversion. The share capital in relation to the Series C Preferred Shares issued on conversion was recorded at the nominal value of the shares issued. Tranche 2 Notes Tranche 2 Notes of $70.0 million were issued on December 16, 2020 and are not interest bearing. The Tranche 2 Notes are exchangeable into a variable number of Series C Preferred Shares upon the earlier of the occurrence of certain events or June 30, 2021. Tranche 2 Notes converted to equity on June 30, 2021. The principal of the Tranche 2 Notes was reclassified from being recognized as a financial liability to be classified as equity. No material gain or loss was recognized on conversion. The share capital in relation to the Series C Preferred Shares issued on conversion was recorded at the nominal value of the shares issued. All shares issued rank pari-passu aside from the following: ● the A Ordinary Shares in issue at any time shall (as a separate class) carry fifty per cent ( 50.0% ) of the total voting rights of the Shares; and ● the B Ordinary Shares and the Series C Preferred Shares in issue at any time shall (as if the B Ordinary Shares and the Series C Preferred Shares constituted one and the same class) carry fifty per cent ( 50.0% ) of the total voting rights of the Shares; ● the Holders of a majority of the A Ordinary Shares shall have the right from time to time to appoint such number of persons to be Directors of each Group Company equal to the number of Directors which the Holders of B Ordinary Shares and Series C Preferred Shares are entitled to appoint (in aggregate) plus one additional Director; and in each case to remove from office any persons appointed and to appoint another person in his or her place ● The Series C Largest Shareholder shall have the right from time to time to appoint one person to be a Director and to remove from office any person so appointed and to appoint another person in his or her place. ● For so long as a holder of B Ordinary Shares or Series C Preferred Shares is also a Qualifying Stakeholder, each such Qualifying Stakeholder shall have the right from time to time to appoint one person to be a Director for each whole Qualifying Stake held by them and to remove from office any person so appointed and to appoint another person in his or her place. ● G1 Ordinary Redeemable Shares do not have the right to vote, nor to receive dividends, and have capital rights to convert into Ordinary B Shares in connection with an exit event. G1 Ordinary Redeemable shares are redeemable at the sole discretion of the Company. On any return of capital on liquidation, the assets of the Group available for distribution shall be distributed: a) first, in paying to each of the Series C Preferred Shareholders, in priority to any other classes of Shares, an amount per Series C Preferred Share held equal to the Preference Amount b) second, in paying to the 2016/2017 Subscribers pro rata to their respective holdings of Hoxton Shares and Kinnevik Shares an amount equal to the Hurdle Amount; and c) the balance of the surplus assets (if any) shall be distributed among the holders of the A Ordinary Shares and the B Ordinary Shares pro rata as if they constituted one and the same class. Foreign Currency Translation Reserve Exchange differences arising on translation of the foreign controlled entities are recognized in other comprehensive loss and accumulated in a separate reserve within equity. The cumulative amount is reclassified to profit or loss when the net investment is disposed of. Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 January 1, 1,675 (1,904) 7,789 Foreign operations – foreign currency translation differences (1,702) 3,579 (9,693) December 31, (27) 1,675 (1,904) ​ Retained Earnings The retained earnings account represents retained profits or losses less amounts distributed to shareholders. Share-based Payment Reserve The share-based payment reserve represents amounts accruing for equity-based share options granted.

Warrant Liability_2

Warrant Liability	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Abstract]
Warrant Liability	15. Warrant Liability The Company’s warrants are classified and accounted for as liabilities at fair value, with changes if fair value recorded in the Condensed Consolidated Statement of Profit and Loss. The following table displays the number of warrants outstanding as of March 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Tradeable Non-tradeable Total ​ No. of warrants No. of warrants No. of warrants In issue at January 1, 2022 8,625 7,691 16,316 Issuance of Additional AlbaCore Warrants on March 31, 2022 — 879 879 In issue at March 31, 2022 8,625 8,570 17,195 ​ Alkuri Warrants Pursuant to the merger agreement with Alkuri Global Acquisition Corp (“Alkuri”), the Company assumed warrants previously issued by Alkuri, consisting of 5,933,333 private placement warrants and 8,625,000 public warrants, which were converted into warrants to purchase 14,558,333 Class A ordinary shares (“Alkuri Warrants”). The warrants to purchase 14,558,333 Class A ordinary shares give the holder the right to purchase such shares at a fixed amount for a period of five years subject to the terms and conditions of the warrant agreement. As of March 31, 2022 there were 14,558,313 Alkuri Warrants outstanding. The warrants entitle the holder to purchase one Class A ordinary share of Babylon Holdings Limited at an exercise price of $11.50 per share. Until warrant holders acquire the Company’s ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on October 21, 2026, or earlier upon redemption or liquidation in accordance with their terms. AlbaCore Warrants As of March 31, 2022 there were 1,757,499 AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share upon occurrence of an exercise event. Until warrant holders acquire the Company’s Class A ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. Additional AlbaCore Warrants As of March 31, 2022 there were 878,750 Additional AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share upon occurrence of an exercise event. Until warrant holders acquire the Company’s Class A ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the Additional AlbaCore Warrants on the date of issuance was determined utilizing a price per warrant of $3.89, which has been derived using a Monte Carlo simulation. Changes in Warrant Liability The fair value of the Alkuri Warrants is determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at March 31, 2022 was $0.53. The fair value of the AlbaCore Warrants and Additional AlbaCore Warrants is determined utilizing a price per warrant of $3.89, which has been derived using a Monte Carlo simulation. See reconciliation of fair values below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ (Level 1) (Level 2) (Level 3) Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at December 31, 2021 5,865 4,035 10,228 20,128 Fair value of Additional AlbaCore Warrants upon issuance — — 3,418 3,418 Change in fair value of warrant liabilities (1,294) (890) (3,391) (5,575) Balance at March 31, 2022 4,571 3,145 10,255 17,971 ​	29. Warrant Liability The Company’s warrants are classified and accounted for as liabilities at fair value, with changes if fair value recorded in the Consolidated Statement of Profit and Loss. The following table displays the number of warrants in issue as of December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable ​ Non-tradeable ​ Total (In thousands) No. of warrants No. of warrants No. of warrants In issue at January 1, 2021 — — — Issuance of Alkuri Warrants on October 21, 2021 8,625 5,933 14,558 Issuance of AlbaCore Warrants on November 4, 2021 — 1,758 1,758 In issue at December 31, 2021 8,625 7,691 16,316 ​ Alkuri Warrants As of December 31, 2021 there were 14,558,333 Alkuri Warrants outstanding related to the Merger. The warrants entitle the holder to purchase one Class A Ordinary Share of Babylon Holdings Limited at an exercise price of $11.50 per share. Until warrant holders acquire the Company’s ordinary shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on October 21, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the Alkuri Warrants on the date of issuance was determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at October 22, 2021 was $2.13. AlbaCore Warrants As of December 31, 2021 there were 1,757,499 AlbaCore Warrants outstanding. The warrants entitle the holder to purchase one ordinary share of Babylon Holdings Limited at subscription price of $0.00004 per share. Until warrant holders acquire the Company’s Class A Ordinary Shares upon exercise of such warrants, they have no rights with respect to the Company’s ordinary shares. The warrants expire on November 4, 2026, or earlier upon redemption or liquidation in accordance with their terms. The initial fair value of the AlbaCore Warrants on the date of issuance was determined utilizing a price per warrant of $9.63, which has been derived using a Monte Carlo simulation. Changes in Warrant Liability The fair value of the Alkuri Warrants is determined by using the prevailing market price for warrants that are trading on the NYSE under the ticker BBLN.W. The market price per tradeable warrant as at December 31, 2021 was $0.68. The fair value of the AlbaCore Warrants is determined utilizing a price per warrant of $5.82, which has been derived using a Monte Carlo simulation. See reconciliation of fair values below: ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total ​ ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ Balance at December 31, 2019 ​ — ​ — ​ — ​ — ​ Balance at December 31, 2020 ​ — ​ — ​ — ​ — ​ Fair value of Alkuri Warrants upon issuance ​ 18,371 ​ 12,638 ​ — ​ 31,009 ​ Fair value of AlbaCore Warrants upon issuance ​ — ​ — ​ 16,930 ​ 16,930 ​ Change in fair value of warrant liabilities ​ (12,506) ​ (8,603) ​ (6,702) ​ (27,811) ​ Balance at December 31, 2021 ​ 5,865 ​ 4,035 ​ 10,228 ​ 20,128 ​ ​ ​

Related Parties_2

Related Parties	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Related Parties
Related Parties	16. Related Parties Transactions with Key Management Personnel During the three months ended March 31, 2022, the remuneration of directors and other key management personnel - including company pension contributions made to money purchase schemes on their behalf - amounted to $0.9 million (2021: $0.9 million). The remuneration of the highest paid key manager was $0.2 million (2021: $0.3 million). These remuneration costs are recorded as an operating expense in Sales, general & administrative expenses. For the three months ended March 31, 2022, share-based compensation expense related to key management personnel was $1.0 million (2021: $0.6 million). Directors’ cash remuneration is borne by the Company’s subsidiary, Babylon Partners Limited.	30. Related Parties Transactions with Key Management Personnel During 2021, the remuneration of directors and other key management personnel  — including company pension contributions made to money purchase schemes on their behalf  — amounted to $6.5 million (2020: $1.0 million, 2019: $0.9 million). The remuneration of the highest paid key manager was $2.2 million (2020: $0.3 million, 2019: $0.3 million). These remuneration costs are recorded as an operating expense in Sales, general & administrative expenses. For the year ended December 31, 2021, share-based compensation expense related to key management personnel was $32.1 million (2020: $0.0 million, 2019: $0.1 million). Directors’ remuneration is borne by the Company’s subsidiary, Babylon Partners Limited. ALP Note On June 3, 2020, in connection with our initial investment in Higi, ALP Partners Limited (“ALP”), as lender, entered into a promissory note with Higi, as borrower, in which Higi promised to pay ALP an aggregate principal sum of $5.0 million (the “ALP Note”). On December 7, 2021, we exercised our option to acquire the remaining equity interest in Higi pursuant to the Higi Acquisition Agreement. The closing of this acquisition occurred on December 31, 2021. The exercise price of the option to acquire the remaining Higi equity stake included the payment of $5.4 million at the closing to satisfy the principal and interest payable by a subsidiary of Higi pursuant to the ALP Note. Refer to Note 6. PIPE Transaction On June 3, 2021, we completed the PIPE Transaction, in which we issued and sold, in private placements that closed immediately prior to the Merger, an aggregate of 22,400,000 of our Class A Ordinary Shares to certain Babylon shareholders for $10.00 per share. The PIPE Transaction included the issuance of 500,000 Class A Ordinary Shares to VNV (Cyprus) Limited, 500,000 Class A Ordinary Shares to Black Ice Capital Limited, an affiliate of VNV (Cyprus) Limited, 500,000 Class A Ordinary Shares to Invik S.A. and 200,000 Class A Ordinary Shares to ALP.

Financial Instruments and Risk

Financial Instruments and Risk Management	3 Months Ended
	Mar. 31, 2022
Financial Instruments and Risk Management [Abstract]
Financial Instruments and Risk Management	17. Financial Instruments The Company uses the following hierarchy for determining and disclosing the fair value of financial instruments by valuation technique: ● Level 1: quoted (unadjusted) prices in active markets for identical assets or liabilities; ● Level 2: other techniques for which all inputs which have a significant effect on the recorded fair value are observable, either directly or indirectly; and ● Level 3: techniques which use inputs that have a significant effect on the recorded fair value that are not based on observable market data. The Company recognizes transfers between levels of the fair value hierarchy at the end of the reporting period during which the change has occurred. There were no transfers between fair value levels during the period. The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 4,571 — — 4,571 Non-tradeable Alkuri Warrants — 3,145 — 3,145 AlbaCore Warrants — — 6,837 6,837 Additional AlbaCore Warrants — — 3,418 3,418 ​ 4,571 3,145 10,255 17,971 ​ The tradeable Alkuri Warrants were valued using the instrument’s publicly listed trading price as of the date of the Condensed Consolidated Statement of Financial Position, which is considered to be a Level 1 measurement due to the use of an observable market quote in an active market. As the non-tradeable Alkuri Warrants have identical terms as the tradeable Alkuri Warrants, the non-tradeable Alkuri Warrants were valued using the tradeable Alkuri Warrants’ publicly listed trading price, which is considered to be a Level 2 fair value measurement due to the use of an observable market quote from a similar instrument in an active market. The AlbaCore Warrants and Additional AlbaCore Warrants were valued using a Monte Carlo simulation, which is considered to be a Level 3 fair value measurement. The primary unobservable input utilized in determining the fair value of the AlbaCore Warrants and Additional AlbaCore Warrants is the expected volatility of our ordinary shares. The expected volatility of the Company’s ordinary shares was determined using peer group companies. Due to the nominal exercise price of the AlbaCore Warrants and Additional AlbaCore Warrants, changes in volatility would not result in a material change in the fair value of the warrants. The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants and Additional AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of As of ​ March 31, 2022 December 31, 2021 Underlying stock price (USD) ​ $ 3.89 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 74.1 % 71.6 % Remaining term (years) ​ 4.6 ​ 4.85 ​ Risk-free rate ​ 2.40 % 1.23 % ​

Net Loss Per Share

Net Loss Per Share	12 Months Ended
	Dec. 31, 2021
Earnings per share [abstract]
Net Loss Per Share	32. Net Loss Per Share The following table sets forth the computation of basic and dilutive net loss per share attributable to the Group’s ordinary shareholders: ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Net loss attributable to ordinary shareholders (368,482) (186,799) (140,287) Weighted average shares outstanding – Basic and Diluted 271,321 242,936 241,903 Net loss per ordinary share – Basic and Diluted (1.36) (0.77) (0.58) ​ Basic net loss per share is computed by dividing the net loss attributable to ordinary shareholders by the weighted average number of ordinary shares outstanding during the period, adjusted for the effect of the Reclassification as discussed in Note 27 and applied retrospectively to all prior periods presented. As of December 31, 2021, Stockholder Earnout Shares and Sponsor Earnout Shares of 38,800,000 and 1,237,800, respectively, included in shares outstanding have been excluded from the calculation of weighted average shares outstanding, as they are contingently issuable subject to achieving certain milestones on the trading price of our Class A Ordinary Shares on the New York Stock Exchange discussed in Note 5. For the periods included in these financial statements the Group was loss-making in all periods, therefore, anti-dilutive instruments are excluded in the calculation of diluted weighted average number of ordinary shares outstanding, including certain outstanding equity awards during the periods and warrants issued in 2021 and outstanding as of December 31, 2021. These options, restricted stock, and warrants could potentially dilute basic earnings per share in the future. See Note 27 for details of outstanding options and unvested restricted stock.

Assets and Liabilities Classifi

Assets and Liabilities Classified as Held for Sale	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Assets and Liabilities Classified as Held for Sale	33. Assets and Liabilities Classified as Held for Sale On January 14, 2021, the Group entered into an SPA with TELUS, which is the parent of various telecommunication subsidiaries, for the sale of the Babylon Health Canada Limited business. The entire issued share capital of Babylon Health Canada Limited was transferred to TELUS for a base price of $1.8 million CAD, which has been adjusted for working capital and net indebtedness, through this transaction. An additional $3.5 million CAD payment was made by TELUS that was attributable to a partial repayment of an Intercompany Loan due from Babylon Canada to Babylon Partners Limited. The remaining amount of the Intercompany loan was forgiven immediately prior to the execution of the SPA. The transaction met the criteria to be classified as held for sale at December 31, 2020. The following major classes of assets and liabilities relating to these operations have been classified as held for sale in the Consolidated Statement of Financial Position on December 31, 2020: ​ ​ ​ ​ ​ 2020 ​ ​ $’000 Cash and cash equivalents 577 Prepayments and contract assets 1,125 Property, plant and equipment 621 Right-of-use assets 629 Trade and other receivables 330 Assets held for sale 3,282 ​ ​ ​ Accruals and provisions 813 Lease liabilities 607 Trade and other payables 402 Liabilities directly associated with the assets held for sale 1,822 ​ As of December 31, 2021, there are no major classes of assets and liabilities relating to operations that have been classified as held for sale in the Consolidated Statement of Financial Position.

Subsequent Events_2

Subsequent Events	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Subsequent Events
Subsequent Events	18. Subsequent Events Unsecured Notes Interest is payable on the Unsecured Notes semi-annually on May 4 and November 4 each year, with the first interest payment due on the six-month anniversary of the Note Closing Date on May 4, 2022. As of May 4, 2022, the interest payable on the Unsecured Notes was $8.8 million. In accordance with the Note Subscription Agreement, Babylon elected to satisfy 50.00% of the interest payable by the issuance of further Unsecured Notes, which were immediately consolidated and formed into a single series with the outstanding Unsecured Notes. The remaining $4.4 million of the interest payable was settled in cash.	34. Subsequent Events Austin Office Lease On November 1, 2021, Babylon Inc. entered into a sublease agreement for 37,883 rentable square feet of office space in Austin, Texas. The lease commenced on February 1, 2022 and shall automatically terminate on March 31, 2029. Minimum payments for the non-cancellable lease term are $16.6 million. The Company intends to use the office space as its United States headquarters and will house approximately 200 employees. Grant of RSUs On March 14, 2022, the Remuneration Committee of the Board of Directors granted employees RSUs under the 2021 Equity Incentive Plan, under which the holders have the rights to receive an aggregate 17,233,274 shares of the Company’s Class A Ordinary Shares. Pursuant to the terms of the RSU awards, unvested shares are forfeited upon separation from the Company.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Policies)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Revenue Recognition		Revenue Recognition Revenue is primarily derived from the following sources: (1) capitation revenue from value-based care services, (2) software license fees for the provision of AI services, and (3) patient revenues from the provision of clinical services. Revenue is recognized upon transfer of control of services to customers in an amount that reflects the consideration which the Group expects to receive in exchange for those services. Contract assets are recognized when there is an excess of revenue earned over billings on contracts where the rights are conditional on something other than passage of time. Contract assets primarily relate to the Group’s rights to consideration for work performed but subject to customer acceptance at the reporting date. Income received in advance (“contract liability”) is recognized when there are billings in excess of revenues earned for services rendered. The Group’s contracts with customers could include promises to transfer multiple services to a customer. The Group assesses the services promised in a contract and identifies distinct or bundled performance obligations in the contract. Identification of these performance obligations involves judgement to determine the promises and the ability of the customer to benefit independently from such promises. If multiple performance obligations are identified in the contract the transaction price is allocated to each performance obligation on a relative stand-alone selling price basis, for which the Group recognizes revenue as or when the performance obligations under the contract are satisfied. Transaction prices are adjusted for the effects of a significant financing component if we expect, at contract inception, that the period between the transfer of the promised goods or services to the customer and when the customer pays for that service will be more than one year. The Group exercises judgement in determining whether the performance obligation is satisfied at a point in time or over a period of time. The Group considers indicators such as how a customer consumes benefits as services are rendered, existence of enforceable rights to payment for performance to date, transfer of significant risks and rewards to the customer and acceptance of delivery of the service by the customer.
Value-based Care Revenue		Value-based Care Revenue Value-based care (“VBC”) revenue consists primarily of per member per month (“PMPM”) allocations for care management services by the Group under arrangements with various customers. Under the typical capitation arrangement, we are entitled to PMPM fees to provide a defined range of VBC services to attributed members. PMPM fees are based upon fixed rates per member or a percentage of the per member premium of the health plan and are not dependent upon the volume of specific care services provided. In addition, the arrangements usually include payments dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. Unlike clinical services revenue discussed below, the Group accepts partial or full financial risk (either global or professional) for members attributed to our VBC services in exchange for a fixed monthly allocation, which means we are responsible for the cost of all covered services provided to members. In general, the Group considers all VBC revenue contracts as containing a single performance obligation to stand ready to provide managed VBC services to the attributed members. This performance obligation is satisfied over time as the Group stands ready to fulfill its obligation to the attributed members as a group. Accordingly, the Group recognizes revenue in the month in which attributed members are entitled to receive VBC services during the contract term. Part of the consideration received under VBC revenue contracts is variable as the contracts contain provisions dependent on factors such as the health of our members, our ability to realize savings in healthcare spend for those members and the achievement of certain quality performance metrics. VBC revenue is estimated using the most likely amount methodology and amounts are only included in revenue to the extent that it is highly probable that a significant reversal of cumulative revenue will not occur once any uncertainty is resolved. Such uncertainties may only be resolved several months after the end of the reporting period because of the availability of sufficient reliable data relating to factors such as quality metrics, member specific attributes and healthcare service costs. Subsequent changes in VBC revenue and the amount of PMPM revenue to be recognized by the Company are reflected in subsequent periods. VBC revenue is recognized gross when it is assessed that the performance obligation relates to the whole of the patient journey with the Group responsible for arranging, providing and controlling the VBC services provided to the attributed members, with expenses payable to other healthcare providers.
Software Licensing Revenue		Software Licensing Revenue Under IFRS 15, Revenue from Contracts with Customers In some cases, we have concluded that upfront payments included in software license contracts with customers have a significant financing component considering the period between the upfront payment and the services provided, when the contract term is more than one year. As a result, the transaction price must be adjusted to account for the time value of money by using an appropriate discount rate. The discount rate utilized is determined based on the rate that would be reflected in a separate financing transaction with the customer. When a significant financing component exists, we recognize a contract liability for the entire upfront cash payment received, excluding the amount relating to the financing component from the transaction price. Additionally, interest expense is recognized over the duration of the contract under the amortized interest method.
Clinical Service Revenue	Clinical Care Delivery Expense Clinical care delivery expense includes the internal costs that we incur in the provision of healthcare services to patients, which is substantially composed of employee-related expenses such as salaries and wages for Babylon healthcare professionals. Other costs within Clinical care delivery expense include operating costs incurred for the delivery of healthcare services to patients, such as occupancy, medical supplies, and other support-related costs.	Clinical Service Revenue Clinical service revenue represents clinical services provided to our business and private patients under an arrangement and is recognized when the services are rendered. Our clinical service fees are based on PMPM subscription fees and fees per appointment (“fee-for-service”). PMPM subscription fees give members access to our clinical services over the contractual period as set forth in the arrangement, recognized monthly based on the number of members covered by the plan in a given month. Fee-for-service is based on contracted rates determined in agreed-upon compensation schedules and is recognized when the services are rendered at a point in time. In arrangements where PMPM subscription fees are charged we assess whether any of the transaction price should be allocated to software licensing revenue and allocate on a contract by contract basis.
Cost of Care Delivery		Cost of Care Delivery Cost of care delivery primarily consists of claims costs from physicians and other health professionals in our provider network and costs incurred in connection with our provider network operations, including rent, insurance and other direct costs incurred in the delivery of patient care. Cost of care delivery is mainly driven by patient activity and required medical services that are relatively variable. Costs incurred relating to the delivery of VBC services is recognized as an expense within cost of care delivery over time as the expense is incurred.
Grant Income		Grant Income We recognize income related to grants on a systematic and rational basis when it becomes probable that we have complied with the terms and conditions of the grant and in the period in which the corresponding costs or income related to the grant are recognized. We receive grants in the form of cash contributions towards outreach projects and tax credits for certain qualifying research and development expenditures. These grants are recognized as non-current deferred grant income liability, released either over the period of the grant contract or over the same period that the related capitalized development costs are amortized. The offset to the release of the long term deferred grant income liability is recognized as revenue for outreach grants and a reduction in Platform & application expenses for tax credits.
Platform & Application Expenses		Platform & Application Expenses Platform & application expenses are costs of revenue for our digital healthcare platform. These costs primarily include employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in providing professional services related to support and maintenance of the digital healthcare platform. These costs also include third-party application costs, hosting services, and other direct costs. The amortization of capitalized development costs are also included in Platform & application expenses. Expenditure on development activities, whereby research findings are applied to a plan or design for the production of new or substantially improved products and processes, is capitalized if the product or process is technically and commercially feasible and if the Group has sufficient resources to complete the development. Capitalized development costs are recorded as intangible assets and amortized from the point at which the development is complete, and the asset is available for use. Costs are capitalized based on a model whereby a percentage is allocated to employee related expenses based on the time spent on the development of assets. Subsequent expenditure on capitalized intangible assets is capitalized only when it increases the future economic benefits embodied in the specific asset to which it relates. All employee expenses included in this balance relate to employees in the product and technology departments, and the percentage attributable varies dependent on the nature of the work performed and the type of asset being developed. Expenses that do not meet the criteria for capitalization are expensed as incurred within Platform & application expenses. The technical feasibility of a new product is determined by a management team consisting of product, technology, and finance leads based on understanding the availability of adequate technical, financial and other resources required to develop the product. The commercial feasibility of a new product is determined by understanding how this product feeds into Babylon’s current offering. Commercial leads ascertain market interest by evaluating against existing and potential customer requirements. Feasibility is challenged with input from finance leads to verify the underlying financial implications of development and assess viability. Once the technical and commercial feasibility has been established and the project has been approved for commencement, the project moves into the development phase. As described in Note 3, development costs of $34.0 million (2020: $43.0 million) were capitalized during the year for those development and technology expenses that were deemed technologically feasible and probable of generating future economic benefits. During the period of development, the asset is tested for impairment at least annually.
Research & Development Expenses		Research & Development Expenses Research & development expenses primarily included employee-related salaries, benefits, stock-based compensation, and contractor and consultant expenses that are engaged in performing activities to develop and improve the Group’s digital healthcare platform. These costs also include third-party application costs, hosting services, and other indirect costs. Research costs and development costs that do not meet the criteria for capitalization are expensed as incurred within Research & development expenses.
Sales, General & Administrative Expenses		Sales, General & Administrative Expenses Sales, general & administrative expenses include employee-related expenses, contractors and consultants expense, stock-based compensation, property and facility related expenses, IT and hosting, marketing, training and recruiting expenses. Enterprise IT and hosting costs are primarily software subscriptions, domain and hosting costs. Our Sales, general & administrative expenses also include depreciation of property, fixtures and fittings and amortization of acquired intangible assets.
Claim Expenses and Claims Payable	Claims Expense Claims expense includes the costs of healthcare services rendered by third parties on behalf of patients which the Company is contractually obligated to pay, which includes estimates for medical expenses incurred but not yet paid (“IBNP”) using actuarial processes that are applied on a systematic and consistent basis. This process includes the development of estimates using historical claims experience and actuarial models when sufficient claims history is available from health plans and payors. Claims expense also includes other external costs incurred in the delivery of healthcare services including insurance.	Claim Expenses and Claims Payable Claims expense, presented within Cost of care delivery, and Claims payable includes costs for third party healthcare service providers who provide medical care to our members for which the Group is contractually obligated for financial risks relating to the medical services provided. The estimated reserve for IBNP claims is included in the liability for unpaid claims in the Consolidated Statement of Financial Position. Actual claims expense will differ from the estimated liability due to factors in estimated and actual member utilization of health care services, the amount of charges and other factors. We determine our estimates through a variety of actuarial models based on medical claims history to ensure our estimates represent the best, most reasonable estimate given the data available to us at the time the estimates are made.
Taxation		Taxation Tax on the Consolidated Statement of Profit and Loss for the year comprises current and deferred tax. Tax is recognized in the Consolidated Statement of Profit and Loss except to the extent that it relates to items recognized directly in equity, in which case it is recognized in equity. Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Deferred tax is provided on temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. The following temporary differences are not provided for: the initial recognition of goodwill; the initial recognition of assets or liabilities that affect neither accounting nor taxable profit other than in a business combination, and differences relating to investments in subsidiaries to the extent that they will probably not reverse in the foreseeable future. The amount of deferred tax provided is based on the expected manner of realization or settlement of the carrying amount of assets and liabilities, using tax rates enacted or substantively enacted at the reporting date. Expenditures incurred for R&D activities have been claimed and will be reimbursed through the U.K. research and development expenditure credit scheme (the “RDEC Scheme”). Under the RDEC Scheme tax relief is given at 12.0% (up to April 1, 2020) and 13.0% (after April 1, 2020) of allowable R&D costs, which may result in a payable tax credit at an effective rate of 7.8% of qualifying expenditure for the year ended December 31, 2021. The Group recognizes the gross amount as Deferred grant income on the Consolidated Statement of Financial Position and as a reduction to Platform & application expenses over the period of expected benefit from the expenditure. The related tax charge on the credit is recognized in the year of the tax credit. A deferred tax asset is recognized only to the extent that it is probable that future taxable profits will be available against which the temporary difference can be utilized.
Net Loss Per Share		Net Loss Per Share Basic net loss per share is computed by dividing the net loss by the weighted-average number of shares of ordinary shares of the Group outstanding during the period. Diluted net loss per share is computed by giving effect to all potential ordinary shares, including outstanding stock options, warrants and convertible notes, to the extent dilutive. Basic and diluted net loss per share was the same for each period presented as the inclusion of all potential ordinary shares outstanding would have been anti-dilutive. We have included shares issuable for little or no cash consideration upon the satisfaction of certain conditions (contingently issuable shares), including options and warrants, within the computation of basic net loss per share as of the date that all necessary conditions have been satisfied (in essence, when issuance of the shares is no longer contingent).
Comprehensive Loss		Comprehensive Loss Comprehensive loss consists of cumulative translation gains or losses. Unrealized gains or losses are net of any reclassification adjustments for realized gains and losses included in the Consolidated Statement of Profit and Loss.
Segment Reporting		Segment Reporting IFRS 8, Operating Segments Segment information is presented based on information used by the CODM in its decision-making processes. The CODM is responsible for the Group’s key strategic and business decisions and driving the direction and growth of the Group. These include but are not limited to international growth, new services, material business agreements and corporate and management structures. The CODM’s key decisions are based on the monthly management accounts in which segment information is presented on the basis of geographic areas. Each segment derives its revenues from software license fees for the provision of AI services, patient revenues from the provision of clinical services and VBC services provided by the segment which may differ from the geographic location of the customer. Earnings before depreciation, amortization, net finance income (costs), and income taxes (“EBITDA”) is used to measure performance of each segment because the Group believes that this information is most relevant in evaluating the results of the respective segments. The accounting policies for segment information, including transactions entered between segments are generally the same as those described in the summary of significant accounting policies. The CODM is not provided with total assets and liabilities by segment, and therefore the disclosures below do not include these measures. Segment information is reported from a geographic presence perspective. The Group’s results are provided to CODM disaggregated by geographic region, including the United Kingdom (“UK”), the United States of America (“US”), Canada (until the disposal of our Canadian subsidiary), Rwanda, and Singapore. The Group assessed the geographical segments within the aggregation guidance provided in IFRS 8 and determined that the UK and U.S. segments each exceed the quantitative thresholds and represent individual reportable segments. The remaining geographical regions individually and in aggregate do not exceed the quantitative thresholds for reportable segments. Therefore, the UK and the U.S. segments are the Group’s reportable segments for the purposes of these Consolidated Financial Statements.
Business Combinations		Business Combinations The acquisition consideration is measured at fair value which is the aggregate of the fair values of the assets transferred, the liabilities incurred or assumed and the equity interests in exchange for control. The consideration transferred includes the fair value of any asset or liability resulting from a contingent consideration arrangement. Any contingent consideration to be transferred by the Group is recognized at fair value at the acquisition date. Subsequent changes to the fair value of the contingent consideration are recognized in the Consolidated Statement of Profit and Loss. The consideration transferred in a business combination shall be measured at fair value, which shall be calculated as the sum of the acquisition-date fair values of the assets transferred by the acquirer, the liabilities incurred by the acquirer to former owners of the acquiree and the equity interests issued by the acquirer. The allocation process requires an analysis of acquired contracts, customer relationships, contractual commitments, and legal contingencies to identify and record the fair value of all assets acquired and liabilities assumed. In valuing acquired assets and assumed liabilities, fair values are based on, but are not limited to, future expected cash flows, current replacement cost for similar capacity for certain fixed assets, market rate assumptions for contractual obligations, and appropriate discount rates and growth rates. Where the consideration transferred, together with the non-controlling interest, exceeds the fair value of the net assets, liabilities and contingent liabilities acquired, the excess is recorded as goodwill. Acquisition related costs are expensed as incurred and classified as Sales, general & administrative expenses in the Consolidated Statement of Profit and Loss. Goodwill is capitalized as a separate item in the case of subsidiaries. Goodwill is denominated in the currency of the operation acquired. If the business combination is achieved in stages, the acquisition date carrying value of the acquirer’s previously held equity interest in the acquiree is remeasured to fair value at the acquisition date. Any gains or losses arising from such remeasurement are recognized in the Consolidated Statement of Profit and Loss. When the Group increases its ownership interests held in one of its consolidated subsidiaries, any difference between the consideration given and the aggregate carrying value of the assets and liabilities of the acquired entity at the date of the transaction is included in equity in retained earnings.
Property, Plant and Equipment		Property, Plant and Equipment Property, plant and equipment is stated at historical cost, which includes capitalized borrowing costs, less accumulated depreciation and any accumulated impairment losses. Subsequent expenditure is capitalized only if it is probable that the future economic benefits associated with the expenditure will flow to the Group and the cost of the item can be measured reliably. The carrying amount of any component accounted for as a separate asset is derecognized when replaced. All other repairs and maintenance are charged to the Consolidated Statement of Profit and Loss during the reporting period in which they are incurred. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: ​ ​ ​ ​ – Computer equipment 3 years – Fixtures and fittings 3 – 5 years – Deployed machinery 4 years ​ At the end of each reporting period, the depreciation method, useful life and residual value of each asset is reviewed. Any revisions are accounted for prospectively as a change in estimate. An asset’s carrying amount is written down immediately to its recoverable amount if the asset’s carrying amount is greater than its estimated recoverable amount. When an asset is disposed of, the gain or loss is calculated by comparing proceeds received with its carrying amount and is recognized in the Consolidated Statement of Profit and Loss.
Other Intangible Assets		Other Intangible Assets Intangible assets resulting from capitalized development costs in the normal course of business are recorded at historical cost. Intangible assets acquired in a business combination are recognized at fair value at the acquisition date. Following initial recognition, intangible assets are carried at cost less any accumulated amortization and accumulated impairment losses. The useful lives of intangible assets are assessed as either finite or indefinite. Intangible assets with finite lives are amortized on a straight-line basis over the useful economic life and assessed for impairment whenever there is an indication that the intangible asset may be impaired. The amortization period and the amortization method for an intangible asset with a finite useful life are at least reviewed at the end of each reporting period. The amortization expense on intangible assets with finite lives is recognized in Sales, general & administrative expenses. The useful lives of the Group’s intangible assets are: ​ ​ ​ ​ – Development costs 1 – 10 years – Developed technology ​ 5 years – Customer relationships ​ 15 years – Trade names ​ 5 – 11 years – Physician network ​ 3 – 10 years – Licenses ​ 1 – 2 years ​ An intangible asset is derecognized upon disposal (i.e., at the date the recipient obtains control) or when no future economic benefits are expected from its use or disposal. Any gain or loss arising upon derecognition of the asset (calculated as the difference between the net disposal proceeds and the carrying amount of the asset) is included in the Consolidated Statement of Profit and Loss.
Goodwill		Goodwill Goodwill is measured as described in “Business combinations” above. Goodwill on acquisitions of subsidiaries is included in intangible assets. Goodwill is not amortized and is reviewed for impairment at least annually as of October 1 or more frequently if triggering events occur or impairment indicators exist. Gains and losses on the disposal of an entity include the carrying amount of goodwill relating to the entity sold. For the purpose of impairment testing, goodwill acquired in a business combination is allocated to each of the cash generating units (“CGUs”), or groups of CGUs, that is expected to benefit from the synergies of the combination. Each unit or group of units represents the lowest level within the entity at which the goodwill is monitored for internal management purposes.
Trade Receivables		Trade Receivables We use a forward-looking expected credit loss (“ECL”) model in determining our allowance for doubtful accounts as it relates to trade receivables, contract assets, and other financial assets. Our allowance is based on historical experience, and includes consideration of the aging of the receivables, the economic environment, industry trend analysis, and the credit history and financial conditions of the customers among other factors. We measure an impairment loss as the excess of the carrying amount over the present value of the estimated future cash flows discounted using the financial asset’s original discount rate, and we recognize this loss in our Consolidated Statement of Profit and Loss. A financial asset is written-off or written-down to its net realizable value as soon as it is known to be impaired. We adjust previous write-downs to reflect changes in estimates or actual experience. Our allowance for doubtful accounts is not material.
Non-current Assets Held for Sale and Disposal Groups		Non-current Assets Held for Sale and Disposal Groups Non-current assets and disposal groups are classified as held for sale when: ● They are available for immediate sale, ● Management is committed to a plan to sell, ● It is unlikely that significant changes to the plan will be made or that the plan will be withdrawn, ● An active program to locate a buyer has been initiated, ● The asset or disposal group is being marketed at a reasonable price in relation to its fair value, and ● A sale is expected to complete within 12 months from the date of classification. Non-current assets and disposal groups classified as held for sale are measured at the lower of their carrying amount immediately prior to being classified as held for sale in accordance with the Group’s accounting policy; and fair value less costs of disposal. An impairment loss is recognized for any initial or subsequent write-down of the asset (or disposal group) to fair value less costs to sell. A gain is recognized for any subsequent increases in fair value less costs to sell of an asset (or disposal group), but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the non-current asset (or disposal group) is recognized at the date of derecognition. Following their classification as held for sale, non-current assets (including those in a disposal group) are not depreciated. Interest and other expenses attributable to the liabilities of a disposal group classified as held for sale continue to be recognized.
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents consist of highly liquid investments with original maturities of three months or less from the date of purchase. As of December 31, 2021, the Group had restricted cash of $0.3 million (2020: $0.0 million).
Impairment of Non-financial Assets Excluding Deferred Tax Assets		Impairment of Non-financial Assets Excluding Deferred Tax Assets Assets that are subject to depreciation or amortization are reviewed for impairment whenever events or changes in circumstances indicate that carrying values may not be recoverable. An impairment loss is recognized for the amount by which the asset’s carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset’s fair value less costs of disposal (market value) and value in use determined using estimates of discounted future net cash flows of the asset or group of assets to which it belongs. For the purposes of assessing impairment, assets are grouped at the lowest levels for which there are largely independent cash inflows (cash-generating units).
Employee Benefits		Employee Benefits Defined Contribution Plans Obligations for contributions to defined contribution pension plans are recognized as an expense in the Consolidated Statement of Profit and Loss in the periods during which services are rendered by employees. Short-term Benefits Short-term employee benefits are expensed as the related service is provided. A liability is recognized for the amount expected to be paid if the Group has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee and the obligation can be estimated reliably.
Share-based Payment Transactions		Share-based Payment Transactions The Group and the Company operates an equity compensation scheme. It issues equity settled share-based payments to both employees and non-employees within the Group, whereby services are rendered in exchange for rights to purchase shares of the Company, which are primarily composed of restricted stock awards and options. Non-employees include contractors and advisors. The grant date fair value of share-based payment awards granted to employees is recognized as an employee expense, with a corresponding increase in equity, over the period that the employees become unconditionally entitled to the awards, net of estimated forfeitures. The fair value of the options granted is measured using an option valuation model, taking into account the terms and conditions upon which the options were granted. The amount recognized as an expense is adjusted to reflect the actual number of awards for which the related service and non-market vesting conditions (if applicable) are expected to be met, such that the amount ultimately recognized as an expense is based on the number of awards that do meet the related service and non-market performance conditions at the vesting date. Compensation expense associated with equity compensation awards is recognized on a straight-line basis over the requisite period. The forfeitures rate is estimated and revised at each reporting date based on historical actuals. For share-based payment awards with non-vesting conditions, the grant date fair value of the share-based payment is measured to reflect such conditions, and there is no true-up for differences between expected and actual outcomes.
Valuation of Ordinary Shares		Valuation of Ordinary Shares As there has been no public market for the Group’s ordinary shares prior to October 21, 2021, the estimated fair value of the ordinary shares has been determined by the Board of Directors as of the date of each grant, with input from management, considering the most recently available third-party valuations of the Group’s ordinary shares, and the assessment of additional objective and subjective factors that they believed were relevant and which may have changed from the date of the most recent valuation through the date of the grant.
Foreign Currency		Foreign Currency Transactions in foreign currencies are translated to the respective functional currencies of Group entities at the foreign exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies at the reporting date are retranslated to the functional currency at the foreign exchange rate ruling at that date. Non-monetary assets and liabilities that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currencies that are stated at fair value are retranslated to the functional currency at foreign exchange rates ruling at the dates the fair value was determined. Foreign exchange differences arising on translation are recognized in the Consolidated Statement of Profit and Loss. The assets and liabilities of foreign operations, including goodwill and fair value adjustments arising on consolidation, are translated to the Group’s presentational currency, United States Dollars, at foreign exchange rates ruling at the reporting date. The revenues and expenses of foreign operations are translated at an average rate for the year where this rate approximates to the foreign exchange rates ruling at the dates of the transactions. Foreign exchange differences arising on translation are recognized as other comprehensive loss.
Provisions		Provisions A provision is recognized in the Consolidated Statement of Financial Position when the Group has a present legal or constructive obligation as a result of a past event, that can be reliably measured, and it is probable that an outflow of economic benefits will be required to settle the obligation. Provisions are determined by discounting the expected future cash flows at a pre-tax rate that reflects risks specific to the liability.
Equity Issuance Costs		Equity Issuance Costs The Group recognizes incremental external costs directly attributable to an equity issuance transaction as a deduction from equity. Any transaction costs are therefore deducted from share premium where possible to do so.
Debt Issuance Costs		Debt Issuance Costs The Group recognizes incremental external costs directly attributable to a debt issuance transaction as a reduction of the carrying value of the related debt liability. The costs are amortized over the life of the debt using the effective interest rate method. The amortized costs are reported as Finance costs on the Consolidated Statement of Profit and Loss.
Leases		Leases Our lease contracts primarily include real estate leases for buildings and are accounted for under IFRS 16, Leases We assess whether a contract is or contains a lease, at inception of a contract. We recognize a right-of-use asset and a corresponding lease liability with respect to all lease agreements in which we are the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, we recognize the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed.
Financial Instruments		Financial Instruments Derivatives Derivatives are initially measured at fair value and are subsequently remeasured to fair value at each reporting date. Warrants are derivatives that give the holder the right, but not the obligation to subscribe to the Company’s Ordinary Shares at a fixed or determinable price for a specified period. Changes in fair value are recognized in Change in fair value of warrant liabilities in the Consolidated Statement of Profit and Loss. For warrants that are tradeable, fair value is determined using market price on the NYSE under the ticker BBLN.W. For non-tradeable warrants, fair value is determined based on the terms of the warrants. For non-tradeable warrants with identical terms to the tradeable warrants, fair value is determined using market price of the tradeable warrants. For non-tradeable warrants with terms that are not identical to the tradeable warrants, fair value is determined using a Monte Carlo simulation that takes into account the exercise price, the term of the warrant, the underlying share price (BBLN) at the measurement date, the risk-free rate, and a volatility rate derived from peer group companies. Loans and Borrowings Interest-bearing loans and borrowings are recognized initially at fair value, net of transaction costs incurred. Borrowings are subsequently carried at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the income statement over the period of the borrowings using the effective interest method. Convertible Loan Notes Under IAS 32, the liability and equity components of convertible loan notes must be presented separately on the Consolidated Statement of Financial Position. If the conversion option exchanges a fixed number of shares for a fixed amount of cash (“fixed for fixed”) then it is classified as an equity instrument. The Group has examined the terms of each issue of convertible loan notes and determined their accounting treatment accordingly. The Group considers loans where the holder on the principal amount, for which there is no obligation to settle in cash, is also recognized in the share premium reserve. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the share premium reserve to share capital and share premium. The Group considers convertible loans where the holder does have the option to repay in cash or where there is not a fixed for fixed conversion feature to be convertible debt instruments with an embedded equity conversion feature and recognizes the principal of the loan note as a debt liability in the liabilities section of the Consolidated Statement of Financial Position and the equity conversion feature as an equity derivative instrument that is measured at fair value through profit or loss. The accrued interest on the principal amount is recorded as interest expense in the Consolidated Statement of Profit and Loss and as an increase in the debt liability. Upon redemption of the instrument and the issue of share capital, the amount is reclassified from the debt liability to share capital and share premium. Fair Value Measurements The accounting standard regarding fair value of financial instruments and related fair value measurements defines financial instruments and requires disclosure of the fair value of financial instruments held by the Group. The accounting standards define fair value, establish a three-level valuation hierarchy for disclosures of fair value measurement and enhance disclosure requirements for fair value measures. The three levels are defined as follow: ● Level 1 inputs to the valuation methodology are quoted prices (unadjusted) for identical assets or liabilities in active markets. ● Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument. ● Level 3 inputs to the valuation methodology are unobservable and significant to the fair value measurement. Financial assets and liabilities are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. For assets and liabilities that are recognized in the financial statements at fair value on a recurring basis, the Group determines whether transfers have occurred between levels in the fair value hierarchy by re-assessing categorization at the end of each reporting period. The carrying amounts reported in the Consolidated Statement of Financial Position for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their fair values because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The Group does not have any other material assets or liabilities that are recognized at fair value on a recurring basis.
New Standards and Interpretations Not Yet Adopted		New Standards and Interpretations Not Yet Adopted The following new and amended standards have been issued but have not been applied by the Group in these Consolidated Financial Statements. Their adoption is not expected to have a material effect on the financial statements unless otherwise indicated. ● Amendments to References to the Conceptual Framework in IFRS 3: Business Combinations, Amendments to IAS 16: Property, Plant and Equipment — Proceeds before Intended Use, and Annual Improvements to IFRS Standards 2018-2020 (effective date January 1, 2022) ● Amendments to IAS 1: Presentation of Financial Statements: Classification of Liabilities as Current or Non-current and Classification of Liabilities as Current or Non-current, Amendments to Disclosure of Accounting Policies in IAS I: Presentation of Financial Statements and IFRS Practice Statement 2: Making Materiality Judgements , Amendments to Definition of Accounting Estimates in IAS 8, Accounting Policies, Changes in Accounting Estimates and Errors , and Amendments to Deferred Tax related to Assets and Liabilities arising from a Single Transaction in IAS 12: Income Taxes (effective date January 1, 2023) ● Amendments to Sale or Contribution of Assets between an Investor and its Associate or Joint Venture in IFRS 10: Consolidated Financial Statements and IAS 28: Investments in Associates and Joint Ventures (effective date deferred indefinitely) The adoption of the following new and amended standards may have a material effect on the financial statements. The Company is still assessing the impact. ● Amendments to IAS 37: Onerous Contracts — Cost of Fulfilling a Contract (effective date January 1, 2022) ● IFRS 17: Insurance Contracts (effective date January 1, 2023)

Basis of Preparation (Tables)

Basis of Preparation (Tables)	12 Months Ended
	Dec. 31, 2021
Basis of Preparation
Reclassification Impact on Consolidated Statement of Profit and Loss	The reclassifications resulted in the following impact on the Consolidated Statement of Profit and Loss: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ As previously ​ ​ ​ ​ ​ ​ reported ​ Adjustment ​ As reported ​ ​ $’000 ​ $’000 ​ $’000 Platform & application expenses ​ (48,664) ​ 10,527 ​ (38,137) Research & development expenses (35,524) (19,187) (54,711) Sales, general & administrative expenses (103,341) 8,660 (94,681) Operating loss (175,511) — (175,511) Loss for the financial year (188,030) — (188,030) ​ The reclassifications also had an immaterial impact on the Consolidated Statement of Profit and Loss for the year ended December 31, 2019, which is not shown in the table above.

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Significant Accounting Policies [Abstract]
Schedule of Useful Lives of the Property, Plant and Equipment	Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets as follows: ​ ​ ​ ​ – Computer equipment 3 years – Fixtures and fittings 3 – 5 years – Deployed machinery 4 years
Schedule of Useful Lives of the Group's Intangible Assets	The useful lives of the Group’s intangible assets are: ​ ​ ​ ​ – Development costs 1 – 10 years – Developed technology ​ 5 years – Customer relationships ​ 15 years – Trade names ​ 5 – 11 years – Physician network ​ 3 – 10 years – Licenses ​ 1 – 2 years

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure of detailed information about business combination [abstract]
Disclosure of transactions recognised separately from acquisition of assets and assumption of liabilities in business combination	The acquisition-date fair value of Higi has been allocated on a preliminary basis as follows: ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Carrying value of existing equity interest ​ 11,274 Gain on remeasurement of existing equity interest 10,495 Fair value of non-controlling interest 64,274 Acquisition date fair value of Higi 86,043 Accounts receivable 2,314 Property, plant and equipment 17,618 License arrangements 2,650 Trade names 3,100 Developed technology 5,900 Deferred tax liability (730) Other assets and liabilities, net (5,983) Net assets acquired 24,869 Goodwill 61,174 The estimated fair value of assets acquired as of the acquisition date were as follows: ​ ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Cash paid, net of cash acquired ​ 13,798 Issuance of warrants 2,349 Aggregate purchase price 16,147 Accounts receivable 751 Customer relationships 11,600 Physician’s network 3,500 Trademark 1,900 License 590 Claims payable (13,436) Deferred tax liability (2,610) Other assets and liabilities, net (817) Net assets acquired 1,478 Goodwill 14,669 The fair value of assets acquired as of the acquisition date were as follows: ​ ​ ​ ​ Recognized ​ ​ values on ​ ​ acquisition ​ ​ $‘000 Acquiree’s net assets at the acquisition date: ​ Intangible assets 7,900 Right-of-use asset 153 Lease liability (153) Net identifiable assets and liabilities 7,900 Goodwill 17,771 Consideration paid 25,671

Disposals of Subsidiaries (Tabl

Disposals of Subsidiaries (Tables)	12 Months Ended
	Dec. 31, 2021
Disposals Of Subsidiaries [Abstract]
Schedule of Effect of Disposal	Effect of disposal: ​ ​ ​ ​ For the Year ​ ​ Ended December ​ ​ 31, 2021 ​ ​ $‘000 Cash and cash equivalents (57) Prepayments and contract assets (1,322) Property, plant and equipment (922) Right-of-use assets (797) Trade and other receivables (619) Accruals and provisions 658 Lease liabilities 837 Borrowings 3,075 Trade and other payables 588 Net assets and liabilities derecognized 1,441 Consideration received 2,344 Working capital adjustment 132 Gain on disposal 3,917

Revenue (Tables)_2

Revenue (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Disclosure of disaggregation of revenue from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Value-based care 246,575 27,259 Software licensing 7,756 35,964 Clinical services 12,115 8,070 ​ 266,446 71,293	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Value-based care ​ 220,852 ​ 26,038 ​ — Software licensing 60,052 24,603 2,002 Clinical services 42,017 28,631 14,032 ​ 322,921 79,272 16,034
Disclosure of receivables, contract assets, and contract liabilities	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Trade receivables 7,068 8,278 Contract assets 5,557 4,484 Contract liabilities 86,426 94,182	The following table provides information about receivables, contract assets and contract liabilities from contracts with customers. ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 20) ​ 8,278 ​ 4,674 Contract assets (Note 20) 4,484 2,378 Contract liabilities (Note 8 iii) 94,182 76,018
Disclosure of performance obligations	The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ Remainder ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ of 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ $’000 $’000 $’000 $’000 $’000 $’000 As of March 31, 2022 ​ 22,663 ​ 18,366 ​ 18,959 ​ 15,539 ​ 10,899 ​ 86,426	The following table includes revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the reporting date: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2026 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ and ​ ​ ​ ​ 2022 ​ 2023 ​ 2024 ​ 2025 ​ beyond ​ Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 As of December 31, 2021 ​ 23,786 ​ 18,918 ​ 19,349 ​ 17,852 ​ 14,277 ​ 94,182
Disclosure of contract liabilities	The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2022 ​ $’000 Balance on January 1, 94,182 Amounts billed but not recognized 849 Revenue recognized (6,091) Effect of movements in foreign exchange (2,514) Balance on March 31, 86,426	The table below shows significant changes in contract liabilities: ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance on January 1 ​ 76,018 ​ 81,584 Amounts billed but not recognized 61,176 18,080 Revenue recognized (43,012) (23,646) Balance on December 31 94,182 76,018

Segment Information (Tables)_2

Segment Information (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of operating segments [abstract]
Schedule of Consolidated Statements of Profit and Loss	Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Condensed Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue 15,670 250,512 335 266,517 (71) 266,446 Inter-segment revenue — — (64) (64) 64 — Segment revenue 15,670 250,512 271 266,453 (7) 266,446 Clinical care delivery expense (11,872) (12,394) (261) (24,527) 600 (23,927) Claims expense — (247,552) — (247,552) — (247,552) Other operating expenses, excluding amortization and depreciation (31,225) (34,176) (9,505) (74,906) (706) (75,612) Change in fair value of warrant liabilities — — 5,575 5,575 — 5,575 Exchange (loss) / gain (4,078) 2,353 (16,657) (18,382) 17,935 (447) Segment EBITDA (31,505) (41,257) (20,577) (93,339) 17,822 (75,517) Depreciation and amortization ​ (9,458) Change in fair value of warrant liabilities ​ (5,575) Exchange gain ​ 447 Operating loss ​ (90,103) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue 41,242 29,244 434 70,920 373 71,293 Inter-segment revenue — — 4 4 (4) — Segment revenue 41,242 29,244 438 70,924 369 71,293 Clinical care delivery expense (9,269) (4,597) (596) (14,462) 2,639 (11,823) Claims expense — (23,917) — (23,917) — (23,917) Other operating expenses, excluding amortization and depreciation (26,442) (11,316) (2,386) (40,144) (2,311) (42,455) Exchange (loss) / gain (632) (49) 1,788 1,107 (1,680) (573) Gain on sale — — 3,917 3,917 — 3,917 Share of loss of equity-accounted investees — (455) — (455) — (455) Segment EBITDA 4,899 (11,090) 3,161 (3,030) (983) (4,013) Depreciation and amortization ​ (5,848) Exchange loss ​ 573 Gain on sale of subsidiary ​ (3,917) Share of loss of equity-accounted investees ​ 455 Operating loss ​ (12,750)	Below is a summary of the Group’s segments and a reconciliation between the results from operations as per segment information and the results from operations as per the Consolidated Statements of Profit and Loss. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Revenue ​ 88,967 ​ 232,296 ​ 1,610 ​ 322,873 ​ 48 ​ 322,921 Inter-segment revenue ​ 2,205 ​ (3,964) ​ 1,756 ​ (3) ​ 3 ​ 0 Segment revenue ​ 91,172 ​ 228,332 ​ 3,366 ​ 322,870 ​ 51 ​ 322,921 Cost of care delivery ​ (41,542) ​ (253,998) ​ (1,590) ​ (297,130) ​ 7,458 ​ (289,672) Other operating expenses, excluding amortization and depreciation ​ (114,975) ​ (105,602) ​ (171,951) ​ (392,528) ​ (8,226) ​ (400,754) Change in fair value of warrant liabilities ​ — ​ — ​ 27,811 ​ 27,811 ​ — ​ 27,811 Exchange (loss) / gain ​ (1,844) ​ 189 ​ 1,390 ​ (265) ​ 1,133 ​ 868 Gain on sale of subsidiary ​ — ​ — ​ 2,687 ​ 2,687 ​ 1,230 ​ 3,917 Gain on remeasurement of equity interest ​ — ​ — ​ 10,495 ​ 10,495 ​ — ​ 10,495 Share of loss of equity-accounted investees ​ — ​ (2,602) ​ — ​ (2,602) ​ — ​ (2,602) Segment EBITDA ​ (67,189) ​ (133,681) ​ (127,792) ​ (328,662) ​ 1,646 ​ (327,016) Depreciation and amortization ​ ​ ​ ​ ​ ​ ​ (35,004) Change in fair value of warrant liabilities ​ ​ ​ ​ ​ ​ ​ (27,811) Exchange gain ​ ​ ​ ​ ​ ​ ​ (868) Gain on sale of subsidiary ​ ​ ​ ​ ​ ​ ​ (3,917) Gain on remeasurement of equity interest ​ ​ ​ ​ ​ ​ ​ (10,495) Share of loss of equity-accounted investees ​ ​ ​ ​ ​ ​ ​ 2,602 Operating loss ​ ​ ​ ​ ​ ​ ​ (402,509) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2020 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ ​ UK ​ US ​ segments ​ segments ​ adjustments ​ and loss ​ $’000 $’000 $’000 $’000 $’000 $’000 Revenue ​ 44,000 ​ 32,226 ​ 2,968 ​ 79,194 ​ 78 ​ 79,272 Inter-segment revenue 1,194 (3,094) 1,766 (134) 134 0 Segment revenue 45,194 29,132 4,734 79,060 212 79,272 Cost of care delivery (34,600) (34,381) (7,205) (76,186) 8,932 (67,254) Other operating expenses, excluding amortization and depreciation (127,762) (27,190) (3,990) (158,942) (14,100) (173,042) Exchange (loss) / gain 403 (246) 17,060 17,217 (20,053) (2,836) Share of loss of equity-accounted investees — — (1,124) (1,124) — (1,124) Segment EBITDA (116,765) (32,685) 9,475 (139,975) (25,009) (164,984) Depreciation and amortization ​ (14,487) Exchange loss ​ 2,836 Share of loss of equity-accounted investees ​ 1,124 Operating loss ​ (175,511) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, 2019 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total as ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ per ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ statement ​ ​ ​ ​ ​ ​ All other ​ Total ​ Reconciliation ​ of profit ​ UK US segments segments adjustments and loss ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 External revenue ​ 14,633 ​ — ​ 1,410 ​ 16,043 ​ (9) ​ 16,034 Inter-segment revenue ​ 4,081 ​ (2,669) ​ (1,382) ​ 30 ​ (30) ​ — Segment revenue ​ 18,714 ​ (2,669) ​ 28 ​ 16,073 ​ (39) ​ 16,034 Cost of care delivery ​ (25,707) ​ (160) ​ (373) ​ (26,240) ​ 6,430 ​ (19,810) Other operating expenses, excluding amortization and depreciation ​ (119,895) ​ (23,273) ​ (5,340) ​ (148,508) ​ (8,040) ​ (156,548) Exchange (loss) / gain 314 (83) 16,584 16,815 260 17,075 Segment EBITDA (126,574) (26,185) 10,899 (141,860) (1,389) (143,249) Depreciation and amortization ​ (2,496) Exchange gain ​ (17,075) Operating loss ​ (162,820) ​
Disaggregation of Revenue	Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $‘000 % of revenue $‘000 % of revenue Customer 1 145,043 54.4 % 12,420 17.4 % Customer 2 61,446 23.1 % — — ​ Customer 3 14,381 5.0 % 12,148 17.0 % Customer 4 ​ 2,530 ​ 1.0 % 30,129 ​ 42.3 % ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 UK 9,435 7,786 US 250,597 29,808 Asia-Pacific 3,634 3,410 Canada 2,530 30,129 Rest of World 250 160 Total 266,446 71,293	Below is a summary of the revenue derived from the Group’s major customers: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue ​ $‘000 ​ % of revenue Customer 1 ​ 119,785 ​ 37.1 % 11,918 ​ 15.0 % 2,215 ​ 13.8 % Customer 2 39,764 12.3 % 9,706 12.3 % 2,465 15.4 % Customer 3 38,705 12.0 % 9,505 12.0 % 5,607 34.9 % Customer 4 N/A N/A 14,937 18.9 % N/A N/A ​ ​ Geographical Information Revenue from external customers attributed to individual countries is summarized as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 UK ​ 35,490 ​ 28,827 ​ 12,189 US 232,708 32,689 — Asia-Pacific 14,965 11,585 2,215 Canada 38,705 3,207 564 Rest of World 1,053 2,964 1,066 Total 322,921 79,272 16,034 ​

Employee Benefits Expense (Tabl

Employee Benefits Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Claims Payable
Summary of employee benefits expense	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Wages and salaries ​ 148,728 ​ 108,018 ​ 57,388 Social security and pension contributions ​ 17,118 ​ 13,404 ​ 8,254 Share-based compensation 46,307 9,557 7,966 Total 212,153 130,979 73,608
Disclosure of staff members	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 2020 2019 Engineers ​ 427 ​ 515 ​ 670 Sales & marketing 89 88 108 Finance, HR & legal 242 146 178 Clinical operations 856 586 476 Clinicians 959 773 124 ​ 2,573 2,108 1,556

Platform & Application Expense

Platform & Application Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Platform & Application Expenses [Abstract]
Schedule of Platform & Application Expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020* ​ 2019* ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits 6,873 8,800 7,225 Depreciation and amortization 16,842 11,088 1,182 IT and hosting costs 14,760 8,660 6,621 Contractors and consultants expense 1,941 3,010 7,381 Impairment 941 6,436 — Other 1,472 143 1,160 Total 42,829 38,137 23,569 * Restated to reflect reclassification of certain expense items described in Note 2.

Research & Development Expenses

Research & Development Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Claims Payable
Disclosure of summary of research and development expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ 2021 ​ 2020* ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits ​ 42,877 53,332 ​ 36,630 Contractors and consultants expense 3,917 645 14,752 Other 740 734 (177) Total 47,534 54,711 51,205 * Restated to reflect reclassification of certain expense items described in Note 2 .

Sales, General & Administrati_2

Sales, General & Administrative Expenses (Tables)	12 Months Ended
	Dec. 31, 2021
Claims Payable
Disclosure of summary of selling, general and administrative expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020* ​ 2019* ​ ​ $’000 ​ $’000 ​ $’000 Employee benefits expense 100,095 34,362 26,020 Professional fees 19,200 8,645 4,469 IT and hosting costs 16,430 11,559 9,988 Depreciation and amortization 16,222 3,399 1,315 Marketing 9,982 6,575 7,691 Insurance 9,598 4,172 2,444 Contractors and consultants expense 7,425 2,501 7,008 Staffing, training and recruitment 6,321 3,494 6,393 Property related expenses 5,677 8,651 10,214 Local taxes 2,311 2,359 2,321 Office and clinical supplies 1,119 2,120 2,362 Other 2,293 6,844 4,045 Total 196,673 94,681 84,270

Finance Income and Costs (Table

Finance Income and Costs (Tables)	12 Months Ended
	Dec. 31, 2021
Finance Income and Costs [Abstract]
Schedule of Finance Costs	​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Finance costs(i) (14,291) (4,530) (1,116) Finance income(ii) 326 610 1,015 Change in fair value of warrant liabilities 27,811 — — Exchange gain / (loss) 868 (2,836) 17,075 Net finance income (expense) 14,714 (6,756) 16,974 (i) The following items are included under finance costs: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Interest payable 10,234 252 851 Interest on leases 617 572 265 Interest on contract liabilities 3,440 3,706 — Total finance costs 14,291 4,530 1,116 (ii) In 2021, 2020 and 2019 finance income related to interest received .

Recapitalization Transaction _2

Recapitalization Transaction Expense (Tables)	12 Months Ended
	Dec. 31, 2021
Disclosure Of Recapitalization Transaction Expense [Abstract]
Summary of Displays Calculation of Recapitalization Transaction Expense	The following table displays the calculation of the Recapitalization transaction expense: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Number of ​ Amount shares/warrants ​ ​ $’000 ​ ​ (a) Alkuri Ordinary Shares 12,267,653 (b) Opening price of Babylon Ordinary Shares on NYSE as of October 22, 2021 10.01 (c) Fair value of Company shares issued to Alkuri shareholders (a*b) 122,799 (d) Outstanding Alkuri Warrants on October 22, 2021 14,558,333 (e) Opening price of Babylon Warrants on NYSE as of October 22, 2021 Public warrants 2.13 8,625,000 Private placement warrants 2.13 5,933,333 (f) Fair value of outstanding Alkuri Warrants (d*e) 31,009 Total fair value of Alkuri Ordinary Shares and Alkuri Warrants (c+f) 153,808 Alkuri’s identifiable net assets 5,310 IFRS 2 Expense on the closing date 148,498 PIPE Transaction (a) PIPE Ordinary Shares 22,400,000 (b) Opening price of Babylon Ordinary Shares on NYSE as of October 22, 2021 10.01 (c) Fair value of Company shares issued to PIPE investors (a*b) 224,224 PIPE’s identifiable net assets 224,000 IFRS 2 Expense on the closing date 224 Total IFRS 2 Expense 148,722 ​ ​ ​ ​ ​ Total cash proceeds received 229,311 Expense of share issue (32,787) Cash proceeds 196,524

Taxation (Tables)

Taxation (Tables)	12 Months Ended
	Dec. 31, 2021
Major components of tax expense (income) [abstract]
Schedule of Consolidated Statement of Profit and Loss	Recognized in the Consolidated Statement of Profit and Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Current tax Current tax on loss for the period 801 569 (3,457) Adjustments to tax in respect of previous periods 31 4,070 (2,102) Total current tax 832 4,639 (5,559) ​ ​ ​ ​ ​ ​ ​ Deferred tax Origination and reversal of timing differences (2,306) — — Total deferred tax (2,306) — — ​ ​ ​ ​ ​ ​ ​ Tax (benefit) provision (1,474) 4,639 (5,559) ​
Schedule of Analysis of Tax Recognized in the Consolidated Statement of Profit and Loss	Analysis of tax recognized in the Consolidated Statement of Profit and Loss ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Loss before tax (375,985) (183,391) (145,846) Tax on loss on ordinary activities at standard CT rate (19.00%) (71,437) (34,844) (27,711) State and local income taxes, net of federal benefit (320) — — Benefit of foreign operations (218) — — Deferred tax not recognized 38,563 31,271 25,552 Expenses not deductible for tax purposes 33,512 4,142 187 Non-taxable income (11,003) — — Change in fair value of warrants 8,903 — — Tax arising on share in associates 495 — — Adjustments to tax in respect of previous periods 31 4,070 (2,102) All other, net — — (1,485) Tax (benefit) provision (1,474) 4,639 (5,559)

Property, Plant and Equipment (

Property, Plant and Equipment (Tables) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022	Dec. 31, 2020	Dec. 31, 2019
Property, plant and equipment [abstract]
Schedule of Property, Plant and Equipment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Computer ​ Fixtures and ​ Deployed ​ ​ ​ Equipment Fittings Machinery Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost Balance at January 1, 2020 2,463 390 — 2,853 Additions 308 411 — 719 Reclassification to assets held for sale — (621) — (621) Effect of movements in foreign exchange 89 — — 89 Balance at December 31, 2020 2,860 180 — 3,040 Balance at January 1, 2021 2,860 180 — 3,040 Additions 2,830 5,273 — 8,103 Acquisitions through business combinations 105 41 17,618 17,764 Effect of movements in foreign exchange (107) (103) — (210) Balance at December 31, 2021 5,688 5,391 17,618 28,697 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Computer ​ Fixtures and ​ Deployed ​ ​ ​ Equipment Fittings Machinery Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Depreciation Balance at January 1, 2020 991 61 — 1,052 Depreciation 931 3 — 934 Effect of movements in foreign exchange (346) 66 — (280) Balance at December 31, 2020 1,576 130 — 1,706 Balance at January 1, 2021 1,576 130 — 1,706 Depreciation 1,255 81 750 2,086 Effect of movements in foreign exchange (76) (9) — (85) Balance at December 31, 2021 2,755 202 750 3,707 Net book value At January 1, 2020 1,472 329 — 1,801 At December 31, 2020 and January 1, 2021 1,284 50 — 1,334 At December 31, 2021 2,933 5,189 16,868 24,990
Property, plant and equipment	$ 24,990	$ 25,694	$ 1,334	$ 1,801

Intangible Assets and Goodwil_4

Intangible Assets and Goodwill (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Intangible Assets and Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [text block]	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ $’000 $’000 $’000 $’000 $’000 $’000 $’000 $’000 Cost Balance at January 1, 2022 93,678 109,356 21,868 14,700 8,300 5,000 590 159,814 Additions — — 10,071 — — — — 10,071 Transfers — 6,803 (6,803) — — — — — Effect of movements in foreign exchange (23) (2,759) (530) — — — — (3,289) Balance at March 31, 2022 93,655 113,400 24,606 14,700 8,300 5,000 590 166,596 Amortization and impairment Balance at January 1, 2022 — 39,724 — 3,680 3,533 1,063 393 48,393 Amortization for the period — 5,064 — 193 750 329 131 6,467 Effect of movements in foreign exchange — (1,094) — — — — — (1,094) Balance at March 31, 2022 — 43,694 — 3,873 4,283 1,392 524 53,766 Net book value At January 1, 2022 93,678 69,632 21,868 11,020 4,767 3,937 197 111,421 At March 31, 2022 93,655 69,706 24,606 10,827 4,017 3,608 66 112,830 ​	The changes in the carrying amount of goodwill and intangible assets for the years ended December 31, 2021 and 2020 were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total Other ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Intangible ​ ​ ​ ​ ​ ​ Intangibles ​ ​ ​ ​ ​ ​ ​ ​ ​ Assets ​ ​ ​ ​ Development ​ under ​ Customer ​ ​ ​ Physician ​ ​ ​ (Excluding ​ ​ Goodwill ​ Costs ​ Development ​ Relationships ​ Trademarks ​ Networks ​ Licenses ​ Goodwill) ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Cost ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ 61 ​ 15,558 ​ 28,873 ​ — ​ — ​ — ​ — ​ 44,431 Acquisitions through business combinations ​ 17,771 ​ — ​ — ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 7,900 Additions ​ — ​ 940 ​ 43,027 ​ — ​ — ​ — ​ — ​ 43,967 Transfers ​ — ​ 51,932 ​ (51,932) ​ — ​ — ​ — ​ — ​ — Effect of movements in foreign exchange ​ — ​ 632 ​ 1,170 ​ — ​ — ​ — ​ — ​ 1,802 Balance at December 31, 2020 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Balance at January 1, 2021 ​ 17,832 ​ 69,062 ​ 21,138 ​ 3,100 ​ 3,300 ​ 1,500 ​ — ​ 98,100 Acquisitions through business combinations ​ 75,846 ​ 8,550 ​ — ​ 11,600 ​ 5,000 ​ 3,500 ​ 590 ​ 29,240 Additions ​ — ​ — ​ 33,999 ​ — ​ — ​ — ​ — ​ 33,999 Transfers ​ — ​ 33,056 ​ (33,056) ​ ​ ​ ​ — ​ — Effect of movements in foreign exchange ​ — ​ (1,312) ​ (213) ​ — ​ — ​ — ​ — ​ (1,525) Balance at December 31, 2021 ​ 93,678 ​ 109,356 ​ 21,868 ​ 14,700 ​ 8,300 ​ 5,000 ​ 590 ​ 159,814 Amortization and impairment ​ ​ ​ ​ ​ ​ ​ ​ Balance at January 1, 2020 ​ — ​ 680 ​ — ​ — ​ — ​ — ​ — ​ 680 Amortization for the year ​ — ​ 10,157 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 11,123 Impairment charge ​ — ​ 6,436 ​ — ​ — ​ — ​ — ​ — ​ 6,436 Effect of movements in foreign exchange ​ — ​ 1,008 ​ — ​ — ​ — ​ — ​ — ​ 1,008 Balance at December 31, 2020 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Balance at January 1, 2021 ​ — ​ 18,281 ​ — ​ 845 ​ 83 ​ 38 ​ — ​ 19,247 Amortization for the year ​ — ​ 21,287 ​ — ​ 2,835 ​ 3,450 ​ 1,025 ​ 393 ​ 28,990 Impairment charge ​ — ​ 941 ​ — ​ — ​ — ​ — ​ — ​ 941 Effect of movements in foreign exchange ​ — ​ (785) ​ — ​ — ​ — ​ — ​ — ​ (785) Balance at December 31, 2021 ​ — ​ 39,724 ​ — ​ 3,680 ​ 3,533 ​ 1,063 ​ 393 ​ 48,393 Net book value ​ ​ ​ ​ ​ ​ ​ ​ At January 1, 2020 ​ 61 ​ 14,878 ​ 28,873 ​ — ​ — ​ — ​ — ​ 43,751 At December 31, 2020 and January 1, 2021 ​ 17,832 ​ 50,781 ​ 21,138 ​ 2,255 ​ 3,217 ​ 1,462 ​ — ​ 78,853 At December 31, 2021 ​ 93,678 ​ 69,632 ​ 21,868 ​ 11,020 ​ 4,767 ​ 3,937 ​ 197 ​ 111,421

Investments in Subsidiaries a_5

Investments in Subsidiaries and Associates (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Investments in Subsidiaries and Associates
Disclosure of significant judgements and assumptions made in relation to interests in other entities		​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Ownership Ownership ​ ​ ​ ​ ​ ​ (As of ​ (As of ​ ​ Country of ​ ​ ​ December 31, ​ December 31, Subsidiary Undertakings ​ Incorporation ​ Principal Activity ​ 2021) ​ 2020) Company: ​ ​ ​ ​ ​ ​ ​ ​ Babylon Partners Limited UK Application development 100.0% ​ 100.0% Babylon Healthcare Services Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Rwanda Limited Rwanda Digital Healthcare services 100.0% ​ 100.0% Babylon Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Health Canada Limited Canada Digital Healthcare services — ​ 100.0% Babylon Liberty Corp. USA Digital Healthcare services 100.0% ​ — Babylon Malaysia SDN BHD Malaysia Digital Healthcare services 100.0% ​ 100.0% Babylon International Limited UK Digital Healthcare services 100.0% ​ 100.0% Babylon Health Ireland Limited Ireland Digital Healthcare services 100.0% ​ 100.0% Babylon Singapore PTE Limited Singapore Digital Healthcare services 100.0% ​ 100.0% Health Innovators Inc. USA Digital Healthcare services 100.0% ​ 70.1% Babylon Acquisition Corp. USA Digital Healthcare services — ​ 100.0% Babylon Technology LTDA Brazil Digital Healthcare services 100.0% ​ 100.0% Higi SH Holdings Inc. USA Digital Healthcare services 100.0% ​ 19.0% Group: ​ ​ ​ ​ Babylon Healthcare Inc. USA Digital Healthcare services 100.0% ​ 100.0% Babylon Healthcare NJ, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PLLC USA Healthcare services 100.0% ​ 100.0% Babylon Medical Group (formerly Marcus Zachary DO), PC USA Healthcare services 100.0% ​ 100.0% California Telemedicine Associates, PC USA Healthcare services 100.0% ​ 100.0% Telemedicine Associates, P.C. USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare, PC USA Healthcare services 100.0% ​ 100.0% Babylon Healthcare NC, PC USA Healthcare services — ​ 100.0% Babylon Healthcare, PA USA Healthcare services 100.0% ​ — Meritage Medical Network USA Healthcare services 100.0% ​ — Meritage Health Ventures, LLC USA Healthcare services 100.0% ​ — Meritage Health Plan USA Healthcare services 100.0% ​ — Meritage Management, LLC USA Healthcare services 100.0% ​ — Higi SH LLC USA Digital Healthcare services 100.0% ​ 19.0% Higi Health Holdings LLC USA Digital Healthcare services 100.0% ​ — Higi SH Canada ULC Canada Digital Healthcare services 100.0% ​ 19.0% Higi Health LLC USA Digital Healthcare services 51.0% ​ — Health Innovators Limited UK Digital Healthcare services 100.0% ​ 70.1% DTDHI Health India PVT Ltd India Digital Healthcare services 97.8% ​ 68.6%
Summarized financial information for unconsolidated professional service corporations	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Total assets 131,429 104,703 Total liabilities 213,222 168,240 ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ ​ 2022 ​ 2021 ​ $’000 $’000 Total revenues 127,138 19,756 Clinical care delivery expense (8,912) (2,256) Claims expense (118,985) (15,793) Sales, general & administrative expenses (15,012) (2,875)	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total assets 104,703 35,535 Total liabilities 168,240 42,699 ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Total revenues 154,508 17,436 Cost of care delivery (155,191) (20,175) Sales, general & administrative expenses (55,006) (3,799)

Trade and Other Receivables, _2

Trade and Other Receivables, Prepayments and Contract Assets (Tables)	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Current Trade and Other Receivables, Prepayments and Contract Assets	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade receivables (Note 8) 8,278 4,674 Other receivables 13,796 8,914 Prepayments 21,516 6,463 Contract assets 4,484 2,378 VAT receivable (payable) 2,045 (63) ​ 50,119 22,366
Description of Changes in Contract Assets	​ ​ ​ ​ ​ ​ ​ 2021 2020 ​ ​ $’000 ​ $’000 Balance at January 1 2,378 1,541 Revenues recognized but not billed 3,444 1,511 Amounts reclassified to trade receivable (1,338) (674) Balance at December 31 4,484 2,378

Trade and Other Payables, Acc_2

Trade and Other Payables, Accruals and Provisions (Tables)	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Current Trade and Other Payables	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Trade payables 17,178 3,739 Accruals 36,366 15,409 Provisions 490 3,227 Taxation and Social Security 4,039 4,006 Employee loans 1,193 — Other 276 — ​ 59,542 26,381

Deferred Grant Income (Tables)

Deferred Grant Income (Tables)	12 Months Ended
	Dec. 31, 2021
Deferred Grant Income [Abstract]
Disclosure of Deferred Grants	​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Grants related to prior years 3,173 Grants received in 2020 4,315 Grant income recognized — Adjustment, net — Balance at December 31, 2020 7,488 ​ ​ ​ Balance at January 1, 2021 7,488 Grants related to prior years — Grants received in 2021 2,769 Grant income recognized (1,959) Adjustment, net 146 Balance at December 31, 2021 8,444

Claims Payable (Tables)_2

Claims Payable (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Claims Payable
Summary of Claims Activity	​ ​ ​ ​ ​ $’000 Balance at January 1, 2022 24,628 Claims expense 247,552 Claims paid (233,015) Adjustment, net — Balance at March 31, 2022 39,165	​ ​ ​ ​ ​ $’000 Balance at January 1, 2020 — Claims expense 24,146 Claims paid (21,137) Adjustment, net 881 Balance at December 31, 2020 3,890 Balance at January 1, 2021 3,890 Claims expense 216,791 Claims paid (196,053) Adjustment, net — Balance at December 31, 2021 24,628

Cash and Cash Equivalents (Ta_2

Cash and Cash Equivalents (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Cash and Cash Equivalents
Summary of Cash and Cash Equivalents	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Cash in hand and at banks 274,978 262,276 Short term investment funds — — Restricted cash — 305 ​ 274,978 262,581	​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Cash in hand and at banks 262,276 97,757 Short term investment funds — 4,000 Restricted cash 305 — ​ 262,581 101,757

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Schedule of Right-of-Use Asset, Amortization, Net Book Value And Lease Liability	Therefore, the disclosures below for the Group’s right-of-use assets relate only to buildings. ​ ​ ​ ​ Right-of-use asset $’000 Cost Balance at January 1, 2020 6,501 Additions to right-of-use-assets 2,300 Reclassification to assets held for sale (872) Effect of change in foreign currency 228 Balance at December 31, 2020 8,157 Balance at January 1, 2021 8,157 Additions to right-of-use-assets 11,399 Disposals (4,291) Effect of change in foreign currency (166) Balance at December 31, 2021 15,099 Amortization Balance at January 1, 2020 1,272 Amortization charge for the year 2,430 Reclassification to assets held for sale (243) Effect of change in foreign currency 184 Balance at December 31, 2020 3,643 Balance at January 1, 2021 3,643 Amortization charge for the year 3,929 Disposals (4,291) Effect of change in foreign currency (25) Balance at December 31, 2021 3,256 Net book value Balance at January 1, 2020 5,229 Balance at December 31, 2020 and January 1, 2021 4,514 Balance at December 31, 2021 11,843 ​ ​ ​ ​ Lease liability $’000 Balance at January 1, 2020 3,583 Additions to lease liabilities 2,362 Interest expense on lease liabilities (i) 572 Payments on leases (1,541) Reclassification to liabilities associated with the assets held for sale (607) Effect of change in foreign currency 130 Balance at December 31, 2020 4,499 Balance at January 1, 2021 4,499 Additions to lease liabilities 11,826 Interest expense on lease liabilities (i) 617 Payments on leases (4,156) Reclassification to liabilities associated with the assets held for sale — Effect of change in foreign currency (154) Balance at December 31, 2021 12,632 (i) Interest paid on lease liabilities are presented within cash flows from financing activities.
Schedule of Recognized in the Consolidated Statement of Profit and Loss	The following amounts have been recognized in the Consolidated Statement of Profit and Loss for which the Group is a lessee: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Depreciation expense on right-of-use assets 3,929 2,430 1,272 Interest expense on lease liabilities 617 572 265 Expenses relating to short term leases 2,489 4,756 6,127 Profit and loss impact 7,035 7,758 7,664
Schedule of Undiscounted Maturities of Lease Liabilities	The following table provides the undiscounted maturities of lease liabilities: ​ ​ ​ ​ ​ ​ ​ ​ As of December 31, ​ ​ 2021 ​ 2020 ​ ​ $’000 ​ $’000 Less than one year 4,595 2,348 One to two years 5,612 684 Two to three years 4,290 598 Three to four years 362 572 Four to five years 371 375 More than five years 705 1,282 Total 15,935 5,859

Loans and Borrowings (Tables)_2

Loans and Borrowings (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Borrowing costs [abstract]
Schedule of Non-Current and Current Liabilities	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185	​ ​ ​ ​ ​ ​ ​ ​ As of ​ ​ March 31, 2022 ​ December 31, 2021 ​ $’000 $’000 Non-current liabilities Loan notes 300,000 200,000 Unamortized fair value adjustment, discount, and debt issuance costs (37,858) (31,399) ​ 262,142 168,601 ​ ​ ​ ​ ​ Current liabilities Other — 185 ​ — 185
Disclosure of Changes in Loans and Borrowings from Financing Activities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other Total Loans ​ ​ AlbaCore ​ Loans and ​ and ​ ​ Notes ​ Borrowings ​ Borrowings ​ $’000 $’000 $’000 Balance at January 1, 2022 ​ 168,601 ​ 185 ​ 168,786 Changes from financing cash flows ​ ​ ​ Proceeds from issuance of notes and warrants ​ 100,000 ​ — ​ 100,000 Payment of debt issuance costs ​ (4,000) ​ — ​ (4,000) Total changes from financing cash flows ​ 96,000 ​ — ​ 96,000 Other changes ​ ​ ​ Fair value of warrants issued ​ (3,418) ​ — ​ (3,418) Unpaid debt issuance costs ​ (257) ​ — ​ (257) Amortization of fair value adjustment, discount, and debt issuance costs ​ 1,202 ​ — ​ 1,202 Other loans and borrowings activity, net ​ — ​ (171) ​ (171) Total other changes ​ (2,473) ​ (171) ​ (2,644) Balance at March 31, 2022 ​ 262,128 ​ 14 ​ 262,142	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Other ​ Total Loans ​ ​ Albacore ​ VNV Loan ​ Unsecured ​ Convertible ​ Loans and ​ and ​ Notes Notes Bonds Loan Notes Borrowings Borrowings ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at January 1, 2020 — — — — — — Changes from financing cash flows Proceeds from issuance of notes and warrants — — — 100,000 357 100,357 Total changes from financing cash flows — — — 100,000 357 100,357 Other changes Convertible loan notes converted — — — (30,000) — (30,000) Total other changes — — — (30,000) — (30,000) Balance at December 31, 2020 — — — 70,000 357 70,357 Balance at January 1, 2021 — — — 70,000 357 70,357 Changes from financing cash flows Proceeds from issuance of notes and warrants 191,000 15,000 64,563 — — 270,563 Payment of debt issuance costs (3,429) — (1,375) — — (4,804) Repayment of cash loan — (7,000) (75,000) — — (82,000) Total changes from financing cash flows 187,571 8,000 (11,812) — — 183,759 Other changes Fair value of warrants issued (16,930) — — — — (16,930) Unpaid debt issuance costs (2,801) — (171) — — (2,972) Amortization of fair value adjustment, discount, and debt issuance costs 761 — 3,983 — — 4,744 Convertible loan notes converted — — — (70,000) — (70,000) Non-cash conversion of loan notes to bonds — (8,000) 8,000 — — — Other loans and borrowings activity, net — — — — (172) (172) Total other changes (18,970) (8,000) 11,812 (70,000) (172) (85,330) Balance at December 31, 2021 168,601 — — — 185 168,786 ​

Employee Benefits (Tables)_2

Employee Benefits (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Employee Benefits
Disclosure of Share-based Payments Recognized As Expense for RSUs, RSAs and Options, Net of Forfeitures	Share-based payments are recognized as expense for RSUs, RSAs and options, net of estimated forfeitures, as follows: ​ ​ ​ ​ ​ ​ ​ ​ For the Three Months Ended March 31, ​ 2022 2021 ​ ​ $’000 ​ $’000 Total share-based compensation expense 8,402 2,802	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ $’000 ​ $’000 ​ $’000 Total share-based compensation expense 46,307 9,557 7,966
Disclosure of Restricted Stock Unit Activity and Weighted Average Grant Date Fair Values	The following table displays RSU activity for the periods presented: ​ ​ ​ ​ ​ RSUs Balance at January 1, 2022 6,997,284 Granted 14,758,592 Vested and issued (895,627) Forfeited / canceled during the period (1,099,073) Balance at March 31, 2022 19,761,176 Vested and unissued at March 31, 2022 39,022 Unvested at March 31, 2022 19,722,154	​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ Grant Date Fair Value ​ ​ RSUs ​ Per RSU (1) Balance at January 1, 2021 — ​ $ — Granted 6,997,284 ​ $ 6.23 Vested and issued — ​ $ — Forfeited — ​ $ — Balance at December 31, 2021 6,997,284 ​ $ 6.23 Vested and unissued at December 31, 2021 1,760,363 ​ $ 6.23 Unvested at December 31, 2021 5,236,921 ​ $ 6.23
Disclosure of Stock Options Granted		​ ​ ​ ​ Fair value of underlying stock $2.97  – $9.20 Volatility ​ 63.4%  – 70.0% Risk-free interest rate ​ 0.12%  – 1.68% Dividend yield ​ 0%  – 0% Expected term (in years) ​ 10.00  – 14.50
Disclosure of Number and Weighted Average Exercise Prices of Share Options	The following table displays option activity and weighted average exercise price for the periods presented: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ March 31, 2022 December 31, 2021 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ $ ​ $ ​ Outstanding at the beginning of the period 1.47 22,896,265 0.02 21,107,487 Granted during the period — — 3.67 8,155,289 Forfeited / canceled during the period 1.26 (650,232) 0.18 (6,204,471) Exercised during the period 0.35 (27,942) 1.42 (162,040) Outstanding at the end of the period 1.48 22,218,091 1.47 22,896,265	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2021 ​ 2020 ​ 2019 ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercise ​ Number of ​ exercise ​ Number of ​ exercise ​ Number of ​ ​ price ​ options ​ price ​ options ​ price ​ options ​ ​ $ ​ ​ ​ $ ​ ​ ​ $ ​ ​ Outstanding at the beginning of the year 0.02 ​ 21,107,487 — ​ 20,120,425 — 19,666,539 Granted during the year ​ 3.67 ​ 8,155,289 ​ 0.11 ​ 4,109,243 ​ — ​ 2,786,856 Forfeited / canceled during the year ​ 0.18 ​ (6,204,471) ​ 0.04 ​ (3,122,181) ​ — ​ (2,332,970) Exercised during the year ​ 1.42 ​ (162,040) ​ — ​ — ​ — ​ — Outstanding at the end of the year ​ 1.47 ​ 22,896,265 ​ 0.02 ​ 21,107,487 ​ — ​ 20,120,425 Exercisable at the end of the year ​ 1.54 ​ 19,105,908 ​ 0.01 ​ 16,461,945 ​ — ​ 11,817,828

Capital and Reserves (Tables)_2

Capital and Reserves (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of classes of share capital [abstract]
Disclosure of Share Capital	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A Ordinary Class B Ordinary ​ In thousands of shares Shares Shares Deferred Shares Authorized 6,500,000 3,100,000 100,000 On issue at January 1, 2022 333,925 79,638 — Issued during the period 924 — — On issue at March 31, 2022—fully paid 334,848 79,638 —	The share capital of Babylon Holdings Limited immediately following the closing of the transaction is as follows: ​ ​ ​ ​ ​ ​ ​ In thousands of shares Number of Shares Share Capital Description Class A Ordinary Shares 295,589 12 Issuance to Babylon Shareholders Class A Ordinary Shares 22,400 1 Issuance to PIPE Investors Class A Ordinary Shares 12,268 — Issuance to SPAC Investors and Shareholders ​ 330,257 13 ​ ​ Class B Ordinary Shares 79,638 3 Issuance to Babylon Shareholders ​ 409,895 16 ​ ​ The following tables display the number of shares of Babylon Holdings Limited prior and following the Merger: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Class A ​ Class B ​ ​ ​ ​ ​ ​ ​ Ordinary ​ ​ Ordinary ​ Ordinary ​ Ordinary A ​ Ordinary B ​ Preference C ​ Redeemable G1 ​ Shares Shares Shares Shares Shares Shares In thousands of shares ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 ​ 2021 Authorized ​ 6,500,000 ​ 3,100,000 ​ 10,000,000 ​ 11,000,000 ​ 10,000,000 ​ 50,000 On issue at January 1, 2021 ​ — ​ — ​ 135,136 ​ 664,605 ​ 252,065 ​ — Issued during the year prior to Merger — — — 17,206 41,012 10,150 Conversion into Class A and B Shares 330,257 79,638 (135,136) (681,811) (293,077) (10,150) Issued following the Merger 3,668 — — — — — On issue at December 31, 2021  –  fully paid 333,925 79,638 — — — —
Disclosure of Other Comprehensive Income Accumulated in Reserves, Net of Tax	​ ​ ​ ​ ​ ​ 2022 ​ $’000 January 1, (27) Foreign operations – foreign currency translation differences (3,753) March 31, (3,780)	Other Comprehensive Income (“OCI”) Accumulated in Reserves, Net of Tax ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 January 1, 1,675 (1,904) 7,789 Foreign operations – foreign currency translation differences (1,702) 3,579 (9,693) December 31, (27) 1,675 (1,904)

Warrant Liability (Tables)_2

Warrant Liability (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Abstract]
Number of Warrants in Issue	​ ​ ​ ​ ​ ​ ​ ​ (In thousands) ​ Tradeable Non-tradeable Total ​ No. of warrants No. of warrants No. of warrants In issue at January 1, 2022 8,625 7,691 16,316 Issuance of Additional AlbaCore Warrants on March 31, 2022 — 879 879 In issue at March 31, 2022 8,625 8,570 17,195	​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable ​ Non-tradeable ​ Total (In thousands) No. of warrants No. of warrants No. of warrants In issue at January 1, 2021 — — — Issuance of Alkuri Warrants on October 21, 2021 8,625 5,933 14,558 Issuance of AlbaCore Warrants on November 4, 2021 — 1,758 1,758 In issue at December 31, 2021 8,625 7,691 16,316 ​
Schedule of Reconciliation of Fair Values	See reconciliation of fair values below: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ (Level 1) (Level 2) (Level 3) Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Balance at December 31, 2021 5,865 4,035 10,228 20,128 Fair value of Additional AlbaCore Warrants upon issuance — — 3,418 3,418 Change in fair value of warrant liabilities (1,294) (890) (3,391) (5,575) Balance at March 31, 2022 4,571 3,145 10,255 17,971	See reconciliation of fair values below: ​ ​ ​ Tradeable Non-tradeable Non-tradeable ​ ​ ​ (Level 1) ​ (Level 2) ​ (Level 3) ​ Total ​ ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 ​ Balance at December 31, 2019 ​ — ​ — ​ — ​ — ​ Balance at December 31, 2020 ​ — ​ — ​ — ​ — ​ Fair value of Alkuri Warrants upon issuance ​ 18,371 ​ 12,638 ​ — ​ 31,009 ​ Fair value of AlbaCore Warrants upon issuance ​ — ​ — ​ 16,930 ​ 16,930 ​ Change in fair value of warrant liabilities ​ (12,506) ​ (8,603) ​ (6,702) ​ (27,811) ​ Balance at December 31, 2021 ​ 5,865 ​ 4,035 ​ 10,228 ​ 20,128 ​

Financial Instruments and Ris_2

Financial Instruments and Risk Management (Tables)	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Financial Instruments and Risk Management [Abstract]
Schedule of Assets and Liabilities that are Measured at Fair Value	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at March 31, 2022 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 4,571 — — 4,571 Non-tradeable Alkuri Warrants — 3,145 — 3,145 AlbaCore Warrants — — 6,837 6,837 Additional AlbaCore Warrants — — 3,418 3,418 ​ 4,571 3,145 10,255 17,971	The following table presents information about the Company’s assets and liabilities that are measured at fair value on a recurring basis at December 31, 2021 and indicates the fair value hierarchy of the valuation inputs the Company utilized to determine such fair value. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Fair Value ​ Level 1 Level 2 Level 3 Total ​ ​ $’000 ​ $’000 ​ $’000 ​ $’000 Tradeable Alkuri Warrants 5,865 — — 5,865 Non-tradeable Alkuri Warrants — 4,035 — 4,035 AlbaCore Warrants — — 10,228 10,228 ​ 5,865 4,035 10,228 20,128
Schedule of the Monte Carlo Simulation Model for the AlbaCore Warrants	The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants and Additional AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of As of ​ March 31, 2022 December 31, 2021 Underlying stock price (USD) ​ $ 3.89 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 74.1 % 71.6 % Remaining term (years) ​ 4.6 ​ 4.85 ​ Risk-free rate ​ 2.40 % 1.23 %	The key inputs into the Monte Carlo simulation model for the AlbaCore Warrants were as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ As of ​ As of ​ November 4, 2021 December 31, 2021 Underlying stock price (USD) ​ $ 9.66 ​ $ 5.83 ​ Exercise price (USD) ​ $ 0.00004 ​ $ 0.00004 ​ Volatility ​ 66.7 % 71.6 % Remaining term (years) ​ 5.00 ​ 4.85 ​ Risk-free rate ​ 1.09 % 1.23 %
Schedule of Significant Exchange Rates		The Group has applied the following significant exchange rates: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Average Rate ​ Year-end spot rate United States Dollar 2021 2020 2019 2021 2020 2019 GBP 0.7277 0.7760 0.7835 0.7409 0.7321 0.7618 CAD 1.2536 1.3433 1.3251 1.2725 1.2750 1.3033 RWF 1,003.4066 959.1820 914.2488 1,037.6458 988.0837 947.0750 SGD 1.3427 1.3789 1.3111 1.3496 1.3224 1.3456 INR 73.7902 74.0038 N/A 74.3047 73.2901 N/A
Schedule of Sensitivity Analysis		This analysis assumes that all other variables, in particular interest rates, remain constant and ignores any impact of forecast sales and purchases. The fluctuation seen primarily relates to the impacts of Brexit and COVID-19 over the last two years but is expected to stabilize moving forward. ​ ​ ​ ​ ​ ​ ​ ​ Profit or loss ​ Strengthening Weakening ​ ​ $’000 ​ $’000 December 31, 2021 GBP (5.0% movement) (373,578) (371,938) December 31, 2020 GBP (5.0% movement) (184,067) (184,416) December 31, 2019 GBP (5.0% movement) (156,489) (150,290) ​ ​ ​ ​ ​ ​ ​ ​ Equity, net of tax ​ ​ Strengthening ​ Weakening ​ ​ $’000 ​ $’000 December 31, 2021 GBP (5.0% movement) (168,522) (168,930) December 31, 2020 GBP (5.0% movement) (48,743) (48,394) December 31, 2019 GBP (5.0% movement) (175,371) (173,872)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings per share [abstract]
Summary of Basic and Dilutive Net Loss Per Share	The following table sets forth the computation of basic and dilutive net loss per share attributable to the Group’s ordinary shareholders: ​ ​ ​ ​ ​ ​ ​ ​ 2021 2020 2019 ​ ​ $’000 ​ $’000 ​ $’000 Net loss attributable to ordinary shareholders (368,482) (186,799) (140,287) Weighted average shares outstanding – Basic and Diluted 271,321 242,936 241,903 Net loss per ordinary share – Basic and Diluted (1.36) (0.77) (0.58)

Assets and Liabilities Classi_2

Assets and Liabilities Classified as Held for Sale (Tables)	12 Months Ended
	Dec. 31, 2021
Subclassifications of assets, liabilities and equities [abstract]
Disclosure of Assets and Liabilities Classified as Held for Sale	The following major classes of assets and liabilities relating to these operations have been classified as held for sale in the Consolidated Statement of Financial Position on December 31, 2020: ​ ​ ​ ​ ​ 2020 ​ ​ $’000 Cash and cash equivalents 577 Prepayments and contract assets 1,125 Property, plant and equipment 621 Right-of-use assets 629 Trade and other receivables 330 Assets held for sale 3,282 ​ ​ ​ Accruals and provisions 813 Lease liabilities 607 Trade and other payables 402 Liabilities directly associated with the assets held for sale 1,822

Basis of Preparation - Narrat_2

Basis of Preparation - Narrative (Details) - USD ($) $ in Thousands	Oct. 21, 2021	Oct. 08, 2021	Jun. 03, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Basis of Preparation
Profit (loss)				$ (91,357)	$ (10,847)	$ (374,511)	$ (188,030)	$ (140,287)
Recapitalization Transaction Expense			$ 148,700			148,722
Net cash used in operating activities				68,957	(21,500)	145,868	143,430	143,614
Equity				79,531	$ 38,940	165,271	48,359	173,797	$ (50,484)
Cash and cash equivalents				274,978		262,581	101,757
Proceeds from issuance of share capital	$ 229,300			$ 329,300		$ 229,311	$ 12,096	$ 320,334
Issuance unsecured notes		$ 200,000

Basis of Preparation - Consolid

Basis of Preparation - Consolidated Statement of Profit and Loss (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of detailed information about investment property [line items]
Platform & application expenses	$ (16,703)	$ (6,434)	$ (42,829)	$ (38,137)	$ (23,569)
Research & development expenses	(10,057)	(10,390)	(47,534)	(54,711)	(51,205)
Sales, general & administrative expenses	(58,310)	(31,479)	(196,673)	(94,681)	(84,270)
Operating loss	(90,103)	(12,750)	(402,509)	(175,511)	(162,820)
Loss for the financial year	$ (91,357)	$ (10,847)	$ (374,511)	(188,030)	$ (140,287)
Reclassified Expenses
Disclosure of detailed information about investment property [line items]
Platform & application expenses				(38,137)
Research & development expenses				(54,711)
Sales, general & administrative expenses				(94,681)
Operating loss				(175,511)
Loss for the financial year				(188,030)
As previously reported | Reclassified Expenses
Disclosure of detailed information about investment property [line items]
Platform & application expenses				(48,664)
Research & development expenses				(35,524)
Sales, general & administrative expenses				(103,341)
Operating loss				(175,511)
Loss for the financial year				(188,030)
Adjustment | Reclassified Expenses
Disclosure of detailed information about investment property [line items]
Platform & application expenses				10,527
Research & development expenses				(19,187)
Sales, general & administrative expenses				8,660
Operating loss				0
Loss for the financial year				$ 0

Significant Accounting Judgem_2

Significant Accounting Judgements, Estimates and Assumptions (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Development costs			$ 34,000	43,000
Warrant term			5 years
Value-Base Care Agreements
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue			$ 220,900	$ 26,000	$ 0

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disclosure of changes in accounting estimates [line items]
Contract period (in year)	1 year
Development costs	$ 34,000	$ 43,000
Restricted cash	$ 305	$ 0
Lease term	12 months
Bottom of range
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	12.00%
Top of range
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	13.00%
Weighted average
Disclosure of changes in accounting estimates [line items]
Tax rate effect from change in tax rate	7.80%
Software Licensing
Disclosure of changes in accounting estimates [line items]
Contract period (in year)	1 year

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Useful Lives of the Property, Plant and Equipment (Details)	12 Months Ended
	Dec. 31, 2021
Computer equipment
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of the assets	3 years
Fixtures and fittings | Bottom of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of the assets	3 years
Fixtures and fittings | Top of range
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of the assets	5 years
Deployed machinery
Disclosure of detailed information about property, plant and equipment [line items]
Estimated useful lives of the assets	4 years

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Useful Lives of the Group's Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2021
Development costs | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Development costs | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	10 years
Developed technology
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	5 years
Customer relationships
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	15 years
Trade names | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	5 years
Trade names | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	11 years
Physician network | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	3 years
Physician network | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	10 years
Licenses | Bottom of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	1 year
Licenses | Top of range
Disclosure of detailed information about intangible assets [line items]
Useful life measured as period of time, intangible assets other than goodwill	2 years

Alkuri Merger and PIPE Transa_2

Alkuri Merger and PIPE Transaction (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 03, 2021	Mar. 31, 2022	Dec. 31, 2021
Disclosure of detailed information about business combination [line items]
Number of securities called by warrants (in shares)			14,558,333
Conversion of warrant and rights, term	5 years	5 years
Share premium	$ 122,800
Assets acquired	5,300
Cash held in trust	36,400
Current liabilities	31,100
Recapitalization transaction expense	148,700		$ 148,722
PIPE Investors
Disclosure of detailed information about business combination [line items]
Share premium	224,200
Proceeds from exercise of warrants	$ 224,000
Class A ordinary shares
Disclosure of detailed information about business combination [line items]
Reverse recapitalization, share price (in usd per share)	$ 10
Number of shares issued (in shares)	10,973,903
Converted warrants to purchase ordinary shares (in shares)	14,558,333	14,558,333
Redemption price, per share (in usd per share)	$ 1
Class A ordinary shares | PIPE Investors
Disclosure of detailed information about business combination [line items]
Issuance of private placement shares (in shares)	22,400,000
Private Placement Warrants
Disclosure of detailed information about business combination [line items]
Number of securities called by warrants (in shares)	5,933,333	5,933,333
Public Warrants
Disclosure of detailed information about business combination [line items]
Number of securities called by warrants (in shares)	8,625,000	8,625,000
Class B ordinary shares
Disclosure of detailed information about business combination [line items]
Number of shares issued (in shares)	38,800,000
Sponsor Earnout Shares
Disclosure of detailed information about business combination [line items]
Number of shares issued (in shares)	1,293,750
Sponsor Earnout Shares | Milestone One
Disclosure of detailed information about business combination [line items]
Share issued, price per share (in usd per share)	$ 12.50
Sponsor Earnout Shares | Milestone Two
Disclosure of detailed information about business combination [line items]
Share issued, price per share (in usd per share)	15
Sponsor Earnout Shares | Milestone Three
Disclosure of detailed information about business combination [line items]
Share issued, price per share (in usd per share)	17.50
Sponsor Earnout Shares | Milestone Four
Disclosure of detailed information about business combination [line items]
Share issued, price per share (in usd per share)	$ 20

Acquisitions- Narrative (Detail

Acquisitions- Narrative (Details) $ in Thousands	Dec. 07, 2021USD ($)item	Oct. 01, 2021USD ($)	Dec. 31, 2021USD ($)item	Dec. 31, 2020USD ($)	Nov. 01, 2021	Apr. 01, 2021USD ($)	Oct. 01, 2020USD ($)	Dec. 31, 2019USD ($)
Royalty Rate | Development Costs
Disclosure of detailed information about business combination [line items]
Significant unobservable input, assets	3
Royalty Rate | Trademarks
Disclosure of detailed information about business combination [line items]
Significant unobservable input, assets	1
Higi SH Holdings Inc.
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired					25.00%
Cash paid, net of cash acquired	$ 8,400
Number of instruments or interests issued or issuable (in shares) | item	3,412,107
Repayments of assumed borrowings	$ 7,400
Fair Value of non-controlling interest, percentage			74.70%
Fair value of non-controlling interest			$ 64,274
Investment interest at acquisition date			25.50%
Non-controlling interest in acquiree recognised at acquisition date			$ 21,800
Gain on remeasurement of existing equity interest			10,495
Transaction costs, at acquisition date			400
Revenue of acquiree since acquisition date			2,100
Profit (loss) of acquiree since acquisition date			4,000
Revenue of combined entity as if combination occurred at beginning of period			331,000
Increase by revenue of acquire since acquisition date,			7,900
Profit (loss) of combined entity as if combination occurred at beginning of period			390,000
Increase by profit (loss) of acquire since acquisition date			14,100
Goodwill			$ 61,174
Higi SH Holdings Inc. | Founder and Chief Executive Officer
Disclosure of detailed information about business combination [line items]
Number of instruments or interests issued or issuable (in shares) | item	490,782
Estimated financial effect, contingent liabilities in business combination	$ 300
Indemnification holdback period			15 months
Higi SH Holdings Inc. | Continuing Employees
Disclosure of detailed information about business combination [line items]
Number of instruments or interests issued or issuable (in shares) | item			1,980,000
Meritage Medical Network
Disclosure of detailed information about business combination [line items]
Cash paid, net of cash acquired						$ 27,900
Transaction costs, at acquisition date			$ 200
Revenue of acquiree since acquisition date			53,000
Profit (loss) of acquiree since acquisition date			15,500
Revenue of combined entity as if combination occurred at beginning of period			339,400
Increase by revenue of acquire since acquisition date,			16,500
Profit (loss) of combined entity as if combination occurred at beginning of period			376,100
Increase by profit (loss) of acquire since acquisition date			$ 100
Aggregate purchase price						16,147
Cash and cash equivalents recognised as of acquisition date						14,100
Issuance of warrants						2,349
Net identifiable assets and liabilities						1,478
Goodwill						$ 14,669
Health Innovators Inc.
Disclosure of detailed information about business combination [line items]
Percentage of voting equity interests acquired				80.00%				80.00%
Cash paid, net of cash acquired				$ 6,600				$ 4,000
Number of instruments or interests issued or issuable (in shares) | item			247,112
Issuance of warrants								$ 56,700
Net identifiable assets and liabilities			$ 3,900
Indemnification assets, range of outcomes, value, low as of acquisition date			$ 4,000
Net asset, holding percentage at acquisition date			100.00%	100.00%
Fresno
Disclosure of detailed information about business combination [line items]
Cash paid, net of cash acquired			$ 25,700
Revenue of acquiree since acquisition date				$ 16,100
Profit (loss) of acquiree since acquisition date				2,800
Revenue of combined entity as if combination occurred at beginning of period				128,300
Profit (loss) of combined entity as if combination occurred at beginning of period				179,400
Aggregate purchase price			$ 25,700	25,671
Net identifiable assets and liabilities				7,900
Liabilities incurred		$ 700
Revenue attributable period			10 years
Royalty rate of percentage at acquisition date			0.50%
Discount rate of percentage at acquisition date			10.00%
Goodwill				17,771			$ 17,800
Increase by revenue of acquire since acquisition date				49,000
Decrease By Profit (loss) of acquiree since acquisition date				$ 4,000

Acquisitions - Acquisition Date

Acquisitions - Acquisition Date Fair Value (Details) - Higi SH Holdings Inc. $ in Thousands	12 Months Ended
	Dec. 31, 2021USD ($)
Disclosure of detailed information about business combination [line items]
Carrying value of existing equity interest	$ 11,274
Gain on remeasurement of existing equity interest	10,495
Fair value of non-controlling interest	64,274
Acquisition date fair value of Higi	86,043
Accounts receivable	2,314
Property, plant and equipment	17,618
License arrangements	2,650
Trade names	3,100
Developed technology	5,900
Deferred tax liability	(730)
Other assets and liabilities, net	(5,983)
Net assets acquired	24,869
Goodwill	$ 61,174

Acquisitions Estimated Fair Val

Acquisitions Estimated Fair Value of Assets Acquired (Details) - Meritage Medical Network $ in Thousands	Apr. 01, 2021USD ($)
Disclosure of detailed information about business combination [line items]
Cash paid, net of cash acquired	$ 13,798
Issuance of warrants	2,349
Aggregate purchase price	16,147
Accounts receivable	751
Customer relationships	11,600
Claims payable	(13,436)
Deferred tax liability	(2,610)
Other assets and liabilities, net	(817)
Net identifiable assets and liabilities	1,478
Goodwill	14,669
Physician network
Disclosure of detailed information about business combination [line items]
Intangible assets	3,500
Trade names
Disclosure of detailed information about business combination [line items]
Intangible assets	1,900
Licenses
Disclosure of detailed information about business combination [line items]
Intangible assets	$ 590

Acquisitions - Estimated Fair V

Acquisitions - Estimated Fair Value of Assets Acquired of Acquisition Date (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Oct. 01, 2020
Disclosure of detailed information about business combination [line items]
Right-of-use assets	$ 20,014	$ 7,844	$ 2,572
Fresno
Disclosure of detailed information about business combination [line items]
Intangible assets			7,900
Right-of-use assets			153
Lease liability			(153)
Net identifiable assets and liabilities			7,900
Goodwill			17,771	$ 17,800
Aggregate purchase price		$ 25,700	$ 25,671

Disposals of Subsidiaries - Nar

Disposals of Subsidiaries - Narrative (Details) $ in Millions	Jan. 14, 2021CAD ($)
Disclosure of detailed information about business combination [line items]
Consideration received	$ 1.8
Discontinued operations
Disclosure of detailed information about business combination [line items]
Consideration received consisting of repayment of borrowings	$ 3.5

Disposals of Subsidiaries - Eff

Disposals of Subsidiaries - Effect of Disposal (Details) $ in Thousands, $ in Millions	Jan. 14, 2021CAD ($)	Dec. 31, 2021USD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Disclosure of detailed information about business combination [line items]
Cash and cash equivalents		$ (262,581)	$ (274,978)	$ (101,757)
Prepayments and contract assets		(26,000)	(21,971)	(8,841)
Property, plant and equipment		(24,990)	(25,694)	(1,334)	$ (1,801)
Right-of-use assets		(7,844)	(20,014)	(2,572)
Trade and other receivables		(24,119)	(27,981)	(13,525)
Accruals and provisions		36,366		15,409
Lease liabilities		8,442	20,143	2,011
Borrowings		168,786	262,142
Trade and other payables		22,686	$ 25,198	$ 7,745
Consideration received	$ 1.8
Disposal Groups Classified As Held For Sale | Discontinued operations
Disclosure of detailed information about business combination [line items]
Cash and cash equivalents		(57)
Prepayments and contract assets		(1,322)
Property, plant and equipment		(922)
Right-of-use assets		(797)
Trade and other receivables		(619)
Accruals and provisions		658
Lease liabilities		837
Borrowings		3,075
Trade and other payables		588
Net assets and liabilities derecognized		1,441
Consideration received		2,344
Working capital adjustment		132
Gain on disposal		$ 3,917

Revenue - Disaggregation of R_2

Revenue - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Value-based care
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	246,575	27,259	220,852	26,038
Software licensing
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	7,756	35,964	60,052	24,603	2,002
Clinical services
Disclosure of disaggregation of revenue from contracts with customers [line items]
Revenue from contracts with customers	$ 12,115	$ 8,070	$ 42,017	$ 28,631	$ 14,032

Revenue - Narrative (Details)_2

Revenue - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Revenue from contracts with customers [Abstract]
Upfront payment on license and support agreement	$ 66.9	$ 66.9
Post contract support period	24 months	24 months
Right to access enhancements period	7 years	7 years

Revenue - Contract Balances (_2

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Revenue from contracts with customers [Abstract]
Trade receivables (Note 20)	$ 7,068	$ 8,278	$ 4,674
Contract assets (Note 20)	5,557	4,484	2,378	$ 1,541
Contract liabilities (Note 8 iii)	$ 86,426	$ 94,182	$ 76,018	$ 81,584

Revenue - Contract Liabilitie_2

Revenue - Contract Liabilities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Revenue from contracts with customers [Abstract]
Contract liabilities at beginning of period	$ 94,182	$ 76,018	$ 81,584
Amounts billed but not recognized	849	61,176	18,080
Revenue recognized	(6,091)	(43,012)	(23,646)
Contract liabilities at end of period	$ 86,426	$ 94,182	$ 76,018

Revenue - Revenue to Be Recog_2

Revenue - Revenue to Be Recognized (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	$ 86,426	$ 94,182
2022
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	22,663	23,786
2023
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	18,366	18,918
2024
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	18,959	19,349
2025
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	15,539	17,852
2026 and beyond
Disclosure of transaction price allocated to remaining performance obligations [line items]
Transaction price allocated to remaining performance obligations	$ 10,899	$ 14,277

Segment Information - Consoli_2

Segment Information - Consolidated Statements of Profit and Loss (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of operating segments [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
Cost of care delivery	(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Other operating income (expense)			(400,754)	(173,042)	(156,548)
Change in fair value of warrant liabilities	5,575		27,811
Exchange gain / (loss)	(447)	(573)	868	(2,836)	17,075
Gain on sale of subsidiary		3,917	3,917
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees		(455)	(2,602)	(1,124)
Segment EBITDA	(75,517)	(4,013)	(327,016)	(164,984)	(143,249)
Depreciation and amortization	(9,458)	(5,848)	(35,004)	(14,487)	(2,496)
Operating loss	(90,103)	(12,750)	(402,509)	(175,511)	(162,820)
Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	266,517	70,920	322,873	79,194	16,043
Operating segments
Disclosure of operating segments [line items]
Revenue	266,453	70,924	322,870	79,060	16,073
Cost of care delivery	(24,527)	(14,462)	(297,130)	(76,186)	(26,240)
Other operating income (expense)			(392,528)	(158,942)	(148,508)
Change in fair value of warrant liabilities	5,575		27,811
Exchange gain / (loss)	(18,382)	1,107	(265)	17,217	16,815
Gain on sale of subsidiary		3,917	2,687
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees		(455)	(2,602)	(1,124)
Segment EBITDA	(93,339)	(3,030)	(328,662)	(139,975)	(141,860)
Reconciliation adjustments
Disclosure of operating segments [line items]
Revenue	(7)	369	51	212	(39)
Cost of care delivery	600	2,639	7,458	8,932	6,430
Other operating income (expense)			(8,226)	(14,100)	(8,040)
Exchange gain / (loss)	17,935	(1,680)	1,133	(20,053)	260
Gain on sale of subsidiary			1,230
Segment EBITDA	17,822	(983)	1,646	(25,009)	(1,389)
Unallocated amounts
Disclosure of operating segments [line items]
Revenue	(71)	373	48	78	(9)
Inter-segment revenue
Disclosure of operating segments [line items]
Revenue	(64)	4	3	134	(30)
UK | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	15,670	41,242	88,967	44,000	14,633
UK | Operating segments
Disclosure of operating segments [line items]
Revenue	15,670	41,242	91,172	45,194	18,714
Cost of care delivery	(11,872)	(9,269)	(41,542)	(34,600)	(25,707)
Other operating income (expense)			(114,975)	(127,762)	(119,895)
Exchange gain / (loss)	(4,078)	(632)	(1,844)	403	314
Segment EBITDA	(31,505)	4,899	(67,189)	(116,765)	(126,574)
UK | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue			2,205	1,194	4,081
US | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	250,512	29,244	232,296	32,226
US | Operating segments
Disclosure of operating segments [line items]
Revenue	250,512	29,244	228,332	29,132	(2,669)
Cost of care delivery	(12,394)	(4,597)	(253,998)	(34,381)	(160)
Other operating income (expense)			(105,602)	(27,190)	(23,273)
Exchange gain / (loss)	2,353	(49)	189	(246)	(83)
Share of loss of equity-accounted investees		(455)	(2,602)
Segment EBITDA	(41,257)	(11,090)	(133,681)	(32,685)	(26,185)
US | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue			(3,964)	(3,094)	(2,669)
All other segments | Operating segment, excluding materially reconciling items
Disclosure of operating segments [line items]
Revenue	335	434	1,610	2,968	1,410
All other segments | Operating segments
Disclosure of operating segments [line items]
Revenue	271	438	3,366	4,734	28
Cost of care delivery	(261)	(596)	(1,590)	(7,205)	(373)
Other operating income (expense)			(171,951)	(3,990)	(5,340)
Change in fair value of warrant liabilities	5,575		27,811
Exchange gain / (loss)	(16,657)	1,788	1,390	17,060	16,584
Gain on sale of subsidiary		3,917	2,687
Gain on remeasurement of equity interest			10,495
Share of loss of equity-accounted investees				(1,124)
Segment EBITDA	(20,577)	3,161	(127,792)	9,475	10,899
All other segments | Inter-segment revenue
Disclosure of operating segments [line items]
Revenue	$ (64)	$ 4	$ 1,756	$ 1,766	$ (1,382)

Segment Information - Major C_2

Segment Information - Major Customers (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of operating segments [line items]
Revenue	$ 266,446	$ 71,293	$ 322,921	$ 79,272	$ 16,034
UK
Disclosure of operating segments [line items]
Percentage of revenue	39.40%		38.30%	64.80%
Revenue	$ 9,435	7,786	$ 35,490	$ 28,827	12,189
US
Disclosure of operating segments [line items]
Percentage of revenue	59.50%		61.10%	34.50%
Revenue	$ 250,597	29,808	$ 232,708	$ 32,689
Asia-Pacific
Disclosure of operating segments [line items]
Revenue	3,634	3,410	14,965	11,585	2,215
Canada
Disclosure of operating segments [line items]
Revenue	2,530	30,129	38,705	3,207	564
Rest of World
Disclosure of operating segments [line items]
Revenue	$ 250	$ 160	$ 1,053	$ 2,964	$ 1,066
Customer 1
Disclosure of operating segments [line items]
Percentage of revenue	54.40%	17.40%	37.10%	15.00%	13.80%
Revenue	$ 145,043	$ 12,420	$ 119,785	$ 11,918	$ 2,215
Customer 2
Disclosure of operating segments [line items]
Percentage of revenue	23.10%		12.30%	12.30%	15.40%
Revenue	$ 61,446		$ 39,764	$ 9,706	$ 2,465
Customer 3
Disclosure of operating segments [line items]
Percentage of revenue	5.00%	17.00%	12.00%	12.00%	34.90%
Revenue	$ 14,381	$ 12,148	$ 38,705	$ 9,505	$ 5,607
Customer 4
Disclosure of operating segments [line items]
Percentage of revenue	1.00%	42.30%		18.90%
Revenue	$ 2,530	$ 30,129		$ 14,937

Segment Information - Narrati_2

Segment Information - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of operating segments [line items]
Non-current assets	$ 252,193	$ 237,933	$ 109,467
UK
Disclosure of operating segments [line items]
Percentage of revenue	39.40%	38.30%	64.80%
Non-current assets	$ 99,300	$ 92,600	$ 70,900
Trade receivables	$ 4,900	$ 7,000	$ 2,200
Percentage of receivables	69.40%	84.50%	47.60%
US
Disclosure of operating segments [line items]
Percentage of revenue	59.50%	61.10%	34.50%
Non-current assets	$ 150,100	$ 147,800	$ 37,800
Trade receivables	$ 2,000	$ 900	$ 2,300
Percentage of receivables	27.70%	11.00%	50.10%

Employee Benefits Expense - Sum

Employee Benefits Expense - Summary of Employee Benefit Expense (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Claims Payable
Wages and salaries			$ 148,728	$ 108,018	$ 57,388
Social security and pension contributions			17,118	13,404	8,254
Share-based compensation	$ 8,402	$ 2,802	46,307	9,557	7,966
Total			$ 212,153	$ 130,979	$ 73,608

Employee Benefits Expense - Nar

Employee Benefits Expense - Narrative (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense	$ 212,153	$ 130,979	$ 73,608
Capitalized employee costs	34,000	43,000	36,000
Cost of sales
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense	62,300	34,500	3,700
Platform and Application Expense
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense	6,900	8,800	7,200
Research and Development Expense
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense	42,900	53,300	36,600
Selling, general and administrative expense
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense	$ 100,095	$ 34,362	$ 26,020

Employee Benefits Expense - S_2

Employee Benefits Expense - Summary of Employees (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	2,573	2,108	1,556
Engineers
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	427	515	670
Sales & marketing
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	89	88	108
Finance, HR & legal
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	242	146	178
Clinical operations
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	856	586	476
Clinicians
Disclosure of attribution of expenses by nature to their function [line items]
Number of employees	959	773	124

Platform & Application Expens_2

Platform & Application Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Platform & Application Expenses [Abstract]
Employee benefits	$ 6,873	$ 8,800	$ 7,225
Depreciation and amortization	16,842	11,088	1,182
IT and hosting costs	14,760	8,660	6,621
Contractors and consultants expense	1,941	3,010	7,381
Impairment	941	6,436
Other	1,472	143	1,160
Total	$ 42,829	$ 38,137	$ 23,569

Research & Development Expens_2

Research & Development Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Claims Payable
Employee benefits			$ 42,877	$ 53,332	$ 36,630
Contractors and consultants expense			3,917	645	14,752
Other			740	734	(177)
Total	$ 10,057	$ 10,390	$ 47,534	$ 54,711	$ 51,205

Sales, General & Administrati_3

Sales, General & Administrative Expenses (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense			$ 212,153	$ 130,979	$ 73,608
Depreciation and amortization	$ 9,458	$ 5,848	35,004	14,487	2,496
Total	$ 58,310	$ 31,479	196,673	94,681	84,270
Selling, general and administrative expense
Disclosure of attribution of expenses by nature to their function [line items]
Employee benefits expense			100,095	34,362	26,020
Professional fees			19,200	8,645	4,469
IT and hosting costs			16,430	11,559	9,988
Depreciation and amortization			16,222	3,399	1,315
Marketing			9,982	6,575	7,691
Insurance			9,598	4,172	2,444
Contractors and consultants expense			7,425	2,501	7,008
Staffing, training and recruitment			6,321	3,494	6,393
Property related expenses			5,677	8,651	10,214
Local taxes			2,311	2,359	2,321
Office and clinical supplies			1,119	2,120	2,362
Other			2,293	6,844	4,045
Total			$ 196,673	$ 94,681	$ 84,270

Finance Income and Costs (Detai

Finance Income and Costs (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Finance Income and Costs [Abstract]
Finance costs	$ 6,628	$ 992	$ 14,291	$ 4,530	$ 1,116
Finance income	255	14	326	610	1,015
Change in fair value of warrant liabilities	5,575		27,811
Exchange Gain / (Loss)			868	(2,836)	17,075
Finance Income (Loss), Net			14,714	(6,756)	16,974
Interest expense			10,234	252	851
Interest expense on lease liabilities			617	572	265
Interest expense on other financial liabilities			3,440	3,706
Finance costs	$ (6,628)	$ (992)	$ (14,291)	$ (4,530)	$ (1,116)

Recapitalization Transaction _3

Recapitalization Transaction Expense - Narrative (Details) - USD ($) $ / shares in Units, $ in Thousands	Jun. 03, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Oct. 22, 2021
Disclosure of detailed information about business combination [line items]
Issuance of shares			$ 11,907	$ 377,273
Recapitalization transaction expense	$ 148,700	$ 148,722
Alkuri Global Acquisition Corp
Disclosure of detailed information about business combination [line items]
Net identifiable assets and liabilities		5,310
Recapitalization transaction expense		148,498
Alkuri Global Acquisition Corp | PIPE Investors
Disclosure of detailed information about business combination [line items]
Issuance of shares		$ 224,224
Share issued, price per share (in usd per share)		$ 10.01
Share price (in usd per share)		$ 10.01
Net identifiable assets and liabilities		$ 224,000
Recapitalization transaction expense		148,722
IFRS 2 Expense on the closing date		224
Alkuri Global Acquisition Corp | Class A ordinary shares
Disclosure of detailed information about business combination [line items]
Issuance of shares		153,808
Share issued, price per share (in usd per share)					$ 10.01
Alkuri Global Acquisition Corp | Warrant
Disclosure of detailed information about business combination [line items]
Issuance of shares		$ 31,009
Share price (in usd per share)					$ 2.13

Recapitalization Transaction _4

Recapitalization Transaction Expense (Details) - USD ($) $ / shares in Units, $ in Thousands	Oct. 21, 2021	Jun. 03, 2021	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Oct. 22, 2021
Disclosure of detailed information about business combination [line items]
Issuance of shares					$ 11,907	$ 377,273
Number of securities called by warrants (in shares)				14,558,333
Recapitalization transaction expense		$ 148,700		$ 148,722
Total cash proceeds received				229,311
Expense of share issue				(32,787)
Proceeds from issuance of share capital	$ 229,300		$ 329,300	229,311	$ 12,096	$ 320,334
Alkuri Global Acquisition Corp
Disclosure of detailed information about business combination [line items]
Net identifiable assets and liabilities				5,310
Recapitalization transaction expense				$ 148,498
Alkuri Global Acquisition Corp | PIPE Investors
Disclosure of detailed information about business combination [line items]
Number of shares issued (in shares)				22,400,000
Share issued, price per share (in usd per share)				$ 10.01
Issuance of shares				$ 224,224
Share price (in usd per share)				$ 10.01
Net identifiable assets and liabilities				$ 224,000
Recapitalization transaction expense				148,722
IFRS 2 Expense on the closing date				224
Proceeds from issuance of share capital				$ 196,524
Alkuri Global Acquisition Corp | Public Warrants
Disclosure of detailed information about business combination [line items]
Number of securities called by warrants (in shares)				8,625,000
Share price (in usd per share)				$ 2.13
Alkuri Global Acquisition Corp | Private Placement Warrants
Disclosure of detailed information about business combination [line items]
Number of securities called by warrants (in shares)				5,933,333
Share price (in usd per share)				$ 2.13
Alkuri Global Acquisition Corp | Warrant
Disclosure of detailed information about business combination [line items]
Issuance of shares				$ 31,009
Share price (in usd per share)							$ 2.13
Alkuri Global Acquisition Corp | Class A Ordinary Shares [Member]
Disclosure of detailed information about business combination [line items]
Share issued, price per share (in usd per share)							10.01
Issuance of shares				$ 153,808
Alkuri Global Acquisition Corp | Ordinary share capital
Disclosure of detailed information about business combination [line items]
Number of shares issued (in shares)				12,267,653
Share issued, price per share (in usd per share)							$ 10.01
Issuance of shares				$ 122,799

Taxation - Recognized in the Co

Taxation - Recognized in the Consolidated Statement of Profit and Loss (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Current tax
Current tax on loss for the period			$ 801	$ 569	$ (3,457)
Adjustments to tax in respect of previous periods			31	4,070	(2,102)
Total current tax			832	4,639	(5,559)
Deferred tax
Origination and reversal of timing differences			(2,306)
Total deferred tax			(2,306)
Tax benefit (provision)	$ 9	$ 8	$ (1,474)	$ 4,639	$ (5,559)

Taxation - Analysis of Tax Reco

Taxation - Analysis of Tax Recognized in the Consolidated Statement of Profit and Loss (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Major components of tax expense (income) [abstract]
Loss before tax	$ (91,348)	$ (10,839)	$ (375,985)	$ (183,391)	$ (145,846)
Tax on loss on ordinary activities			(71,437)	(34,844)	(27,711)
State and local income taxes, net of federal benefit			(320)
Benefit of foreign operations			(218)
Deferred tax not recognized			38,563	31,271	25,552
Expenses not deductible for tax purposes			33,512	4,142	187
Non-taxable income			(11,003)
Change in fair value of warrants			8,903
Tax arising on share in associates			495
Adjustments to tax in respect of previous periods			31	4,070	(2,102)
All other, net					(1,485)
Tax (benefit) provision	$ 9	$ 8	$ (1,474)	$ 4,639	$ (5,559)

Taxation - Narrative (Details)

Taxation - Narrative (Details) - USD ($) $ in Millions	Mar. 03, 2021	Dec. 31, 2021	Dec. 31, 2020
Disclosure Of Income Taxes [Line Items]
Unrecognized deferred tax assets		$ 179.3	$ 80.8
Effective From April 1, 2017
Disclosure Of Income Taxes [Line Items]
Applicable tax rate		19.00%
Effective From April 1, 2020
Disclosure Of Income Taxes [Line Items]
Applicable tax rate		17.00%
Effective For April 1, 2020 & 2021
Disclosure Of Income Taxes [Line Items]
Applicable tax rate		19.00%
Effective From April 1, 2023
Disclosure Of Income Taxes [Line Items]
Applicable tax rate	25.00%

Property, Plant and Equipment_2

Property, Plant and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	$ 1,334	$ 1,801
Ending balance	24,990	1,334
Cost
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	3,040	2,853
Additions	8,103	719
Reclassification into available-for-sale financial assets		621
Acquisitions through business combinations	17,764
Effect of movements in foreign exchange	(210)	89
Ending balance	28,697	3,040
Depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(1,706)	(1,052)
Depreciation expense	2,086	934
Effect of movements in foreign exchange	(85)	(280)
Ending balance	(3,707)	(1,706)
Computer Equipment
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	1,284	1,472
Ending balance	2,933	1,284
Computer Equipment | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	2,860	2,463
Additions	2,830	308
Reclassification into available-for-sale financial assets		0
Acquisitions through business combinations	105
Effect of movements in foreign exchange	(107)	89
Ending balance	5,688	2,860
Computer Equipment | Depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(1,576)	(991)
Depreciation expense	1,255	931
Effect of movements in foreign exchange	(76)	(346)
Ending balance	(2,755)	(1,576)
Fixtures and Fittings
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	50	329
Ending balance	5,189	50
Fixtures and Fittings | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	180	390
Additions	5,273	411
Reclassification into available-for-sale financial assets		621
Acquisitions through business combinations	41
Effect of movements in foreign exchange	(103)	0
Ending balance	5,391	180
Fixtures and Fittings | Depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	(130)	(61)
Depreciation expense	81	3
Effect of movements in foreign exchange	(9)	66
Ending balance	(202)	(130)
Deployed Machinery
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	0	0
Ending balance	16,868	0
Deployed Machinery | Cost
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	0	0
Additions	0	0
Reclassification into available-for-sale financial assets		0
Acquisitions through business combinations	17,618
Effect of movements in foreign exchange	0	0
Ending balance	17,618	0
Deployed Machinery | Depreciation
Reconciliation of changes in property, plant and equipment [abstract]
Beginning balance	0	0
Depreciation expense	750	0
Effect of movements in foreign exchange		0
Ending balance	$ (750)	$ 0

Intangible Assets and Goodwil_5

Intangible Assets and Goodwill - Schedule of Goodwill and Intangible Assets Rollforward (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	$ (111,421)	$ (78,853)	$ (43,751)
Intangible assets and goodwill at end of period	(112,830)	(111,421)	(78,853)
Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(93,678)	(17,832)	(61)
Intangible assets and goodwill at end of period	(93,655)	(93,678)	(17,832)
Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(69,632)	(50,781)	(14,878)
Intangible assets and goodwill at end of period	(69,706)	(69,632)	(50,781)
Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(21,868)	(21,138)	(28,873)
Intangible assets and goodwill at end of period	(24,606)	(21,868)	(21,138)
Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(11,020)	(2,255)	0
Intangible assets and goodwill at end of period	(10,827)	(11,020)	(2,255)
Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(4,767)	(3,217)	0
Intangible assets and goodwill at end of period	(4,017)	(4,767)	(3,217)
Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(3,937)	(1,462)	0
Intangible assets and goodwill at end of period	(3,608)	(3,937)	(1,462)
Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(197)	0	0
Intangible assets and goodwill at end of period	(66)	(197)	0
Cost
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(159,814)	(98,100)	(44,431)
Acquisitions through business combinations		29,240	7,900
Additions	10,071	33,999	43,967
Transfers		0	0
Effect of movements in foreign exchange	(3,289)	(1,525)	1,802
Intangible assets and goodwill at end of period	(166,596)	(159,814)	(98,100)
Cost | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(93,678)	(17,832)	(61)
Acquisitions through business combinations		75,846	17,771
Additions		0	0
Transfers		0	0
Effect of movements in foreign exchange	(23)	0	0
Intangible assets and goodwill at end of period	(93,655)	(93,678)	(17,832)
Cost | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(109,356)	(69,062)	(15,558)
Acquisitions through business combinations		8,550	0
Additions		0	940
Transfers	6,803	33,056	51,932
Effect of movements in foreign exchange	(2,759)	(1,312)	632
Intangible assets and goodwill at end of period	(113,400)	(109,356)	(69,062)
Cost | Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(21,868)	(21,138)	(28,873)
Acquisitions through business combinations		0	0
Additions	10,071	33,999	43,027
Transfers	(6,803)	(33,056)	(51,932)
Effect of movements in foreign exchange	(530)	(213)	1,170
Intangible assets and goodwill at end of period	(24,606)	(21,868)	(21,138)
Cost | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(14,700)	(3,100)	0
Acquisitions through business combinations		11,600	3,100
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(14,700)	(14,700)	(3,100)
Cost | Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(8,300)	(3,300)	0
Acquisitions through business combinations		5,000	3,300
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(8,300)	(8,300)	(3,300)
Cost | Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(5,000)	(1,500)	0
Acquisitions through business combinations		3,500	1,500
Additions		0	0
Transfers			0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(5,000)	(5,000)	(1,500)
Cost | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	(590)	0	0
Acquisitions through business combinations		590	0
Additions		0	0
Transfers		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	(590)	(590)	0
Amortization and impairment
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	48,393	19,247	680
Amortization for the period	6,467	28,990	11,123
Impairment charge		(941)	(6,436)
Effect of movements in foreign exchange	(1,094)	(785)	1,008
Intangible assets and goodwill at end of period	53,766	48,393	19,247
Amortization and impairment | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	0	0	0
Amortization for the period		0	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period		0	0
Amortization and impairment | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	39,724	18,281	680
Transfers	6,800
Amortization for the period	5,064	21,287	10,157
Impairment charge		(941)	(6,436)
Effect of movements in foreign exchange	(1,094)	(785)	1,008
Intangible assets and goodwill at end of period	43,694	39,724	18,281
Amortization and impairment | Intangibles under Development
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	0	0	0
Amortization for the period		0	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period		0	0
Amortization and impairment | Customer Relationships
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	3,680	845	0
Amortization for the period	193	2,835	845
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	3,873	3,680	845
Amortization and impairment | Trademarks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	3,533	83	0
Amortization for the period	750	3,450	83
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	4,283	3,533	83
Amortization and impairment | Physician Networks
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	1,063	38	0
Amortization for the period	329	1,025	38
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	1,392	1,063	38
Amortization and impairment | Licenses
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Intangible assets and goodwill at beginning of period	393	0	0
Amortization for the period	131	393	0
Impairment charge		0	0
Effect of movements in foreign exchange		0	0
Intangible assets and goodwill at end of period	$ 524	$ 393	$ 0

Intangible Assets and Goodwil_6

Intangible Assets and Goodwill - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Terminal value Growth Rate
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Terminal growth value (as a percent)		3.00%
Possible change in terminal growth rate 1 (as a percent)		2.75%
Possible change in fair value due to change in terminal value 1		$ 1,300
Possible change in terminal growth rate 2 (as a percent)		2.50%
Possible change in fair value due to change in terminal value 2		$ 3,200
Discount rate, measurement input [member]
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Discount rate (as a percent)		14.50%
Possible change in discount rate 1 (as a percent)		15.00%
Possible change in fair value due to change in discount rate 1		$ 4,800
Possible change in discount rate 2 (as a percent)		15.50%
Possible change in fair value due to change in discount rate 2		$ 9,200
Cost
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Acquisitions through business combinations		29,240	$ 7,900
Transfers		0	0
Cost | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Acquisitions through business combinations		75,846	17,771
Transfers		0	0
Cost | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Acquisitions through business combinations		8,550	0
Transfers	$ 6,803	33,056	51,932
Amortization and impairment
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Impairment charge		941	6,436
Amortization and impairment | Goodwill
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Impairment charge		0	0
Amortization and impairment | Development Costs
Disclosure of reconciliation of changes in intangible assets and goodwill [line items]
Transfers	$ 6,800
Impairment charge		$ 941	$ 6,436

Investments in Subsidiaries a_6

Investments in Subsidiaries and Associates - Schedule of Ownership Percentage (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Babylon Partners Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Healthcare Services Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Rwanda Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Inc.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Health Canada Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)		100.00%
Babylon Liberty Corp.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Babylon Malaysia SDN BHD
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon International Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Health Ireland Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Singapore PTE Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Health Innovators Inc.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	70.10%
Babylon Acquisition Corp.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)		100.00%
Babylon Technology LTDA
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Higi SH Holdings Inc.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	19.00%
Babylon Healthcare Inc.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Healthcare NJ, PC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Healthcare, PLLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Medical Group (formerly Marcus Zachary DO), PC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
California Telemedicine Associates, PC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Telemedicine Associates, P.C.
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Healthcare, PC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	100.00%
Babylon Healthcare NC, PC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)		100.00%
Babylon Healthcare, PA
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Meritage Medical Network
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Meritage Health Ventures, LLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Meritage Health Plan
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Meritage Management, LLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Higi SH LLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	19.00%
Higi Health Holdings LLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%
Higi SH Canada ULC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	19.00%
Higi Health LLC
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	51.00%
Health Innovators Limited
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	100.00%	70.10%
DTDHI Health India PVT Ltd
Disclosure of information about unconsolidated subsidiaries [line items]
Ownership (as a percent)	97.80%	68.60%

Investments in Subsidiaries a_7

Investments in Subsidiaries and Associates - Professional Service Corporations (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of information about unconsolidated structured entities controlled by investment entity [line items]
Total assets	$ 582,577		$ 554,632	$ 238,814
Total liabilities	503,046		389,361	190,455
Revenue	266,446	$ 71,293	322,921	79,272	$ 16,034
Cost of care delivery	(23,927)	(11,823)	(289,672)	(67,254)	(19,810)
Sales, general & administrative expenses	(58,310)	(31,479)	(196,673)	(94,681)	$ (84,270)
Professional Service Corporations
Disclosure of information about unconsolidated structured entities controlled by investment entity [line items]
Total assets	131,429		104,703	35,535
Total liabilities	213,222		168,240	42,699
Revenue	127,138	19,756	154,508	17,436
Cost of care delivery	(8,912)	(2,256)	(155,191)	(20,175)
Sales, general & administrative expenses	$ (15,012)	$ (2,875)	$ (55,006)	$ (3,799)

Trade and Other Receivables, _3

Trade and Other Receivables, Prepayments and Contract Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Trade receivables (Note 20)	$ 7,068	$ 8,278	$ 4,674
Other current receivables		13,796	8,914
Current prepayments		21,516	6,463
Current contract assets		4,484	2,378
Current value added tax receivables		2,045
Current value added tax payables			(63)
Trade and other receivables		$ 50,119	$ 22,366

Trade and Other Receivables, _4

Trade and Other Receivables, Prepayments and Contract Assets - Narrative (Details) $ in Millions	Dec. 31, 2020USD ($)
Subclassifications of assets, liabilities and equities [abstract]
Immaterial trade receivable	$ 0

Trade and Other Receivables, _5

Trade and Other Receivables, Prepayments and Contract Assets - Changes in Contract Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Contract Assets [Roll Forward]
Contract assets at beginning of period	$ 2,378	$ 1,541
Revenues recognized but not billed	3,444	1,511
Amounts reclassified to trade receivable	(1,338)	(674)
Contract assets at end of period	$ 4,484	$ 2,378

Trade and Other Payables, Acc_3

Trade and Other Payables, Accruals and Provisions (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Subclassifications of assets, liabilities and equities [abstract]
Trade payables	$ 17,178	$ 3,739
Accruals	36,366	15,409
Provisions	490	3,227
Taxation and Social Security	4,039	4,006
Employee loans	1,193	0
Other	276	0
Trade and other current payables	$ 59,542	$ 26,381

Deferred Grant Income (Details)

Deferred Grant Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Deferred Grants [Roll Forward]
Deferred grant income beginning balance	$ 7,488
Grants related to prior years		$ 3,173
Grants received in 2020	2,769	4,315
Grant income recognized	(1,959)
Adjustment, net	146
Deferred grant income ending balance	$ 8,444	$ 7,488

Claims Payable (Details)_2

Claims Payable (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Claims Payable
Claims payable beginning balance	$ 24,628	$ 3,890
Claims expense		216,791	$ 24,146
Claims paid	(233,015)	(196,053)	(21,137)
Adjustment, net			881
Claims payable ending balance	$ 39,165	$ 24,628	$ 3,890

Cash and Cash Equivalents (De_2

Cash and Cash Equivalents (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Cash and Cash Equivalents
Cash in hand and at banks	$ 274,978	$ 262,276	$ 97,757
Short term investment funds			4,000
Restricted cash		305	0
Cash and cash equivalents	$ 274,978	$ 262,581	$ 101,757

Leases - Right-of-Use Asset, Am

Leases - Right-of-Use Asset, Amortization And Net Book Value (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Net book value
Beginning balance, net book value	$ 2,572
Ending balance, net book value	7,844	$ 2,572
Buildings
Right-of-use asset
Beginning balance, right-of-use assets	8,157	6,501
Additions to right-of-use-assets	11,399	2,300
Disposals	(4,291)
Reclassification to assets held for sale		(872)
Effect of change in foreign currency	(166)	228
Ending balance, right-of-use assets	15,099	8,157
Amortization
Beginning balance, amortization	3,643	1,272
Amortization charge for the year	3,929	2,430
Disposals	(4,291)
Reclassification to assets held for sale		(243)
Effect of change in foreign currency	(25)	184
Ending balance, amortization	3,256	3,643
Net book value
Beginning balance, net book value	4,514	5,229
Ending balance, net book value	$ 11,843	$ 4,514

Leases - Lease Liability (Detai

Leases - Lease Liability (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Presentation of leases for lessee [abstract]
Beginning balance, lease liabilities	$ 4,499	$ 3,583
Additions to lease liabilities	11,826	2,362
Interest expense on lease liabilities	617	572	$ 265
Payments on leases	(4,156)	(1,541)
Reclassification to liabilities associated with the assets held for sale		(607)
Effect of change in foreign currency	(154)	130
Ending balance, lease liabilities	$ 12,632	$ 4,499	$ 3,583

Leases - Recognized in the Cons

Leases - Recognized in the Consolidated Statement of Profit and Loss (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Presentation of leases for lessee [abstract]
Depreciation expense on right-of-use assets	$ 3,929	$ 2,430	$ 1,272
Interest expense on lease liabilities	617	572	265
Expenses relating to short term leases	2,489	4,756	6,127
Profit and loss impact	$ 7,035	$ 7,758	$ 7,664

Leases - Undiscounted Maturitie

Leases - Undiscounted Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	$ 15,935	$ 5,859
Less than one year
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	4,595	2,348
One to two years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	5,612	684
Two to three years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	4,290	598
Three to four years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	362	572
Four to five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	371	375
More than five years
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Undiscounted maturities of lease liabilities	$ 705	$ 1,282

Leases - Narrative (Details)_2

Leases - Narrative (Details) - USD ($) $ in Millions	1 Months Ended
	Mar. 31, 2020	Dec. 31, 2021
Presentation of leases for lessee [abstract]
Initial term of the lease	39 months
Annual lease rent	$ 4.9
Rent free period	12 months
Weighted-average rate		12.00%

Loans and Borrowings - Non-Cu_2

Loans and Borrowings - Non-Current and Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	$ 262,142	$ 168,601	$ 0
Current liabilities		185	70,357
Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		185	70,357
Unamortized fair value adjustment, discount, and debt issuance costs
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	(37,858)	(31,399)	0
Loan Notes | Cost
Disclosure of detailed information about borrowings [line items]
Non-current liabilities	$ 300,000	200,000	0
Convertible Loan Notes | Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		0	70,000
Other Borrowings | Cost
Disclosure of detailed information about borrowings [line items]
Current liabilities		$ 185	$ 357

Loans and Borrowings - Narrat_2

Loans and Borrowings - Narrative (Details) $ / shares in Units, $ in Thousands

Nov. 04, 2026

Jan. 01, 2024item

Nov. 04, 2022

Dec. 23, 2021USD ($)$ / sharesshares

Nov. 04, 2021USD ($)

Oct. 08, 2021USD ($)shares

Aug. 18, 2021USD ($)

Aug. 10, 2021

Jul. 15, 2021USD ($)

Apr. 11, 2021

Nov. 12, 2020USD ($)

Jun. 30, 2021USD ($)shares

Mar. 31, 2022USD ($)shares

Nov. 04, 2024

Nov. 04, 2022

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)shares

Nov. 05, 2026

Nov. 04, 2023

Jan. 01, 2024

Nov. 04, 2026

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 100,000

Debt instrument interest rate

50.00%

50.00%

50.00%

Debt instrument, interest rate stated percentage

104.00%

Proceeds from issuance of notes and warrants

$ 100,000

$ 270,563

Repayments of borrowings, and transaction expenses

$ 32,100

Share capital

16

16

Debt instrument, payment frequency, term

6 months

6 months

Interest expense on borrowings

1,400

$ 200

Interest payable

2,500

$ 0

Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

104.00%

Unsecured Notes due 2026

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 200,000

Unsecured Notes

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 100,000

$ 200,000

$ 50,000

$ 4,000

$ 3,400

Debt discount percentage

95.50%

4.00%

Debt instrument, basis rate

6.50%

6.50%

Debt instrument, term

5 years

1 year

Debt instrument, redemption price, percentage

100.00%

Proceeds from issuance of notes and warrants

$ 7,200

Debt instrument, step-up margin, target number of Medicaid Lives to value-based care contracts

100,000

100,000

Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

107.00%

107.00%

Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

100.00%

Debt instrument principal amount

$ 100,000

VNV Loan

Disclosure of defined benefit plans [line items]

Debt instruments issued

$ 15,000

Debt discount percentage

10.00%

Debt instrument interest rate

14.00%

Debt instruments non-cash conversion

$ 8,000

Convertible Loan Note Agreement

Disclosure of defined benefit plans [line items]

Borrowing capacity

$ 200,000

Share capital

1

Convertible Loan Note Agreement | Tranche 1 Notes

Disclosure of defined benefit plans [line items]

Borrowing capacity

30,000

Convertible Loan Note Agreement | Tranche 2 Notes

Disclosure of defined benefit plans [line items]

Borrowing capacity

70,000

GHE | Tranche 1 Notes

Disclosure of defined benefit plans [line items]

Issue of convertible instruments

$ 30,000

Debt of issuance to redemption or conversion percentage

11.00%

Class A ordinary shares

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

1,757,499

334,848

333,925

0

Warrant exercised shares (in shares) | shares

1,757,499

Warrant exercise price per share (in usd per share) | $ / shares

$ 15

$ 15

Redemption price per share (in usd per share) | $ / shares

$ 15

Class A ordinary shares | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

878,750

878,750

C Preference Shares

Disclosure of defined benefit plans [line items]

Debt converted in preference shares (in shares) | shares

41,012,358

C Preference Shares | Tranche 2 Notes

Disclosure of defined benefit plans [line items]

Issue of convertible instruments

$ 70,000

Bottom of range | Forecast

Disclosure of defined benefit plans [line items]

Debt instrument, interest rate stated percentage

104.00%

104.00%

Bottom of range | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

8.00%

Bottom of range | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

8.00%

Bottom of range | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument principal amount

$ 75,000

Weighted average. | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

10.00%

Weighted average. | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

10.00%

Weighted average. | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instruments issued

75,000

Top of range | Unsecured Notes

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

12.00%

Top of range | Unsecured Notes | Forecast

Disclosure of defined benefit plans [line items]

Capitalized interest rate, percentage

12.00%

Top of range | Second Note Subscription Agreement

Disclosure of defined benefit plans [line items]

Debt instrument principal amount

$ 100,000

Loans and Borrowings - Loans _2

Loans and Borrowings - Loans and Borrowings from Financing Activities (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	$ 168,786
Changes from financing cash flows
Proceeds from issuance of notes and warrants	100,000
Payment of debt issuance costs	(4,000)
Total changes from financing cash flows	96,000
Other changes
Fair value of warrants issued	(3,418)
Unpaid debt issuance costs	(257)
Amortization of fair value adjustment, discount, and debt issuance costs	1,202
Other loans and borrowings activity, net	(171)
Total other changes	(2,644)
Changes in loans and borrowings, Ending balance	262,142	$ 168,786
Albacore Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	168,601	0	$ 0
Changes from financing cash flows
Proceeds from issuance of notes and warrants	100,000	191,000	0
Payment of debt issuance costs	(4,000)	(3,429)
Repayment of cash loan		0
Total changes from financing cash flows	96,000	187,571	0
Other changes
Fair value of warrants issued	(3,418)	(16,930)
Unpaid debt issuance costs	(257)	(2,801)
Amortization of fair value adjustment, discount, and debt issuance costs	1,202	761
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		0
Total other changes	(2,473)	(18,970)	0
Changes in loans and borrowings, Ending balance	262,128	168,601	0
VNV Loan Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	0	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		15,000	0
Payment of debt issuance costs		0
Repayment of cash loan		(7,000)
Total changes from financing cash flows		8,000	0
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		(8,000)
Other loans and borrowings activity, net		0
Total other changes		(8,000)	0
Changes in loans and borrowings, Ending balance		0	0
Unsecured Bonds
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	0	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		64,563	0
Payment of debt issuance costs		(1,375)
Repayment of cash loan		(75,000)
Total changes from financing cash flows		(11,812)	0
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		(171)
Amortization of fair value adjustment, discount, and debt issuance costs		3,983
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		8,000
Other loans and borrowings activity, net		0
Total other changes		11,812	0
Changes in loans and borrowings, Ending balance		0	0
Convertible Loan Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	0	70,000	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		0	100,000
Payment of debt issuance costs		0
Repayment of cash loan		0
Total changes from financing cash flows		0	100,000
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		(70,000)	(30,000)
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		0
Total other changes		(70,000)	(30,000)
Changes in loans and borrowings, Ending balance		0	70,000
Other Loans and Borrowings
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	185	357	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		0	357
Payment of debt issuance costs		0
Repayment of cash loan		0
Total changes from financing cash flows		0	357
Other changes
Fair value of warrants issued		0
Unpaid debt issuance costs		0
Amortization of fair value adjustment, discount, and debt issuance costs		0
Convertible loan notes converted		0	0
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net	(171)	(172)
Total other changes	(171)	(172)	0
Changes in loans and borrowings, Ending balance	14	185	357
Unsecured Notes
Loans and Borrowings [Roll Forward]
Changes in loans and borrowings, Beginning balance	$ 168,786	70,357	0
Changes from financing cash flows
Proceeds from issuance of notes and warrants		270,563	100,357
Payment of debt issuance costs		(4,804)
Repayment of cash loan		(82,000)
Total changes from financing cash flows		183,759	100,357
Other changes
Fair value of warrants issued		(16,930)
Unpaid debt issuance costs		(2,972)
Amortization of fair value adjustment, discount, and debt issuance costs		4,744
Convertible loan notes converted		(70,000)	(30,000)
Non-cash conversion of loan notes to bonds		0
Other loans and borrowings activity, net		(172)
Total other changes		(85,330)	(30,000)
Changes in loans and borrowings, Ending balance		$ 168,786	$ 70,357

Employee Benefits - Narrative_2

Employee Benefits - Narrative (Details)

Oct. 21, 2021shares

Oct. 31, 2021shares

Mar. 31, 2021shares

Feb. 28, 2021employee$ / shares

Mar. 31, 2022USD ($)

Mar. 31, 2021USD ($)

Dec. 31, 2021item

Dec. 31, 2021itemshares

Dec. 31, 2021item

Dec. 31, 2021USD ($)item

Dec. 31, 2021itemOptions

Dec. 31, 2021item$ / shares

Dec. 31, 2020USD ($)

Dec. 31, 2019USD ($)

Dec. 07, 2021item

Jun. 03, 2021shares

Disclosure of defined benefit plans [line items]

Fixed contribution

$ 6,300,000

$ 5,200,000

$ 3,100,000

Stock conversion ratio

0.3

0.3

Stock options granted (in shares) | shares

7,223,177

Stock options vested percentage

25.00%

Option vesting period

3 years

Share-based compensation

$ 8,402,000

$ 2,802,000

46,307,000

$ 9,557,000

$ 7,966,000

Unrecognized compensation cost

24,400,000

Weighted average contractual life

3 years 4 months 24 days

Weighted average share price, share options granted | $ / shares

$ 7.79

Granted (in shares)

8,155,289

8,155,289

4,109,243

2,786,856

Subscription price (in usd per share) | $ / shares

$ 0.03

Redeemable stock price per share (in usd per share) | $ / shares

$ 0.00001227

Granted value

9,700,000

Pre-money equity valuation

$ 3,500,000,000

Volatility (in percent)

54.00%

Higi SH Holdings Inc.

Disclosure of defined benefit plans [line items]

Number of instruments or interests issued or issuable (in shares) | item

3,412,107

Continuing Employees | Higi SH Holdings Inc.

Disclosure of defined benefit plans [line items]

Number of instruments or interests issued or issuable (in shares) | item

1,980,000

1,980,000

1,980,000

1,980,000

1,980,000

1,980,000

Bottom of range

Disclosure of defined benefit plans [line items]

Expiration of options, term

10 years

Weighted average remaining contractual life of outstanding share options

6 years 10 months 24 days

Volatility (in percent)

63.40%

Top of range

Disclosure of defined benefit plans [line items]

Expiration of options, term

15 years

Weighted average remaining contractual life of outstanding share options

15 years

Volatility (in percent)

70.00%

Class A ordinary shares

Disclosure of defined benefit plans [line items]

Number of shares issued (in shares) | shares

10,973,903

Conversion of stock, shares (in shares) | shares

712,413

Number of shares authorised for issuance | shares

13,700,125

Number of shares authorised for issuance, automatic annual increase percentage

5.00%

Class G

Disclosure of defined benefit plans [line items]

Granted (in shares)

10,150,368

Number of employees granted options | employee

3

Vesting term

1 year

Restricted Stock Award

Disclosure of defined benefit plans [line items]

Options cancelled (in shares) | shares

5,046,059

Share-based compensation

$ 3,600,000

Unrecognized compensation cost

1,300,000

Restricted Stock Award | Bottom of range

Disclosure of defined benefit plans [line items]

Weighted average contractual life

1 year

Restricted Stock Award | Top of range

Disclosure of defined benefit plans [line items]

Weighted average contractual life

2 years

Restricted Stock Unit

Disclosure of defined benefit plans [line items]

Share-based compensation

6,500,000

$ 0

Unrecognized compensation cost

812,331

Vested (in shares) | shares

1,167,669

Unvested value

$ 5,400,000

Weighted average contractual life

1 year 3 months 18 days

Long Term Incentive Plan

Disclosure of defined benefit plans [line items]

Options cancelled (in shares) | shares

4,265,770

Number of stock options shares (in shares) | shares

6,660,027

Company Share Option Plan

Disclosure of defined benefit plans [line items]

Options cancelled (in shares) | shares

7,726,002

Employee Benefits - Share-bas_2

Employee Benefits - Share-based Payments (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Employee Benefits
Total share-based compensation expense	$ 8,402	$ 2,802	$ 46,307	$ 9,557	$ 7,966

Employee Benefits - Restricte_2

Employee Benefits - Restricted Stock Unit Activity and Weighted Average Grant Date Fair Value (Details) - Restricted Stock Award - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
RSUs
Beginning balance (in shares)	6,997,284	0
Granted (in shares)	14,758,592	6,997,284
Vested and issued (in shares)	(895,627)	0
Forfeited (in shares)	(1,099,073)	0
Ending balance (in shares)	19,761,176	6,997,284
Vested and unissued (in shares)	39,022	1,760,363
Unvested (in shares)	19,722,154	5,236,921
Weighted Average Grant Date Fair Value Per RSU
Beginning balance (in usd per share)	$ 6.23	$ 0
Granted (in usd per share)		6.23
Vested and issued (in usd per share)		0
Forfeited (in usd per share)		0
Ending balance (in usd per share)		6.23
Vested and unissued (in usd per share)		6.23
Unvested (in usd per share)		$ 6.23

Employee Benefits - Weighted _2

Employee Benefits - Weighted Average Exercise Price (Details)	3 Months Ended		12 Months Ended
	Mar. 31, 2022$ / shares	Mar. 31, 2022Options	Dec. 31, 2021$ / shares	Dec. 31, 2021Options$ / shares	Dec. 31, 2021$ / shares	Dec. 31, 2020$ / shares	Dec. 31, 2020Options$ / shares	Dec. 31, 2020$ / shares	Dec. 31, 2019$ / shares
Weighted average exercise price
Outstanding at the beginning of the year (in usd per share)	$ 1.47		$ 0.02			$ 0			$ 0
Granted during the year (in usd per share)			3.67			0.11			0
Forfeited / canceled during the year (in usd per share)	1.26		0.18			0.04			0
Exercised during the year (in usd per share)	0.35		1.42			0			0
Outstanding at the end of the year (in usd per share)	$ 1.48		1.47			0.02			0
Exercisable at the end of the year (in usd per share)			$ 1.54	$ 1.54	$ 1.54	$ 0.01	$ 0.01	$ 0.01	$ 0
Number of options
Outstanding at the beginning of the year (in shares)		22,896,265		21,107,487	21,107,487			20,120,425	19,666,539
Granted during the year (in shares)				8,155,289	8,155,289			4,109,243	2,786,856
Forfeited / canceled during the year (in shares)		(650,232)		(6,204,471)	(6,204,471)			(3,122,181)	(2,332,970)
Exercised during the year (in shares)		(27,942)		(162,040)	(162,040)			0	0
Outstanding at the end of the year (in shares)		22,218,091		22,896,265	22,896,265		21,107,487	21,107,487	20,120,425
Exercisable at the end of the year (in shares)			19,105,908	19,105,908	19,105,908	16,461,945	16,461,945	16,461,945	11,817,828

Employee Benefits - Fair Value

Employee Benefits - Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2021$ / shares
Disclosure of defined benefit plans [line items]
Volatility (in percent)	54.00%
Bottom of range
Disclosure of defined benefit plans [line items]
Fair value of underlying stock (in dollars per share)	$ 2.97
Volatility (in percent)	63.40%
Risk free interest rate (in percent)	0.12%
Dividend yield (in percent)	0.00%
Top of range
Disclosure of defined benefit plans [line items]
Fair value of underlying stock (in dollars per share)	$ 9.20
Volatility (in percent)	70.00%
Risk free interest rate (in percent)	1.68%
Dividend yield (in percent)	0.00%

Capital and Reserves - Share _2

Capital and Reserves - Share Capital of Babylon Holdings Limited (Details)	12 Months Ended
	Dec. 31, 2021shares
Class A ordinary shares
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	330,257,000
Share Capital (in shares)	13,000
Class A ordinary shares | Babylon Shareholders
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	295,589,000
Share Capital (in shares)	12,000
Class A ordinary shares | PIPE Investors
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	22,400,000
Share Capital (in shares)	1,000
Class A ordinary shares | SPAC Investors And Shareholders
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	12,268,000
Share Capital (in shares)	0
Class B ordinary shares
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	409,895,000
Share Capital (in shares)	16,000
Class B ordinary shares | Babylon Shareholders
Disclosure of classes of share capital [line items]
Number of Shares (in shares)	79,638,000
Share Capital (in shares)	3,000

Capital and Reserves - Narrat_2

Capital and Reserves - Narrative (Details) $ / shares in Units, $ in Millions	Nov. 12, 2020USD ($)$ / shares	Dec. 31, 2021USD ($)Vote$ / sharesshares	Dec. 31, 2020USD ($)$ / sharesshares	Mar. 31, 2022Voteshares	Dec. 16, 2020USD ($)	Dec. 02, 2020USD ($)	Nov. 16, 2020USD ($)
Disclosure of classes of share capital [line items]
Number of deferred shares (in shares) | shares		100,000
Deferred shares, par value per share (in usd per share) | $ / shares		$ 0.00004
Deferred shares issued (in shares) | shares		0		0
Loan Notes
Disclosure of classes of share capital [line items]
Debt conversion, related to principal | $			$ 30
Tranche 1 Notes
Disclosure of classes of share capital [line items]
Debt instrument, issued amount | $	$ 30					$ 15	$ 15
Accrued interest, percentage	11.00%
Tranche 2 Notes
Disclosure of classes of share capital [line items]
Debt instrument, issued amount | $					$ 70
Class A ordinary shares
Disclosure of classes of share capital [line items]
Number of votes per share | Vote		1		1
Deferred shares, par value per share (in usd per share) | $ / shares		$ 0.000422573245084686
Voting rights, percentage		50.00%
Class B ordinary shares
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares		$ 0.0000422573245084686
Number of votes per share | Vote		15		15
Voting rights, percentage		50.00%
Preference C Shares
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares			$ 0.00001277
Number of shares issued (in shares) | shares			24,796,225
Aggregate purchase price | $			$ 42.1
Debt conversion, shares issued (in shares) | shares			111,239
Number of shares settled in cash (in shares) | shares			6,976,194
Cash paid, net of cash acquired | $			$ 11.9
Preference C Shares | Loan Notes
Disclosure of classes of share capital [line items]
Debt conversion, amount | $		$ 70
Debt conversion, shares issued (in shares) | shares		41,012,358
Debt conversion, related to principal | $			$ 0.2
Debt conversion, shares issued (in shares) | shares			17,708,792
Preference C Shares | Tranche 1 Notes
Disclosure of classes of share capital [line items]
Ordinary share (in usd per share) | $ / shares	$ 1.706802577

Capital and Reserves - Share _3

Capital and Reserves - Share Capital (Details) - shares	12 Months Ended
	Dec. 31, 2021	Mar. 31, 2022
Class A ordinary shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	6,500,000	6,500,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	330,257,000
Issued following the Merger (in shares)	3,668,000
Issued (in shares)	333,925
Class B ordinary shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	3,100,000	3,100,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	79,638,000
Issued following the Merger (in shares)	0
Issued (in shares)	79,638
Ordinary A Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	10,000,000
Issued (in shares)	135,136,000
Issued during the year prior to Merger (in shares)	0
Conversion into Class A and B Shares (in shares)	(135,136,000)
Issued following the Merger (in shares)	0
Issued (in shares)	0
Ordinary B Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	11,000,000
Issued (in shares)	664,605,000
Issued during the year prior to Merger (in shares)	17,206,000
Conversion into Class A and B Shares (in shares)	(681,811,000)
Issued following the Merger (in shares)	0
Issued (in shares)	0
Preference C Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	10,000,000
Issued (in shares)	252,065,000
Issued during the year prior to Merger (in shares)	41,012,000
Conversion into Class A and B Shares (in shares)	(293,077,000)
Issued following the Merger (in shares)	0
Issued (in shares)	0
Ordinary Redeemable G1 Shares
Disclosure of classes of share capital [line items]
Authorized (in shares)	50,000
Issued (in shares)	0
Issued during the year prior to Merger (in shares)	10,150,000
Conversion into Class A and B Shares (in shares)	(10,150,000)
Issued following the Merger (in shares)	0
Issued (in shares)	0

Capital and Reserves - Other _2

Capital and Reserves - Other Comprehensive Income Accumulated in Reserves (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Other Comprehensive Income (Loss) Accumulated in Reserves [Roll Forward]
Beginning balance	$ (27)	$ 1,675	$ 1,675	$ (1,904)	$ 7,789
Foreign exchange movement	(3,753)	$ (1,754)	(1,702)	3,579	(9,693)
Ending balance	$ (3,780)		$ (27)	$ 1,675	$ (1,904)

Warrant Liability - Table Dis_2

Warrant Liability - Table Displays the Number of Warrants in Issue (Details) - shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Warrant Liability [Line Items]
Number of warrants issued at, beginning	16,316	0
Number of warrants issued at, ending	17,195	16,316
Tradeable Warrants
Warrant Liability [Line Items]
Number of warrants issued at, beginning	8,625	0
Number of warrants issued at, ending	8,625	8,625
Non-Tradeable Warrants
Warrant Liability [Line Items]
Number of warrants issued at, beginning	7,691	0
Number of warrants issued at, ending	8,570	7,691
Alkuri Warrants
Warrant Liability [Line Items]
Issued during period		14,558,000
Alkuri Warrants | Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		8,625,000
Alkuri Warrants | Non-Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		5,933,000
AlbaCore Warrants
Warrant Liability [Line Items]
Issued during period	879	1,758,000
AlbaCore Warrants | Tradeable Warrants
Warrant Liability [Line Items]
Issued during period		0
AlbaCore Warrants | Non-Tradeable Warrants
Warrant Liability [Line Items]
Issued during period	879	1,758,000

Warrant Liability - Reconcili_2

Warrant Liability - Reconciliation of Fair Values (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021
Disclosure of financial liabilities [line items]
Fair value at beginning	$ 20,128	$ 0
Change in fair value of warrant liabilities	(5,575)	(27,811)
Fair value at ending	17,971	20,128
Tradeable Warrants | Level 1
Disclosure of financial liabilities [line items]
Fair value at beginning	5,865	0
Change in fair value of warrant liabilities	(1,294)	(12,506)
Fair value at ending	4,571	5,865
Non-Tradeable Warrants | Level 2
Disclosure of financial liabilities [line items]
Fair value at beginning	4,035	0
Change in fair value of warrant liabilities	(890)	(8,603)
Fair value at ending	3,145	4,035
Non-Tradeable Warrants | Level 3
Disclosure of financial liabilities [line items]
Fair value at beginning	10,228	0
Change in fair value of warrant liabilities	(3,391)	(6,702)
Fair value at ending	10,255	10,228
Alkuri Warrants
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		31,009
Alkuri Warrants | Tradeable Warrants | Level 1
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		18,371
Alkuri Warrants | Non-Tradeable Warrants | Level 2
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance		12,638
AlbaCore Warrants
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance	3,418	16,930
AlbaCore Warrants | Non-Tradeable Warrants | Level 3
Disclosure of financial liabilities [line items]
Fair value of warrants upon issuance	$ 3,418	$ 16,930

Warrant Liability - Narrative_2

Warrant Liability - Narrative (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Oct. 22, 2021
Disclosure of financial liabilities [line items]
Tradeable warrant, market price per warrant (in dollars per share)	$ 0.53	$ 0.68
Price per warrant (in dollars per share)	$ 3.89	$ 5.82
Alkuri Warrants
Disclosure of financial liabilities [line items]
Number of warrants outstanding (in shares)	14,558,313	14,558,333
Warrants exercise price, per share (in dollars per share)	$ 11.50	$ 11.50
Tradeable warrant, market price per warrant (in dollars per share)			$ 2.13
Warrant, Shares Issued Per Warrant On Exercise	1	1
AlbaCore Warrants
Disclosure of financial liabilities [line items]
Number of warrants outstanding (in shares)	1,757,499	1,757,499
Warrants subscription price, per share (in dollars per share)	$ 0.00004	$ 0.00004
Price per warrant (in dollars per share)		$ 9.63
Warrant, Shares Issued Per Warrant On Exercise	1	1

Related Parties (Details)_2

Related Parties (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 07, 2021	Jun. 03, 2021	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019	Jun. 03, 2020
Disclosure of transactions between related parties [line items]
Pension contributions to related party transactions			$ 900	$ 900	$ 6,500	$ 1,000	$ 900
Remuneration of the highest paid key manager			200	300	2,200	300	300
Key management personnel compensation			$ 1,000	$ 600	32,100	$ 0	100
Repayments of current borrowings					$ 82,000		$ 1,231
Class A ordinary shares
Disclosure of transactions between related parties [line items]
Reverse recapitalization, share price (in usd per share)		$ 10
Number of shares issued (in shares)		10,973,903
PIPE Investors | Class A ordinary shares
Disclosure of transactions between related parties [line items]
Issuance Of Shares In Reverse Recapitalization, Shares		22,400,000
Higi
Disclosure of transactions between related parties [line items]
Notes and debentures issued								$ 5,000
ALP Partners limited | Class A ordinary shares
Disclosure of transactions between related parties [line items]
Number of shares issued (in shares)		200,000
ALP Partners limited | Higi
Disclosure of transactions between related parties [line items]
Repayments of current borrowings	$ 5,400
VNV (Cyprus) Limited | Class A ordinary shares
Disclosure of transactions between related parties [line items]
Number of shares issued (in shares)		500,000
Black Ice Capital Limited | Class A ordinary shares
Disclosure of transactions between related parties [line items]
Number of shares issued (in shares)		500,000
Invik S. A. | Class A ordinary shares
Disclosure of transactions between related parties [line items]
Number of shares issued (in shares)		500,000

Financial Instruments and Ris_3

Financial Instruments and Risk Management - Assets and Liabilities that are Measured at Fair Value (Details) - USD ($) $ in Thousands	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Disclosure of fair value measurement of assets [line items]
Total liabilities	$ 503,046	$ 389,361	$ 190,455
Recurring fair value measurement
Disclosure of fair value measurement of assets [line items]
Total liabilities	17,971	20,128
Recurring fair value measurement | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities	4,571	5,865
Recurring fair value measurement | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities	10,255	10,228
Recurring fair value measurement | Tradeable Alkuri Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	6,837	5,865
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities		5,865
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | Tradeable Alkuri Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities	6,837	0
Recurring fair value measurement | Non-tradeable Alkuri Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities	3,145	4,035
Recurring fair value measurement | Non-tradeable Alkuri Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | AlbaCore Warrants
Disclosure of fair value measurement of assets [line items]
Total liabilities	4,571	10,228
Recurring fair value measurement | AlbaCore Warrants | Level 1
Disclosure of fair value measurement of assets [line items]
Total liabilities	$ 4,571	0
Recurring fair value measurement | AlbaCore Warrants | Level 2
Disclosure of fair value measurement of assets [line items]
Total liabilities		0
Recurring fair value measurement | AlbaCore Warrants | Level 3
Disclosure of fair value measurement of assets [line items]
Total liabilities		$ 10,228

Financial Instruments and Ris_4

Financial Instruments and Risk Management - The Monte Carlo Simulation Model for the AlbaCore Warrants (Details) - $ / shares	Mar. 31, 2022	Dec. 31, 2021	Nov. 04, 2021
Financial Instruments and Risk Management [Abstract]
Underlying stock price (USD)	$ 3.89	$ 5.83	$ 9.66
Exercise price (USD)	$ 0.00004	$ 0.00004	$ 0.00004
Volatility (in percent)	74.10%	71.60%	66.70%
Remaining term (years)		4 years 10 months 6 days	5 years
Risk-free rate (in percent)	2.40%	1.23%	1.09%

Financial Instruments and Ris_5

Financial Instruments and Risk Management - Significant Exchange Rates (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
GBP
Disclosure of fair value measurement of assets [line items]
Average Rate	0.7277	0.7760	0.7835
Year-end spot rate	0.7409	0.7321	0.7618
CAD
Disclosure of fair value measurement of assets [line items]
Average Rate	1.2536	1.3433	1.3251
Year-end spot rate	1.2725	1.2750	1.3033
RWF
Disclosure of fair value measurement of assets [line items]
Average Rate	1,003.4066	959.1820	914.2488
Year-end spot rate	1,037.6458	988.0837	947.0750
SGD
Disclosure of fair value measurement of assets [line items]
Average Rate	1.3427	1.3789	1.3111
Year-end spot rate	1.3496	1.3224	1.3456
INR
Disclosure of fair value measurement of assets [line items]
Average Rate	73.7902	74.0038
Year-end spot rate	74.3047	73.2901

Financial Instruments and Ris_6

Financial Instruments and Risk Management - Sensitivity Analysis (Details) - GBP - USD ($) $ in Thousands	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disclosure of fair value measurement of assets [line items]
Profit or loss, reasonably possible, strengthening	$ (373,578)	$ (184,067)	$ (156,489)
Profit or loss, reasonably possible, weakening	(371,938)	(184,416)	(150,290)
Equity, net of tax, reasonably possible, strengthening	(168,522)	(48,743)	(175,371)
Equity, net of tax, reasonably possible, weakening	$ (168,930)	$ (48,394)	$ (173,872)
Movement percent (in percent)	5.00%	5.00%

Financial Instruments and Ris_7

Financial Instruments and Risk Management - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Financial Instruments and Risk Management [Abstract]
Repeated customers percentage (in percent)	50.00%
Debtors and general economic conditions	$ 0	$ 0
Net impact from the fluctuation of operational foreign exchange rates amounted	$ (1.7)		$ (9.7)
Net foreign exchange gain		$ 3.6

Net Loss Per Share (Details)

Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2022	Mar. 31, 2021	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Earnings per share [line items]
Equity holders of the parent	$ (91,357)	$ (10,466)	$ (368,482)	$ (186,799)	$ (140,287)
Weighted average number of ordinary shares used in calculating basic earnings per share			271,321	242,936	241,903
Net loss per share, Basic and Diluted	$ (0.24)	$ (0.04)	$ (1.36)	$ (0.77)	$ (0.58)
Net loss per share, Diluted (in usd per share)			$ (1.36)	$ (0.77)	$ (0.58)
Stockholder Earnout Shares
Earnings per share [line items]
Securities excluded from weighted average share outstanding calculation			38,800,000
Sponsor Earnout Shares
Earnings per share [line items]
Securities excluded from weighted average share outstanding calculation			1,237,800

Assets and Liabilities Classi_3

Assets and Liabilities Classified as Held for Sale - Additional Information (Details) - Assets and liabilities classified as held for sale $ in Millions	Jan. 14, 2021CAD ($)
Assets and Liabilities Classified as Held for Sale [Line Items]
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations	$ 1.8
Babylon Partners Limited
Assets and Liabilities Classified as Held for Sale [Line Items]
Proceeds from sale of disposal group attributable to the repayment of debt	$ 3.5

Assets and Liabilities Classi_4

Assets and Liabilities Classified as Held for Sale (Details) $ in Thousands, $ in Millions	Jan. 14, 2021CAD ($)	Mar. 31, 2022USD ($)	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)
Assets and Liabilities Classified as Held for Sale [Line Items]
Cash and cash equivalents		$ 274,978	$ 262,581	$ 101,757
Property, plant and equipment		25,694	24,990	1,334	$ 1,801
Right-of-use assets		$ 20,014	7,844	2,572
Lease liabilities			$ 12,632	4,499	$ 3,583
Assets and liabilities classified as held for sale
Assets and Liabilities Classified as Held for Sale [Line Items]
Cash and cash equivalents				577
Prepayments and contract assets				1,125
Property, plant and equipment				621
Right-of-use assets				629
Trade and other receivables				330
Assets held for sale				3,282
Accruals and provisions				813
Lease liabilities				607
Trade and other payables				402
Liabilities directly associated with the assets held for sale				$ 1,822
Proceeds from disposal of non-current assets or disposal groups classified as held for sale and discontinued operations	$ 1.8

Subsequent Events (Details)_2

Subsequent Events (Details) $ in Millions	Nov. 01, 2021ft²	Mar. 14, 2022shares	Feb. 01, 2022USD ($)employee	Jan. 14, 2022USD ($)	Jan. 06, 2022USD ($)
Disclosure of non-adjusting events after reporting period [line items]
Sublease rentable square feet | ft²	37,883
Minimum payments for the non-cancellable lease | $			$ 16.6	$ 7	$ 6.3
Number of employees housed in lease property | employee			200
Entering into significant commitments or contingent liabilities
Disclosure of non-adjusting events after reporting period [line items]
Minimum payments for the non-cancellable lease | $			$ 16.6
Number of employees housed in lease property | employee			200
Potential ordinary share transactions
Disclosure of non-adjusting events after reporting period [line items]
Number shares authorized | shares		17,233,274